Document:

EX-10.1

 Exhibit 10.1 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 
 Private & Confidential 

EXECUTION VERSION 
 DATED April 24, 2015

  
  

 

					
		 	INNATE PHARMA S.A.	  	(1)
			
		 	and	  	
			
		 	MEDIMMUNE LIMITED	  	(2)

  
  

CO-DEVELOPMENT AND LICENSE AGREEMENT 

RELATING TO IPH2201 
  

 

 TABLE OF CONTENTS 
  

							
	 1
	  	DEFINITIONS	  	 	2	 
			
	 2
	  	CONSTRUCTION; COMPETITION LAW CLEARANCE	  	 	25	 
			
	 3
	  	GRANT OF RIGHTS AND LICENSES; EXCLUSIVITY	  	 	27	 
			
	 4
	  	DEVELOPMENT	  	 	34	 
			
	 5
	  	JOINT PROJECT TEAM AND DEVELOPMENT COLLABORATION COMMITTEE	  	 	41	 
			
	 6
	  	GENERAL PROVISIONS ON DEVELOPMENT AND COMMERCIALIZATION AND REGULATORY MATTERS	  	 	45	 
			
	 7
	  	CO-FUNDING OF DEVELOPMENT	  	 	48	 
			
	 8
	  	COMMERCIALIZATION, CO-PROMOTION IN THE [***] AND SALES COLLABORATION COMMITTEE	  	 	51	 
			
	 9
	  	MANUFACTURE AND SUPPLY	  	 	57	 
			
	 10
	  	CONSIDERATION	  	 	59	 
			
	 11
	  	CONFIDENTIALITY	  	 	70	 
			
	 12
	  	OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS	  	 	73	 
			
	 13
	  	REPRESENTATIONS, WARRANTIES AND COVENANTS	  	 	79	 
			
	 14
	  	RECORD RETENTION, AUDIT AND USE OF NAME	  	 	88	 
			
	 15
	  	TERM AND TERMINATION	  	 	91	 
			
	 16
	  	INDEMNIFICATION	  	 	103	 
			
	 17
	  	GOVERNING LAW AND ARBITRATION	  	 	107	 
			
	 18
	  	ASSIGNMENT; PERFORMANCE BY AFFILIATES; GENERAL	  	 	108	 

 SCHEDULES 
  

			
	 Schedule 1.8

 
	  	 Current Back up

	 Schedule
1.66
  
	  	 Formulation
Patent

	 Schedule 1.85

 
	  	 Current IPH2201

	 Schedule
1.92
  
	  	 Licensed
Shared Patents

	 Schedule 1.95

 
	  	 Listed Patents

	 Schedule
1.109
  
	  	
NKG2A

	 Schedule 1.110

 
	  	 Non-Exclusively Licensed
Patents

	 Schedule
1.124
  
	  	 Profit/Loss
Reporting Schedule

	 Schedule 1.147

 
	  	 Third Party Agreements

	 Schedule
3.11
  
	  	 Form
Confirmatory Patent License

	 Schedule 4.11(a)

 
	  	 Approved Third Parties

	 Schedule
4.11(b)
  
	  	 MedImmune
Code of Conduct

	 Schedule 5.3

 
	  	 Parties Representation on JPT

	 Schedule 5.7

 
	  	 Parties
Representation on DCC

	 Schedule 7.1

 
	  	 Development Costs Sharing Example

	 Schedule 7.4

 
	  	 Form
Development Costs Report

	 Schedule 8.14

 
	  	 Form Commercialization Costs Report

	 Schedule
13.2(a)(i)
  
	  	 Owned
Patents

	 Schedule 13.2(a)(ii)

 
	  	 Exclusively Licensed Patents

	 Schedule
13.2(a)(iv)
  
	  	 Listed Know-How

	 Schedule 13.2(m)

 
	  	 Current Manufacturing
Specification

	 Schedule 13.2(n)

 
	  	 Current Contract Manufacturing
Organisations

 This Co-Development and License Agreement (the
“Agreement”) is made as of the Signing Date by and between: 
  

	 	(1)	 INNATE PHARMA S.A., a company incorporated in France and with its principal place of business at 117, Avenue de Luminy
– BP 30191 13 009 Marseille, France (“Innate”); and 

  

	 	(2)	 MEDIMMUNE LIMITED, a company incorporated in England and Wales with company number 2451177 and with its registered
office at Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom (“MedImmune”). 

 Background 

 

	 	(A)	 Innate is the owner of certain propriety technology relating to IPH2201, its first in class NKG2A monoclonal antibody,
and is the owner or exclusive licensee or sublicensee of certain Patents and Know-How associated therewith, including Patents and Know-How exclusively licensed to Innate
by Novo Nordisk pursuant to an agreement dated 28 March 2006 (as amended) (capitalised terms are defined below); 

  

	 	(B)	 Innate has developed and studied IPH2201 for the treatment of cancer, in particular head and neck cancer, chronic
lymphocytic leukaemia and ovarian cancer, both alone and in combination with other compounds; 

  

	 	(C)	 MedImmune is, directly or indirectly, a wholly owned subsidiary of AstraZeneca PLC. MedImmune and its Affiliates have
experience in the research, development, manufacturing and commercialisation of pharmaceutical products worldwide, including treatments for cancer both using small molecules and large molecules, some of which, have the potential for use in
combination with IPH2201 (capitalised terms are defined below); 

  

	 	(D)	 Innate granted an exclusive option to MedImmune pursuant to a Development and Option Agreement entered into on the
same date as this Agreement (the “Development and Option Agreement”) and MedImmune desires to exercise such option and take such license, under Innate’s rights in and to the Licensed

  
 1 

	 	 
Antibodies, IPH2201, Back-Up Licensed Antibodies and associated Patents and Intellectual Property Rights to Exploit one or several of the Licensed
Antibodies for the treatment of cancer or any other indication, in accordance with the terms and conditions set forth below (as such capitalised terms are defined below). 

 

	 	(E)	 The Parties are interested in co-developing and
co-commercialising Licensed Products and in collaborating and sharing certain expenses and revenues, with respect to the Development and Commercialisation of Licensed Products, in accordance with the terms and
conditions set forth below (as such capitalised terms are defined below). 

  

	 	(F)	 The intent of the Parties is that Medimmune will, as needed, involve the resources of its Affiliates in the activities
contemplated hereunder. 

 NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each of Innate and MedImmune, intending to be legally bound, agree as follows: 
  

	1	 DEFINITIONS 

  Unless otherwise specifically provided in this Agreement, the following terms shall have the following meanings: 

 

	 	1.1	 “Affiliate” means, with respect to a Person, any Person that from time to time
directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with such first Person. For purposes of the definition in this Section 1.1 only, “control”, and with correlative
meanings, the terms “controlled by” and “under common control with” mean (a) to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities, by
contract relating to voting rights or corporate governance, resolution, regulation or otherwise, or (b) to own, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities or other ownership interest of such
Person. 

  
 2 

	 	1.2	 “Annual Net Sales” means the Net Sales made during any given Calendar Year. 

 

	 	1.3	 “Anti-Corruption Laws” means the US Foreign Corrupt Practices Act 1977, the UK Bribery Act 2010 and
any other Applicable Laws for the prevention of fraud, corruption, racketeering, money laundering or terrorism. 

  

	 	1.4	 “Applicable Laws” means the laws, rules, regulations and guidelines in the world, including any
rules, regulations, guidelines or other requirements of the Governmental Bodies that are applicable to the Parties or any particular activity under this Agreement, in each case as may be in effect from time to time, including, without limitation,
(i) GCP, (ii) GMP and (iii) the principles that form the basis of the Helsinki Declaration of the World Medical Association, in each case to the extent they apply to a Party’s performance of its obligations under this Agreement.

  

	 	1.5	 “Arising IP” means any Know-How, inventions, Patents or other
IPR arising after the Effective Date, as a result of the performance of rights or obligations under this Agreement, including the conduct of the Development Plan. 

 

	 	1.6	 “Arising Patent” shall have the meaning assigned in Section 12.3. 

 

	 	1.7	 “Assigned Activities” shall have the meaning assigned in Section 3.5. 

 

	 	1.8	 “Back-Up Licensed Antibodies” means antibodies
(i) described in Schedule 1.8 (the “Current Back up”), (ii) that bind to NGK2A and are within the scope of the claims of the Licensed Patents in any country at any time, or (iii) that bind to NGK2A and are under the
Control of Innate or its Affiliates, and including any fragment or derivative of such an antibody, but excluding IPH2201. 

  

	 	1.9	 “Bankruptcy Code” means Title 11, United States Code, as amended, or analogous provisions of
Applicable Laws outside the United States. 

  

	 	1.10	 “Breaching Party” shall have the meaning assigned in Section 15.2(i). 

 

	 	1.11	 “Breach Invoking Party” shall have the meaning assigned in Section 15.2(i).

  
 3 

	 	1.12	 “Business Day” means a day other than Saturday or Sunday or a public holiday in England or France.

  

	 	1.13	 “Calendar Quarter” means each successive period of three (3) consecutive calendar months
commencing on 1st January, 1st April, 1st July and 1st October. 

  

	 	1.14	 “Calendar Year” means each successive period of twelve (12) consecutive calendar months
commencing on 1st January. 

  

	 	1.15	 “Change of Control” means any of the following with respect to Innate: 

 

	 	(a)	 the sale or disposition of all or substantially all of its assets to an Industrial Competing Party;

  

	 	(b)	 the acquisition by an Industrial Competing Party, acting alone or in concert with other Person(s), of more than fifty
percent (50%) of the combined voting power of Innate’s outstanding voting securities or otherwise the power to control the appointment of the Board of Directors of Innate; or 

 

	 	(c)	 a merger, consolidation, share exchange or other similar transaction of Innate and any Industrial Competing Party
which results in the holders of the outstanding voting securities of Innate immediately prior to such merger, consolidation, share exchange or other similar transaction ceasing to hold more than fifty percent (50%) of the combined voting power of
the surviving, purchasing or continuing entity immediately after such merger, consolidation, share exchange or other similar transaction; 

other than, in each case of subsection (a), (b) and (c), where such transaction is to be entered into between Innate and MedImmune or an
Affiliate of MedImmune. Notwithstanding the foregoing, a Change of Control shall not be deemed to occur solely on account of an (x) initial public or secondary offering, or (y) the acquisition of securities of Innate by one or more
institutional investors, or Affiliates thereof, which are not Industrial Competing Parties, that acquire Innate’s securities in a transaction or series of related transactions (i) 

  
 4 

 
primarily for purposes of equity investment, or (ii) as a sale of assets, merger or other transaction effected exclusively for the purpose of obtaining tax or other fiscal benefit or
changing the corporate domicile of Innate. 
  

	 	1.16	 “Clinical Trials” means Phase 1 Clinical Trials, Phase 2 Clinical Trials, Phase 3 Clinical Trials,
Phase 4 Clinical Trials, or variations of such trials (for example, Phase 2/3 and Phase 2b), and any other clinical study conducted in human subjects in connection with the Development of a Licensed Product. 

 

	 	1.17	 “CMC” means optimization of Manufacturing processes to provide reproducible supply of drug substance
at commercialization scale, including formulation and development work to ensure stability and purity, and to otherwise meet the requirements under Applicable Law to be approved by a Regulatory Health Authority for marketing, sale and distribution.

  

	 	1.18	 “Co-Funding Withdrawal Notice” shall have the meaning
assigned in Section 7.1. 

  

	 	1.19	 “Committees” shall mean the DCC, the SCC and the JTC. 

 

	 	1.20	 “Competition Law Clearance” means the first date upon which all of the following have been met:
(i) the waiting period provided by the HSR Act and all other applicable national legislation has expired or been terminated and all required antitrust clearances have been obtained, (ii) no court or administrative challenges to the
transaction contemplated by this Agreement are pending, and (iii) no court or administrative orders are outstanding blocking the completion of the transactions. 

 

	 	1.21	 “Co-Promote Agreement” shall have the meaning assigned in
Section 8.12. 

  

	 	1.22	 “Co-Promote Option” shall have the meaning assigned in
Section 8.3. 

  

	 	1.23	 “Co-Promote Product” means a Licensed Product marketed and Co-Promoted in [***]. 

  

	 	1.24	 “Co-Promotion” means the conduct of Promotion with respect to
the Licensed 

  
 5 

	 	 
Products in the Field, in [***] by each of the Parties, or their Affiliates, under the same Product trademark in a given country, and
“Co-Promote” shall have a corresponding meaning. 

  

	 	1.25	 “Co-Promotion Withdrawal” shall have the meaning assigned to
it in Section 8.4. 

  

	 	1.26	 “Combination” or “Combination Product” means the combination of a Licensed
Antibody as an active ingredient with one or more other active ingredients including but not limited to MedImmune Compounds, whether sold or anticipated to be sold as a fixed dose or as separate co-prescribed
doses or in a physically co-packaged form. 

  

	 	1.27	 “Commercialization” means all activities undertaken relating to the preparation for and conduct of
marketing and sale of a Licensed Product, including without limitation Pre-Approval Activities, advertising, education, planning, marketing, promotion, distribution, market and product support, seeking pricing
and reimbursement approvals and Phase 4 Clinical Trials anywhere in the Territory. 

  

	 	1.28	 “Commercialization Costs” means, with respect to a Licensed Product during any given period, all
Costs that are incurred [***]. Subject to the foregoing, Commercialization Costs for a Licensed Product shall consist of Costs with respect to such Licensed Product incurred for: 

 

	 	(a)	 [***]; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]. 

  

	 	(d)	 [***]; 

  

	 	(e)	 [***]; 

  

	 	(f)	 [***]; 

  
 6 

	 	(g)	 [***]and 

  

	 	(h)	 [***]. 

  

	 	1.29	 “Commercialize” means the conduct of Commercialization activities. 

 

	 	1.30	 “Commercially Reasonable Efforts” means, with respect to the efforts to be expended by a Party [***]

  

	 	1.31	 “Competing Product” a small molecule or protein used in the Field, including but not limited to an
antibody, that binds [***], but excluding a Licensed Product. 

  

	 	1.32	 “Compulsory License” shall have the meaning assigned in Section 10.17. 

 

	 	1.33	 “Confidential Information” means any and all Know-How and
Materials, whether oral or in writing or in any other form, disclosed before, on or after the date of this Agreement by one Party to the other Party that is either marked or identified as confidential or proprietary or that is of such a nature that
would be considered by a reasonable person to be confidential or proprietary. The Licensed Know-How shall be deemed Innate’s Confidential Information. MedImmune
Know-How shall be deemed MedImmune’s Confidential Information. 

  

	 	1.34	 “Control” means, with respect to an item of Know-How or a
Patent, the ability and authority of a Party or its Affiliates, whether arising by ownership, possession, or pursuant to a license or sublicense, to assign, disclose, grant licenses, sublicenses, or other rights to the other Party under or to such
item of Know-How or such Patent as provided for in this Agreement, without breaching the terms of any agreement between such Party and any Third Party and subject to Section 18.2. Notwithstanding the
foregoing, with respect to any Patent or item of Know-How in-licensed or otherwise acquired by Innate after the Effective Date, the exercise or use of which would result
in a payment obligation to any Third Party, such Patent or item of Know-How shall be deemed to be Controlled by Innate for purposes of this Agreement only if MedImmune agrees in writing to reimburse all
amounts owed to such Third Party as a result 

  
 7 

	 	 
of its exercise of such right, license or sublicense excluding any sums which are payable pursuant to the Third Party Agreements. 

 

	 	1.35	 “Controlled Patents” shall have the meaning assigned in Section 12.3. 

 

	 	1.36	 “Costs” means both internal and external costs and expenses (including the cost of allocated FTEs at
the FTE Rate). Unless otherwise mutually agreed between the Parties, internal costs incurred by a Party shall be determined by multiplying the applicable FTE Rate by the number of FTEs utilized to conduct the applicable activities.

  

	 	1.37	 “Covenant Period 1” shall have the meaning assigned in Section 3.13. 

 

	 	1.38	 “Covenant Period 2” shall have the meaning assigned in Section 3.14. 

 

	 	1.39	 “Damages” means any and all direct liabilities, claims, actions, damages, losses or expenses,
including interest, penalties, and reasonable lawyers’ fees and disbursements. In calculating Damages, the legal duty to mitigate on the part of the Party suffering the loss shall be taken into account. 

 

	 	1.40	 “Detail” means a sales presentation or interaction by a professional sales representative to or with
a target physician or other professional with prescribing authority involved in prescribing a Co-Promote Product or to other individuals influencing prescription activity with respect to a Co-Promote Product, in any case, in which the primary purpose is to discuss the benefits and features of the Co-Promote Product. The term Detail will be further defined in the
Co-Promote Agreement. When used as a verb, “Detail” or “Detailing” means to perform a Detail. 

 

	 	1.41	 “Develop” means the conduct of Development activities. 

 

	 	1.42	 “Development” means all activities relating to obtaining Regulatory Approval of a Licensed Product,
Licensed Product line extensions, alternative delivery systems and new indications therefor, and all activities relating to developing the ability to Manufacture the same, including CMC. This includes, for example,
(i) non-clinical testing, toxicology, formulation, clinical studies, regulatory 

  
 8 

	 	 
affairs, and outside counsel regulatory legal services, (ii) manufacturing process development for bulk and finished forms of Licensed Antibodies and Licensed Products, and manufacturing and
quality assurance technical support activities prior to the First Commercial Sale of a Licensed Product anywhere in the Territory and (iii) the conduct of advisory boards with relevant experts, e.g. clinical experts or payer representatives.
Development shall not include activities associated with Phase 4 Clinical Trials in respect of a Licensed Product commenced after First Commercial Sale of such Licensed Product anywhere in the Territory unless (x) required or requested by a
Regulatory Health Authority as a condition of obtaining, maintaining or extending Regulatory Approval or (y) performed to explore additional indications or alternative formulations of such Licensed Products. 

 

	 	1.43	 “Development and Option Agreement” means the Development and Option Agreement between the Parties
dated 24 April 2015. 

  

	 	1.44	 “Development Budget” shall have the meaning set forth in Section 4.5. 

 

	 	1.45	 “Development Collaboration Committee” or “DCC” means the committee described in
Section 5.5. 

  

	 	1.46	 “Development Costs” means, with respect to each Licensed Product [***]: 

 

	 	(i)	 [***]; 

  

	 	(ii)	 [***]; 

  

	 	(iii)	 [***]; 

  

	 	(iv)	 [***]; 

  

	 	(v)	 [***]; 

  

	 	(vi)	 [***] 

  
 9 

	 	 	 Except to the extent included in subsection (ii) above, Development Costs shall not include either Party’s
Costs to the extent they solely relate to activities associated with overseeing execution of and compliance with this Agreement. 

  

	 	1.47	 “Development Plan” means the plan for Development of Licensed Product, as mutually agreed by the
Parties and approved by the DCC in accordance with Section 4.5. 

  

	 	1.48	 “Development Term” means the period during which Development activities are being performed with
respect to any Licensed Product. 

  

	 	1.49	 “Distributor” shall have the meaning assigned in Section 3.3. 

 

	 	1.50	 “Drug Approval Application” means an application for Regulatory Approval required before commercial
sale or use of a Licensed Product as a drug in a regulatory jurisdiction, but excluding pricing and reimbursement approvals. Drug Approval Application includes a Marketing Approval Application (MAA) in Europe or an New Drug Application (NDA) in the
United States. 

  

	 	1.51	 “Effective Date” means the (i) date of the Competition Law Clearance or (ii) if the Parties
agree in accordance with Section 2.2 that no Competition Law Clearance is required, the Signing Date. 

  

	 	1.52	 “EMA” means the European Medicines Agency or any successor thereto. 

 

	 	1.53	 “Employees” shall have the meaning in Section 16.7.

  

	 	1.54	 “Employment Liabilities” means any Damages resulting from any Unexpected Transferring Employees as
well as any other liability, damage or loss and reasonable costs of legal defence due to or in connection with Applicable Laws or the (possible) violation or the termination of the employment of any Unexpected Transferring Employees.

  

	 	1.55	 “Exploit” means to undertake, or have undertaken, any or all of the following activities: to make,
import, use, sell, or offer for sale, Research, study, Develop, register, modify, enhance, improve, Manufacture, Commercialize, 

  
 10 

	 	 
hold or keep (whether for disposal or otherwise), formulate, optimise, use, export, transport, distribute, promote, market or otherwise dispose or offer to dispose of, a product or process.

  

	 	1.56	 “Exploitation” means the act of Exploiting a product or process. 

 

	 	1.57	 “Europe” or “EU” means the European Economic Area as it may be constituted from time
to time. 

  

	 	1.58	 “[***]”means [***].  

 

	 	1.59	 “EU Commercialization Budget” shall have the meaning assigned in Section 8.5.

  

	 	1.60	 “EU Commercialization Plans” shall have the meaning assigned in Section 8.5.

  

	 	1.61	 “FDA” means the United States Food and Drug Administration or any successor thereto.

  

	 	1.62	 “FFDCA” means the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301, et seq., as
amended from time to time. 

  

	 	1.63	 “Field” means the diagnosis, prevention, and treatment of oncology diseases and conditions in humans
or animals. 

  

	 	1.64	 “Filing Date” means, with respect to a submission to a Regulatory Health Authority, the date that
such submission is confirmed to have been received by the relevant Regulatory Health Authority. 

  

	 	1.65	 “First Commercial Sale” means, with respect to any Licensed Product, the first sale of such Licensed
Product for value by MedImmune, its Affiliate, or its Sublicensees to a Third Party after Regulatory Approval of such Licensed Product has been obtained by MedImmune, its Affiliates, or its Sublicensees; provided, however, that in no
event shall any sale or distribution of a Licensed Product for Pre-Approval Activities or use in a Clinical Trial or otherwise any sales prior to receipt of all Regulatory Approvals necessary to commence

  
 11 

	 	 
regular commercial sales (including so-called “treatment IND sales” and “compassionate use sales”) be deemed a First Commercial Sale.

  

	 	1.66	 “Formulation Patent” means the Licensed Patent listed in Schedule 1.66. 

 

	 	1.67	 “FTE” means a full time equivalent person year of [***] of scientific, technical or operational work
(excluding administrative services). 

  

	 	1.68	 “FTE Rate” means, for the period commencing on the Signing Date until such time as adjusted pursuant
to the following sentence or the Parties agree otherwise, [***] for all activities. The FTE Rate will be increased or decreased on each anniversary of the Signing Date by a percentage equivalent to the change over the preceding twelve month period
in the Consumer Price Index for Urban Wage Earners and Clerical Workers with respect to MedImmune and the index of salaries of the pharmaceutical industry published by LEEM with respect to Innate. The FTE Rate shall include costs of salaries,
benefits, supplies, travel, other employee costs, and supporting general and administration allocations. For clarity, the FTE Rate will not apply to any employee that performs activities related to manufacturing (excluding pharmaceutical development
activities conducted in accordance with the Development Plan), and any costs related to such employee will be included only to the extent consistent with the definition of Transfer Price. 

 

	 	1.69	 “GCP” or “Good Clinical Practices” means, to the extent applicable in the country
where Regulatory Approval is sought, the current standards for good clinical practices relating to clinical trials for pharmaceuticals, as set forth in the United States Code of Federal Regulations or ICH guidelines and applicable regulations, laws
or rules as promulgated thereunder, in each case as amended from time to time, and all other standards of good clinical practice as are required by any Regulatory Health Authority. 

 

	 	1.70	 “Generic Product” means with respect to a Licensed Product in a particular country any product
(i) that is sold in such particular country by a Third Party who is not a Sublicensee or a Distributor selling such product under authorization from MedImmune or its Affiliates, (ii) that has received Regulatory Approval necessary for sale
in such country, (iii) that (a) is 

  
 12 

	 	 
substantially the same as the Licensed Product in dosage form, strength, route of administration, quality and performance characteristics, and intended use or (b) has received Regulatory
Approval based on a reference to a Regulatory Approval of the Licensed Product held by MedImmune, its Affiliates, or Sublicensees, and (iv) that contains as an active ingredient the same compound or substantially the same compound (such as a
biosimilar) (or, solely for products that are described by subsection (iii)(b), an equivalent or biosimilar thereof), as is contained in such Licensed Product. 

 

	 	1.71	 “Global Commercialization Plan” shall have the meaning assigned in Section 8.2.

  

	 	1.72	 “GLP” or “Good Laboratory Practices” means good laboratory practices required under
the regulations set forth in 21 C.F.R. Part 58, as in effect during the Term, and the requirements thereunder imposed by the FDA, and the equivalent thereof in any jurisdiction. 

 

	 	1.73	 “GMP” or “Good Manufacturing Practice” means the principle of good manufacturing
practice in respect of medicinal products for human use and investigational medicinal products for human use as required by Applicable Laws and Requirements, including the laws of the European Community and Directive 2003/94/EC as well as any
national legislation implementing the aforesaid Directive and any relevant guidance relating thereto. 

  

	 	1.74	 “Governmental Body” means any: (i) nation, state, commonwealth, province, territory, county,
municipality, district or other jurisdiction of any nature; (ii) federal, state, local, municipal, foreign or other government; (iii) governmental or quasi-governmental authority of any nature (including any governmental division,
department, agency, commission, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or entity and any court or other tribunal); or (iv) self-regulatory organization (including the NASDAQ Global Market and the
NASDAQ Global Select Market). For the avoidance of doubt, Governmental Bodies includes Regulatory Health Authorities. 

  

	 	1.75	 “Government Official” means any Person employed by or acting on behalf of a

  
 13 

	 	 
Governmental Body, government-controlled entity or public international organization. 

  

	 	1.76	 “HSR Act” means the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended,
including all rules promulgated thereunder. 

  

	 	1.77	 “ICH” means the International Conference on Harmonization of Technical Requirements for Registration
of Pharmaceuticals for Human Use. 

  

	 	1.78	 “IFRS” means International Financial Reporting Standards, or the future equivalent of such reporting
standards, as consistently applied by the applicable Party in the manner used for external reporting. 

  

	 	1.79	 “IND” means an Investigational New Drug Application (as defined in the FFDCA and applicable
regulations promulgated thereunder by the FDA) or an equivalent application filed with or submitted to any Regulatory Health Authority, the filing of which is required for authorization to commence human clinical trials. 

 

	 	1.80	 “Indirect Taxes” means value added taxes, sales taxes, consumption taxes and other similar taxes.

  

	 	1.81	 “Industrial Competing Party” means a Person that is in the top [***] pharmaceutical companies in the
world measured by global sales of prescription drugs based on readily available data from an independent data source such as IMS and which clinically Develops or Commercialize a Competing Product or any product in the specifically directed to
components of the immune checkpoint targets and cell-based therapies supplementing the immune system. 

  

	 	1.82	 “Initial Study” shall have the meaning given in the Development and Option Agreement.

  

	 	1.83	 “Initial Supply” shall have the meaning assigned in Section 9.1. 

 

	 	1.84	 “Intellectual Property Rights” or “IPR” means Patents, trademarks, service marks,
trade secrets (including patentable inventions), trade names, registered 

  
 14 

	 	 
designs, design rights, copyrights (including rights in computer software), domain names, database rights and any rights or property similar to any of the foregoing in any part of the world,
whether registered or not, together with the right to apply for the registration of any such rights. 

  

	 	1.85	 “IPH2201” means the monoclonal antibody to NKG2A (i) as particularised in Schedule 1.85
(the “Current IPH2201”), or (ii) a molecule that binds to NKG2A containing the CDRs (Complimentary Determining Regions) of IPH2201 as noted in Schedule 1.85 and any derivative or fragment thereof and any formulation of
the foregoing. 

  

	 	1.86	 “Know-How” means all inventions, discoveries, data,
information (including scientific, technical or regulatory information), trade secrets, processes, means, methods, practices, formulae, instructions, procedures, techniques, materials, technology, results, analyses, designs, drawings, computer
programs, apparatuses, specifications, technical assistance, laboratory, pre-clinical and clinical data (including laboratory notes and notebooks), and other material or
know-how, in written, electronic or any other form, whether or not confidential, proprietary or patentable, including without limitation: development technology; biology, chemistry, pharmacology, toxicology,
drug stability, Manufacturing and formulation, test procedures, synthesis, purification and isolation techniques, quality control data and information, methodologies and techniques; information regarding clinical and
non-clinical safety and efficacy studies, including study designs and protocols, marketing studies, absorption, distribution, metabolism and excretion studies; assays and biological methodology.

  

	 	1.87	 “knowledge” means the good faith understanding of the officers of Innate and its Affiliates, with
respect to relevant facts and information after performing a commercially reasonable inquiry of the employees having responsibilities in Innate’s organisation with respect to the relevant subject matters and external patent agents of Innate and
its Affiliates with respect to such facts and information relating to the Licensed Patents, that the patent agent is responsible for prosecuting and maintaining. For purposes of the foregoing, Innate will not be deemed to have knowledge of any given
fact or information, which (i) was known or should have been known by any external patent agents 

  
 15 

	 	 
of Innate and its Affiliates but was not disclosed to Innate’s officers or (ii) was not known by the employees of Innate and its Affiliates. 

 

	 	1.88	 “Legal Proceeding” means any action, suit, litigation, arbitration, proceeding (including any civil,
criminal, administrative, investigative or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before, or otherwise involving, any court or other Governmental Body or any
arbitrator or arbitration panel. 

  

	 	1.89	 “Licensed Antibodies” means IPH2201 and all Back-Up Licensed
Antibodies. 

  

	 	1.90	 “Licensed Know-How” means all
Know-How which is Controlled by Innate or its Affiliates, as of the Effective Date or at any time during the term of this Agreement, that may be necessary or useful for the Research, Development,
Commercialization and/or Exploitation of any Licensed Antibody, Licensed Product or Combinations, including Study Results, but excluding in each case, any Know-How related to any active ingredient within a
Combination other than the Licensed Antibody. 

  

	 	1.91	 “Licensed Patents” means all of the Patents which are Controlled by Innate or its Affiliates, as of
the Effective Date or at any time during the Term, that (a) claim any Licensed Antibody, Licensed Product or Licensed Know-How or (b) claim any invention that is necessary or useful for the Research,
Development, Commercialization or Exploitation of any Licensed Antibody, Licensed Product or Combination, but excluding in each case, any (x) Patent related to any active ingredient within a Combination other than the Licensed Antibody and
(y) the Non-Exclusively Licensed Patents. For the avoidance of doubt, Licensed Patents includes the Listed Patents, the Novo Nordisk Patents and the Patents within the Arising IP when such Patents are
owned or co-owned by Innate pursuant to Section 12.2. 

  

	 	1.92	 “Licensed Shared Patents” means those listed Patents listed in Schedule 1.92, which refer to
NKG2A but also to other targets, as such schedule may be updated from time to time by agreement of the Parties. 

  

	 	1.93	 “Licensed Product” shall mean any and all pharmaceutical products including

  
 16 

	 	 
a Licensed Antibody as an active ingredient, including Combinations. 

  

	 	1.94	 “Licensed Technology” means all Licensed Patents and Licensed
Know-How. 

  

	 	1.95	 “Listed Patents” means the Patents listed in Schedule 1.95, and any Patents filed after the
Signing Date claiming priority to the Patents listed on Schedule 1.95, as such schedule may be updated from time to time by agreement of the Parties. 

  

	 	1.96	 “Major Market” means [***]. 

 

	 	1.97	 “Manufacture” or “Manufacturing” means activities in connection with the synthesis,
manufacture, processing, formulating, testing (including, without limitation quality control, quality assurance and lot release testing), bulk packaging, labeling or storage and delivery of Licensed Antibody or Licensed Product (including any
component thereof). 

  

	 	1.98	 “Manufacturing Costs” means the fully-burdened aggregate
Costs incurred and recorded by a Party (in accordance with IFRS) as a result of Manufacturing a Licensed Product or component thereof consisting solely of: 

(i) [***]; 
 (ii)
[***]; 
 (iii) [***]; 

(iv) [***]; 
 (v)
[***]; 
 (vi) [***]; 

(vii) [***]; 

(viii) [***]; and 

  
 17 

 (ix) [***]. 

[***]. 
  

	 	1.99	 “Material Anti-Corruption Law Violation” means a violation of an Anti-Corruption Law relating to the
subject matter of this Agreement which would, if it were publicly known, be reasonably expected to have an adverse effect on the Party committing such violation or on the reputation of the other Party because of its relationship with the Party
committing such violation. 

  

	 	1.100	 “Materials” means compounds, compositions of matter, assays, and biological materials useful for the
Exploitation of Licensed Antibodies or Licensed Products. 

  

	 	1.101	 “MedImmune Compound” means any small molecule, large molecule, antibody or other molecule or compound
that is Controlled by MedImmune or any of its Affiliates. 

  

	 	1.102	 “MedImmune Compound Arising IP” means any IPR arising after the Effective Date to the extent solely
relating to the MedImmune Compounds. 

  

	 	1.103	 “MedImmune Know-How” means
Know-How Controlled by MedImmune or its Affiliates at any time during the Term that may be necessary or useful for the Exploitation of any Licensed Antibody, Licensed Product or Combinations, including any
such MedImmune Compound Arising IP and Study Results. 

  

	 	1.104	 “MedImmune Patents” means all Patents (i) that are Controlled by MedImmune or its Affiliates as
of the Effective Date or that come into the Control of MedImmune or its Affiliates at any time during the Term, including Patents claiming MedImmune Compound Arising IP, and (ii) that claim any MedImmune Compound or any other inventions that
are necessary or useful for the Exploitation of any Licensed Antibody, Licensed Product or Combination, or that claim any Licensed Antibody, Licensed Product, Combination or Study Result. 

 

	 	1.105	 “MedImmune Technology” means MedImmune Know-How and MedImmune

  
 18 

	 	 Patents. 

  

	 	1.106	 “MedImmune Product Data” shall have the meaning assigned in Section 15.3(viii).

  

	 	1.107	 “MedImmune Triggered Termination” shall have the meaning assigned in Section 15.3.

  

	 	1.108	 “Net Sales” [***]. 

 

	 	1.109	 “NKG2A” means the human NKG2-Atype II integral membrane protein (also known as CD159
antigen-like family member A, NK cell receptor A, NKG2-A-activating NK receptor, or CD159a) and all isoforms, fragments or derivatives thereof (including homologs and
orthologs of the human sequence) including the protein described in Schedule 1.109.  

  

	 	1.110	 “Non-Exclusively Licensed Patents” means the Licensed Patents
listed in Schedule 1.110. 

  

	 	1.111	 “Novo Nordisk Patents” shall mean those patents licensed to Innate under an agreement with Novo
Nordisk A/S dated 28 March 2006 (as amended), being those patents owned by Novo Nordisk as listed in Schedule 1.95. 

  

	 	1.112	 “Other Promotional Activities” means both off line and online activities including but not limited
to, sales activities, other than Detailing, such as sales training, sales meetings; marketing activities such as advertising and promotion; and medical or scientific affairs activities such as conferences, speakers bureaus, and continuing medical
education activities; provided that all such activities shall be in accordance with the USFDA Office of Prescription Drug Promotion. 

  

	 	1.113	 “Patents” means (a) all national, regional and international patents and patent applications,
including provisional patent applications, (b) all patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including divisionals,
continuations, continuations-in-part, non-provisional 

  
 19 

	 	 
applications, and continued prosecution patent applications, (c) any and all patents that have issued or in the future issue from the foregoing patent applications ((a) and (b)), including
utility models, petty patents and design patents and certificates of invention, (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates, patent term extensions and the like) of the foregoing patents or patent applications (a), (b) and (c)), and (e) any similar
rights, including so-called pipeline protection, or any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any such foregoing patent applications
and patents. 

  

	 	1.114	 “Payments” shall have the meaning assigned in Section 10.26. 

 

	 	1.115	 “Person” means any individual, sole proprietorship, corporation, partnership, association,
joint-stock company, trust, unincorporated organization, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government. 

 

	 	1.116	 “Phase 1 Clinical Trial” means any clinical study conducted on human subjects [***].

  

	 	1.117	 “Phase 2 Clinical Trial” means any clinical study that is not intended to be used as a pivotal study
for purposes of seeking Regulatory Approval in any country within the Territory that is conducted on human patients [***]. 

  

	 	1.118	 “Phase 3 Clinical Trial” means any clinical study used as a pivotal study for purposes of seeking
Regulatory Approval, [***]. 

  

	 	1.119	 “Phase 4 Clinical Trial” means any clinical study of a pharmaceutical product on human subjects
commenced [***]. 

  

	 	1.120	 “Pre-Approval Activities” means all activities undertaken
with respect to a Licensed Product prior to First Commercial Sale and in preparation for the launch of such Licensed Product in the EU. Pre-Approval Activities shall include without limitation advertising,
education, product-related public relations, 

  
 20 

	 	 
health care economic studies, governmental affairs activities for reimbursement and formulary acceptance, sales force training, trademark selection, filing, prosecution, and enforcement, and
other activities included within the Global Commercialization Plan or (as applicable) EU Commercialization Plan prior to the First Commercial Sale of a Licensed Product. 

 

	 	1.121	 “Principal Investigator” means the person responsible for the conduct of a Clinical Trial at a
Clinical Trial site. 

  

	 	1.122	 “Product Information” shall have the meaning assigned in Section 11.2. 

 

	 	1.123	 “Product Trademark” shall have the meaning assigned in Section 12.16(i). 

 

	 	1.124	 “Profit/Loss” means the Net Sales of the Licensed Product in Europe less [***].

  

	 	1.125	 “Promotion” means solely for the purposes of this Agreement and notwithstanding any more general
meaning of the word “promote” in common parlance or as an industry term, means: 

  

	 	(i)	 the conduct of activities of the Parties to promote the use, prescription, dispensing, administration or sale of the
Licensed Products under the Licensed Product trademark in the Field in the Territory, for commercial purposes, all in accordance with the approved Licensed Product labelling information, including Detailing; and 

 

	 	(ii)	 Medical science liaison and Medical Education Activities related to the Licensed Products in the Field in the
Territory, 

 in each case in accordance with the applicable EU Commercialization Plan and having such activities
undertaken by an Affiliate or, to the extent permitted under this Agreement and in accordance with the terms of this Agreement, a Third Party. 

“Promote” shall have a corresponding meaning. For the avoidance of doubt,

  
 21 

	 	 
Promotion shall not include any Development activities. 

  

	 	1.126	 “Promotion Proposal” shall have the meaning assigned in Section 8.11. 

 

	 	1.127	 “Regulatory Approval” means any and all approvals (including without limitation pricing and
reimbursement approvals), product or establishment licenses, registrations, or authorizations of any regional, federal, state, or local Regulatory Health Authority, department, bureau, or other governmental entity, necessary to commercially
distribute, sell or market a Licensed Product in a regulatory jurisdiction, including, where applicable, (a) pricing or reimbursement approval in such jurisdiction if necessary or desirable, (b) pre-
and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto), and (c) labelling approval. 

 

	 	1.128	 “Regulations” means The Transfer of Undertakings (Protection of Employment) Regulations 2006 or any
equivalent laws in the applicable country. 

  

	 	1.129	 “Regulatory Documentation” means all applications, registrations, licenses, authorizations and
approvals, all correspondence submitted to or received from Regulatory Health Authorities (including minutes and official contact reports relating to any communications with any Regulatory Health Authority) and all supporting documents, including
documentation arising in the course of all Clinical Trials, in each case relating to obtaining or maintaining Regulatory Approval of Licensed Products, including all INDs, regulatory drug lists, advertising and promotion documents, adverse event
files and complaint files. 

  

	 	1.130	 “Regulatory Exclusivity” shall mean any exclusive marketing rights or data exclusivity rights
conferred by any applicable Regulatory Health Authority, other than an issued and unexpired Patent, including any regulatory data protection exclusivity (including, where applicable, pediatric exclusivity or orphan drug exclusivity) or any other
exclusivity afforded by restrictions which restrict the granting by a Regulatory Health Authority of Regulatory Approval to market a Generic Product. 

  

	 	1.131	 “Regulatory Health Authority” means any applicable national (for example,

  
 22 

	 	 
FDA or Japan’s Pharmaceuticals and Medical Devices Agency), supranational (for example, the EMA), regional, state, provincial or local regulatory health authority, department, bureau,
commission, council, or other government entity regulating or otherwise exercising authority with respect to the Exploitation of Licensed Antibodies or Licensed Products in the Territory, including any such entity involved in the granting of
Regulatory Approval for pharmaceutical products. 

  

	 	1.132	 “Research” means the discovery, identification, research, characterisation, modification,
derivatisation, optimisation and preclinical testing of pharmaceutical products. 

  

	 	1.133	 “Safety Agreement” shall have the meaning assigned in Section 4.24. 

 

	 	1.134	 “Sales Collaboration Committee” or “SCC” means the committee described in
Section 8.6. 

  

	 	1.135	 “Senior Executives” means (i) [***] and (ii) [***]. A Party shall be entitled, effective upon written
notice thereof to the other Party, to designate one of its other representatives having equivalent seniority and experience to replace such foregoing representative as that Party’s Senior Executive for the purpose of this Agreement.

  

	 	1.136	 “Serious Adverse Event” means any untoward medical occurrence that at any dose results in death, is
life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect (CPMP/ICH/377/95). Serious Adverse Event includes
any event affecting patient safety that Applicable Law requires reporting to a Regulatory Health Authority. 

  

	 	1.137	 “Signing Date” means the date of the exercise of the Option by MedImmune pursuant to the Development
and Option Agreement. 

  

	 	1.138	 “Specification” means the specification applicable to the Manufacture, packaging, labelling and
storage of any Licensed Antibody or Licensed Products, in effect at a given time. 

  
 23 

	 	1.139	 “Statistical Analysis Plan” shall have the meaning assigned in Section 4.11.

  

	 	1.140	 “Study Results” means any data and information generated as a result of the Clinical Trials performed
as part of the Development Plan. 

  

	 	1.141	 “Sublicensee” shall have the meaning assigned in Section 3.2. 

 

	 	1.142	 “Tax” or “Taxation” means any form of tax or taxation, levy, duty, charge, social
security charge, contribution or withholding of whatever nature (including any related fine, penalty, surcharge or interest) imposed by, or payable to, a Tax Authority. 

 

	 	1.143	 “Tax Authority” means any Governmental Body authorized to levy Tax. 

 

	 	1.144	 “Term” shall have the meaning assigned in Section 15.1. 

 

	 	1.145	 “Territory” means the world. 

 

	 	1.146	 “Third Party” means any Person other than Innate or MedImmune, or their respective Affiliates.

  

	 	1.147	 “Third Party Agreements” shall mean those agreements listed in Schedule 1.147.

  

	 	1.148	 “Third Party Claims” shall have the meaning assigned in Section 16.2. 

 

	 	1.149	 “Third Party Payments” shall have the meaning assigned in Section 10.20. 

 

	 	1.150	 “Transfer Price” means the Manufacturing Cost of the transferred Licensed Antibody or Licensed
Product. 

  

	 	1.151	 “Triggered Termination” means, as the context requires, either a MedImmune Triggered Termination or
(ii) termination by MedImmune for Innate’s uncured material breach pursuant to Section 15.1(i) or Innate’s insolvency pursuant to Section 15.2(iii). 

  
 24 

	 	1.152	 “Unexpected Transfer Employee” shall have the meaning set out in Section 16.7.

  

	 	1.153	 “Valid Claim” means a claim of an issued and unexpired patent or pending patent application within
the Licensed Patents that has not been held unpatentable, invalid, or unenforceable by a court or other government agency of competent jurisdiction in an unappealed or unappealable decision or has not been admitted to be invalid or unenforceable
through reissue, re-examination, disclaimer, or otherwise. Notwithstanding the foregoing, if a claim of a pending patent application has not issued as a claim of a patent within [***] after the filing date,
such claim shall not be a Valid Claim for the purposes of this Agreement, unless and until such claim issues as a claim of any issued patent (from and after which time the same would be deemed a Valid Claim subject to the first sentence of the
definition above). 

  

	 	1.154	 “Written Disclosure” shall have the meaning assigned in Section 14.3. 

 

	2	 CONSTRUCTION; COMPETITION LAW CLEARANCE 

 

	 	2.1	 Except where the context requires otherwise, whenever used the singular includes the plural, the plural includes the
singular, the use of any gender is applicable to all genders and the word “or” has the inclusive meaning represented by the phrase “and/or”. Whenever this Agreement refers to a number of days, unless otherwise specified, such
number refers to calendar days. The headings of this Agreement are for convenience only and do not define, describe, extend or limit the scope or intent of any provision in this Agreement. The term “including” or “includes” as
used in this Agreement means including, without limiting the generality of any description preceding such term. The wording of this Agreement shall be deemed to be the wording mutually chosen by the Parties and no rule of strict construction shall
be applied against any Party. 

  

	 	2.2	 No later than five (5) Business Days following the Signing Date or such later date as the Parties may agree, the
Signing Date, the Parties shall jointly determine whether a filing under the HSR Act or any equivalent competition law statute or regulation (a “Competition Law Filing”) is required for the performance of

  
 25 

	 	 
this Agreement. Upon a joint determination that one or more Competition Law Filings are required, the Parties shall prepare and submit the required notification forms as soon as reasonably
practicable (and for any filing under the HSR Act within ten (10) Business Days after such determination) and use reasonable efforts to obtain clearance for the transactions contemplated hereunder as soon as practicable. Subject to Applicable
Law relating to the exchange of information, MedImmune shall have the right to direct all matters with respect to Competition Law Filings hereunder, consistent with its obligations hereunder, after consultation with Innate. Each Party will consult
with the other on, and consider in good faith the views of the other Party in connection with, all of the information relating to such other Party that appears in any Competition Law Filing.    MedImmune shall bear all fees in
connection with any Competition Law Filing and each Party shall bear their respective attorneys’ fees in connection therewith. This Agreement shall bind the Parties upon execution and continue in full force and effect unless and until the
termination or expiration of the Agreement by its terms, provided, however, that each Party’s grant of license rights hereunder, MedImmune’s obligation to make the payments hereunder, and the Parties’ other rights and obligations
hereunder in connection with the Development and Commercialization of the Licensed Antibodies and Licensed Products shall not become effective unless and until the date of either: 1) the receipt of all Competition Law Clearances or 2) the conclusion
by the Parties pursuant to this Section 2.2 that no Competition Law Clearance is necessary for the implementation of this Agreement. Nothing in this Agreement shall require or be deemed to require either Party (or their Affiliates) to commit to
any divestitures or licenses or agree to hold separate any assets or agree to any similar arrangements or commit to conduct its business in a specified manner, or to submit and respond to a formal discovery procedure initiated by the FTC or DOJ
(i.e., a “Request for Additional Information and Documentary Materials” also known as a “second request”, or Civil Investigative Demand if a filing is not required under the HSR Act), in each case as a condition to obtaining
antitrust clearance for the transactions contemplated hereunder. If Competition Law Clearance is not received in relation to both this Agreement and the Development and Option Agreement on or before ninety (90) days after the date on which both
Parties have submitted to the FTC and DOJ their respective initial filings to request Competition Law Clearance of the transactions hereunder, then either Party 

  
 26 

	 	 
shall have the right to terminate this Agreement without liability therefor at any time thereafter, but prior to receipt of Competition Law Clearance of the transactions contemplated hereunder,
by written notice to the other Party. If Competition Law Clearance is obtained by the Parties in relation to this Agreement prior to the Signing Date this Section 2.2 shall have no effect and the Signing Date and Effective Date shall be the
same date. 

  

	3	 GRANT OF RIGHTS AND LICENSES; EXCLUSIVITY  

 

	 	3.1	 Exclusive License to MedImmune. Subject to the terms of this Agreement, Innate grants to MedImmune and its
Affiliates: 

  

	 	(a)	 an exclusive (including with regard to Innate and its Affiliates, except with respect to the retained rights set forth
in Section 3.5 below) right and license under the Licensed Technology to Develop, Manufacture and Commercialize Licensed Antibodies and Licensed Products in the Field in the Territory; 

 

	 	(b)	 a non-exclusive right and sublicense, under the
Non-Exclusively Licensed Patents, to the extent necessary to Develop, Manufacture and Commercialize Licensed Antibodies and Licensed Products in the Field in the Territory; and 

 

	 	(c)	 an exclusive (including with regard to Innate and its Affiliates, except with respect to the retained rights set forth
in Section 3.5 below), right and license and right of reference in the Territory under Innate’s and its Affiliates’ rights, titles and interests in and to the Regulatory Documentation, INDs and Regulatory Approvals, to all other
clinical and preclinical data and results contained in the Licensed Know-How, to Develop, Manufacture and Commercialize the Licensed Antibodies and Licensed Products in the Field in the Territory.

 MedImmune shall be responsible for its Affiliates compliance with the terms of this Agreement as if MedImmune
hereunder. 
  

	 	3.2	 Sublicenses. Subject to Section 3.4, MedImmune and its Affiliates shall have

  
 27 

	 	 
the right to grant sublicenses, through multiple tiers of sublicenses, under the licenses granted under Section 3.1, to any other Person other than a Person Exploiting a Competing Product,
provided that, in the event of a sublicense to anyone other than a MedImmune Affiliate, MedImmune shall provide Innate with at least [***] prior written notice and any such sublicense shall be consistent with the provisions of this Agreement. Where
MedImmune or its Affiliates grants such sublicense to a Person that is not an Affiliate of MedImmune, and such Person is not a Distributor, such Person shall be a “Sublicensee” for the purposes of this Agreement, and any Person to
which a Sublicensee grants a further sublicense shall also be a Sublicensee; provided, however, that any Person that (i) is granted a sublicense under the license granted to MedImmune and its Affiliates pursuant to
Section 3.1 solely to enable such Person to provide contract research or development services or contract manufacturing services for MedImmune, its Affiliates or Sublicensees, and (ii) does not have the right to distribute, market or sell
the Licensed Products, shall not be a “Sublicensee” for purposes of this Agreement. MedImmune, its Affiliates and its Sublicensees shall ensure that all Persons to which they grant sublicenses comply with all relevant terms and
conditions of this Agreement. 

  

	 	3.3	 Distributorships. Subject to Innate’s rights under the Co-Promote
Option, MedImmune and its Sublicensees shall have the right, in their sole discretion, to appoint any other Persons, in the Territory or in any country of the Territory, to distribute, market and sell the Licensed Products, with or without
packaging rights. In circumstances where such appointed Person purchases its requirements of Licensed Products from MedImmune, its Affiliates or its Sublicensees, but does not otherwise make any royalty or other payment to MedImmune, its Affiliates
or its Sublicensees with respect to Intellectual Property Rights, and where such Person is not an Affiliate of MedImmune and neither MedImmune nor any of its Affiliates or Sublicensees shares in the profits from, or has an equivalent interest in the
proceeds from, the sale of Licensed Products by such Person, that Person shall be a “Distributor” for purposes of this Agreement. The term “packaging rights” in this Section 3.3 means the right for the Distributor to
package Licensed Products supplied in unpackaged bulk form into individual ready-for-sale packs. MedImmune shall remain liable for any action or failure to act by the
Distributor that would constitute a breach of this Agreement as if such action or failure were committed by MedImmune. 

  
 28 

	 	3.4	 Co-Promotion Rights. MedImmune and its Affiliates shall have the right,
in their sole discretion, to co-promote the Licensed Products with any other Person(s), or to appoint one or more Third Parties to promote the Licensed Products without MedImmune in all or any part of the
Territory outside of [***] for which Section 8 shall apply. 

  

	 	3.5	 Rights Retained by Innate. Notwithstanding the foregoing, Innate retains the right under the Licensed
Technology to (i) conduct the Development activities that may be assigned to be performed by Innate under the Development Plan; (ii) Manufacture or have Manufactured the Licensed Product in satisfaction of its obligations under
Section 9; (iii) following the exercise of the Co-Promote Option, promote the Co-Promote Product in [***] subject to Section 8; (iv) conduct any other
activities expressly assigned to Innate by the DCC under this Agreement or as the Parties may otherwise mutually agree (collectively, the activities referred to in (i) to (iv) are the “Assigned Activities”); and (v) to
Exploit the Licensed Technology to Research, Develop and Commercialize Licensed Products outside the Field, subject to the provisions of Section 3.17. Furthermore, Innate retains all rights under the Licensed Shared Patents with respect to all
activities not related to Research, Development, Commercialisation or Exploitation of Licensed Products or any Competing Product, and/or all activities related to antibodies that bind KIR2DL1, -2 and/or -3. 

  

	 	3.6	 Covenant not to Sue. MedImmune shall not, and shall procure that its Affiliates and Sublicensees shall not,
anywhere in the world, institute or prosecute (or in any way aid any Third Party in instituting or prosecuting), at law or in equity, any claim, demand, action or cause of action for damages, costs, expenses or compensation, or for an enjoinment,
injunction, or any other equitable remedy, against Innate alleging the infringement of any MedImmune Technology by Innate due to Innate’s performance of the Assigned Activities or its rights in compliance with this Agreement. For the avoidance
of doubt, the covenant not to sue set forth in this Section 3.6 shall not apply in respect of any activities conducted by or on behalf of Innate or its Affiliates in conflict with this Agreement. 

 

	 	3.7	 No Implied Rights. This Agreement confers no right, license, or interest by

  
 29 

	 	 
implication, estoppel, or otherwise under any Patents, Know-How, or other Intellectual Property Rights of either Party except as expressly set forth in
this Agreement. Each Party hereby expressly retains and reserves all rights and interests with respect to Patents, Know-How, or other Intellectual Property Rights not expressly granted to the other Party
hereunder. 

  

	 	3.8	 No Encumbrance. During the Term, Innate shall not assign, transfer, convey or otherwise encumber its rights to
the Licensed Technology, or Regulatory Approvals, and shall not use any of the foregoing itself or grant any right, title or interest therein with respect to the Licensed Product in the Field to any Person, in all cases in a manner that is
inconsistent with the exclusive licenses or other rights granted to MedImmune under this Agreement. 

  

	 	3.9	 Exclusivity Term. MedImmune’s exclusive licenses granted under Section 3.1, shall expire [***]. Upon
expiry of MedImmune’s exclusive licenses [***]. 

  

	 	3.10	 Assignment of Regulatory Documentation. MedImmune or its nominated Affiliate shall be the lead regulatory party
and hold all Regulatory Documentation and Regulatory Approvals relating to Licensed Products. Innate hereby assigns to MedImmune all of its rights, titles and interests in and to all Regulatory Documentation, including, to the extent permitted by
Applicable Laws, all INDs and Regulatory Approvals Controlled by Innate or its Affiliates as of the Effective Date and from time to time during the Term that relate to the Licensed Antibodies or Licensed Products. Innate shall duly execute and
deliver, or cause to be duly executed and delivered such instruments and shall do and cause to be done such acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary to complete such
assignment, or as MedImmune may reasonably request in connection therewith, or to carry out more effectively the purpose thereof, or to better assure and confirm to MedImmune its rights under this Section 3.10, at MedImmune’s cost and
expense. 

  

	 	3.11	 Confirmatory Patent Licenses. Innate shall, if requested to do so by MedImmune, immediately enter into short
form confirmatory license agreement(s) in the form or substantially the form set out in Schedule 3.11 for purposes of (i) recording the licenses granted under this Agreement with such

  
 30 

	 	 
Patent authorities in the Territory as MedImmune considers appropriate or (ii) otherwise being able to demonstrate the existence of the licenses granted to MedImmune under this Agreement to
relevant authorities, including courts and other bodies, where required without having to disclose this Agreement in its entirety. Until the execution of any such confirmatory licenses, so far as may be legally possible, Innate and MedImmune shall
have the same rights in respect of the licenses granted under this Agreement and be under the same obligations to each other in all respects as if such confirmatory licenses had been executed. 

Non-compete and Restrictive Covenants 

 

	 	3.12	 The words “Develop” and “Commercialize” and all variations thereof included in the below Sections
3.13 to 3.16 with reference to Competing Products shall include the activities described in the definitions of such words in Section 1, but with such activities being with respect to Competing Products rather than with respect to Licensed
Product as set forth in the definition. 

  

	 	3.13	 During the period starting on the Effective Date and continuing until the earlier to occur of (i) [***] and (ii)
[***](such period, “Covenant Period 1”), neither Party nor any of its Affiliates (each, a “Restricted Party”) shall, either by itself or through a Third Party, except as otherwise expressly permitted in this Agreement,
conduct any research or Development in respect of any Competing Product. 

  

	 	3.14	 During the period starting on the Effective Date and continuing until [***] (such period, “Covenant Period
2”), no Restricted Party shall, either by itself or through a Third Party, except as otherwise expressly permitted in this Agreement, Commercialize any Competing Product in the Territory; provided that if this Agreement is
terminated as a result of such Restricted Party’s Triggered Termination, then for the purpose of this Section 3.14, Covenant Period 2 shall expire on the first to occur of (i) [***] and (ii) [***]. 

 

	 	3.15	 Notwithstanding the foregoing, a Restricted Party’s’ direct or indirect acquisition by/of, or merger with,
in whole or in part, a Person (or group of companies) or the business of a Person (or group of companies) having any activity contravening the covenants set forth above in Sections 3.13 and 3.14,

  
 31 

	 	 
shall not constitute a breach of such covenants, if: 

  

	 	(a)	 within [***] following the closing of such acquisition or merger transaction, the Restricted Party shall provide the
other Party with written notice of such transaction and the nature and stage of development of the Competing Product. The Parties will discuss in good faith whether it will be mutually beneficial that the Competing Product be included in their
collaboration and the related terms. 

  

	 	(b)	 If the Restricted Party is Medimmune, if the Competing Product has [***], and the Parties cannot reach an agreement
pursuant to sub-Section (a) within [***] of the closing of the acquisition or merger transaction, then Medimmune shall notify Innate of its intention to either to either (i) divest of the relevant
part of the Competing Product business or (b) terminate this Agreement. In such event, if MedImmune has elected to divest the Competing Product business, MedImmune (or, as the case may be, MedImmune shall cause its relevant Affiliate to)
diligently pursues the sale or transfer to a Third Party of such business, and enter into (or, as the case may be, cause its relevant Affiliate to enter into) a binding definitive agreement with a Third Party for such sale or transfer no later than
[***] after the closing of the acquisition or merger transaction under which the relevant business was acquired. If the Competing Product has [***], then, the provisions of this subclause (b) shall apply, mutatis mutandis, from the day
on which Medimmune or its Affiliates decides to [***] with respect to such Competing Product and the reference date for computing the [***] and the [***] timelines shall be the date of such decision. Until consummation of the sale of transfer of the
business relating to a Competing Product, for purposes of determining MedImmune’s diligence obligations under Sections 4.12 - 4.17, MedImmune’s Commercially Reasonable Efforts shall not take into account the existence of another MedImmune
development program for a Competing Product, the Licensed Product’s competitive position with respect to such Competing Product, the relative profitability of the Competing Product or any other factors relating to such Competing Product.

  
 32 

	 	(c)	 If the Restricted Party is Innate, the DCC and other committees should be dismantled and, if MedImmune so requests,
Innate shall cease to have an active role in the Development and Co-Promotion of the Licensed Product, provided that Innate shall retain its right to co-fund the
Development of the Licensed Product and, if Innate does not provide its Co-Funding Withdrawal Notice, to share the Profit in accordance with Section 10.21. 

 

	 	(d)	 The Restricted Party shall take appropriate steps and actions necessary (including by following commercially
reasonable policies and procedures that are no less stringent than those customarily followed in the pharmaceutical industry when establishing firewalls) to ensure that, as applicable, there is no, direct or indirect, as applicable, disclosure,
sharing or other use of any information obtained or discussed in connection with the Licensed Product and the Competing Product program. 

  

	 	3.16	 The Parties agree that the restrictions contained in these Sections 3.13 to 3.15 are reasonable and necessary for the
protection of the other Party’s and its’ Affiliates’ respective Confidential Information and business and investment in the Licensed Products, that such restrictions are reasonable in all the circumstances and that the Parties would
not have entered into this Agreement without the protections afforded to them under these Sections 3.13 to 3.15. 

  

	 	3.17	 Innate grants to MedImmune a first right to negotiate terms pursuant to which MedImmune’s rights under this
Agreement could be expanded to include all fields of use in humans and animals outside the Field. MedImmune shall be entitled to exercise this right of first negotiation at any time during the term of this Agreement by written notice to Innate
(“ROFN Notice”). If MedImmune serves an ROFN Notice the Parties will negotiate in good faith for a period of [***] following the date of the ROFN Notice the terms of such and expanded agreement. Innate shall not, and shall ensure
that its Affiliates shall not, sell, transfer, assign, out-license, encumber or otherwise grant or offer any rights to (in whole or in part) the Licensed Technology in any field outside the Field without first
offering to MedImmune the right to negotiate terms in accordance with this Section 3.17. 

  
 33 

	4	 DEVELOPMENT  

 

	 	4.1	 The purpose of the collaboration undertaken by the Parties under this Agreement (“Collaboration”) is
for the Parties to collaborate in the development of Licensed Products in the Field in the Territory and for the Parties to share in certain costs and revenues related to the Licensed Products, as described in more detail herein. The Parties desire
to establish the following committees to oversee the Collaboration and to provide a forum for discussion of matters relating to the Collaboration: Joint Project Team, Development Collaboration Committee and Sales Collaboration Committee.

 Initial Studies under the Development and Option Agreement 
  

	 	4.2	 Notwithstanding Section 4.1, if MedImmune exercises the Option before the final Initial Study has been completed
(i.e., before the final study report for such Clinical Trial is completed and approved in accordance with Innate’s quality assurance procedures), Innate shall use Commercially Reasonable Efforts, at its cost in accordance with the Development
Plan (as such terms are defined in the Option Agreement), regardless of its receipt of an Option Notice within the Option Period, continue or commence, as applicable, all of the Initial Studies or any part of them, in accordance with the provisions
of Section 3 of the Development and Option Agreement as if the Option had not been exercised, provided that MedImmune may, subject to Applicable Law, elect to assume the responsibilities and obligations of Innate in relation to the Initial
Studies in which case the provisions of Section 4.4 will apply. 

  

	 	4.3	 In the event that MedImmune exercises the Option as a result an S/R Notice, except to the extent, and for as long as,
otherwise required under Applicable Laws or otherwise to protect the safety, health or well-being of any patient, upon its receipt of an Option Notice within the Option Period in accordance with the Development and Option Agreement, Innate shall
discontinue any then remaining Initial Studies and any part of them at MedImmune’s request. MedImmune may elect to assume the responsibilities and obligations of Innate in relation to the Initial Studies, and any such Initial Studies shall be
conducted at Innate’s cost in accordance with the Development Plan (as such term is defined in the Option Agreement). 

  
 34 

	 	4.4	 In the event that, following exercise of its Option before the final Initial Study has been completed, MedImmune makes
an election to take control of the Initial Studies, (i) the Parties will agree in good faith a detailed plan for transitioning such responsibilities and obligations from Innate to MedImmune, including estimated timelines for such activities,
and shall use Commercially Reasonable Efforts in carrying out such transition plan, (ii) MedImmune will keep Innate regularly informed about the progress and results of the Initial Studies through the DCC, (iii) both Parties shall take
such actions as may be reasonably required or useful to ensure a smooth and orderly transition of the Initial Studies to MedImmune, and (iv) the Parties shall cooperate in good faith to prepare as promptly as possible after the Effective Date
all filings and other actions required by Applicable Laws to be made and taken in order to commence and conduct the Development of Option Products. All such filings and actions shall be approved in advance by MedImmune and be made and taken by or on
behalf of MedImmune. 

 Development Plan and Development Budget  

 

	 	4.5	 The Development of the Licensed Products shall be governed by a global Development Plan, which includes development
plans approved by the DCC as set forth in this Section 4, and costs and expenses relating to the Development of Licensed Products shall be governed by a development budget approved by the DCC and set forth in the Development Plan
(“Development Budget”). The Development Budget shall be broken down by Clinical Trials or other activities and by Calendar Quarter. Within [***] after the Effective Date, the parties, acting through the DCC, shall review and approve
a Development Plan and Development Budget. The Development Plan will include, among other things, (i) the initial indication(s) for which the Licensed Product is planned to be Developed, (ii) other indications for which the Licensed
Product may be developed, (iii) the proposed overall program of Development for the Licensed Product for any indications elected by MedImmune in each applicable Major Market, and any other applicable countries, including without limitation all
material nonclinical studies, toxicology, pharmacology studies, formulation, process development, CMC, clinical studies, and regulatory plans and other main elements of obtaining Regulatory Approval in each applicable Major Market, and any other
applicable country, (iv) critical activities anticipated to 

  
 35 

	 	 
be undertaken, estimated timelines, decision points and relevant decision criteria, and (v) allocation of responsibilities between the Parties for the various activities to be undertaken
under the Development Plan and estimated timelines; all based on what can reasonably be foreseen and planned at the time of preparation of the Development Plan. MedImmune shall review and submit an updated Development Plan and Development Budget to
the DCC for approval at least annually during the Development Term. 

  

	 	4.6	 The Development Plan and Development Budget shall also include the (i) allocation of Development and regulatory
activities between the Parties on a country-specific or activity-specific basis, taking into consideration all relevant factors (including the strategic objectives and capabilities of each Party) and (ii) those activities in relation to which
operational responsibility should be held by either MedImmune or Innate. 

  

	 	4.7	 The Parties may, at any time, produce and submit to the DCC for comment a revised Development Plan and Development
Budget in accordance with this Section 4. While the DCC is in effect, the DCC shall approve the Development Plan and Development Budget, and any revised Development Plan and Development Budget. 

Development Lead 
  

	 	4.8	 MedImmune shall take the lead in Developing the Licensed Products, with Innate performing such activities as may be
allocated to it under the Development Plan. Each Party shall have primary responsibility for day-to-day activities and decisions relating to such Party’s allocated
responsibilities, provided that such activities and decisions are consistent with the Development Plan and the authority granted to such Party thereunder. 

Performance of Development Plan and Reporting 
  

	 	4.9	 During the Development Term, each Party will report on the Development activities, if any, undertaken by it in
accordance with the Development Plan at each meeting of the DCC or at such other intervals as may be set forth in the Development Plan. Whether provided during the period the DCC is in effect, or

  
 36 

	 	 
thereafter, the Development reports shall include a reasonably detailed summary of all results, data and material inventions and Know-How, if any, obtained
from such Development activities. In addition, each Party will, at its own expense, make appropriate scientific and regulatory personnel available to the other Party, either by telephone or in person as the Parties may mutually agree, as reasonably
required to keep the other Party informed of Development activities conducted by such Party. Innate shall provide MedImmune with (i) access, upon MedImmune’s request, to all raw data and individual datasets obtained in relation to the
Assigned Activities from such time when such data becomes available to Innate; (ii) the Study Results – as outlined in the relevant Statistical Analysis Plan within [***] after database lock of the respective study; and (iii) the
relevant final report within [***] after database lock of the respective study. For the purpose of this Agreement “Statistical Analysis Plan” means a document that is prepared for the purpose of a Clinical Trial, that is approved by the
DCC and that pre-specifies the statistical analyses to be performed (statistical methods, endpoint definitions, analysis sets and principles for the handling of missing data) and how the results from the
relevant Clinical Trial will be presented. 

  

	 	4.10	 Each Party shall provide all Clinical Trial results to the DCC in draft form as soon as reasonably practicable and
shall provide each final report to the DCC, within [***] after finalization of the Clinical Trial report. 

  

	 	4.11	 Each Party will have the right to use its Affiliates or Third Parties to perform Development activities allocated to
it under the Development Plan, provided that any Affiliate or Third Party retained by Innate for such purpose that is not listed in Schedule 4.11(a) (as such Schedule may be amended by the DCC from time to time after the Effective Date) shall
first have been approved by MedImmune, such approval not to be unreasonably withheld, and further provided that Innate will use Commercially Reasonable Efforts to obtain agreement by the Third Parties listed on Schedule 4.11(a) to comply with the
MedImmune Code of Conduct (as set forth in the website set forth in Schedule 4.11(b)) within [***] after the Effective Date, and Innate shall confer with the DCC if it is unable to obtain such agreement by any such Third Party.

 Diligence  

  
 37 

	 	4.12	 MedImmune shall use Commercially Reasonable Efforts to (i) continue Development of each Licensed Product in
respect of which clinical Development has been initiated and (ii) Develop and obtain Regulatory Approval for each such Licensed Product at least in each country of the Major Markets and [***]. 

 

	 	4.13	 The responsible Party (as set forth in each Development Plan) shall use Commercially Reasonable Efforts to Manufacture
or have Manufactured Licensed Antibody and Licensed Product for use in the Development and Commercialization thereof in accordance with Section 9. 

  

	 	4.14	 Upon approval of a Drug Approval Application in each of [***], (i) if pricing and reimbursement approval is not
necessary in any country in such jurisdiction, MedImmune shall use Commercially Reasonable Efforts to achieve First Commercial Sale of such Licensed Product in such country(ies) within [***] after approval of the Drug Approval Application, or
(ii) if pricing and reimbursement approval is necessary in such jurisdiction, MedImmune shall use Commercially Reasonable Efforts to obtain such pricing and reimbursement approval in such country(ies) as soon as possible, and shall use
Commercially Reasonable Efforts to achieve First Commercial Sale in such country(ies) within [***] after receipt of pricing and reimbursement approval. 

  

	 	4.15	 MedImmune shall use Commercially Reasonable Efforts to Commercialize Licensed Products in at least each country of the
Major Market [***]. Subject to its exercise of the Co-Promote Option, Innate shall use Commercially Reasonable Efforts to Co-Promote the
Co-Promote Licensed Product in [***]. 

  

	 	4.16	 MedImmune shall perform, or cause its Affiliates or Third Party contractors to perform, its responsibilities under
this Agreement, and Innate shall perform, or cause its Affiliates or Third Party contractors to perform, the Assigned Activities, in each case, in compliance with this Agreement and all Applicable Laws. For the avoidance of doubt, MedImmune shall
not be obligated to obtain Regulatory Approvals for, or Commercialize, a Licensed Product which has not been the subject of a Development Plan. 

  

	 	4.17	 Each Party shall use Commercially Reasonable Efforts to complete its Development activities in accordance with the
Development Plan. With respect 

  
 38 

	 	 
to each Clinical Trial, each Party shall (i) cause the relevant Principal Investigators, relevant study sites and any contractors involved in the performance of such study to conduct the
respective study in accordance with this Agreement, including the provisions set out in this Section 4.17, and (ii) shall, and shall cause the relevant Principal Investigators, relevant Clinical Trial study sites and any contractors
involved in the performance of the Clinical Trial to, comply with all safety reporting procedures set forth in the Safety Agreement in connection with its performance of such studies. 

 

	 	4.18	 A Party shall not be liable for any failure to comply with its obligations under this Agreement to the extent caused
by a breach by the other Party of its obligations hereunder and provided that the non-breaching Party shall use Commercially Reasonable Efforts to mitigate such situation. 

Back-Up Licensed Antibodies 

 

	 	4.19	 Either Party may propose that the Development Plan should include the Development of a
Back-Up Licensed Antibody. The Parties will discuss any such proposal in good faith and in particular whether Innate should bear [***] of the Development Costs associated with Developing such a Back-Up Licensed Antibody and the revised financial terms applicable to any Licensed Product containing such a Back-Up Licensed Antibody to replace those set out in
Section 10. If Innate does not want to co-fund the Development Costs of such a Back-Up Licensed Antibody, MedImmune shall be entitled to Develop such Back-Up Licensed Antibody on its own and shall bear all associated Development Costs. The Parties will negotiate in good faith for a period of [***] the financial terms applicable to any Licensed Product containing
such a Back-Up Licensed Antibody to replace those set out in Section 10. A failure by the Parties to reach agreement on such terms shall not preclude MedImmune from developing or commercializing a Back-Up Licensed Antibody or from otherwise exercising the rights and licenses granted to it by Innate under this Agreement. However, in the event of a failure by the Parties to reach such agreement within the
aforementioned [***] period or any extension of such period mutually agreed by the Parties or otherwise in the event of a dispute as to the financial terms for such a Back-Up Licensed Antibody, each Party
shall be entitled to escalate the matter in accordance with Section 17.2 and, if applicable, to refer the matter 

  
 39 

	 	 
to arbitration in accordance with Section 17.3. 

Transition 
  

	 	4.20	 Following the Effective Date, the Parties will promptly meet to coordinate the transition of Development and
regulatory activities from Innate, its Affiliates or Third Parties to MedImmune, its Affiliates or its designated Third Parties in a manner so as not to unduly delay or hamper the Development of Licensed Products. The Parties will agree a detailed
transition plan which plan will set out in detail the activities to be undertaken, the Party responsible for the activity and an estimated timeframe for the completion of the activity. Unless otherwise agreed, the Parties will each bear their own
costs associated with carrying out the activities in the transition plan. Without prejudice to the foregoing, each Party shall at its cost do all things required in order to achieve a smooth transfer of the Development of the Licensed Products to
MedImmune as a quickly as possible following the Effective Date. 

  

	 	4.21	 The Parties shall cooperate in good faith to prepare as promptly as possible after the Effective Date all filings and
other actions required by Applicable Laws to be made and taken in order to commence and conduct the Development. All such filings and actions shall be approved in advance by MedImmune and be made and taken by or on behalf of MedImmune.

 Manufacturing 
  

	 	4.22	 Innate shall use Commercially Reasonable Efforts to maintain in full force and effect all agreements with contract
manufacturing organisations and Third Parties undertaking Clinical Trials and studies on its behalf, in both cases in relation to the Licensed Antibodies, in place as at the Effective Date and shall not act or fail to act in manner which it knows or
should reasonably anticipate may lead to termination or material breach of such agreements. If requested by MedImmune and consistent with the Development Plan, Innate will use Commercially Reasonable Efforts to permit MedImmune to purchase Licensed
Antibody pursuant to such agreements. 

  
 40 

 Supply of Materials for Development 

 

	 	4.23	 In the event that it becomes reasonably necessary for one Party to provide the other Party with tangible research or
biological Materials (other than a Licensed Product for clinical or commercial use) in connection with the performance of activities hereunder, the Parties may enter into an appropriate material transfer agreement related thereto, which agreement
will be subject to this Agreement and will be interpreted in a manner consistent with the terms hereof. 

Adverse Event Reporting and Product Recall 
  

	 	4.24	 MedImmune will hold the safety database for the Licensed Antibodies and the Licensed Products and Innate will provide
safety information as required by Applicable Laws, in a timely manner. Within [***] of the Effective Date and in any event prior to the initiation of the Development, the Parties will enter into a detailed safety agreement (the “Safety
Agreement”), governing, among other things, appropriate adverse event reporting procedures relating to Licensed Products and reflecting the provisions set forth above in this Section 4.24. 

 

	 	4.25	 In the event that any Regulatory Health Authority issues or requests a recall or takes similar action in connection
with the Licensed Antibodies or the Licensed Products, or in the event either Party determines that an event, incident or circumstance has occurred that may result in the need for a recall or market withdrawal, the Party notified of or desiring such
recall or market withdrawal shall promptly advise the other Party thereof. Following notification of a recall, MedImmune shall have the right to decide whether to conduct a recall or market withdrawal (except in the case of a recall required by
Regulatory Health Authority) in the Territory and shall have control of the manner in which any such recall or market withdrawal shall be conducted. MedImmune shall bear the expenses of any recall of a Licensed Product. 

 

	5	 JOINT PROJECT TEAM AND DEVELOPMENT COLLABORATION COMMITTEE 

Joint Project Team  

  
 41 

	 	5.1	 Provided that Innate has not issued a Co-Funding Withdrawal Notice within the
Opt Out Period, MedImmune and Innate shall establish and maintain a Joint Project Team (the “JPT”) and appoint Alliance Managers pursuant to Section 5.4. 

 

	 	5.2	 The JPT shall remain in effect as from the Effective Date and for as long as Innate is actively performing any
Development activities assigned to Innate under the Development Plan or any Co-Promotion in accordance with Section 3.4. The JPT shall serve as a joint working group for the purpose of implementing the
Development Plan, coordinating the practical aspects of the Parties’ collaboration and Co-Promotion under this Agreement, handling
day-to-day issues in relation thereto, facilitating communication between the Parties in respect thereof and otherwise performing such specific tasks as may be assigned
to it by the DCC. 

  

	 	5.3	 The JPT shall consist of two project leaders, one appointed by MedImmune and the other by Innate, and such additional
members as each Party may appoint from time to time as necessary or useful for the performance of the JPT’s responsibilities hereunder. Each Party shall have the right to withdraw or replace its JPT representatives upon written notice to the
other Party, provided that any such substitute representative shall have substantially the equivalent position and experience as the representative that such person replaces. MedImmune and Innate shall each bear all expenses of its JPT members
related to such members’ participation on the JPT. Each Party’s representatives on the JPT as of the Effective Date are set forth in Schedule 5.3. 

 

	 	5.4	 Alliance Managers. Within [***] following the Effective Date, each Party shall appoint a representative
(“Alliance Manager”) to facilitate communications between the Parties (and to act as a liaison between the Parties with respect to such other matters as the Parties may mutually agree in order to maximize the efficiency of the
collaboration). Each Party may replace its Alliance Manager with an alternative representative at any time with prior written notice to the other Party. Each Party’s Alliance Managers shall be entitled to attend all Committee meetings. Each
Alliance Manager may bring any matter to the attention of the Committees where such Alliance Manager reasonably believes that such matter requires attention of the Committees. Each Alliance Manager

  
 42 

	 	 
shall be responsible with creating and maintaining a collaborative work environment within and among the Committees. 

Development Collaboration Committee  
  

	 	5.5	 Innate and MedImmune shall establish a development collaboration committee in accordance with this Section 5 (the
“DCC”). The DCC shall remain in effect as from the Effective Date through the end of the Development Term. If the DCC is disbanded pursuant to the preceding sentence and the Parties thereafter decide to commence or re-commence any Development activities, the DCC shall be re-established and remain in effect until for the duration of performance of such Development activities.

  

	 	5.6	 The DCC shall serve as a forum for discussing and sharing Information and materials; discussing strategy regarding the
Development of the Licensed Products; and discussing the allocation of Development activities to be conducted by Innate and MedImmune. The DCC’s responsibilities are more fully set forth in Section 5.7 below. 

 

	 	5.7	 Each Party shall appoint three (3) representatives as its voting members of the Development Collaboration
Committee. Each Party’s representatives on the DCC as of the Effective Date are set forth in Schedule 5.7. The DCC shall be chaired by a representative of MedImmune. The chairperson shall be responsible for calling meetings, setting the
agenda, circulating the agenda at least [***] prior to each meeting and distributing minutes of the meetings within [***] following such meetings (provided that the chairperson may elect to delegate the performance of its responsibilities to other
members of the DCC from time to time), but will not otherwise have any greater power or authority than any other member of the DCC. The chairperson shall coordinate with each Party to schedule each DCC meeting in good time in advance of such
meeting. Each Party shall disclose to the chairperson any proposed agenda items, along with appropriate information and materials as early as reasonably practicable in advance of such meeting, but no less than three (3) Business Days. The
chairperson shall not unreasonably reject any proposed call for a DCC meeting or proposed agenda items made by either Party. At least one (1) member of the DCC selected by Innate and one (1) member of the DCC selected by MedImmune

  
 43 

	 	 
shall have substantial experience in pharmaceutical product research and development, and all of the members of the DCC shall have such expertise as appropriate to the activities of the DCC. Each
Party may replace its members of the DCC upon written notice to the other Party, provided that any such substitute member shall have substantially the equivalent functional expertise, experience and seniority as the member that such person replaces
provided that the Parties shall use Commercially Reasonable Efforts to keep replacements to a minimum. From time to time, the DCC may invite non-voting personnel of either Party to participate in discussions
of the DCC. An alternate voting member designated by a Party may serve temporarily in the absence of a permanent voting member appointed by such Party, and either Party may also designate one or more
non-voting consultants to such Party who are under written obligations of confidentiality to such Party as DCC observers who may attend the DCC meetings in an observational or advisory capacity only.

  

	 	5.8	 The DCC shall hold meetings at such times and places as shall be determined by a majority of the entire membership of
the committee, but in no event shall such meetings be held less frequently than once every three (3) months. Meetings of the DCC will alternate between the offices of the Parties, unless otherwise agreed upon by the members of the DCC, or may
be held via internet, telephonically or by videoconference; provided that at least two (2) meetings per year shall be held in person. Meetings of the DCC will be effective only if at least two DCC members of each Party are in attendance or
participating in the meeting. Each Party will be responsible for the expenses incurred in connection with its employees, consultants and its members of the DCC attending or otherwise participating in DCC meetings. 

Responsibilities of the DCC 
  

	 	5.9	 The DCC’s responsibilities will include, among others, (i) reviewing and approving the Development Plan and
Development Budget, and any amendments thereto, (ii) reviewing and approving protocols for nonclinical studies and Clinical Trials and any amendments or modifications to such protocols or studies, (iii) performing quarterly reviews of the
progress of Development and considering any proposed additional studies, (iv) facilitating the exchange of information and materials, (iv) facilitating the timely transfer

  
 44 

	 	 
of Manufacturing responsibility to MedImmune in accordance with Section 9, (v) reviewing and advising on a proposal by either Party to stop a Clinical Trial of a Licensed Product,
(vi) reviewing and commenting on allocation of responsibility for Development activities between the Parties, (vii) discussing each Party’s progress under the Development Plan, including reviewing progress toward timelines and budget,
Study Results and the status of achieving Regulatory Approval; (viii) providing strategic direction and consultation with respect to Development of Licensed Products; (ix) coordinating communication between the Parties; (x) resolving
disputes between the Parties relating to the Development Plan, and (xi) performing such other functions as designated to the DCC under this Agreement or mutually agreed between the Parties. Notwithstanding anything to the contrary set forth in
this Agreement, the DCC will have no authority to (a) amend, modify or waive compliance with this Agreement or otherwise impose any obligation on the Parties in deviation from this Agreement, or (b) resolve any dispute concerning the
validity, compliance with, or breach of, this Agreement. 

  

	 	5.10	 The DCC shall make decisions on all matters within the scope it its authority only by unanimous consent, with the
MedImmune voting members cumulatively having one (1) vote and the Innate voting members cumulatively having one (1) vote, irrespective of the number of members actually in attendance at a meeting. In the event that unanimity cannot be
reached by the DCC on a matter before it for decision within [***] after the matter was first considered by it then the matter may be referred by either Party to the Senior Executives, who shall meet (in person, via internet, telephonically or by
videoconference) and attempt to resolve the matter within [***] of such referral. In the event that the Senior Executives are unable to reach consensus within such [***] period, [***]. 

 

	6	 GENERAL PROVISIONS ON DEVELOPMENT AND COMMERCIALIZATION AND REGULATORY MATTERS 

Information Disclosure; Assistance; Record Keeping 
  

	 	6.1	 Innate acknowledges that it has, prior to the Effective Date, made available to MedImmune all material Regulatory
Documentation Controlled by Innate or its 

  
 45 

	 	 
Affiliates and tangible and electronic embodiments of all material Licensed Know-How existing as of the Effective Date. After the Effective Date, and
promptly following MedImmune’s request to do so, Innate shall transfer to MedImmune copies of all of the Essential Documents (as defined in Chapter 8 of ICH-GCP) that are Controlled by Innate relating to
IPH2201 (the “Essential Documents”). Innate will have the right to retain original copies of the foregoing but shall make such original copies available to MedImmune at Innate’s site of business for inspection upon reasonable
advance written notice by MedImmune. 

  

	 	6.2	 After the Effective Date, to the extent not done so already, Innate shall, and shall cause its Affiliates to, without
additional compensation, disclose and make available to MedImmune, in whatever form MedImmune may reasonably request, as soon as reasonably practicable after the earlier of the development, making, conception or reduction to practice of each of the
following: copies or tangible embodiments of all Regulatory Documentation Controlled by Innate. Subject to Section 6.5 Innate will have the right to retain original copies of the foregoing, and shall make such original copies available to
MedImmune at Innate’s site of business for inspection upon reasonable advance written notice by MedImmune. 

  

	 	6.3	 Without prejudice to its other obligations under this Agreement, including activities explicitly assigned by the DCC
to be performed by Innate in connection with the Development hereunder, Innate shall, at its cost and expense, provide MedImmune with all reasonable assistance required in order to transfer the Licensed
Know-How to MedImmune in a timely manner or, at the cost and expense of Innate, assist MedImmune with respect to the practice of the Licensed Know-How in connection with
Development, Manufacture or Commercialization of the Licensed Products. 

  

	 	6.4	 From and after the Effective Date, each Party shall maintain, or cause to be maintained, records of its Development
activities under this Agreement, including the Essential Documents and including records in the form of laboratory notebooks, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes including GLP and GCP,
which shall be complete and accurate and shall fully and properly reflect all work 

  
 46 

	 	 
done and results achieved in the performance of its activities hereunder, which shall record only such activities and shall not include or be commingled with records of activities outside the
scope of this Agreement, and which shall be retained by such Party for at least five (5) years after the termination of this Agreement, or for such longer period as may be required by Applicable Laws. Each Party shall have the right, during
normal business hours and upon reasonable prior notice, to inspect any such records of the other Party. 

Regulatory Matters 
  

	 	6.5	 Following the transfer of the Regulatory Documentation, including INDs to MedImmune pursuant to Section 3.9,
subject to the terms set forth below, MedImmune shall be solely responsible for all regulatory filings and communications with each Regulatory Health Authority with respect to that Regulatory Documentation including any INDs relating to the Licensed
Product, and MedImmune shall be solely responsible for any and all subsequent filings and communications with the Regulatory Health Authority including, without limitation, for the preparation and filing of all additional INDs relating to the
Licensed Product and for providing, in the format required by Regulatory Health Authorities, the data and information required to be submitted to such Regulatory Health Authorities for Regulatory Approval of Licensed Products, including without
limitation data from all Clinical Trials and all Manufacturing and controls information required for Regulatory Approval of such Licensed Product by the Regulatory Health Authorities. Notwithstanding the foregoing, MedImmune shall (i) provide
Innate with copies of all material Regulatory Documentation received from Regulatory Health Authorities, (ii) provide Innate with advance copies of all material Regulatory Documentation for submission to Regulatory Health Authorities in the
Major Markets, with sufficient time for Innate to review and provide comment, and give reasonable, good faith consideration to Innate’s suggestions therefor, (iii) permit at least one Innate representative to be present at all discussions
and meetings with the EMA and the FDA relating to Licensed Products subject to Applicable Law and any applicable restrictions imposed by the FDA or EMA and (iv) generate true and accurate minutes of all discussions and meetings with Regulatory
Health Authorities relating to Licensed Products in the Major Markets and provide copies of such minutes to Innate as promptly as possible following any such 

  
 47 

	 	 
meeting. 

  

	 	6.6	 During the Development Term, MedImmune shall keep Innate reasonably informed of the status of each pending or proposed
IND application or Drug Approval Application covering a Licensed Product in the Territory through the DCC. 

  

	 	6.7	 MedImmune shall immediately (within 24 hours) inform Innate in the event that Regulatory Health Authority threatens or
initiates any action to remove a Licensed Product from any market in the Territory. 

  

	7	 CO-FUNDING OF DEVELOPMENT 

 

	 	7.1	 Subject to the remaining provisions of this Section 7 Innate shall participate in the funding of each of the
Phase 3 Clinical Trials of Licensed Products supporting Drug Approval Application in [***], such funding to be provided by Innate in the amount of thirty percent (30%) of the total Development Costs for each of such Phase 3 Clinical Trials with the
remaining seventy (70%) percent being provided by MedImmune, provided that neither Party shall be required to contribute more than their agreed percentage share of Development Costs for the Phase 3 Clinical Trials in accordance with the Development
Budget. The Development Budget is anticipated to be [***] for each Clinical Trial in average across [***] and [***] in total based on up to [***]. To the extent that a Party’s share of the Development Costs in accordance with the Development
Budget exceeds [***] in the case of Innate or [***] in the case of MedImmune of the anticipated budget of [***] per Phase 3 Clinical Trial, then the excess portion shall be payable by the Party sponsoring the applicable Phase 3 Clinical Trial. The non-sponsoring Party’s share of the Development Costs of the subsequent Phase 3 Clinical Trial shall be increased by such excess amount provided that the non-sponsoring
Party’s share shall never exceed [***] of [***]in the case of Innate and [***] of [***] in the case of MedImmune for any given Phase 3 Clinical Trial. For the avoidance of doubt, the excess amount shall not be payable other than pursuant to the
preceding sentence and if it cannot be paid in accordance with the preceding sentence, it shall not be payable by the non-sponsoring Party. The Parties have agreed that the first Phase 3 Clinical Trial will be
sponsored by MedImmune, as will any additional Phase 3 Clinical Trials related 

  
 48 

	 	 
to Licensed Products unless the Parties otherwise mutually agree. An example of such payment mechanism is attached as Schedule 7.1. The Parties may agree that Innate’s co-funding amount pursuant to this Section 7.1 may be used to finance other Clinical Trials than the Phase 3 Clinical Trials. Innate shall have the option, upon providing written notice to MedImmune (“Co-Funding Withdrawal Notice”) within [***] after receiving MedImmune’s updated Development Plan and Development Budget in accordance with Section 4.2 (“Opt Out Period”), to not
participate in the Co-Funding. Such right to withdraw shall be exercisable once only in respect of the first Licensed Product. If Innate does not provide a Co-Funding
Withdrawal Notice within the Opt Out Period described above Innate will be obliged to provide co-funding with respect to the applicable Licensed Product as described in this Section 7.1.

  

	 	7.2	 If Innate provides a Co-Funding Withdrawal Notice, the following provisions
shall apply: 

  

	 	(a)	 Innate’s role on the DCC shall be limited to discussing with MedImmune the matters within the remit of the DCC
but Innate shall have no rights to vote on any such matter and MedImmune shall have final say; 

  

	 	(b)	 Innate’s Co-Promote Option shall terminate and be of no further effect;

  

	 	(c)	 Innate’s right to share in 50% of the Profit in Europe shall terminate. Instead Net Sales in Europe will be
included for the purposes of the Sales Related Payments due under Section 10.5 and royalties under Section 10.11 and the first five subsequent Phase 3 Clinical Trial milestones payable pursuant to Section 10.2 shall each be reduced by
[***] and all [***] milestones shall be extinguished entirely. For the avoidance of doubt, any other Payments shall remain unchanged. 

  

	 	7.3	 Expense Sharing. The provisions set out in this Section 7.3 and in Section 7.4 -7.9 shall apply if Innate has not served MedImmune with a Co-Funding Withdrawal Notice within the Opt Out Period. The Parties will share all Development Costs related to the
Phase 3 Clinical Trials of Licensed Products under the Development Plan and in accordance with the Development Budget (the “Shared Development Costs”) so that subject to Section 7.1, Innate pays thirty percent (30%) and

  
 49 

	 	 
MedImmune shall pay the remainder as set out below in this Section 7.  

  

	 	7.4	 Development Costs. Within [***] days after the end of each Calendar Quarter each Party will provide the other
Party with detailed, itemized accounting of the Shared Development Costs incurred by it in undertaking its Development activities, which report shall be itemized on a Licensed
Product-by-Licensed Product basis in such quarter in the form set forth in Schedule 7.4 or in such other form as the Parties may mutually agree from time-to-time. For clarity, for calculation of Costs pursuant to this Section with respect to any activity performed by a Third Party (including any subcontracted Third Party),
the Costs shall be the pass-through costs, with no mark-up, charged to the applicable Party by such Third Party. 

  

	 	7.5	 Income Taxes. Subject to Section 10.26 (Taxes), income and withholding taxes imposed on either of the
Parties hereunder will not be included in cost sharing hereunder. 

  

	 	7.6	 Exchange Rate. For the purposes of calculating the Shared Development Costs, the Parties’ Development
Costs will be converted from local currency (if different from US Dollars) to US Dollars in accordance with Section 10.30 (Payment Currency).  

  

	 	7.7	 Overruns. Each Party will promptly notify the other Party upon becoming aware that the anticipated Costs to be
incurred by such Party for a given Calendar Year will be in excess of [***] of the aggregate amounts budgeted to be incurred by or on behalf of such Party for its activities for such Product in such Calendar Year in the then-current applicable
Development Budget respectively (“Excess Costs”), will not be included in the calculation of the Development Costs for the purposes of this Section provided, that a given Excess Cost will be included to the extent such Excess Cost
is or was attributable to: (i) a change in Applicable Law; (ii) a Force Majeure event; (iii) variation in actual patient enrolment from projected patient enrolment not caused by the default of the relevant Party; (iv) a change to
a clinical trial protocol required or requested by any Regulatory Health Authority; (v) increases in the cost of raw materials; (vi) is approved by the DCC. Notwithstanding the foregoing, in no circumstance shall Innate be liable for
Shared Development Costs with respect to any given 

  
 50 

	 	 
Clinical Trial or other activity in accordance with the Development Plan or any Development Costs other than in accordance with Section 7.1. 

 

	 	7.8	 Reconciliation Discussion. In the event that either Party has any questions or concerns regarding the
Development Costs reported by the other Party pursuant to this Section 7 it shall promptly notify the other Party with respect thereto and the Parties shall work together in good faith, including through involving any applicable Committee, to
resolve such questions and concerns within [***] the end of each Calendar Quarter. In the event that a Party disagrees with, or identifies a discrepancy in, the Development Costs submitted by the other Party and the disagreement or discrepancy
cannot be resolved or rectified between the Parties within a period of [***] of the matter being first raised by a Party, the Parties shall appoint an independent, internationally recognised accountant to review the alleged discrepancy. The costs of
carrying out such review shall be borne by the Party requesting it unless the accountant finds a discrepancy in favour of the Party requesting of greater than [***] in which case the other Party will bear the costs  

 

	 	7.9	 True-up. Within [***] after the end of each Calendar Quarter, the Party
having paid more than its share of the Shared Development Costs (on a cumulative basis) shall deliver to the other Party an invoice for amounts to be reimbursed by the other Party, and the other Party shall make a balancing payment in order to
effect the sharing of Development Costs as set forth in this Section within [***] after its receipt of such invoice. 

  

	8	 COMMERCIALIZATION, CO-PROMOTION IN THE [***] AND SALES COLLABORATION
COMMITTEE 

  

	 	8.1	 MedImmune shall be responsible for all Promotion of the Licensed Products outside of [***] and, subject to the
operation of Innate’s Co-Promotion rights in this Section 8, shall be responsible for all Promotion of the Licensed Products in [***]. In the event that Innate elects not to Co-Promote the Licensed Products in [***], in accordance with Section 8.3 below, all such activities shall be conducted, as between the Parties, solely by MedImmune (whether directly or by its Affiliates,
Sublicensees or contractors (excluding Innate)) upon expiration of the notice period in accordance with Section 8.3. 

  
 51 

 Sole Promotion by MedImmune 

 

	 	8.2	 With respect to Commercialization of Licensed Products (other than with respect to a
Co-Promote Product in [***]), such Commercialization shall be conducted independently of Innate by MedImmune, its Affiliates and Sublicenses, and MedImmune shall provide to Innate its overall plans for
Commercialization and launch of Licensed Products in the Territory (each a “Global Commercialization Plan”), which plans shall contain reasonable details as to the commercialization resources committed by MedImmune, timelines
for launch and sale projections over [***] with respect to the Major Markets. MedImmune shall provide to Innate the first Global Commercialization Plan as soon as reasonably practicable following the Filing Date of the first Drug Approval
Application for a Licensed Product in the Territory and updates within [***] from the beginning of each Calendar Year. 

Co-Promote Option 

 

	 	8.3	 Subject to the remaining provisions of this Section 8, Innate shall have the right to Co- Promote the Licensed Products in [***], (“Co-Promote Option”). 

 

	 	8.4	 Promptly following the date on which MedImmune has filed for the first Drug Approval Application, the Parties shall
meet to discuss whether or not Innate is interested in principle in exercising its Co-Promote Option. MedImmune shall provide Innate with reasonable details of its plans for Commercialization of the Licensed
Product in [***] in advance of such meeting. No later than ninety (90) days after MedImmune notifies Innate that it has filed for the first Drug Approval Application for a Licensed Product in the EU, Innate shall provide to MedImmune a written
notice confirming whether or not Innate is opting in to Co-Promote Licensed Products in the [***]. If Innate confirms in such notice that it is not exercising its
Co-Promote Option, such notice shall be deemed to be a “Co-Promotion Withdrawal”. Any failure by Innate to notify MedImmune as to whether or not it is
exercising its Co-Promote Option in [***] within such [***] shall also be deemed to be a Co-Promotion Withdrawal. Such right to withdraw shall be exercisable once only
and must be exercised by way of a Co-Promotion Withdrawal pursuant to this Section 8.4 in respect of the first Drug Approval Application for the first Licensed Product. If Innate makes a Co-Promotion 

  
 52 

	 	 
Withdrawal, Innate’s right to share in the Profit/Loss shall be adjusted so that MedImmune receives/bears [***] and Innate receives/bears [***]. 

 

	 	8.5	 If Innate confirms to MedImmune in writing within the [***] referred to in Section 8.4 above that it does wish to
exercise the Co-Promote Option MedImmune shall prepare detailed plans for Commercialization in the EU including plans for the launch of the Licensed Product in the EU (“EU Commercialization
Plans”), and related budgets (the “EU Commercialization Budgets”), and shall furnish the SCC for discussion with such plans. 

Sales Collaboration Committee  
  

	 	8.6	 If Innate exercises its Co-Promote Option, Innate and MedImmune shall create,
within [***] after such exercise, a Sales Collaboration Committee (“SCC”). The SCC shall remain in effect throughout the Term unless and until the Parties cease Co-Promotion of the Co-Promote Product in [***]. The SCC shall serve as a forum for discussing and sharing information and materials; discussing strategy regarding the Commercialization of the
Co-Promote Product in the [***]; and discussing the allocation of Commercialization activities to be conducted by Innate and MedImmune, all in accordance with the
Co-Promote Agreement and the provisions set forth below in this Section 8. 

  

	 	8.7	 Composition of SCC. Each Party shall appoint three (3) representatives as its voting members of the Sales
Collaboration Committee. The SCC shall be chaired by a representative of MedImmune. The chairperson shall be responsible for calling meetings, setting the agenda, circulating – where reasonably possible given the urgency of the matter at hand
– the agenda at least ten (10) days prior to each meeting and distributing minutes of the meetings within thirty (30) days following such meetings (provided that the chairperson may elect to delegate the performance of such
responsibilities to other members of the SCC from time to time), but will not otherwise have any greater power or authority than any other member of the SCC. The chairperson shall coordinate with Innate’s SCC members to schedule each SCC
meeting in good time in advance of such meetings. Each Party shall disclose to the chairperson any proposed agenda items, along with appropriate information and materials as early as reasonably practical before each meeting of the SCC, but no less
than three (3) 

  
 53 

	 	 
Business Days. The chairperson shall not unreasonably reject any proposed call for a meeting or proposed agenda items proposed by either Party. The chairperson shall coordinate with the Parties
to schedule SCC meetings in good time in advance of the meetings. The members of the SCC shall have substantial experience in pharmaceutical sales and marketing and all of the members of the SCC shall have such expertise as appropriate to the
activities of the SCC. Each Party may replace its members of the SCC upon written notice to the other Party, provided that any such substitute member shall have substantially the equivalent functional expertise, experience and seniority as the
member that such person replaces provided that the Parties shall use Commercially Reasonable Efforts to keep replacements to a minimum. From time to time, the SCC may invite non-voting personnel of either
Parties to participate in discussions of the SCC. An alternate voting member designated by a Party may serve temporarily in the absence of a permanent voting member appointed by such Party, and either Party may also designate one or more non-voting consultants to such Party, who are under written obligations of confidentiality to such Party, as SCC observers who may attend the SCC meetings in an observational or advisory capacity only.

  

	 	8.8	 Responsibilities of the SCC. The SCC’s responsibilities will include, (i) reviewing and approving the
EU Commercialization Plans and EU Launch Plans and related budgets, and reviewing plans for trademark selection for the Licensed Product in the EU, such plans shall be prepared and updated by MedImmune, (ii) receiving and providing to the
Parties all sales, pricing, and financial reports pertaining to Pre-Approval Activities and Commercialization of the Licensed Product in the EU, (iii) facilitating the flow of information and materials
with respect to the Commercialization of the Licensed Product in the EU, (iv) performing quarterly reviews of the progress of launch and Commercialization activities in the EU with respect to the Product, and (v) coordinating the efforts
of the Parties in connection with Commercialization of the Licensed Product in the EU. 

  

	 	8.9	 Meetings of the SCC. The SCC shall hold meetings at such times and places as shall be determined by a majority
of the entire membership of the committee, but in no event shall such meetings be held less frequently than once every six (6) months. Meetings of the SCC will alternate between the offices of the

  
 54 

	 	 
Parties, unless otherwise agreed upon by the members of the SCC, or may be held via internet telephonically or by video conference; provided that at least two (2) meetings per year shall be
held in person. Meetings of the SCC will be effective only if at least two (2) SCC representatives of each Party are in attendance or participating in the meeting. Each Party will be responsible for the expenses incurred by its employees,
consultants and its members of the SCC attending or otherwise participating in SCC meetings. 

  

	 	8.10	 SCC Decision Making. The SCC shall endeavour to make decisions within its remit by unanimous consent, with the
MedImmune members cumulatively having one (1) vote and the Innate members cumulatively having one (1) vote, irrespective of the number of members in attendance at a meeting. [***]. 

Allocation of Co-Promote activities in [***] 

 

	 	8.11	 Within thirty (30) days of the later of: (a) creation of the SCC, and (b) receipt of the EU
Commercialization Plans and EU Launch Plan, the Parties shall, based on such plans, provide to the SCC a joint proposal (“Promotion Proposal”) describing the Detail commitments and Other Promotional Activities proposed to be
undertaken by Innate in connection with the Commercialization of the Licensed Product in [***]. Such Promotion Proposal shall include, among other things, (i) the level of, and target audience, for the Detailing to be performed by Innate in
[***], which shall be [***] of the total Detailing efforts required in [***] for the Co-Promote Product, and (ii) any Pre-Approval Activities and Other Promotional
Activities that the Parties propose Innate conduct in [***] which shall be [***] with respect to Medical Scientific Liaisons and, to the extent reasonably practicable, any Other Promotional Activities. In allocating these activities, Innate shall be
given a meaningful role with respect to key opinions leaders in France. The Promotion Proposal shall be considered, discussed and approved by the SCC and the Parties or the SCC may propose further or alternative promotional activities to be
undertaken by Innate. 

  

	 	8.12	 Based on such discussions, Innate and MedImmune (or, at MedImmune’s option, one of MedImmune’s Affiliates)
shall negotiate in good faith to execute as promptly as possible a separate agreement (the “Co-Promote Agreement”) that shall regulate the detailed activities and responsibilities of Innate in

  
 55 

	 	 
respect of the marketing and promotion of the Licensed Product in [***]. The Co-Promote Agreement shall contain such reasonable terms and conditions as the
Parties deem appropriate. 

  

	 	8.13	 Innate shall be entitled and obligated to carry out those promotional tasks agreed in the Co-Promote Agreement within [***] in respect of the Co-Promote Products, subject to relevant EU Launch Plans and EU Commercialization Plans. 

Reimbursement of Commercialization Costs  
  

	 	8.14	 Commercialization Costs. Within [***] after the end of each Calendar Quarter, each Party will provide the other
Party with detailed, itemized accounting of its Commercialization Costs in accordance with the Global Commercialization Plan and EU Commercialization Budget, in such quarter in the form set forth in Schedule 8.14 or in such other form as the
Parties may mutually agree from time-to-time. 

  

	 	8.15	 Reimbursement. Within [***] after the end of each Calendar Quarter, Innate shall deliver to MedImmune an
invoice for its Commercialization Costs incurred in such Calendar Quarter in accordance with the EU Commercialization Budget, and MedImmune shall pay such costs within [***] after its receipt of such invoice. In addition, within [***]after the end
of each Calendar Quarter, Innate shall deliver to MedImmune an invoice for the total of any royalties or other sums payable by Innate to any Third Party with respect to Intellectual Property Rights that become Controlled by Innate and which
MedImmune has agreed to reimburse Innate according to Section 1.34 after the Effective Date in connection with the Licensed Product, and MedImmune shall pay such costs within [***] after its receipt of such invoice. 

 

	 	8.16	 Calculation. The procedures set forth in Section 7.8 shall apply mutatis mutandis to the
reimbursement of Innate’s Commercialization Costs.  

  

	 	8.17	 MedImmune (or, as the case may be, its Affiliates or Sublicensees) shall book all of their sales of each Licensed
Product, coordinate the Manufacture and supply of all Licensed Products required for Commercialization, invoice Third Parties (including Distributors) that purchase Licensed Products from

  
 56 

	 	 
MedImmune (or its Affiliates or Sublicensees), and collect payment for all Licensed Products sold by MedImmune (or its Affiliates or Sublicensees) both in the EU and outside of the EU.

  

	9	 MANUFACTURE AND SUPPLY 

 

	 	9.1	 Initial Supply of Licensed Product. Innate shall assume initial responsibility for supplying IPH2201 for
use in the Development of IPH2201 under this Agreement until such time as the Parties agree, but no later than the point at which manufacturing for the first Phase 3 Clinical Trial is due to start, MedImmune shall assume responsibility for such
supply hereunder (the “Initial Supply”). Innate shall use Commercially Reasonable Efforts to procure, from its current contract manufacturing organization, such Initial Supply of IPH2201 as MedImmune may reasonably require in
relation to the Development of the Licensed Product and in accordance with the Development Plan. Innate shall deliver the Initial Supply and perform the activities in such a manner and within such timelines as are required under the Development
Plan. Innate will ensure that the Initial Supply is Manufactured, packaged, stored and labelled in accordance with Applicable Laws and the Specification. 

  

	 	9.2	 Initial Supply of MedImmune Compound. MedImmune shall be responsible for the provision of such GMP quantities
of the MedImmune Compound as are specified in the Development Plan or otherwise required for the conduct of the Development. In the event that Development activities involving MedImmune Compound are Innate’s Assigned Activities, MedImmune shall
supply MedImmune Compound to Innate in accordance with the terms of a combination supply agreement which will be agreed by the Parties in good faith prior to any such supply being made. MedImmune will be responsible for any costs and payments
(including without limitation upfront fees, annual fees, milestone payments and royalties) due to any Third Party in connection with the use of an MedImmune Compound in accordance with this Agreement. 

 

	 	9.3	 Costs. The Parties will discuss and agree the Transfer Price on an annual basis. The Transfer Price for any
Licensed Products or Licensed Antibodies supplied by Innate will be treated as a Development Cost. In the event that Innate is co-funding Development in accordance with Section 7, the Transfer Price shall
be 

  
 57 

	 	 
included in the calculation of Innate’s contribution in Section 7.4. In the event that Innate is not co-funding Development, the Transfer Price
shall be reimbursed by MedImmune within [***] of the receipt of an invoice for the Transfer Price for Licensed Product supplied from Innate. 

  

	 	9.4	 Manufacturing and Supply Agreement. If a manufacturing and supply agreement (“MSA”) is
required with regard to the supply of Initial Supply by Innate, the Parties shall negotiate and agree in good faith the terms of such agreement. The Parties shall also enter into a separate Quality Assurance Agreement (“QAA”) that
shall define the manufacturing and supply quality responsibilities of the Parties. The QAA shall further include provisions obligating Innate to report to MedImmune any regulatory compliance issues with its suppliers as well as any critical quality non-conformances relating to IPH2201. The MSA and the QAA shall be negotiated in good faith between the Parties and be executed within ninety (90) days following the Effective Date. 

 

	 	9.5	 Transfer of responsibility. Subject to Section 9.1, MedImmune shall use Commercially Reasonable Efforts to
assume responsibility for the supply of all Licensed Antibodies and Licensed Products for use in the Development and Commercialization of Licensed Products beginning with the supplies of drug substance necessary to conduct Phase 3 Clinical Trials of
the Licensed Product and continuing thereafter for the remainder of the Term; provided, however, that MedImmune may, by written notice to Innate, elect to assume responsibility for Development work associated with the Manufacture of
the Licensed Product or Licensed Antibody at any earlier time after the Effective Date. In such case, the timing of the transition of such activities, and the impact of the transition of such Development work on the supply of Licensed Product or
Licensed Antibody for Clinical Trials, shall be determined by the DCC, taking into account, among other things, the contractual obligations that Innate may have to its current suppliers. 

 

	 	9.6	 Material Transfer. The DCC shall coordinate the transfer of all Licensed
Know-How and Materials Controlled by Innate that are necessary or useful to Manufacture Licensed Antibodies and Licensed Products. Such transfer shall take place in a manner and at such time as not to disrupt
the manufacture and delivery of any Initial Supplies under Section 9.1. At such time as is determined 

  
 58 

	 	 
by the DCC, Innate shall, and shall cause its manufacturing contractors at its own cost and expense to, provide to MedImmune or its designee, all reasonable assistance, including the right to
observe the Manufacturing at a facility of Innate’s manufacturing contractors, and transfer all Licensed Know-How and Materials Controlled by Innate, that are necessary or useful to Manufacture the
Licensed Antibodies and the Licensed Products, including without limitation all production and quality control Specification and process and manufacturing technology, for the purpose of allowing MedImmune or its designee to develop and establish
such Manufacturing. MedImmune shall have the right to disclose all such information to Third Parties for purposes of allowing MedImmune to assess the feasibility of such Third Parties Manufacturing the Licensed Antibodies and the Licensed Products
and to allow such Manufacturing. The Parties shall cooperate to obtain all necessary assurances and cooperation from any Third Party contract manufacturers of Licensed Antibodies or Licensed Products with respect to the foregoing material transfer
activities. Innate covenants to MedImmune that any Third Party agreements under which Innate engages such Third Party to Manufacture Licensed Antibodies or Licensed Products contain provisions regarding the allocation of Intellectual Property Rights
and rights in work product that are consistent with the terms of this Agreement and will enable Innate to fulfil its obligations to MedImmune under this Section 9. 

 

	 	9.7	 Other Supply. MedImmune may supply Licensed Antibody or Licensed Products to any Third Party for any Third
Party solely for use in the Field. 

  

	10	 CONSIDERATION 

Upfront fee 
  

	 	10.1	 As partial payment for the rights and licenses granted to MedImmune by Innate under this Agreement, MedImmune shall
pay to Innate a nonrefundable one-time upfront payment of one hundred million US dollars (USD 100,000,000) within [***] the Effective Date. The upfront payment shall not be refundable or creditable against any other payments MedImmune is obligated
to make to Innate under this Agreement. 

  
 59 

 Milestone Payments 

 

	 	10.2	 MedImmune shall make the following one-time, nonrefundable and non-creditable milestone payments to Innate within [***] receipt of an invoice from Innate (fulfilling the requirements set forth in Section 10.27) following the first achievement of each of the following
milestone events for a Licensed Product containing IPH2201, subject to the limitations and additional provisions set forth below in this Section 10. 

  

					
	 Milestone Event for a Licensed Product Containing IPH2201

    
	 	    Milestone Payment    

	 	 	 
	
I. Dosing of the first patient in the first Phase 3 Clinical Trial
	  	
A. For the first Phase 3 Clinical Trial to support a Drug Approval Application in a
Major Market
	 	US $100,000,000
	  	  

B. [***]

      
	 	  

[***]

	 	 	 
	
II.[***]
     
	  	
A. [***]
	 	[***]
	 	 	 
	
III.[***]
     
	  	
A. [***]
	 	[***]

 [***] 
 [***] 

 

	 	10.3	 None of the milestone payments set forth in Section 10.2 shall be payable more than once, irrespective of the
number of Licensed Products or indications that have achieved the milestone events or the number of countries in which such milestone events have been achieved, provided that milestone I(B) shall be payable up to [***]. 

 

	 	10.4	 Except as permitted in Section 10.2, no payments pursuant to Section 10.2 shall be creditable against any
other payments MedImmune is obligated to make to 

  
 60 

	 	 
Innate under this Agreement. 

 Sales Related
Milestones 
  

	 	10.5	 MedImmune shall make the following one-time,
non-refundable milestone payments to Innate within [***] after receipt of an invoice from Innate, fulfilling the requirements set forth in Section 10.29, following the first achievement of each of the
following milestones in respect of Annual Net Sales of all Licensed Products containing IPH2201 in all countries subject to Section 10.8 below and subject to the limitations and additional provisions set forth below in this Section 10,
including Section 1 0.21: 

  

			
	 	 
	[***]	  	                [***]  
              
	 	 
	
[***]
     

    
     

    
	  	[***]
	 	 
	
[***]
     

    
     

    
	  	[***]
	 	 
	
[***]
     

    
     

    
	  	[***]
	 	 
	
[***]
     

    
     

    
	  	[***]

  

	 	10.6	 In the event that more than one of the sales milestones set forth in Section 10.5

  
 61 

	 	 
are achieved in the same Calendar Quarter, the payment associated with each sales milestone achieved in such Calendar Quarter shall be due and payable [***] after MedImmune’s receipt of an
invoice from Innate following the end of such Calendar Quarter. 

  

	 	10.7	 Notwithstanding anything else set forth herein, no milestone payment pursuant to Section 10.5 will be made more
than once. 

  

	 	10.8	 The Territory shall exclude Europe for the purposes of the calculation of Annual Net Sales if Innate has not provided
its Co-Funding Withdrawal Notice. 

  

	 	10.9	 MedImmune will notify Innate as soon as reasonably practicable and not later than within [***] of the end of each
Calendar Quarter if any of the milestones events set out above in Section 10.5 have been achieved in that Calendar Quarter. 

  

	 	10.10	 Except as provided in Section 10.21, no payments pursuant to Section 10.5 shall be creditable against any
other payments MedImmune is obligated to make to Innate under this Agreement. 

 Royalties 

 

	 	10.11	 Subject to the provisions set forth below in Sections 10.12, 10.13, 10.14, 10.15, 10.16, 10.17, 10.18, 10.19, 10.20
and 10.22, MedImmune shall pay to Innate, with respect to each Licensed Product containing IPH2201, an incremental royalty on aggregate Annual Net Sales of each such Licensed Product containing IPH2201 made by MedImmune, its Affiliates, or its
Sublicensees as follows: 

  
 62 

			
	 	 
	
Portion of aggregate Annual Net Sales of relevant Licensed Product

    
	  	  

      Royalty Rate      

    

	
    
 [***]

 
	  	 [***]

    

	
    
 [***]

 
	  	 [***]

    

	
    
 [***]

 
	  	 [***]

    

 [***] 
  

	 	10.12	 The calculation of royalties under Section 10.11 shall be conducted separately for each Licensed Product. Thus,
if MedImmune sells more than one Licensed Product in the Territory, the thresholds and ceilings in Section 10.11 shall apply separately to each Licensed Product. For purposes of the foregoing, all Licensed Products containing IPH2201 shall be
deemed the same Licensed Product. 

  

	 	10.13	 The Territory shall exclude Europe for the purposes of calculating royalties above if Innate has not provided its Co-Funding Withdrawal Notice. 

  

	 	10.14	 Sales between MedImmune, its Affiliates and Sublicensees shall not be subject to royalties hereunder. Royalties shall
be calculated on MedImmune’s, its Affiliates’ and Sublicensees’ sales of the Licensed Products to a Third Party, including Distributors (but excluding, for the avoidance of doubt, Affiliates and Sublicensees). Royalties shall be
payable only once for any given batch of the Licensed Products. For the purpose of determining Net Sales, the Licensed Product shall be deemed to be sold when invoiced and a “sale” shall not include, and no royalties shall be payable on,
transfers by MedImmune, its Affiliates or Sublicensees of free samples of Licensed Product or clinical trial materials, or other transfers or dispositions for charitable, promotional, pre-clinical, clinical,
manufacturing, testing or qualification, regulatory or governmental purposes to the extent that such transfer is made at the Transfer Price or less. 

  

	 	10.15	 If, at any time, in any particular country in the Territory, a given Licensed

  
 63 

	 	 
Product [***], then, the royalty rates set forth in the table in Section 10.11 shall be reduced by [***] for the purposes of calculating royalties due under this Agreement as from the first
Calendar Quarter in which this Section 10.15 applies, and thereafter for so long as this Section 10.15 applies in such particular country. The calculation of the royalty reduction under this Section 10.15 shall be conducted separately
for each Licensed Product in each country. 

  

	 	10.16	 If, at any time, in any particular country in the Territory, (i) a Generic Product receives Regulatory Approval
in such country and (ii) in any two consecutive Calendar Quarters such Generic Product(s), by unit equivalent volume in such country, exceed a [***] share of the market for the Licensed Product and relevant Generic Products; then, the royalty
rates set forth in the table in Section 10.11 shall be reduced by [***] as from the first Calendar Quarter in which this Section 10.16 applies and thereafter for the remainder of the period during which royalties are payable with regard to
such Licensed Product in such country. The calculation of the royalty reduction under this Section 10.16 shall be conducted separately for each Licensed Product in each country. For purposes of this Section “market” refers to the
aggregate of the sales of the Generic Product(s) and the applicable Licensed Product in a country. 

  

	 	10.17	 If, at any time, in any particular country in the Territory, a court or a governmental agency of competent
jurisdiction requires MedImmune or its Affiliate or Sublicensee to grant a compulsory license to a Third Party permitting such Third Party to make and sell Licensed Product containing IPH2201 in one or more countries in the Territory (a
“Compulsory License”), and the royalty rate for royalties payable to MedImmune, its Affiliate or Sublicensee on Net Sales (which term for the purpose of this Section 10.17 shall apply mutatis mutandis to sales by such
grantee) of Licensed Product containing IPH2201 by or on behalf of such grantee of the Compulsory License is less than the royalty rate for royalties on Net Sales due to Innate pursuant to Section 10.11 in such country, then if MedImmune has in
due time informed Innate of the start of such action or proceedings by such court or governmental agency of competent jurisdiction and taken into account Innate’s reasonable comments, the royalty rate applicable to Net Sales for royalties due
to Innate in such country shall be reduced to be equal to the royalty rate for royalties payable by the grantee of the Compulsory License. The royalty rate reduction 

  
 64 

	 	 
set forth herein shall be effective as from the first Calendar Quarter in which this Section 10.17 applies and thereafter for so long as this Section 10.17 applies. The calculation of
the royalty rate reduction under this Section 10.17 shall be conducted separately for each Licensed Product in each country. 

  

	 	10.18	 Any reductions set forth in this Section 10 shall be applied in the order in which the event triggering such
reduction occurs, provided that in no event shall, due to the cumulative reductions set out in Sections 10 the royalties that would otherwise have been payable to Innate in application of the royalty rates set forth in the table in
Section 10.11 be reduced by more than [***] in any given country. Credits not exhausted in any Calendar Quarter in any given country may however be carried into future Calendar Quarters in such country, subject to the foregoing sentence.

  

	 	10.19	 MedImmune’s obligation to pay royalties due under Section 10.11 shall expire, on a country-by-country basis, with respect to such Licensed Product, at the latest of: (i) the tenth (10th) anniversary of the First Commercial Sale of such Licensed Product
in such country (or, in the case of any country in Europe, the tenth (10th) anniversary of the First Commercial Sale of such Licensed Product in any country in Europe), (ii) the expiry of the Regulatory Exclusivity covering the Licensed Product in
such country and (iii) the date on which there is no longer a Valid Claim covering the use, manufacture or sale of Licensed Product in such country. At such time as MedImmune’s obligation to pay royalties under Section 10.11 have
terminated in a country, the Net Sales of such Licensed Product in such country shall be excluded from royalty calculations under Section 10.11 (including for purposes of applying thresholds and ceilings). 

 

	 	10.20	 Subject to Sections 12.9 and 12.10, if (i) MedImmune, [***] (“Third Party Payment”), then for the
period during which MedImmune owes royalties to Innate hereunder, the amounts that would otherwise have been payable as royalties to Innate under this Agreement shall be reduced by [***] of all Third Party Payment payable by or on behalf of
MedImmune to such Third Party. As used herein, [***]. 

  

	 	10.21	 In consideration of Innate paying thirty percent (30%) of the Shared Development Costs in accordance with
Section 7.1 (including the limitations 

  
 65 

	 	 
therein), Innate will be entitled to receive fifty percent (50%) of the Profit/Loss earned by MedImmune and its Affiliates on sales of the Licensed Products in Europe. MedImmune will provide a
report to Innate within [***] of the end of each Calendar Quarter setting out the Profit /Loss in that quarter and if such calculation shows a Profit shall pay fifty percent (50%) of such amount to Innate within [***] of receiving an invoice for
such amount from Innate. Any Loss shall be carried forward and offset against (i) subsequent Profits, (ii) any other sums due to Innate under this Agreement other than reimbursement of Development Costs and Commercialization Costs in
accordance with this Agreement, provided that Innate shall always be entitled to receive, and MeImmune shall pay to Innate, any amount corresponding to payments which Innate is obliged to pass through to the applicable counter Party under the Third
Party Agreements. Subject to the foregoing, no Profit will be shared hereunder until all Losses have been recouped by MedImmune. If after all Losses have been recouped pursuant to the preceding sentence, a Profit is made and shared equally between
the Parties in [***] consecutive Calendar Quarters, any Loss which may be made in any period after such three (3) consecutive Calendar Quarters of Profit shall be borne by the Parties in equal shares and a balancing payment shall be payable by
the applicable Party within [***] of receipt of an invoice from the Party which has borne more than fifty percent (50%) of any such Loss in any applicable Calendar Quarter. 

Provisions affecting consideration 
  

	 	10.22	 Combination Products. With regard to sales of the Licensed Antibodies when incorporated in or combined with another
article, composition or product, which [***], and sold or otherwise supplied as a Combination Product [***], the Net Sales of the Licensed Product, for the purposes of determining royalty payments, shall be determined by [***].

 In the event that, with respect to any Combination Product, [***], Net Sales for purposes of determining royalty
payments shall be calculated by [***]. 
 [***] 

[***]. 

  
 66 

 [***]. 

[***]. 
 For
purposes of the calculations set forth in this Section 10.22, [***]. 
  

	 	10.23	 Separate Licensed Product. Notwithstanding anything else set forth in this Agreement to the contrary, the
milestones and royalties in this Section 10shall not apply to development or commercialization of a Licensed Product for diagnostic, veterinary or any other use other than as a therapeutic pharmaceutical product in humans (“Separate
Licensed Product”). If MedImmune develops a Separate Licensed Product, MedImmune shall pay to Innate such separate milestones and royalties for the development, commercialization or sale of such Separate Licensed Product as are commercially
reasonable taking into account each Party’s respective investment to date in the Separate Licensed Product, the commercial potential of such product, the future cost of developing and commercializing such product, the then current stage of
development and the probability of successfully launching such product. In the event that MedImmune decides to initiate development of a Separate Licensed Product, MedImmune shall notify Innate thereof in writing and the Parties shall thereafter
negotiate in good faith within a period of [***] from such notice to agree on such separate milestones and royalties. A failure by the Parties to reach such agreement shall not preclude MedImmune from developing or commercializing a Separate
Licensed Product or from otherwise exercising the rights and licenses granted to it by Innate under this Agreement. However, in the event of a failure by the Parties to reach such agreement within the aforementioned [***] period or any extension of
such period mutually agreed by the Parties or otherwise in the event of a dispute as to the separate milestones and royalties for a Separate Licensed Product, each Party shall be entitled to escalate the matter in accordance with Section 17.2
and, if applicable, to refer the matter to arbitration in accordance with Section 17.1. 

  

	 	10.24	 Sales by Sublicensees. In the event MedImmune grants sublicenses to one or more Sublicensees to make or sell
Licensed Products to the extent permitted hereunder, such sublicenses shall include without limitation an obligation for 

  
 67 

	 	 
the Sublicensee to account for and report its Net Sales of such Licensed Products on the same basis as if such sales were Net Sales by MedImmune, and MedImmune shall pay royalties to Innate as if
the Net Sales of the Sublicensee were Net Sales of MedImmune. 

  

	 	10.25	 Royalty Payments and Reports. The royalties payable under Section 10.11 shall be calculated quarterly as
of the last day of each Calendar Quarter, for the Calendar Quarter ending on that date. MedImmune shall deliver to Innate a report summarizing the Net Sales of Licensed Products during each Calendar Quarter following the First Commercial Sale of a
Licensed Product in the Territory. Such report shall be delivered within [***] following the end of each Calendar Quarter for which royalties are due from MedImmune. Any royalties payable to Innate or its designee under this Agreement shall be paid
on the due date for the report in the foregoing sentence of this Section 10.25. 

  

	 	10.26	 Taxes. The royalties, milestones and other amounts payable by MedImmune to Innate pursuant to this Agreement
(“Payments”) shall [***] (and, if necessary, the receipt by MedImmune of appropriate governmental authorization) at least [***] prior to the time that the Payments are due. If MedImmune [***]. 

 

	 	10.27	 Notwithstanding anything to the contrary contained in this Section 10 or elsewhere in this Agreement, the
following shall apply with respect to Indirect Taxes. All Payments are stated exclusive of Indirect Taxes. If any Indirect Taxes are chargeable in respect of any Payments, MedImmune shall pay such Indirect Taxes at the applicable rate in respect of
any such Payments following the receipt, where applicable, of an Indirect Taxes invoice issued in the appropriate form by Innate in respect of those Payments, such Indirect Taxes to be payable on the due date of the payment of the Payments to which
such Indirect Taxes relate or at the time such Indirect Taxes are required to be collected by Innate, in the case of payment of Indirect Taxes to Innate. The Parties shall issue invoices for all goods and services supplied under this Agreement
consistent with Indirect Tax requirements, and to the extent any invoice is not initially issued in an appropriate form, MedImmune shall promptly inform Innate and shall cooperate with Innate to provide such information or assistance as may be
necessary to enable the issuance of such invoice consistent with Indirect Tax requirements. 

  
 68 

	 	10.28	 Payments or Reports by Affiliates. Any Payment required under any provision of this Agreement to be made to
Innate or any report required to be made by MedImmune shall be made by an Affiliate of MedImmune if such Affiliate is designated by MedImmune as the appropriate payer or reporting entity. 

 

	 	10.29	 Mode of Payment and Invoice Requirements. All payments set forth in this Section 10, or otherwise in this
Agreement due from MedImmune to Innate, shall be remitted by wire transfer to the bank account of Innate as designated in writing to MedImmune. All invoices submitted by Innate to MedImmune as provided in this Agreement shall fulfil the requirements
set forth in this Section 10. Unless otherwise instructed by MedImmune, Innate’s invoices to MedImmune shall be sent to MedImmune Limited, Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom , and shall contain
(a) MedImmune’s Agreement ID number or purchase order number, (b) the number and date of the invoice, (c) the latest date of payment, not to be less than [***] following MedImmune’s receipt of the invoice and in no event
prior to the due date, (d) name and address of Innate, (e) invoice amount and currency (USD), (f) bank details, i.e. bank number and bank code, and (g) SWIFT-address and (h) contain Innate’s VAT number. All payments set
forth in this Section 10, or otherwise in this Agreement due from Innate to MedImmune, shall be remitted by wire transfer to the bank account of MedImmune as designated in writing to Innate. 

 

	 	10.30	 Payment Currency. All payments and reports required from MedImmune or Innate under this Agreement shall be paid
and stated respectively in US dollars. With respect to amounts required to be converted into US dollars from another currency for calculation or payment hereunder, such amounts will be converted using a rate of exchange which corresponds to the rate
used for conversion between the relative currencies by whichever Party recorded the relevant receipt or expenditure, for the respective reporting period in its books and records that are maintained in accordance with IFRS, as applicable, and used
for its external reporting. If a Party is not required to perform such a currency conversion for its IFRS reporting with respect to the applicable period, then for such period such Party will make such conversion using the rate of exchange
calculated using the Foreign Exchange rates set at 14:15 CET and as published by the European Central Bank 

  
 69 

	 	 
(https://www.ecb.europa.eu/stats/exchange/eurofxref/html/index.en.html) on the second to last business day of the calendar month (or such other publication as
agreed-upon by the Parties) in which such receipt or expenditure was incurred. 

  

	 	10.31	 Set-off. Where a Party is due to make a payment to the other in
accordance with the terms of this Agreement, that Party shall be entitled to set-off against such payment any amount owed to it from the other Party or that other Party’s Affiliates, under this Agreement
or otherwise, provided that set-off shall not be permitted in respect of sums that are disputed, until such disputed payments have been agreed or finally determined by arbitration. 

 

	 	10.32	 Imports. For the avoidance of doubt, the Parties acknowledge and agree that none of the milestones or royalties
payable under this Agreement are related to the license (or right) to import or any import of Licensed Products. The receiving Party shall be responsible for any import clearance, including payment of any import duties and similar charges, in
connection with any Licensed Products transferred to such Party under this Agreement. The Parties shall co-operate in accordance with Applicable Laws to ensure where permissible that no import duties are paid
on imported materials. Where import duties are payable, the Parties shall co-operate to ensure that the Party responsible for shipping values the materials in accordance with Applicable Laws and minimizes
where permissible any such duties and any related import taxes that are not reclaimable from the relevant authorities. 

  

	11	 CONFIDENTIALITY 

  

	 	11.1	 At all times during the Term and for a period of [***] following termination or expiration thereof, each Party (the
“Receiving Party”) shall (i) keep confidential and not disclose to any Third Party, other than its and its Affiliates’ officers, directors, other employees, contractors and advisors on a need to know basis, any
Confidential Information provided to it by the other Party (the “Disclosing Party”) and (ii) not publish or otherwise use, directly or indirectly, for any purpose, such Confidential Information, except to the extent permitted
by the terms of this Agreement or to the extent such use is necessary for the fulfilment of the Receiving Party’s obligations under this Agreement. The 

  
 70 

	 	 
Receiving Party shall cause all of its and its Affiliates’ officers, directors, other employees, contractors and advisors to whom the Receiving Party has disclosed Confidential Information
to comply with confidentiality and non-use obligations at least as restrictive as those set out in this Agreement and shall be liable to the Disclosing Party for any breach thereof by such Affiliates,
officers, directors, other employees, contractors and advisors. 

  

	 	11.2	 Innate recognizes that by reason of, among other things, MedImmune’s status as an exclusive licensee pursuant to
the grants under Section 3, MedImmune has an interest in Innate’s retention in confidence of information relating to the Licensed Antibodies or Licensed Products, and the Exploitation thereof. Innate shall, and shall cause its Affiliates
and their respective officers, directors, employees and agents to, until the expiration of MedImmune’s obligation to pay royalties hereunder, keep confidential and not publish or otherwise disclose, and not use directly or indirectly for any
purpose other than to perform Innate’s obligations under this Agreement or as expressly permitted hereunder, any Confidential Information relating to any Licensed Antibody or Licensed Product that is Controlled by Innate (“Product
Information”). In the event this Agreement is terminated in its entirety, this Section shall have no continuing force or effect. 

  

	 	11.3	 The obligations of confidentiality and non-use herein shall not extend to any
Confidential Information that, in the case of Sections 11.1 and 11.2, (a) is or comes into the public domain without breach of this Agreement, (b) is received by a Party from a Third Party (other than an Affiliate of Disclosing Party) without
any obligation of confidentiality and without breach of this Agreement, or, in the case of Sections 11.1 and 11.2, or (c) in the case of Section 11.1, the Receiving Party can prove was already in its possession without any limitation on
use or disclosure prior to the Effective Date. 

  

	 	11.4	 Nothing in this Section 11 shall prevent either Party from using and disclosing Confidential Information to the
extent reasonably required for te Receiving Party’s performance of its obligations and exercise of its rights granted to it under this Agreement or other agreement between the Parties. In particular either Party shall be entitled to use and
disclose Confidential Information of Innate relating to Licensed Products for Patent filing and prosecution purposes, 

  
 71 

	 	 
for the purposes of making Drug Approval Applications and for the purposes of appointing Third Parties to manufacture Licensed Products; provided, however, that MedImmune may [***].

  

	 	11.5	 In addition each Party shall be entitled to disclose the terms of this Agreement on a confidential basis to actual or
potential investors or in connection with any permitted assignment under this Agreement or in connection with any proposed grant of a sub-license by MedImmune as permitted by this Agreement, provided that in
each case the Receiving Party shall cause any and all parties to whom such disclosure is made to comply with confidentiality and non-use obligations at least as restrictive as those set out in this Agreement
and shall be liable to the Disclosing Party for any breach thereof by such parties. 

  

	 	11.6	 This Agreement shall not restrict the Receiving Party from complying with a lawfully issued governmental order or
legal requirement or requirement under applicable stock exchange rules to produce or disclose Confidential Information; provided, however, that, in the event of governmental orders, the Receiving Party shall promptly notify the
Disclosing Party to enable the Disclosing Party to oppose the order or obtain a protective order and the Receiving Party shall cooperate fully with the Disclosing Party in any such proceeding. If the Receiving Party is legally required or required
under applicable stock exchange rules to disclose Confidential Information, the Receiving Party and the Disclosing Party will endeavour to agree to a mutually satisfactory means to disclose such information. Nothing contained herein shall prohibit
either of the Parties from immediately disclosing results of any Clinical Trial to the extent necessary to prevent or mitigate a serious health hazard; provided, however, that the Party intending to make such disclosure shall notify
the other Party prior to and immediately after such disclosure and, to the extent it is reasonably practicable to do so, the nature and content of such disclosure shall be agreed between the Parties. 

 

	 	11.7	 The Parties acknowledge that each of them shall use Commercially Reasonable Efforts to monitor scientific publications
to prevent any adverse effect from premature publication relating to the Licensed Antibodies or Licensed Products. The Party wishing to make a publication or communication on shall provide a draft to the other Party, which will have [***] to provide
comments. The Party 

  
 72 

	 	 
proposing to make a publication or communication shall, in good faith, consider the comments made by the other Party and shall defer the publication or communication for a period of time not
exceeding [***] if a Patent may be filed using the Data or Know How covered in the proposed publication or communication. MedImmune shall have the final decision making with respect to any proposed publication or communication, provided that
MedImmune shall acknowledge the contribution of Innate to the development of the Licensed Product. Publications by Innate relating to Licensed Products following First Commercial Sale of the first Licensed Product by Innate shall only to be made
with MedImmune’s prior written approval. MedImmune will use Commercially Reasonable Efforts to provide a copy of any proposed publication to be made following First Commercial Sale of the first Licensed Product to Innate before it is published.
Notwithstanding the foregoing, neither Party will publish or present any Confidential Information of the other Party without such other Party’s prior written consent. 

 

	 	11.8	 This Section 11 (other than Section 11.2) shall survive the termination or expiration of this Agreement for
a period of ten (10) years. 

  

	12	 OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS 

 

	 	12.1	 Disclosure. During the Term, each Party shall promptly disclose to the other Party all Arising IP (whether
patentable or not) which is created by or on behalf of such Party as a result of carrying out the activities assigned to it under this Agreement. 

  

	 	 	 Ownership 

  

	 	12.2	 Innate shall retain all rights, title and interest in and to any and all Licensed Technology, subject only to the
licenses granted to MedImmune in this Agreement. MedImmune shall retain all rights, title and interest in and to any and all MedImmune Technology. Subject to such licenses and the remainder of this Agreement, (a) if Innate has not provided its Co-Funding Withdrawal Notice, any Arising IP conceived or made by any Party or their employees or independent contractors (including those of its Affiliates, Sublicensees and other Third Parties) shall be jointly
owned by the Parties and the relevant Party 

  
 73 

	 	 
shall assign which shall transfer a [***] co-ownership interest in such Arising IP to the other Party, and (b) if Innate has provided its Co-Funding Withdrawal Notice, any Arising IP conceived or made by a Party or its employees or independent contractors (including those of its Affiliates, Sublicensees and other Third Parties) shall belong to such
Party and any Arising IP conceived or made by both Parties or their employees or independent contractors (including those of its Affiliates, Sublicensees and other Third Parties) shall be jointly owned by the Parties as determined based on
inventorship in accordance with US patent laws; provided that in either case any Arising IP arising from either Party’s conduct of CMC development work and solely related to such Party’s proprietary CMC technology shall be owned by such
Party, and further provided that in either case any MedImmune Compound Arising IP conceived or made by a Party or its employees or independent contractors (including those of its Affiliates, Sublicensees and other Third Parties) shall belong to
MedImmune. To the extent permissible under Applicable Laws, each Party will cause each employee and contractor (including those of its Affiliates, Sublicensees and other Third Parties) conducting work on its behalf under this Agreement to sign a
contract that (i) compels prompt disclosure of all Arising IP, (ii) automatically assigns to such Party all right, title and interest in and to such Arising IP, and (iii) obligates such persons to maintain confidentiality in respect
of the Arising IP (on terms at least as restrictive as those contained herein). Each Party will require each employee and contractor conducting work on its behalf under this Agreement to maintain records in sufficient detail and in a good scientific
manner appropriate for regulatory purposes and purposes of pursuing Patent protection on inventions to properly reflect all work done. 

  

	 	 	 Prosecution and Maintenance of Patent Rights 

 

	 	12.3	 The Parties will each appoint a patent coordinator for the purposes of coordinating their activities under this
Section 12. MedImmune (the “Responsible Party”) shall be primarily responsible for and shall use Commercially Reasonable Efforts in control the preparation, filing, prosecution (including without limitation conducting or handling any
interferences, oppositions, action for declaratory judgment, nullity actions, reissue proceedings, reexaminations and challenges to title) and maintenance of the Licensed Patents (other than the Formulation Patent, the
Non-Exclusively 

  
 74 

	 	 
Licensed Patents and the Licensed Shared Patents) and Patents claiming Arising IP (“Arising Patents”) (collectively, the “Controlled Patents”); provided
that the Responsible Party shall provide the other Party with advance copies of, and a reasonable opportunity to comment upon, proposed patent filings, related prosecution strategies and proposed correspondence with patent officials or other Third
Parties relating to any Controlled Patents (excluding any such Patents protecting MedImmune Compound Arising IP or any Arising IP relating to MedImmune’s proprietary CMC technology), and will consider comments received from the other Party with
respect to such proposed filings, strategies and correspondence in good faith. Innate shall use Commercially Reasonable Efforts to explore [***] and, to the extent reasonably practicable, ensure [***]. 

 

	 	12.4	 The Responsible Party shall further be responsible for all costs and expenses associated with the filing, prosecution
and maintenance of the Controlled Patents, and where applicable, the Licensed Shared Patents. 

  

	 	12.5	 If the Responsible Party decides not to file, prosecute or maintain a Controlled Patent (excluding any such Patents
protecting MedImmune Compound Arising IP or any Arising IP relating to MedImmune’s proprietary CMC technology), it shall give the other Party reasonable notice to that effect sufficiently in advance of any deadline for any filing with respect
to such Patent. After receiving such notice, the other Party may elect by written notice to the Responsible Party within [***] after receiving such notice from the Responsible Party to file, prosecute and maintain the relevant Licensed Patent, at
its sole cost and expense. If the other Party does so elect, the Responsible Party shall cooperate with Innate as necessary to enable Innate to perform such acts as may be reasonably necessary for Innate to file, prosecute or maintain such Patent,
including the execution and filing of appropriate instruments and to facilitate the transition of such patent activities to Innate. For the avoidance of doubt, Innate shall not have any comment rights or rights to assume prosecution of any Arising
Patents claiming MedImmune Compound Arising IP or any Arising IP relating to MedImmune’s proprietary CMC technology. 

  

	 	12.6	 The Responsible Party shall be responsible for and shall control, in consultation with the other Party, the selection
of the appropriate Controlled Patents as listed in the patent information section of the Drug Approval Application for 

  
 75 

	 	 
Licensed Products for filing to obtain a Patent Term Extension (“PTE”) pursuant to all Applicable Laws, including without limitation supplementary protection certificates and any
other extensions that are now or become available in the future wherever applicable to Controlled Patents that are applicable to the Licensed Product. 

  

	 	12.7	 Promptly after the Effective Date, Innate shall (a) provide to MedImmune all information, including a correct and
complete list of all Patents covering the Licensed Product(s) or otherwise necessary or reasonably useful to enable MedImmune to make filings with Regulatory Health Authorities with respect to the Licensed Patents, including as required or allowed
in connection with (i) in the United States, the FDA’s Purple Book and (ii) outside the United States, under the national implementations of Section 10.1(a)(iii) of Directive 2001/EC/83 or other international equivalents, and
(b) cooperate with MedImmune at MedImmune’s reasonable request in connection therewith, including meeting submission deadlines, in each case, to the extent required or permitted by Applicable Laws. Promptly after the Effective Date and not
less than [***] prior to any subsequent deadline with respect to the foregoing, the Parties shall discuss and identify those Patents claiming or covering the Licensed Product and the process of review of such Patents for submission to the applicable
Regulatory Health Authorities. MedImmune shall have the right, at its sole discretion, to submit or de-list any Licensed Patent with respect to any Regulatory Health Authority with prior notice to Innate.

  

	 	12.8	 Notwithstanding anything to the contrary in this Section 11, neither Party shall have the right to make an
election under the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. 103(c)(2)-(c)(3) (the “CREATE Act”) when exercising its rights under this Section 11 without the prior written consent of the other
Party. With respect to any such permitted election, the Parties shall use reasonable efforts to cooperate and coordinate their activities with respect to any submissions, filings or other activities in support thereof. The Parties acknowledge and
agree that this Agreement is a “joint research agreement” as defined in the CREATE Act. 

  

	 	 	 In-licensed IP and Third-Party Patent Rights 

  
 76 

	 	12.9	 Innate shall, during the Term, not make any material changes or alterations to the Third Party Agreements adversely
impacting MedImmune’s rights under this Agreement except with the prior written consent of MedImmune. Innate will be responsible for any costs and payments (including without limitation upfront fees, annual fees, milestone payments and
royalties) due to any Third Party in relation to the Third Party Agreements. Innate shall notify MedImmune immediately if Innate becomes aware of any dispute arising under a Third Party Agreement. In the event that [***]. 

 

	 	12.10	 MedImmune will be responsible for any costs and payments (including without limitation upfront fees, annual fees,
milestone payments and royalties) due to any Third Party in connection with the use of an MedImmune Compound in a Combination which is Researched, Developed, Commercialized and/or Exploited under this Agreement. 

 

	 	12.11	 Defense of Third Party Claims. Except as otherwise provided in Section 13, neither Party makes any
warranty with respect to the validity, perfection, or dominance of any Patent or proprietary right or with respect to the absence of rights in Third Party Patents which may be infringed by the manufacture or sale of any Licensed Antibody or Licensed
Product. If a Third Party asserts a Patent or other right owned by it is infringed by the Development, Manufacture or Exploitation of any Licensed Antibody or Licensed Product, or either Party discovers such a Patent or right, the Party first
obtaining knowledge of such a claim or potential claim shall immediately provide the other Party written notice and the related facts in reasonable detail. In the event the Parties cannot agree on the defense of any such claim, such defense shall be
controlled by the Responsible Party; provided that the other Party shall have the right to participate and to be represented in any such action by counsel of its selection at its sole discretion. The Responsible Party shall also have the right to
control settlement of such claim; if such settlement requires the Responsible Party to pay a royalty to the Third Party, such expense shall be treated pursuant to Section 10.20. 

 

	 	12.12	 Oppositions. Either Party may commence an opposition, action for declaratory judgment, nullity action,
interference, re-examination, or other attack upon the validity, title, or enforceability of any Patents Controlled by a Third Party 

  
 77 

	 	 
that cover the Manufacture, use, or sale or other Exploitation of any Licensed Antibody or Licensed Product and are not Licensed Patents, MedImmune Patents or Patents in the Arising IP, at its
own expense, but shall notify the other before commencing such action to enable the Parties to cooperate, if they see fit. 

Infringement by Third Parties  
  

	 	12.13	 The Party first having knowledge that any Controlled Patent has been infringed or misappropriated by a Third Party in
any country in the Territory shall promptly notify the other in writing, such notice setting forth the facts of that infringement in reasonable detail. 

  

	 	12.14	 The Responsible Party shall have the first right, but not the obligation, to institute, prosecute, and control any
action or proceeding or negotiation of any settlements with respect to any infringement of Controlled Patents (with the other Party having the right to participate in such action or negotiations at its expense and be represented if it so desires).
If necessary, the other Party agrees in any such action to be joined as a claimant and to give the Responsible Party reasonable assistance and any needed authority to control, file, and to prosecute such action, at the Responsible Party’s
expense. If the Responsible Party elects not to institute and prosecute such action or proceeding or to conduct such negotiation, the Responsible Party will discuss with the other Party the reasons for this decision and the other Party may step in
the Responsible Party’s rights for purposes of this Section 12.14, with the consent of the Responsible Party not to be unreasonably withheld. 

  

	 	12.15	 Compensation. Any damages or monetary awards relating to the Controlled Patents shall be applied as follows:
(a) to reimburse any and all out-of-pocket costs incurred by the Responsible Party in bringing suit; (b) to reimburse any and all out-of-pocket costs incurred by the other Party in relation to the suit; and (c) any remaining damages shall be allocated at [***] to the Responsible Party and [***] to
the other Party. 

 Trademarks, Packaging and Labelling 

  
 78 

	 	12.16	 MedImmune shall have the sole right and discretion to: 

 

	 	(i)	 select the trademarks to be used specifically for the marketing and sale of all Licensed Products in the Territory
(each a “Product Trademark”). MedImmune shall own all rights, title and interests in and to the Product Trademarks and all IP rights and other rights and goodwill associated therewith. Innate shall not use any trademark that is the
same or confusingly similar to, misleading or deceptive with respect to, or that dilutes any of the Product Trademarks. MedImmune shall have the right; 

  

	 	(ii)	 use internal or external counsel of its own choosing and at its sole expense to, file, prosecute, maintain, protect,
defend and enforce the Product Trademarks; 

  

	 	(iii)	 design and procure packaging and labeling of the Licensed Products. 

Each Party shall notify the other Party promptly in writing upon learning of any actual, alleged, or threatened infringement of a
Product Trademark used in connection with the Licensed Products or in relation to the indications for which they are marketing, of any unfair trade practices, trade dress imitation, passing off of counterfeit goods, or like offenses. Innate shall
cooperate as reasonably requested by MedImmune in any actions or proceedings brought by MedImmune to halt the infringement. 
  

	13	 REPRESENTATIONS, WARRANTIES AND COVENANTS  

 

	 	13.1	 Mutual Warranties. Each Party provides the following representations and warranties to the other as at the
Effective Date: 

  

	 	(a)	 Corporate Power. It is duly organized, validly existing and in good standing under the laws of its jurisdiction of
incorporation or formation, has full legal power to grant the rights granted to the other Party under this Agreement, and has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof.

  
 79 

	 	(b)	 Due Authorisation. The execution, delivery, and performance of the Agreement by it does not conflict with any agreement,
instrument, or understanding, oral or written, to which it is a party or by which it is bound, nor violate any material law or regulation of any court, Governmental Body, or administrative or other agency having jurisdiction over it.

  

	 	(c)	 Binding Agreement. This Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance
with its terms. 

  

	 	13.2	 Innate Warranties. Innate provides the following representations, warranties and covenants to MedImmune as of
the date of signing of the Development and Option Agreement (or as of such other dates or time periods as may be specified below). Such representations, warranties and covenants shall be considered to be restated by Innate as at the Effective Date,
subject to Innate’s right to make disclosures against such representations, warranties and covenants with respect to matters which have arisen or come to the knowledge of Innate (with respect to representations made to Innate’s knowledge)
between the date of signing of the Development and Option Agreement and the Effective Date of this Agreement. For the avoidance of doubt, Innate shall not be liable for facts and circumstances fairly disclosed to MedImmune in accordance with the
preceding sentence. 

  

	 	(a)	 Innate is: (i) the sole and exclusive owner of the entire right, title and interest in the Licensed Patents
listed in Schedule 13.2(a)(i) (the “Owned Patents”), (ii) the sole and exclusive licensee of the Licensed Patents listed in Schedule 13.2(a)(ii) (the “Exclusively Licensed Patents”), in connection with the Licensed
Antibodies, and (iii) the non-exclusive licensee of the Non-Exclusively Licensed Patents, in connection with the Licensed Antibodies, and (iv) either itself or
through its Affiliates, the sole and exclusive owner or licensee of the entire right, title and interest in the Licensed Know-How listed in Schedule 13.2(a)(iv) and has the right to grant an exclusive
license to MedImmune in connection with the Development and Commercialization of the Licensed Antibodies in the Field under the other Licensed Know How. To the extent any rights, title or interests in the Licensed
Know-How are owned by its Affiliates, Innate 

  
 80 

	 	 
shall procure that such rights are transferred to Innate such that MedImmune shall receive from Innate all rights and licenses granted to it under this Agreement and such that Innate shall be
entitled without restriction to grant the rights to MedImmune specified in the License Agreement. 

  

	 	(b)	 Other than for the restrictions set forth in the Third Party Agreements, which have been disclosed to MedImmune prior
to the date of signing of the Development and Option Agreement, and the licenses granted to the Licensed Shared Patents for use in connection with [***], none of the Licensed Patents is subject to any encumbrance or lien permitted by Innate and none
of the Owned Patents is subject to any encumbrance or lien permitted by Innate or, to Innate’s knowledge, to any claim of ownership by any Third Party. For the duration of the Term, Innate shall not encumber the rights granted to MedImmune
hereunder with respect to the Licensed Technology in a manner that would have an material adverse effect on MedImmune’s rights hereunder. 

  

	 	(c)	 The Third Party Agreements are in full force and effect and Innate has no knowledge of any circumstances that may lead
to the termination of such agreements. 

  

	 	(d)	 As at the Effective Date, Innate does not own or Control any Product Trademarks,
Know-How or Patents, other than the Licensed Technology, that are necessary for the Research, Development and Exploitation of the Licensed Products. The Patents specified in Schedules 9.2(a)(i) and
9.2(a)(ii) constitute all of the Licensed Patents existing at the Effective Date. To Innate’s and its Affiliates’ knowledge, the Licensed Patents have as of the Effective Date been diligently and properly filed, prosecuted and
maintained in accordance with Applicable Law where applicable in the course of normal patent prosecution of patents that are intended to be maintained, and all applicable fees have been paid on or before the due date for payment.

  

	 	(e)	 To the knowledge of Innate’s and its Affiliates’ personnel responsible for patent matters, in respect of all
US patent applications in the Listed 

  
 81 

	 	 
Patents, Innate (or, as appropriate, its licensor) has submitted all material prior art of which it is aware in accordance with the requirements of the United States Patent and Trademark Office.

  

	 	(f)	 To Innate’s and its Affiliates’ knowledge, as of the Effective Date, the Licensed Patents properly identify
each and every inventor of the claims of the Licensed Patents. To Innate’s and its Affiliates’ knowledge, each Person who has contributed to the conception of inventions claimed in the Licensed Patents owned by Innate and existing as of
the Effective Date, has duly assigned and has executed an agreement assigning to Innate, or as appropriate, Innate’s licensor, such Person’s entire right, title and interest in and to such Licensed Patents. 

 

	 	(g)	 Where Licensed Know-How has been disclosed to a Third Party
under terms of confidentiality, to Innate’s knowledge no breach of such confidentiality obligations has been committed by any such Third Party. MedImmune shall not, before, on or after the Effective Date, have any obligation to contribute to
any remuneration of any inventor employed or previously employed by Innate or any of its Affiliates in respect of the Current IPH2201, Licensed Patents or Licensed Know-How. Innate or its Affiliates are solely
responsible for paying all such remuneration and neither Innate nor any of its Affiliates has received notification that such payments are insufficient compensation. 

 

	 	(h)	 Innate and its Affiliates have not been notified of any actual or threatened infringements or misappropriation of the
Licensed Technology. 

  

	 	(i)	 Innate and its Affiliates have not been notified of any threatened or pending proceedings in any court, arbitration,
patent office, administrative or other tribunal which are concerned with (a) the ownership of any of the Licensed Technology, or (b) the validity of any of the Licensed Patents (other than pending Patent applications), and, in both cases,
to Innate’s and its Affiliates’ knowledge, there have been no allegations or assertions by a Third Party which are likely to give rise to a claim by such Third Party for ownership or invalidity of the Licensed Patents.

  
 82 

 Third Party Rights 

 

	 	(j)	 The conception, development and reduction to practice of the Licensed Know-How
and Licensed Patents existing as of the Effective Date has not, to Innate’s knowledge, constituted or involved the misappropriation of trade secrets of any Person. Other than the amounts owed by Innate under the Third Party Agreements, there
are no claims, judgments or settlements against or amounts with respect thereto owed by Innate or any of its Affiliates as of the Effective Date relating to the Regulatory Documentation, Listed Patents or Licensed
Know-How, or amounts owed by Innate or its Affiliates with respect to any such claims, judgments or settlements. 

  

	 	(k)	 To Innate’s and its Affiliates’ knowledge, as of the Effective Date, the Development and the
Commercialization of the Current IPH2201 does not infringe or misappropriate the Patents, of any Third Party, and no claim or litigation has been brought or threatened by written notice to Innate as of the Effective Date by any Person making such
allegations. 

  

	 	(l)	 MedImmune shall not, before, on or after the Effective Date, have any obligation to pay any fees, charges or other
sums due to a Third Party under the Third Party Agreements in relation to Licensed Products containing the Current IPH2201. 

Development and Manufacture 
  

	 	(m)	 As at the Effective Date, since the adoption of the Specification in Schedule 13.2(m), all Current IPH2201
produced by, to Innate’s knowledge, on behalf of Innate, has been, Manufactured, packaged, stored and labelled (as applicable) in accordance with all Applicable Laws and the Specification in Schedule 13.2(m).

  

	 	(n)	 As at the Effective Date, Innate’s contract manufacturing organizations for the Licensed Product are those
specified in Schedule 13.2(n) and the manufacturing agreements listed on that schedule are in full force and effect and Innate has no knowledge any circumstances that would lead to

  
 83 

	 	 
the termination of such agreements. 

 Regulatory and
Compliance 
  

	 	(o)	 As of the Effective Date, Innate, its Affiliates and, to their knowledge, their contractors, have at all times
(a) researched and developed the Licensed Product in accordance with all Applicable Laws, and (b) undertaken clinical trials and prepared, maintained and retained all Regulatory Documentation in accordance with GLP, GCP, regulations and
other Applicable Laws. 

  

	 	(p)	 Innate has made available to MedImmune all Regulatory Documentation, Licensed
Know-How and other information in its possession or Control as of the Effective Date regarding or related to any Licensed Antibody or Licensed Product that MedImmune has specifically requested, with reasonable
clarity, in writing to Innate to make available or that Innate would reasonably consider based on the information available at the Effective Date to be material to MedImmune’s evaluation of whether to enter this Agreement and all such items are
true, complete and correct. 

  

	 	(q)	 All Regulatory Documentation that are the material regulatory filings or approvals held by Innate or its Affiliates in
relation to the Research, Development and Manufacture of the Licensed Products have been provided to MedImmune prior to the Effective Date. 

  

	 	(r)	 Innate and its Affiliates have not knowingly withheld from a Regulatory Health Authority or from MedImmune any
material information, including CMC Know-How, Serious Adverse Events and results from Clinical Trials (whether or not completed) relating to the safety, toxicity, quality or efficacy of the Licensed Products.

  

	 	(s)	 Innate and its Affiliates have the right to refer to and use any data that has been created by the manufacturers of
the Licensed Product which is necessary for the use and registration of the Licensed Product and MedImmune will have the same rights under this Agreement. 

  
 84 

	 	(t)	 In the course of the Development of the Licensed Product, Innate has not knowingly used, any employee or consultant
that is debarred by any Regulatory Health Authority or, to its knowledge, is the subject of debarment proceedings by any Regulatory Health Authority. 

  

	 	(u)	 The information provided by Innate to MedImmune (for the purposes of MedImmune’s assessment as to whether or not
filing is required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to this Agreement or the transactions contemplated herein) regarding Innate’s and its Affiliates’ corporate structure and financial
status is correct, complete and not misleading. 

 General 

 

	 	(v)	 Neither Innate nor any Innate Affiliate is engaged in any litigation, opposition or arbitration affecting or relating
to the Current IPH2201 and, as to Innate and its Affiliates’ knowledge as at the Effective Date, there are no such litigation, opposition or arbitration pending or threatened by written notice to Innate and no material facts which are likely to
result in a material judgment against Innate or its Affiliates relating to the Licensed Products. 

  

	 	(w)	 The rights granted to MedImmune under this Agreement are not subject to any right, license or interest under the
Licensed Patents in favour of any government due to funding obtained with respect to Licensed Products or clinical trials carried out in government owned hospitals which would conflict with the rights granted to MedImmune under this Agreement.

  

	 	13.3	 MedImmune Warranties. MedImmune provides the following representations, warranties and covenants to Innate as
of the date of signing of the Development and Option Agreement (or as of such other dates or time periods as may be specified below). Such representations, warranties and covenants shall be considered to be restated by MedImmune as at the Effective
Date, subject to MedImmune’s right to make disclosures against such representations, warranties and covenants with respect to matters which have arisen or come 

  
 85 

	 	 
to the knowledge of Innate (with respect to representations made to MedImmune’s knowledge) between the effective date of the Development and Option Agreement and the Effective Date of this
Agreement. 

  

	 	(a)	 No claim or litigation has been brought or threatened as of the Effective Date in relation to an MedImmune Compound by
any Person making such allegations by written notice to MedImmune. 

  

	 	(b)	 MedImmune will not knowingly use in any capacity, in connection with the Development of the Licensed Product, any
employee or consultant that is debarred by any Regulatory Health Authority or, to the best of such its knowledge, is the subject of debarment proceedings by any Regulatory Health Authority. If either Party learns that any employee or consultant
performing on its behalf under this Agreement has been debarred by any Regulatory Health Authority, or has become the subject of debarment proceedings by any Regulatory Health Authority, such Party shall promptly notify the other Party and shall
prohibit such employee or consultant from performing on its behalf under this Agreement. 

  

	 	(c)	 The information provided by MedImmune to Innate (for the purposes of Innate’s assessment as to whether or not
filing is required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to this Agreement or the transactions contemplated herein) regarding MedImmune’s and its Affiliates’ corporate structure and
financial status is correct, complete and not misleading. 

  

	 	(d)	 MedImmune is not researching, Developing or otherwise Exploiting a Competing Product. 

Mutual Covenants 
  

	 	13.4	 If either Party learns that any employee or consultant performing on its behalf under this Agreement has been debarred
by any Regulatory Health Authority, or has become the subject of debarment proceedings by any Regulatory Health Authority, such Party shall promptly notify the other Party and shall prohibit such employee or consultant from performing on its behalf
under this 

  
 86 

	 	 
Agreement.  

  

	 	13.5	 Each Party shall, and shall procure that its Affiliates and its/their contractors shall, during the Term,
(a) Manufacture, research and develop the Licensed Product in accordance with all Applicable Laws, and (b) undertake clinical trials and prepare, maintain and retain all Regulatory Documentation in accordance with GLP, GCP, regulations and
other Applicable Laws. 

  

	 	13.6	 Anti-Corruption Laws 

 

	 	(a)	 Both Parties shall ensure that in connection with this Agreement, they shall conduct their activities in a manner that
is consistent with the Anti-Corruption Laws. Each Party further undertakes that none of its or its Affiliates’ employees, directors or officers shall, directly or indirectly, engage in any activities that violate any Anti-Corruption Law
(a) in order to influence official action of any Government Official, or (b) with the intention of or as a condition to inducing any person to carry out a duty or function improperly or to reach a favourable decision on an improper basis,
in each case in connection with the activities contemplated under this Agreement. 

  

	 	(b)	 Each Party shall promptly provide the other Party with written notice of (a) becoming aware of a Material
Anti-Corruption Law Violation by it or any of its or its Affiliates’ employees, directors or officers with respect to the subject matter of this Agreement, or (b) upon receiving a formal notification that it or any of its or its
Affiliates’ employees, directors or officers is the target of a formal investigation by any Governmental Authority for a Material Anti-Corruption Law Violation. 

 

	 	(c)	 Innate acknowledges that its undertakings given in this Section (c) are material to MedImmune in entering into
this Agreement. Notwithstanding any other provision of this Agreement, if MedImmune becomes aware of what it determines, acting reasonably, to be a breach of these undertakings, then MedImmune shall be entitled to terminate this Agreement in its
entirety, and to terminate any other agreement between the Parties, on notice with immediate effect. Subject to the accrued 

  
 87 

 
rights of the Parties pursuant to termination, MedImmune shall have no liability to Innate for any fees, reimbursements or other compensation or for any loss, cost, claim or damage resulting,
directly or indirectly, from such termination. At the sole discretion of MedImmune, any breach of an Innate obligation with respect to its obligation in this subsection (c) may be cured (if capable of being cured) within a reasonable period of
time after learning of such material breach or Material Anti-Corruption Law Violation. 
 13.4 DISCLAIMER OF WARRANTY. EXCEPT
FOR THE EXPRESS WARRANTIES SET FORTH IN SECTION 13 NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER
WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE
NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. 
  

	14	 RECORD RETENTION, AUDIT AND USE OF NAME 

 

	 	 	 Records Retention; Audit 

 

	 	14.1	 Each Party shall keep or cause to be kept accurate records of account in accordance with IFRS, showing information
that is necessary for the accurate determination of the royalties and other payments due under Section 10, or any other payment due hereunder. Such records or books of account shall be kept until the third (3rd) anniversary of December 31
of the Calendar Year in which the relevant Licensed Product is sold (in the case of royalty or other payments due under Section 10) or in the period for which any other payment hereunder is required to be made. For clarity, each Party shall
cause its Affiliates to keep, and shall require pursuant to a written agreement that any Sublicensee, other sublicensee or subcontractor performing activities hereunder keep accurate records or books of account in a manner that will permit such
Party to comply with its obligations under the foregoing sentence. 

  
 88 

	 	14.2	 Upon the written request of the other Party, each Party shall permit a qualified accountant or a person possessing
similar professional status and associated with an independent accounting firm acceptable to the Parties to inspect during regular business hours and no more than once a year and once in any given Calendar Year, and going back no more than three
(3) years preceding the current Calendar Year, all or any part of the audited Party’s records and books necessary to check the accuracy of any payments made or required to be made hereunder. The accounting firm shall disclose to Innate and
MedImmune only whether the payments made are correct and details concerning any discrepancies, but no other information. The charges of the accounting firm shall be paid by the Party requesting the inspection, except that if the payments being
audited have been underpaid or the costs being reimbursed have been overstated by more than [***], the charges will be paid by the Party whose records and books are being inspected. Any failure by a Party to exercise its rights under this
Section 14.2 with respect to a Calendar Year within the three (3) year period allotted therefor shall constitute a waiver by such Party of its right to later object to any payments made by the other Party under this Agreement during such
Calendar Year. 

  

	 	 	 Publicity Review 

  

	 	14.3	 Subject to the remainder of this Section 14.3 and to Section 11, no Party shall originate any written
publicity, news release, or other announcement relating to this Agreement or the existence of it or to performance hereunder (collectively, “Written Disclosure”), without the prior written approval of the other, which approval shall
not be unreasonably withheld or delayed. Notwithstanding the foregoing, any Party may make public Written Disclosures it believes in good faith are required by Applicable Laws or any listing or trading agreement concerning its publicly traded
securities, provided that, prior to such Written Disclosure, the disclosing Party shall where reasonably practicable provide the other Party with a copy of the materials proposed to be disclosed and an opportunity to promptly review and comment. If
the receiving Party reasonably requests that any information in the materials proposed to be disclosed be deleted, the disclosing Party shall use reasonable efforts to request confidential treatment of such information pursuant to any applicable
regulation relating to the confidential treatment of information. The terms of 

  
 89 

	 	 
this Agreement may be disclosed to (a) Government Agencies where required by Applicable Laws, provided that the Party making such disclosure seeks a protective order or confidential
treatment of this Agreement to the extent allowed under Applicable Laws, (b) Third Parties having a need to know information for purposes of performing under this Agreement or advising a Party with respect to its performance under this
Agreement or its business or legal obligations, or (c) Third Party investment bankers, financial advisors, actual or potential Third Party partners, licensors, investors, licensees, sublicensees or acquirers of any of the assets to which this
Agreement relates; provided, that, disclosures under subsections (b) or (c) shall be made on a need to know basis under confidentiality obligations at least as strict as those contained herein and the Party having made such disclosures shall be
liable to the other for any breach of such confidentiality obligation by the Third Party recipient. Notwithstanding the foregoing, the Parties intend to issue jointly press releases regarding material events occurring with respect to the Development
or Commercialization of Licensed Products pursuant to this Agreement. Such material events may include without limitation the commencement or completion of a Phase 3 Clinical Trial for Licensed Products, the filing of a Drug Approval Application,
and the receipt of Regulatory Approval for Licensed Products. The content of any such press releases shall be agreed upon by the Parties in advance of any such announcement being provided to any Third Party. 

Use of Names 
  

	 	14.4	 Neither Party shall use the name, insignia, symbol, trademark, trade name or logotype of the other Party or its
Affiliates in relation to this transaction or otherwise in any public announcement, press release, or other public document without the prior written consent of such other Party, which consent shall not be unreasonably withheld, delayed or
conditioned, except for those disclosures for which consent has previously been obtained; provided, however, that either Party may use the name of the other Party in any document required to be filed with any government authority,
including without limitation the FDA and the Securities and Exchange Commission or otherwise as may be required by Applicable Laws, provided that such disclosure shall be governed by Section 11. Further, the restrictions imposed on each Party
under this Section 14.4 are not intended, and shall not be construed, to prohibit a Party from identifying the 

  
 90 

	 	 
other Party in its internal business communications, provided that any Confidential Information in such communications remains subject to Section 11. Moreover, and notwithstanding the
foregoing, MedImmune and its Affiliates and Sublicensees and Innate and its Affiliates shall have the right to use the name of Innate and its Affiliates to the extent necessary or useful in connection with the Exploitation of the Licensed Products
or perform the activities as contemplated by this Agreement in their negotiations and work with subcontracting and sublicensing transactions in connection therewith provided that any Confidential Information in such communications remains subject to
Section 11. 

  

	15	 TERM AND TERMINATION 

 

	 	15.1	 Term. The term of this Agreement shall commence as of the Effective Date and, unless sooner terminated as
provided herein, shall continue in effect until the date on which all of MedImmune’s payment obligations under Section 10 have been performed or have expired (the “Term”). 

 

	 	15.2	 Termination Rights 

  

	 	 	 Termination for Cause 

 

	 	(i)	 Subject to the provisions of this Section 15.2(i), if either Party (the “Breaching Party”) shall
have committed a material breach of any of its material obligations under this Agreement, and such material breach shall remain uncured and shall be continuing for a period of [***] following the Breaching Party’s receipt of notice of such
breach from the other Party (the “Breach Invoking Party”) stating the Breach Invoking Party’s intent to terminate this Agreement in its entirety pursuant to this Section 15.2(i) if such breach remains uncured, then, in
addition to any and all other rights and remedies that may be available, the Breach Invoking Party shall have the right to terminate this Agreement effective upon the expiration of such [***] period (subject, however, to the provisions set forth
below in this Section 15.2(i). Notwithstanding the above, if (i) such material breach cannot reasonably be cured within such [***], (ii) 

  
 91 

	 	 
the Breaching Party provides, within such [***], the Breach Invoking Party with a written detailed plan that contains measures that can be reasonably expected to cure such breach as soon as
reasonably practicable but no later than within [***], and (iii) the Breaching Party commences to perform such measures in accordance with such plan, and (iv) the Breaching Party thereafter diligently continues to perform such measures as
detailed in such plan, then the Breach Invoking Party shall not be entitled to terminate this Agreement (and any notice of termination issued pursuant to the foregoing sentence shall not become effective) unless and until the Breaching Party ceases
to diligently perform such measures despite then not having cured the breach or does not cure the breach during the timeframe set forth in the plan. Notwithstanding the above, if within the aforementioned [***] period either Party takes measures to
resolve the dispute (for which termination is being sought) pursuant to Section 17.2 and thereafter (if the dispute then remains unresolved) within a period of [***] after the expiry of the time period set forth in Section 17.2, initiates
arbitration as permitted under Section 17.3 to resolve the dispute and diligently pursues such procedure, then termination shall be suspended until the arbitration tribunal determines through its final resolution of the dispute that such breach
exists. This Section 15.2(i) defines exclusively the Parties’ right to terminate this Agreement for any material breach of contract. 

  

	 	 	 Termination for Convenience   

 

	 	(ii)	 Prior to its expiration, this Agreement may be terminated in its entirety at any time by MedImmune effective upon one
hundred and twenty (120) days (or such longer period as MedImmune may elect at its sole discretion) prior written notice to Innate. 

  

	 	 	 Termination for Insolvency   

 

	 	(iii)	 A Party may terminate this Agreement effective immediately upon written notice to the other Party if at any time
during the Term, 

  
 92 

	 	 
the other Party (the “Debtor”) (i) becomes insolvent, (ii) files for or is subject to the institution of bankruptcy, liquidation or receivership proceedings, (iv) assigns all
or a substantial portion of its assets for the benefit of creditors, (v) has a receiver or custodian appointed for the Debtor’s business, or (vi) has a substantial part of its business being subject to attachment or similar process;
provided, however, that in the event of any involuntary case the first Party shall not be entitled to terminate this Agreement pursuant to this subsection 15.2(iii) if the case is dismissed within sixty (60) days after the commencement thereof.

  

	 	 	 Termination for Patent Challenge 

 

	 	(iv)	 Termination by Innate for Patent Challenge. Except to the extent the following is not enforceable under the law of a
particular jurisdiction, this Agreement may be terminated by Innate in its entirety upon written notice to that effect to MedImmune, if MedImmune or any of its Affiliates has challenged the validity, enforceability or scope of any Licensed Patent
(an “IP Challenge”) and failed to withdraw the IP Challenge within [***] after having received Innate’s written notice of the IP Challenge requiring such IP Challenge to be withdrawn (including notice of Innate’s intention
to otherwise terminate this Agreement). This Section 15.3(iv) shall not apply in relation to any IP Challenge made by MedImmune as a counterclaim or defence in response to an action brought by Innate, its Affiliates or any Third Party licensee
or licensor of Innate or its Affiliates alleging infringement of a Licensed Patent by MedImmune for activities that do not relate to NKG2A. 

  

	 	 	 Consequences of a MedImmune Triggered Termination 

 

	 	15.3	 In the event (a) Innate terminates this Agreement pursuant to Section 15.2(i) for MedImmune’s material
breach; (b) Innate terminates this Agreement 

  
 93 

	 	 
pursuant to Section 15.2(iii) for MedImmune’s insolvency; (c) Innate terminates this Agreement pursuant to Section 15.2(iv); or (d) MedImmune terminates this Agreement
pursuant to Section 15.2(ii) for convenience; (a termination as per (a) through (d) being an “MedImmune Triggered Termination”), MedImmune shall, subject to Section 15.4(i), continue to be obligated during the
termination notice period (as applicable) to perform as far as reasonably practicable all of its obligations under this Agreement, except in the event of a termination pursuant to Section 15.2(ii) for material safety concerns. For purposes of
this Section 15.3 and Section 15.4, “material safety concerns” shall the reasonable belief, based upon new scientific data that there are safety and public health issues relating to the Licensed Product such that the medical
benefit/risk ratio of such Product is sufficiently unfavorable as to materially compromise the welfare of patients. If a MedImmune Triggered Termination occurs after the first Regulatory Approval of a Licensed Product, MedImmune shall continue to
use Commercially Reasonable Efforts to Commercialize such Licensed Product until the earlier of (i), if applicable, the expiration of the one hundred twenty (120) day notice period, in the event of a termination by MedImmune pursuant to
Section 15.2(ii) other than for material safety concerns; (ii) receipt of Innate’s written notice that MedImmune may cease such Commercialization activities; or (iii), if applicable, the effective date of the termination notice. In
addition, as a result of a MedImmune Triggered Termination the following shall apply: 

  

	 	(i)	 All licenses and rights to the Licensed Technology granted to MedImmune hereunder shall terminate as of the effective
date of such termination, except to the extent and for so long as is necessary to permit MedImmune to meet its obligations under this Agreement, to finish
work-in-progress and sell any inventory as per Section 15.3(xi) and to otherwise perform any responsibilities in connection with any then ongoing Clinical Trial or
other activity that cannot be terminated as of such date under Applicable Laws, including GCP, it being agreed that all such activities and responsibilities shall be discontinued and ceased (unless otherwise agreed or required under Applicable Laws
by transitioning such activities and responsibilities to Innate) as promptly as possible, subject to Applicable Laws, including GCP. 

  
 94 

	 	(ii)	 If the notice of the MedImmune Triggered Termination is given at a time when the Clinical Trials or any other Assigned
Activities have been initiated but not yet completed, then the Parties shall work together in good faith during the termination notice period to ensure that MedImmune’s involvement in and responsibilities for such activities will be
discontinued and ceased as efficiently and promptly as possible (by way of transitioning such involvement and responsibilities to Innate or by other means agreed to by the Parties), subject to Applicable Laws, including GCP, and provided that the
foregoing shall be without prejudice to MedImmune’s obligations under this Agreement and rights under Section 15.3(xi) and that provided further that, with respect to any Clinical Trial related to the Licensed Product for which a Contract
Research Organisation has been contracted or the first patient has been dosed, whichever is the earlier, MedImmune shall pay to Innate, upon the effective date of termination, its unpaid portion of the Shared Development Costs, as budgeted in the
corresponding Development Budget until completion of such Clinical Trial (i.e., final report sent to the Regulatory Authorities). 

  

	 	(iii)	 MedImmune shall grant, and hereby grants to Innate an exclusive, worldwide, royalty-bearing right and license, with
the right to grant sublicenses, under any MedImmune Technology solely to the extent incorporated into or necessary for the Exploitation of the Licensed Products, or applicable to the use, formulation, method of making or method of treatment of
Licensed Products as they exist as of the effective date of the MedImmune Triggered Termination solely to Exploit Licensed Antibodies and Licensed Products in the Territory, provided that Innate shall indemnify, defend and hold harmless MedImmune,
its Affiliates and each of its and their respective employees, officers, directors and agents as set forth in Section 16.3 from and against any Damages arising out of or resulting from Third Party Claims that arise or result from Innate’s
or its sublicensees’ activities performed under the foregoing license and further provided that such license shall not include a license to any confidential manufacturing or CMC related

  
 95 

	 	 
Information (“MedImmune Manufacturing Technology”) related to the Licensed Products. If any MedImmune Manufacturing Technology is being used in relation to the Licensed Products at the
date of termination the Parties will negotiate in good faith to agree within [***] of the notice of termination terms under which MedImmune will continue to make the Licensed Products on behalf of Innate, which terms shall include a supply price
equal to the Transfer Price plus a mark-up of [***], or such technology will be provided to a CMO on terms satisfactory to MedImmune to allow the CMO to make the Licensed Product on behalf of Innate, provided
that such technology transfer (including any comparability studies costs) shall be at MedImmune’s costs. 

  

	 	(iv)	 Each Party shall return all data, files, records and other materials in its possession or Control containing or
comprising the other Party’s Confidential Information to which such first Party does not retain rights hereunder (except one copy thereof, which may be retained by the returning Party solely for legal archive purposes). 

 

	 	(v)	 MedImmune shall, where permitted under Applicable Laws, as promptly as reasonably practical transfer to Innate all
INDs, Drug Approval Applications, and Regulatory Approvals with respect to Licensed Antibodies and Licensed Products (but not with respect to any other compounds or products), and shall take such other actions and execute such other instruments,
assignments, and documents as may be necessary to effect the transfer of rights hereunder to Innate or its designee at MedImmune’s expense. Innate shall indemnify and hold harmless MedImmune, its Affiliates and each of its and their respective
employees, officers, directors, and agents as set forth in Section 16.3 from and against any Losses arising out of or resulting from Third Party Claims that arise or result from Innate’s, its Affiliates’ or its sublicensees’
Exploitation of the Licensed Antibodies or Licensed Products under any INDs, Drug Approval Applications or Regulatory Approvals transferred hereunder. 

  
 96 

	 	(vi)	 MedImmune will assign (or cause its Affiliates to assign) to Innate or its designee, at Innate’s request, all of
MedImmune’s (or its Affiliates’) rights and obligations under agreements with Third Parties with respect to (i) the conduct of Clinical Trials for each Licensed Product, including Agreements with contract research organizations,
clinical sites and investigators that relate to Clinical Trials in support of Regulatory Approvals in the Territory, (ii) the Manufacture of Licensed Antibodies or Licensed Product (subject to MedImmune’s obligations to manufacture after
termination), and (iii) any other Third Party agreements involving the Development or Commercialization of the Licensed Products, unless in each of (i) through (iii), such agreement is not permitted to be assigned pursuant to its terms or
relates to products other than Licensed Products, in which case MedImmune will cooperate with Innate in all reasonable respects to transfer as promptly as reasonably practical to Innate the benefit of such contract (against Innate undertaking to
perform all the obligations and assume all liabilities under such contract) in another mutually acceptable manner and upon Innate’s request facilitate discussions between Innate and such Third Parties to assist Innate in entering into a direct
agreement with such Third Parties. 

  

	 	(vii)	 MedImmune shall at MedImmune’s sole cost and expense assign all of its rights in and to all Product Trademarks
for Licensed Products (and all registrations and applications for registration therefor) that it owns pursuant to Section 12.6 (trademarks packaging and labelling) to Innate or its designee and Innate shall have the exclusive right (but not the
obligation) to enforce the Product Trademark rights against infringers. 

  

	 	(viii)	 Upon Innate’s request, MedImmune shall transfer to Innate copies of all materials, data, results, analyses,
reports, websites, marketing materials, technology, regulatory filings and other Information and Materials existing in tangible or electronic form at the effective date of the MedImmune Triggered Termination, that is Controlled by MedImmune and has
been generated on or 

  
 97 

	 	 
before the effective date of such termination by or on behalf of MedImmune, its Affiliates or Sublicensees with respect to the Licensed Products (“MedImmune Product Data”) and
Innate shall have the right to use on a non-exclusive basis such MedImmune Product Data solely related to the Licensed Products and non-exclusive basis all other MedImmune Product Data to the extent necessary
or useful to enable Innate to proceed to Develop, Manufacture and Commercialize Licensed Products upon and after termination of this Agreement, provided that Innate shall indemnify and hold harmless MedImmune, its Affiliates and each of its and
their respective employees, officers, directors and agents as set forth in Section 16.3 from and against any Damages arising out of or resulting from Third Party Claims that arise or result from the use of any MedImmuna Product Data hereunder.

  

	 	(ix)	 As the sole consideration of the foregoing transfer of MedImmune Product Data and, if applicable, INDs, Drug Approval
Applications, Regulatory Approvals, Product Trademarks and license and any other rights granted under the above provisions in this Section 15.4, Innate shall pay to MedImmune royalty payments pursuant to Section 10 at rates reduced by
[***] if the Agreement is terminated [***] or reduced by [***] if this Agreement is terminated [***], calculated as if all Net Sales by Innate or its Affiliates or sublicensees in the Territory were Net Sales by MedImmune, provided that in the event
that the Agreement has been terminated by Innate pursuant to Section 15.2(i) due to MedImmune’s material breach no royalty shall be due by Innate to MedImmune; 

 

	 	(x)	 For the avoidance of doubt the rights granted to Innate under this Section 15.3 are restricted to Licensed
Antibodies and Licensed Products and MedImmune does not grant any rights whatsoever to any other compounds or products (other for the avoidance of doubt than the MedImmune Compounds forming part of the Licensed Product prior to the effective date of
termination as a fixed dose combination or in a co-packaged form, in relation to 

  
 98 

	 	 
which the Parties will agree reasonable terms relating to the supply by MedImmune of the MedImmune Compound contained in such fixed dose combination or
co-packaged form within [***] of the date of notice of termination and at a supply price equal to the Transfer Price plus a mark-up of [***] or to any Intellectual
Property Rights other than as set forth in this Agreement. If the Licensed Product is being promoted to be co-prescribed with a MedImmune Compound, Innate’s rights under this Section 15.3 shall be
limited to being able to promote the Licensed Product in such co-prescribed combination. Moreover, MedImmune shall not be obligated to provide Innate with any other IPR or other rights or services than that
which is explicitly provided for under this Section 15.3. 

  

	 	(xi)	 MedImmune shall be entitled, during a period of [***] following the MedImmune Triggered Termination, to finish any work-in-progress to sell any inventory of the Licensed Product that remains on hand as of the date of the termination, so long as MedImmune pays to Innate the royalties
applicable to said subsequent sales in accordance with the terms and conditions set forth in this Agreement; provided that MedImmune’s rights under this Section 15.3(xi) shall be subject to Innate’s prior written consent, which shall
not be unreasonably withheld, delayed or conditioned, further provided that Innate’s consent shall not be required if MedImmune is selling Licensed Product to satisfy existing obligations to MedImmune customers. 

 

	 	(xii)	 Notwithstanding anything else set forth in this Agreement but without prejudice to MedImmune’s obligations
pursuant to Section 15.3 (ii), (i) MedImmune shall not have any obligations to continue any Development, Manufacture or Commercialization of the relevant Licensed Antibody or Licensed Product if MedImmune has terminated this Agreement pursuant
to Section 15.2(ii) with reference to any material safety concerns; and (ii) should Innate elect to pursue any Development, Manufacture or Commercialization of the relevant Licensed Antibody or Licensed

  
 99 

	 	 
Product following any such termination by MedImmune, Innate shall - without prejudice to or limitation of any other or further obligations Innate may have to MedImmune under this Agreement
(including Section 16.3) - indemnify MedImmune for any Third Party claims arising from Innate’s Development, Manufacture or Commercialization after the effective date of the termination of the relevant Licensed Antibody or Licensed Product
as set forth in Section 16. 

  

	 	(xiii)	 The provisions of this Section 15 shall be Innate’s exclusive remedy in the event of MedImmune’s
termination pursuant to Section 15.2 (ii). 

 Consequences of Termination (or Right to Terminate) by
MedImmune for Innate’s breach or insolvency 
  

	 	15.4	 If MedImmune is entitled to terminate this Agreement pursuant to Section 15.2(ii) as a result of a material
breach by Innate or Section 15.2(iii) for an insolvency or other transaction described therein affecting Innate, MedImmune may elect to terminate this Agreement subject to the provisions set forth in Section 15.4(i), or to continue the
Agreement subject to the provisions set forth in Section 15.4 (ii). 

  

	 	(i)	 If MedImmune terminates the Agreement under Section 15.2(i) or under Section 15.2(iii), the Parties will
negotiate in good faith the transfer of rights back to Innate in respect of Licensed Products consistent with the terms of Section 15.3, provided that such transfer shall be at Innate’s cost. 

 

	 	(ii)	 If MedImmune has the right to terminate this Agreement under Section 15.2(i) or Section 15.2(iii), MedImmune
may elects to continue this Agreement by providing written notice to Innate that it is invoking this clause. In such event, this Agreement shall continue in full force and effect except as follows: 

 

	 	(A)	 Innate’s rights under the Co-Promote Option (whether or

  
 100 

	 	 
not exercised prior to the termination) shall terminate and the Profit/Loss share will be adjusted in accordance with Section 8.4. 

 

	 	(B)	 Innate shall, at MedImmune’s request, cease any Development, Manufacturing or Commercialization activities
performed by Innate pursuant to this Agreement (but Innate’s right to co-fund the Development pursuant to this Agreement and share Profit shall continue in full force and effect subject to any adjustment
made pursuant to (A) above), Innate shall cease to have the right to participate in the DCC and SCC, and, upon such request, Innate shall furnish MedImmune with reasonable cooperation to assure a smooth transition to MedImmune (or its designee)
of any such activities then being conducted or performed by Innate. 

  

	 	(C)	 Innate shall return all data, files, records and other materials in its possession or Control containing or comprising
MedImmune’s Confidential Information to which Innate does not retain rights hereunder (except one copy thereof, which may be retained by Innate solely for legal archive purposes). 

 

	 	15.5	 Except where expressly provided for otherwise in this Agreement, termination of this Agreement by either Party shall
not relieve the Parties of any liability, including without limitation any obligation to make payments hereunder, which accrued hereunder prior to the effective date of such termination, nor preclude any Party from pursuing all rights and remedies
it may have hereunder or at law or in equity with respect to any breach of this Agreement, nor prejudice any Party’s right to obtain performance of any obligation. In the event of such termination, this Section 15.5 shall survive in
addition to others specified in this Agreement to survive in such event. 

  

	 	15.6	 Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by a Party are, and shall
otherwise be deemed to be, for the purposes of Section 

  
 101 

	 	 
365(n) of the United States Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101 of the United States Bankruptcy Code or equivalent
provisions of applicable legislation in any other jurisdiction. The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under the United States
Bankruptcy Code, or equivalent provisions of applicable legislation in any other jurisdiction. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the Unites States Bankruptcy
Code or equivalent provisions of applicable legislation in any other jurisdiction, the Party that is not a party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property
and all embodiments of such intellectual property, which, if not already in the non-subject Party’s possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy
proceeding upon the non-subject Party’s written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations under this Agreement, or (b) if not
delivered under subsection (a) above, following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party.

  

	 	15.7	 Change of Control of Innate. Innate shall provide to MedImmune written notice of any Change of Control of
Innate as soon as practicable after the effective date of an agreement pursuant to which such Change of Control would be effected, but in any event within [***] of the closing of the Change of Control transaction. Upon any Change of Control of
Innate, the following shall apply [***]. 

  

	 	15.8	 Surviving Rights and Obligations. The rights and obligations set forth in this Agreement shall extend beyond
the expiration or termination of the Agreement only to the extent expressly provided for herein, or to the extent that the survival of such rights or obligations are necessary to permit their complete fulfilment or discharge. Without limiting the
foregoing, the Parties have identified various rights and obligations which are understood to survive, as follows: In the event of expiration or termination of this Agreement for any reason, the following provisions shall survive in addition to
others specified in 

  
 102 

	 	 
this Agreement to survive in such event: Sections 1, 2.1, 3.14, 6.4, 10 (solely to the extent provided in Sections 15.3 and 15.4), 11, 12.2, 14.1, 14.2, 15.3, 15.4, 15.5, 15.8, 15.9, 16 (solely
as to actions arising during the term of this Agreement, or as to activities conducted in the course of a Party’s exercise of licenses surviving after the term of this Agreement), 17 and 18.6 to 18.12. 

 

	 	15.9	 Accrued Rights. Termination, relinquishment, or expiration of the Agreement for any reason shall be
without prejudice to any rights that shall have accrued to the benefit of either Party prior to such termination, relinquishment, or expiration, including without limitation damages arising from any breach hereunder. Such termination,
relinquishment, or expiration shall not relieve either Party from obligations that are expressly indicated to survive termination or expiration of the Agreement. 

 

	16	 INDEMNIFICATION  

 

	 	16.1	 LIMITATION OF LIABILITY. EXCEPT IN CIRCUMSTANCES OF NEGLIGENCE OR INTENTIONAL MISCONDUCT BY A PARTY OR ITS
AFFILIATES, OR WITH RESPECT TO THIRD PARTY CLAIMS UNDER SECTIONS 16.1 AND 16.2, IN NO EVENT SHALL EITHER PARTY OR ITS RESPECTIVE AFFILIATES AND SUBLICENSEES BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL, OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT,
WARRANTY, TORT, STRICT LIABILITY, OR OTHERWISE. This Section 16 shall not limit either Party’s obligations under Section 11. 

  

	 	16.2	 Indemnification. MedImmune hereby agrees to indemnify, defend, and hold harmless Innate, its Affiliates, and
each of its and their respective employees, officers, directors and agents from and against any and all Damages incurred by them resulting from or arising out of or in connection with any suits, claims, actions or demands made or brought by a Third
Party (collectively, “Third Party Claims”) against Innate, its Affiliates or their respective employees, officers, directors or agents, that result from or arise out of the Development, Manufacture, use, handling, storage,
Commercialization, or other disposition of Licensed Products by MedImmune or its Affiliates, agents, Distributors, Sublicensees or other sublicensees in the Territory (including with respect to any Product Liability Claim), except in any case, to
the extent such Damages are Damages for which Innate has an obligation to indemnify MedImmune, its 

  
 103 

	 	 
Affiliates or their respective employees, officers, directors or agents pursuant to Section 15.3(viii) and 15.3(xiii) or Section 16.3, as to which Damages each Party shall indemnify the
other to the extent of their respective liability for such Damages. For purposes of the foregoing “Product Liability Claim” means any product liability claims asserted or filed by Third Parties (without regard to their merit or lack
thereof), seeking damages or equitable relief of any kind, relating to personal injury, wrongful death, medical expenses, an alleged need for medical monitoring, consumer fraud or other alleged economic Damages, allegedly caused by any Licensed
Product, and including claims by or on behalf of users of any Licensed Product (including spouses, family members and personal representatives of such users) relating to the use, sale, distribution or purchase of any Licensed Product sold by or on
behalf of MedImmune, its Affiliates or Sublicensees, including, but not limited to, claims by third party payers, such as insurance carriers and unions). 

  

	 	16.3	 Innate hereby agrees to indemnify, defend and hold harmless MedImmune, its Affiliates, and each of its and their
respective employees, officers, directors and agents from an against any and all Damages incurred by them resulting from or arising out of or in connection with any Third Party Claims against MedImmune, its Affiliates or their respective employees,
officers, directors or agents, that result from or arise out of (i) the Manufacture, use, handling, storage, sale or other disposition of Licensed Products by Innate or its Affiliates, agents, distributors or sublicensees prior to the Effective
Date or (ii) any material breach by Innate of its obligations hereunder with respect to Innate’s activities in the Development, Detailing, Pre-Approval Activities and Other Promotional Activities
related to the Licensed Product and assigned to Innate pursuant to this Agreement; except in any case, to the extent such Damages are Damages for which MedImmune has an obligation to indemnify Innate, its Affiliates or their respective employees,
officers, directors or agents pursuant to Section 16.2, as to which Damages each Party shall indemnify the other to the extent of their respective liability for such Damages. 

 

	 	16.4	 Mechanism. In the event that a Party (the “Indemnified Party”) is seeking indemnification
under Section 16.2 or 16.3, it shall notify the other Party (the “Indemnifying Party”) in writing of the relevant Third Party Claim and the relevant Damage for which indemnification is sought as soon as reasonably

  
 104 

	 	 
practicable after becoming aware of such claim. Such notices shall contain a description of the Third Party Claim and the nature and amount of the Damage (to the extent known). The Indemnified
Party shall furnish promptly to the Indemnifying Party copies of all papers and official documents received in respect of such Third Party Claim or Damage. For the avoidance of doubt, all indemnification claims in respect of a Party, its Affiliates,
and each of its and their respective employees, officers, directors and agents shall be made solely by such Party to this Agreement. To the extent that the Indemnifying Party irrevocably commits to indemnify any Indemnified Party in respect of the
Third Party Claim, the Indemnified Party shall permit the Indemnifying Party to assume direction and control of the defense of the relevant Third Party Claim (including without limitation the right to settle the claim solely for monetary
consideration), and shall cooperate as requested (at the expense of the Indemnifying Party) in the defense of the claim. 

  

	 	16.5	 Notwithstanding Section 16.1, the failure to give timely notice to the Indemnifying Party shall not release the
Indemnifying Party from liability to the Indemnified Party to the extent the Indemnifying Party is not prejudiced thereby and, for the avoidance of doubt, the Indemnifying Party shall not be liable to the extent any Damage is caused by any delay by
the Indemnified Party in providing such notice. Notwithstanding the provisions of Section 16.4 requiring the Indemnified Party to tender to the Indemnifying Party the exclusive ability to defend such claim, if the Indemnifying Party does not
satisfy the condition set forth in Section 16.4 to, or declines to or fails to timely assume control of the relevant Third Party Claim, the Indemnified Party shall be entitled to assume such control, conduct the defense of, and settle such
claim, all at the sole costs and expense of the Indemnifying Party; provided, however, that neither Party shall settle or dispose of any such claim in any manner that would adversely affect the rights or interests or admit fault, of
the other Party without the prior written consent of such other Party, which shall not be unreasonably withheld, delayed or conditioned. Each Party, at the other Party’s expense and reasonable request, shall cooperate with such other Party and
its counsel in the course of the defense or settlement of any such claim, such cooperation to include without limitation using reasonable efforts to provide or make available documents, information, and witnesses. 

  
 105 

	 	16.6	 Insurance. Each Party shall have and maintain such type and amounts of liability insurance covering the
Manufacture, supply, use and sale of the Licensed Antibodies and the Licensed Products as is normal and customary in the pharmaceutical industry generally for Persons similarly situated, and shall upon request provide the other Party with a copy of
its policies of insurance in that regard, along with any amendments and revisions thereto. 

  

	 	16.7	 Employees who Transfer under the Regulations. Innate and MedImmune do not intend that as a consequence
of the transaction effected hereunder any employees of Innate or any of its Affiliates (“Employees”) shall transfer to MedImmune or to Innate (or their Affiliates or successors) under this Agreement or by operation of law. If, under the
Regulations, the contract of employment of any person is found or alleged to have effect after the Effective Date as if originally made with MedImmune or Innate or their Affiliates or successors) (the “Concerned Party”), as a consequence
of the transaction effected hereunder and to the extent permitted by Applicable Laws (an “Unexpected Transfer Employee”): 

  

	 	(a)	 The Concerned Party will, upon becoming aware of any Unexpected Transfer Employee, notify the other Party immediately
or as soon as is reasonably practicable in writing; 

  

	 	(b)	 The other Party agrees that in consultation with the Concerned Party, it will within [***] of being so requested by
the Concerned Party (as long as the request is made no later than [***] after notification under Section 16.7(a) above), make (or procure there is made) to that Unexpected Transfer Employee an offer in writing to employ him under a new contract
of employment to take effect upon the termination referred to below on the same terms and conditions as that person’s contract of employment immediately before the Effective Date, or on terms and conditions which, when taken as a whole, do not
materially differ from the terms and conditions of employment of that person immediately before the Effective Date (save as to the identity of the employer and any terms relating to an occupational pension scheme). The Concerned Party shall give the
other Party all reasonable co-operation and assistance to procure that the Unexpected Transfer Employee accepts the offer of employment; 

  
 106 

	 	(c)	 upon the expiry of [***] following the offer in Section 16.7(b) being made (or on the expiry of [***] from the
Concerned Party’s request under Section 16.7(b) if the offer is not made as requested), the Concerned Party may terminate the employment of the Unexpected Transfer Employee provided that: 

 

	 	(i)	 it does so in accordance with all legal requirements and any procedure that may be given to it by the other Party; and

  

	 	(ii)	 it takes all other steps to mitigate any payments or entitlements due to the Unexpected Transfer Employee and any
potential liability of the other Party under the indemnity at Section 16.7(d). 

  

	 	(d)	 Provided that the termination is effected within [***] of the notification under Section 16.7(a) above, the other
Party shall indemnify the Concerned Party for any Employment Liabilities in relation to: 

  

	 	(A)	 the employment of the Unexpected Transfer Employee after the Effective Date until any such termination (save to the
extent that the Concerned Party has acted unlawfully in respect thereof); and 

  

	 	(B)	 the termination of employment of the Unexpected Transfer Employee. 

 

	 	16.8	 Mutual Assistance. MedImmune and Innate shall give each other any assistance that either may reasonably require to
comply with the Regulations in relation to the Unexpected Transferring Employees and in contesting any claim by any Employee at or before the Effective Date resulting from or in connection with this Agreement. 

 

	17	 GOVERNING LAW AND ARBITRATION  

 

	 	17.1	 Governing Law. The interpretation and construction of this Agreement (including
non-contractual disputes) shall be governed by the laws of England and Wales excluding any conflicts or choice of law rule or principle that might

  
 107 

	 	 
otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. 

 

	 	17.2	 Referral of Disputes to the Parties Senior Executives. In the event of any dispute between the Parties arising
out of or in connection with this Agreement, either Party may, by written notice to the other, have such dispute referred to the Senior Executives for attempted resolution by good faith negotiations within [***] after such notice is received.

  

	 	17.3	 Arbitration. In the event the Parties are unable to resolve a dispute in accordance with Section 17.2 any
dispute arising out of or in connection with this Agreement, including any question regarding its existence, validity or termination, shall be referred to and finally resolved by arbitration under the Arbitration Rules of the International Chamber
of Commerce (ICC), which Rules are deemed to be incorporated by reference into this clause. The seat, or legal place, of arbitration shall be London. The language to be used in the arbitral proceedings shall be English. 

 

	 	17.4	 Preliminary Injunctions. Notwithstanding anything to the contrary, a Party may seek a temporary restraining
order or a preliminary injunction from any court of competent jurisdiction in order to prevent immediate and irreparable injury, loss, or damage on a provisional basis, pending the decision of the arbitrator(s) on the ultimate merits of any dispute.

  

	 	17.5	 Patent Disputes. Notwithstanding anything to the contrary, any and all issues regarding the scope,
inventorship, construction, validity, or enforceability of Patents shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patents in question. 

 

	18	 ASSIGNMENT; PERFORMANCE BY AFFILIATES; GENERAL 

 

	 	18.1	 Neither Party may assign any of its rights or obligations under this Agreement in any country in whole or in part
without the prior written consent of the other Party, except that each Party shall have the right, without such consent, (i) to perform any of its obligations and exercise any of its rights under this Agreement through, and to assign all of its
rights and obligations under this 

  
 108 

	 	 
Agreement to, any of its Affiliates; and (ii) on written notice to the other Party, to assign all of its rights and obligations under this Agreement to a
non-Affiliate successor in interest, whether by merger, consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar transaction, to all or substantially all of the business to
which this Agreement relates (meaning a business which constitutes more than solely the Research, Development, Exploitation of Licensed Products). In the event that a Party performs its obligations or exercises its rights under this Agreement
through an Affiliate or assigns its rights and obligations to an Affiliate as permitted under this Section 18, doing so shall not relieve the relevant Party of its responsibilities for the performance of its obligations under this Agreement,
and the relevant Party shall remain responsible for the performance by its Affiliates and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance). 

 

	 	18.2	 This Agreement shall survive any succession of interest permitted pursuant to Section 18, whether by merger,
consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar transaction, provided, that, in the event of such merger, consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar
transaction, no Intellectual Property Rights of the acquiring corporation and its Affiliates (other than a Party and its Affiliates prior to such acquisition) shall be included in the technology licensed hereunder, unless such Intellectual Property
Rights arise as a result of the performance of this Agreement by such corporation after such transaction becomes effective. 

  

	 	18.3	 This Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties.
Any assignment not in accordance with this Agreement shall be void. 

  

	 	18.4	 Further Actions. Each Party agrees to execute, acknowledge, and deliver such further instruments, and to do all
such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

  

	 	18.5	 Force Majeure. In this Agreement, “Force Majeure” means an event which is beyond a non-performing Party’s reasonable control, including an act of God, 

  
 109 

	 	 
strike, lock-out or other industrial/labour disputes (whether involving the workforce of the Party so prevented or of any other Person), war, riot, civil
commotion, terrorist act, epidemic, quarantine, fire, flood, storm, earthquake or natural disaster. A Party that is prevented or delayed in its performance under this Agreement by an event of Force Majeure (a “Force Majeure Party”)
shall, as soon as reasonably practical but no later than thirty (30) days after the occurrence of a Force Majeure event, give notice in writing to the other Party specifying the nature and extent of the event of Force Majeure, its anticipated
duration and any action being taken to avoid or minimize its effect. Subject to providing such notice and to this Section 18.5, the Force Majeure Party shall not be liable for delay in performance or for
non-performance of its obligations under this Agreement, in whole or in part, except as otherwise provided in this Agreement, where non-performance or delay in
performance has resulted from an event of Force Majeure. The suspension of performance allowed hereunder shall be of no greater scope and no longer duration than is reasonably required and the Force Majeure Party shall exert all reasonable efforts
to avoid or remedy such Force Majeure. 

  

	 	18.6	 Notices. Any notice, request, or other communication permitted or required under this Agreement shall be in
writing, shall refer specifically to this Agreement, and shall be deemed given only if hand delivered, sent by an internationally recognised overnight delivery service, costs prepaid, or sent by email (providing such email is read receipted and such
notice is also despatched by an internationally recognised overnight delivery service, costs prepaid, on same day) to the Party to whom notice is to be given at the following address (or at such other address such Party may have provided to the
other Party in accordance with this Section 18. 

 If to MedImmune: 

Address: 
 One
MedImmune Way 
 Gaithersburg 

MD20878 
 For the
attention of:  [***] 

  
 110 

 Email address:            
[***] 
 If to Innate: 

Address: 
 Innate
Pharma S.A. 
 17, Avenue de Luminy - BP 30191 

13276 Marseille Cedex 09 FRANCE 

Attention: [***] 

Email: [***] 
 Such
notice, shall be deemed to have been given as of the date delivered by hand, or on the second business day (at the place of delivery) after deposit with an internationally recognised overnight delivery service, whichever is the earlier. 

 

	 	18.7	 Waiver. A Party’s failure to enforce, at any time or for any period of time, any provision of this
Agreement, or to exercise any right or remedy shall not constitute a waiver of that provision, right or remedy or prevent such Party from enforcing any or all provisions of this Agreement and exercising any rights or remedies. To be effective any
waiver must be in writing. 

  

	 	18.8	 Severability. If any provision of this Agreement is held to be invalid, illegal or unenforceable, in any
respect, then such provision will be given no effect by the Parties and shall not form part of this Agreement. To the fullest extent permitted by Applicable Law and if the rights and obligations of a Party will not be materially and adversely
affected all other provisions of this Agreement shall remain in full force and effect and the Parties will use all reasonable efforts to negotiate a provision in replacement of the provision held invalid, illegal or unenforceable that is consistent
with Applicable Law and achieves, as nearly as possible, the original intention of the Parties. To the fullest extent permitted by Applicable Law, the Parties waive any provision of law that would render any provision in this Agreement invalid,
illegal or unenforceable in any respect. 

  

	 	18.9	 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an
original and all of which taken together shall be deemed to constitute one and the same instrument. 

  
 111 

	 	18.10	 Entire Agreement. This Agreement, including without limitation all schedules attached hereto, constitutes the
entire agreement between the Parties with respect to the subject matter of the Agreement. This Agreement supersedes all prior agreements, whether written or oral, with respect to the subject matter of the Agreement. Each Party confirms that it is
not relying on any representations, warranties or covenants of the other Party except as specifically set out in this Agreement. Nothing in this Agreement is intended to limit or exclude any liability for fraud. All Schedules referred to in this
Agreement are intended to be and are hereby specifically incorporated into and made a part of this Agreement. In the event of any inconsistency between any such Schedules and this Agreement, the terms of this Agreement shall govern.

  

	 	18.11	 Amendment. Any amendment or modification of this Agreement must be in writing and signed by authorised
representatives of both Parties. 

  

	 	18.12	 No Partnership. It is expressly agreed that the relationship between Innate and MedImmune shall not constitute
a partnership, joint venture, or agency. Neither Innate nor MedImmune shall have the authority to make any statements, representations, or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior
consent of such other Party to do so. 

  

	 	18.13	 Further Assurance. Each Party shall perform all further acts and things and execute and deliver such further
documents as may be necessary or as the other Party may reasonably require to implement or give effect to this Agreement. 

  

 
 [Signature page overleaf] 

  
 112 

 THIS AGREEMENT IS EXECUTED by the authorised representatives of the Parties as of the date first
written above. 
  

									
	 SIGNED for and on behalf of
Innate Pharma S.A.

 
 /s/ Mondher Mahjoubi
	 		 	 SIGNED for and on behalf of
MedImmune Limited

 
 /s/ Jane Osbourn

	  

Signature
	 		 	 Signature

					
	 Name:
	 		 		 	 Name:
	 	
		 	 Mondher Mahjoubi
	 		 		 	 Jane Osbourn

					
	 Title:
	 	 CEO
	 		 	 Title:
	 	 VP of R&D

 Schedule 1.8 

Current Back-up 

[***] 

 Schedule 1.66 

Formulation Patent 

[***] 

 Schedule 1.85 

Current IPH2201 
 [***]

 Schedule 1.92 

Licensed Shared Patents 
 [***]

 Schedule 1.95 

Listed Patents 
 [***] 

 Schedule 1.109 

DEFINITION OF NKG2A 
 [***] 

 Schedule 1.110 

Non-Exclusively Licensed Patents 

[***] 

 Schedule 1.124 

Profit and Loss Reporting Schedule 

[***] 

 Schedule 1.147 

Third Party Agreements 
 [***] 

 Schedule 3.11 

Confirmatory Patent License 
 FORM
CONFIRMATORY PATENT LICENSE 
 [***] 

 Schedule 4.11(a) 

Approved Third Parties 
 [***] 

 Schedule 4.11(b) 

MedImmune Code of Conduct 
 [***] 

 Schedule 5.3 

Parties’ Representation on JPT 

[***] 

 Schedule 5.7 

Parties’ Representation on DCC 

[***] 

 Schedule 7.1 

Development Costs Sharing Example 

[***] 

 Schedule 7.4 

Form Development Costs Report 
 [***]

 Schedule 8.14 

Form Commercialization Costs Report 

[***] 

 Schedule 13.2(a)(i) 

Owned Patents 
 [***] 

 Schedule 13.2(a)(ii) 

Exclusively Licensed Patents 
 [***]

 Schedule 13.2(a)(iv) 

Listed Know-How 

[***] 

 Schedule 13.2(m) 

Current Manufacturing Specification 

[***] 

 Schedule 13.2(n) 

Current Contract Manufacturing Organisations 

[***] 

 Certain information has been excluded from this agreement (indicated by “[***]”) because
such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 
 Confidential 

 

	
	  

AMENDMENT N°1
TO THE DEVELOPMENT AND OPTION AGREEMENT RELATING TO IPH2201

 

 THIS AMENDMENT (the “Amendment n°1”), effective as of October
22, 2018 (the “Amendment Effective Date”), is made by and between; 
  

	1.	 INNATE PHARMA S.A., a company incorporated in France having its principal place of business at 117, Avenue de
Luminy — BP 30191 13009 Marseille, France (“Innate”); and 

  

	2.	 MEDIMMUNE LIMITED, a company incorporated in England and Wales with company number 2451177 and with its
registered office at Milstein Building, Granta Park, Cambridge CB21 6GH, United Kingdom (“MedImmune”). 

 Innate
and Medimmune shall hereinafter be referred to individually as a “Party” and collectively as the “Parties”. 
 BACKGROUND:

  

	(A)	 On 24 April 2015, Innate and MedImmune entered into, inter alia, a Development and Option Agreement
relating to IPH2201 (the “Option Agreement”) to further develop IPH2201 and, upon MedImmune’s exercise of the Option (as such term is defined in the Option Agreement), enter into an agreed form
Co-Development and License Agreement relating to IPH2201, attached to the Option Agreement at Schedule 1.41 (the “License Agreement”); 

 

	(B)	 Medlmmune and Innate have agreed to transfer to Medlmmune the responsibility for the manufacturing activities for
IPH2201 prior to the exercise of the Option so that Medimmune will be responsible for supplying IPH2201 after depletion of Innate’s current inventory of GMP quantities of IPH2201 (the “Inventory”). 

 

	(C)	 Medimmune has indicated to Innate its intent to exercise the Option pursuant to the Option Agreement, by providing the
exercise notice set forth in Exhibit 1, immediately after the amendment of certain terms of the License Agreement pursuant to this Amendment n°1. 

  

	(D)	 Accordingly, the Parties have agreed to modify certain terms of the License Agreement as set forth below.

 NOW THEREFORE, THE PARTIES HAVE AGREED AS FOLLOWS: 

Article 1 - Definitions 
 Capitalized terms used in
this Amendment n°1 shall have the meaning ascribed to them in the Option Agreement or License Agreement (as applicable), except if they are otherwise defined in this Amendment n°1, in which case they shall have the meaning ascribed to them
in this Amendment n°1. 

  
 1 

 Confidential 

Article 2 – Manufacturing, Revision of Development Plan 
  

	2.1	 The Parties acknowledge that, prior to the Amendment Effective Date, MedImmune has elected to assume responsibility
for the Manufacturing activities of IPH2201 and that, as far as each Party is aware, Innate has transferred to MedImmune prior to the Amendment Effective Date all information and documentation necessary or useful to Manufacture IPH2201 to
MedImmune’s satisfaction. Accordingly, MedImmune shall assume responsibility for the Manufacturing activities of IPH2201 (including the completion of the CMC activities specified in the Development Plan with respect to IPH2201 and the
manufacture of the Option Products), and, after depletion of the Inventory, shall supply or have supplied all of Innate’s requirements for IPH2201 for (i) the Initial Studies (as defined in the Option Agreement) and (ii) any
Development activities assigned to be performed by Innate under the Development Plan (as defined in the License Agreement), all at [a Transfer Price (as defined in the License Agreement)] to be agreed upon between the Parties pursuant to
Section 9.3 of the License Agreement (as amended below). The Parties have further agreed that Innate will perform, as part of the IPH2201-203 study (which forms part of the Initial Studies as defined in
the Option Agreement), a study on the combination or combinations of IPH2201 with MEDI4736 as set out in the Development Plan to the Option Agreement (as amended) and that MedImmune will supply MEDI4736 to Innate for this purpose.

 In view of the foregoing, Sections 9.1, 9.5 and 9.6 of the License Agreement are hereby deleted in their
entirety. Sections 9.3 and 9.4 of the License Agreement are hereby amended to read in their entirety as follows: 
  

	 	“9.3	 Costs. The Parties will discuss and agree the Transfer Price on an annual basis. The Transfer
Price for any Licensed Products, Licensed Antibodies or MedImmune Compound supplied by MedImmune to Innate for the purposes of the Initial Studies (as defined in the Option Agreement) conducted by Innate pursuant to Section 4.2 shall be
invoiced by MedImmune and paid by Innate within [***] after its receipt of such invoice. The Transfer Price for any Licensed Products or Licensed Antibodies otherwise supplied under this Agreement will be treated as [***]. In the event
that Innate is co-funding Development in accordance with Section 7, the Transfer Price for such Licensed Products or Licensed Antibodies shall be [***].” 

 

	 	“9.4	 Manufacturing and Supply Agreement. If a manufacturing and supply agreement (“MSA”)
is required with regard to the supply of Licensed Product, Licensed Antibodies or MedImmune Compound by MedImmune to Innate, the Parties shall as soon as reasonably practicable negotiate and agree in good faith the terms of such MSA. The Parties
shall then also enter into a separate Quality Assurance Agreement(s) (“QAA”) that shall define the manufacturing and supply quality responsibilities of the Parties. “ 

 

	2.2	 The Parties acknowledge that all Initial Studies (as defined in the Option Agreement) have not been completed on the
Amendment Effective Date and that such studies will continue or commence, as applicable, pursuant to Section 4.2 of the License Agreement following MedImmune’s exercise of the Option. [***]. 

 

	2.3	 The Parties agree to co-fund the Phase 1 Clinical Trials and Phase 2 Clinical
Trials outlined in Exhibit 3 to this Amendment n°1 pursuant to Section 7 of the License Agreement (as amended below). Such Clinical Trials shall form part of and be further described the Development Plan and Development Budget to be
provided by MedImmune to Innate and reviewed and approved by the Parties, acting through the DCC pursuant to Section 4.5 of the License Agreement. 

Furthermore, in view of the foregoing, Sections 7.1 and 7.3 of the License Agreement shall be amended to read in their entirety as
follows: 

  
 2 

 Confidential 
  

	 	“7.1	 It is acknowledged that on the Effective Date the [***] budget previously agreed by the Parties for the
Initial Combination Study under the Combination License Agreement has not been fully spent. The Parties agree that the remaining unspent portion of such budget, as at the Effective Date estimated to be [***], (the “Residual
Budget”) shall be used to [***] (the “Co-Funded Phase 2 Clinical Trials”), some of which have been initiated prior to the date hereof,
in accordance with the below provisions in this Section 7.1. The “Combination License Agreement” means the Co-Development and License Agreement Relating to IPH2201 in
Combination with MEDI4736 and Tremelimumab entered into by the Parties on 24 April 2015. 

 The Parties
agree to co -fund the Co-Funded Phase 2 Clinical Trials as follows: Until such time when the total Development Costs for the Co-Funded Phase 2 Clinical Trials equal the
[***], each Party will provide [***] of the Development Costs for such trials (it being acknowledged that MedImmune’s [***] of the [***] has been pre-paid to Innate pursuant to
the Combination License Agreement) and thereafter Innate will provide [***] of the total Development Costs for the Co-Funded Phase 2 Clinical Trials, with the remaining [***] being provided by
MedImmune, provided, however, that Innate shall not be required to contribute more than [***] in accordance with the Development Budget. For clarity, Innate’s current commitment for Co-Funded Phase
2 Clinical Trials shall not exceed [***] unless [***]. For the avoidance of doubt, Innate’s refusal to [***] shall not be deemed a Co-Funding Withdrawal Notice for purposes of the
License Agreement. 
 The co-funding arrangements in respect of the Co-Funded Phase 2 Clinical Trials pursuant to the above provisions in this Section 7.1 shall be separate from and without prejudice to Innate’s co-funding of Phase 3
Clinical Trials pursuant to the remaining provisions of this Section 7. 
 Subject to the remaining provisions of this
Section 7 Innate shall further participate in the funding of each of the Phase 3 Clinical Trials of Licensed Products supporting Drug Approval Application in [***], such funding to be provided by Innate in the amount of thirty percent
(30%) of the total Development Costs for each of such Phase 3 Clinical Trials with the remaining seventy (70%) percent being provided by MedImmune, provided that neither Party shall be required to contribute more than their agreed percentage share
of Development Costs for the Phase 3 Clinical Trials in accordance with the Development Budget. The Development Budget is anticipated to be [***] for each Clinical Trial in average across [***]. To the extent that a Party’s share
of the Development Costs in accordance with the Development Budget exceeds [***] in the case of Innate or [***] in the case of MedImmune of the anticipated budget of [***], then the excess portion shall be payable by
[***]. For the avoidance of doubt, the excess amount shall not be payable other than pursuant to the preceding sentence and if it cannot be paid in accordance with the preceding sentence, it shall not be payable by the non-sponsoring Party. The Parties have agreed that the first Phase 3 Clinical Trial will be sponsored by MedImmune, as will any additional Phase 3 Clinical Trials related to Licensed Products unless the Parties
otherwise mutually agree. An example of such payment mechanism is attached as Schedule 7.1. The Parties may agree that Innate’s co -funding amount pursuant to this final paragraph of this Section 7.1 may be used to finance other Clinical
Trials than the Phase 3 Clinical Trials. Innate shall have the option, upon providing written notice to MedImmune (“Co-Funding Withdrawal Notice”) within [***] after
receiving MedImmune’s Development Plan and Development Budget in accordance with Section 4.5 (“Opt Out Period”), to not participate in the Co-Funding. Such right to
withdraw shall be exercisable once only in respect of the first Licensed Product. If Innate does not provide a Co-Funding Withdrawal Notice within the Opt Out Period described above Innate will be obliged to
provide co -funding with respect to the applicable Licensed Product as described in this Section 7.1.” 

  
 3 

 Confidential 
  

	 	“7.3	 Expense Sharing. The provisions set out in this Section 7.3 and in Sections 7.4 -7.9 shall apply with regard to the Co-Funded Phase 2 Clinical Trials and, if Innate has not served MedImmune with a Co-Funding
Withdrawal Notice within the Opt Out Period, the Phase 3 Clinical Trials referred to in the final paragraph of Section 7.1. The Parties will share all Development Costs related to the Co-Funded Phase 2
Clinical Trials and the Phase 3 Clinical Trials of Licensed Products under the Development Plan and in accordance with the Development Budget (the “Shared Development Costs”) so that subject to Section 7.1, Innate and MedImmune each
pays its relevant percentage share of such costs.” 

 Article 3– Upfront Payment Term; Preparation of the Exercise of the
Option; Effective Date of the License Agreement; Warranties; Notices 
  

	3.1	 Subject to the Option being exercised on or prior to 23 October 2018, Section 10.1 of the License Agreement
is hereby deleted and replaced by the following clause: 

  

	 	“10.1	 As partial payment for the rights and licenses granted to MedImmune by Innate under this Agreement, MedImmune shall
pay to Innate a nonrefundable one-time upfront payment of one hundred million US dollars (USD 100,000,000) no later than on [***]. The upfront payment shall not be refundable or creditable against any
other payments MedImmune is obligated to make to Innate under this Agreement.” 

  

	3.2	 Exhibit 4.1 hereto constitutes an updated set of disclosure Schedules with respect to Innate’s representations
and warranties in the License Agreement. Exhibit 4.2 hereto sets out certain disclosures made by MedImmune with respect to MedImmune’s warranties in Section 13.3(a) of the License Agreement (as amended below). Exhibit 3 hereto is the
Option exercise notice in its agreed form. 

  

	3.3	 The Parties have jointly determined and hereby agree that no Competition Law Filing will be required for the
performance of the License Agreement. Pursuant to Clause 2.2 of the License Agreement, the Parties acknowledge and agree that the Effective Date will be the Signing Date, as such terms are defined in the License Agreement. 

 

	3.4	 The second sentence of Section 13.3 shall be amended to read in its entirety as follows: 

“Such representations, warranties and covenants shall be considered to be restated by MedImmune as at the Effective Date,
subject to MedImmune’s right to make disclosures against such representations, warranties and covenants with respect to matters which have arisen or come to the knowledge of MedImmune (with respect to representations made to MedImmune’s
knowledge) between the effective date of the Development and Option Agreement and the Effective Date of this Agreement.” 

Section 13.3(a) shall be amended to read in its entirety as follows: 

 

	 	“(a)	 No claim or litigation has been brought or threatened as of the Effective Date in relation to MEDI4736 (as defined
below) or Tremelimumab (as defined below) by any Person making such allegations by written notice to MedImmune. 

“MEDI4736” means the proprietary antibody Controlled by MedImmune or its Affiliate(s) known as
MEDI4736, which is an antibody that binds PD-L1 and blocks the interaction of PD-L1 with programmed cell death protein 1. “Tremelimumab”
means the proprietary antibody Controlled by MedImmune or its Affiliate(s) known as Tremelimumab, which is an antibody that targets CTLA-4.” 

  
 4 

 Confidential 
  

	3.5	 The second paragraph of Section 18.6 (MedImmune’s address) shall be amended as follows:

 “If to MedImmune 

Address: 

One MedImmune Way 

Gaithersburg 

MD 20878 

[***] 
 Article 4 - Miscellaneous 

 

	4.1	 This Amendment n°1 represents an amendment to the Option Agreement and except as specifically set forth in this
Amendment n°1, all of the provisions of the Option Agreement remain unchanged and in full force and effect as originally agreed. 

  

	4.2	 The interpretation and construction of this Amendment n°1 (including
non-contractual disputes) shall be governed by the laws of England and Wales excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this
Amendment n°1 to the substantive law of another jurisdiction. Any dispute arising out of or in connection with this Amendment n°1 shall be resolved pursuant to the dispute resolution provisions in the Option Agreement. 

 

	4.3	 This Amendment n°1 may be executed in any number of counterparts, each of which shall be deemed an original and
all of which taken together shall be deemed to constitute one and the same instrument. 

  
 5 

 IN WITNESS WHEREOF, the Parties hereto have caused the Amendment n°1 to be executed as of
the first date written above. 
  

					
	 INNATE PHARMA S.A.
	  		  	 MEDIMMUNE LIMITED

			
	 By: /s/ Mondher Mahjoubi
	  		  	 By:

	 Name : Mondher Mahjoubi
	  		  	 Name:

	 Title : CEO
	  		  	 Title:

 IN WITNESS WHEREOF, the Parties hereto have caused the Amendment n°1 to be executed as of
the first date written above. 
  

					
	 INNATE PHARMA S.A.
	  		  	 MEDIMMUNE LIMITED

			
	 By:
	  		  	 By:    /s/ Jane Osbourn

	 Name :
	  		  	 Name:    Jane Osbourn

	 Title :
	  		  	 Title:        VP R&D

 Exhibit 1 – Exercise Notice 

[***] 

  
 i 

 Exhibit 2 

Initial Studies 
 [***] 

  
 ii 

 Exhibit 3 

Co-funded Phase 1 and 2 - Revised Development Plan 

[***] 

  
 iii 

 Exhibit 4.1 – Innate’s Updated Disclosure Schedule 

[***] 

  
 iv 

 Exhibit 4.2 – MedImmune Disclosure Schedule 

[***] 

  
 v 

 Certain information has been excluded from this agreement (indicated by “[***]”) because
such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 
 THIS SECOND AMENDMENT TO
THE CO-DEVELOPMENT AND LICENSE AGREEMENT RELATING TO IPH2201 (this “Second Amendment”) is made and entered into as of July 26, 2019 (the “Amendment
Effective Date”), by and between MedImmune Limited, a company organized under the laws of England and Wales (“MedImmune”) and Innate Pharma S.A, a company organized under the laws of France
(“Innate”). MedImmune and Innate are each referred to in this Amendment as a “Party” and collectively, as the “Parties”. 

RECITALS 
  

	A.	 WHEREAS, MedImmune and Innate are parties to a Co-Development
and License Agreement relating to IPH2201 effective as of April 24, 2015, as amended (the “Agreement”). 

  

	B.	 WHEREAS, MedImmune and Innate are parties to the
Co-Development and License Agreement Relating to IPH2201 in Combination with MEDI4736 and TREMELIMUMAB, dated April 24, 2015 (the “Combination License Agreement”).

  

	C.	 WHEREAS, MedImmune provided Innate with the updated Development Plan and Development Budget on
December 18, 2018. Accordingly, pursuant to Section 7.1 of the Agreement Innate must provide the Co-Funding Withdrawal Notice by [***]. 

 

	D.	 WHEREAS, Innate [***]. 

 

	E.	 WHEREAS, MedImmune has agreed to [***]. 

 

	F.	 WHEREAS, the Parties have agreed to extend the Opt Out Period to allow Innate to consider the
Additional Study Details. 

  

	G.	 WHEREAS, in accordance with Section 18.11 of the Agreement, the Parties hereto desire to amend
and modify the Agreement in accordance with the terms and subject to the conditions set forth in this Amendment. 

 NOW, THEREFORE, IN
CONSIDERATION OF THE MUTUAL COVENANTS, CONDITIONS AND AGREEMENTS HEREIN CONTAINED, THE PARTIES HEREBY AGREE AS FOLLOWS: 
  

	1.	 Section 7.1 of the Agreement is hereby amended and restated in
its entirety to read as follows: 

 “7.1    It is acknowledged
that on the Effective Date the [***] budget previously agreed by the Parties for the Initial Combination Study under, and as defined in the Combination License Agreement has not been fully spent. The Parties agree that the remaining unspent portion
of such budget, as at the Amendment Effective Date, estimated to be [***], (the “Residual Budget”), shall be used to [***] (the “Co-Funded Phase 2 Clinical
Trials”), some of which have been initiated prior to the date hereof, in accordance with the below provisions in this Section 7.1. 

  
 1 

 Certain information has been excluded from this agreement (indicated by “[***]”) because
such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. 
 The Parties
agree to co-fund the Co-Funded Phase 2 Clinical Trials as follows: Until such time when the total Development Costs for the
Co-Funded Phase 2 Clinical Trials equal [***], each Party will provide [***] of the Development Costs for such trials (it being acknowledged that MedImmune’s [***] of [***] has been pre-paid to Innate pursuant to the Combination License Agreement) and thereafter Innate will provide [***] of the total Development Costs for the Co-Funded Phase 2 Clinical
Trials, with the remaining [***] being provided by MedImmune, provided, however, that Innate shall not be required to contribute more than [***] in accordance with the Development Budget. For clarity, Innate’s current commitment for Co-Funded Phase 2 Clinical Trials shall not exceed [***] unless [***]. For the avoidance of doubt, Innate’s refusal to [***] shall not be deemed a Co-Funding Withdrawal
Notice for purposes of the License Agreement. The co-funding arrangements in respect of the Co-Funded Phase 2 Clinical Trials pursuant to the above provisions in this
Section 7.1 shall be separate from and without prejudice to Innate’s co-funding of Phase 3 Clinical Trials pursuant to the remaining provisions of this Section 7. 

Subject to the remaining provisions of this Section 7 Innate shall further participate in the funding of each of the
Phase 3 Clinical Trials of Licensed Products supporting Drug Approval Application in [***], such funding to be provided by Innate in the amount of thirty percent (30%) of the total Development Costs for each of such Phase 3 Clinical Trials with the
remaining seventy (70%) percent being provided by MedImmune, provided that neither Party shall be required to contribute more than their agreed percentage share of Development Costs for the Phase 3 Clinical Trials in accordance with the Development
Budget. The Development Budget is anticipated to be [***] for each Clinical Trial in average across [***]. To the extent that a Party’s share of the Development Costs in accordance with the Development Budget exceeds [***] in the case of Innate
or [***] in the case of MedImmune of the anticipated budget of [***], then the excess portion shall be payable by [***]. For the avoidance of doubt, the excess amount shall not be payable other than pursuant to the preceding sentence and if it
cannot be paid in accordance with the preceding sentence, it shall not be payable by the non-sponsoring Party. The Parties have agreed that the first Phase 3 Clinical Trial will be sponsored by MedImmune, as
will any additional Phase 3 Clinical Trials related to Licensed Products unless the Parties otherwise mutually agree. An example of such payment mechanism is attached as Schedule 7.1. The Parties may agree that Innate’s co-funding amount pursuant to this final paragraph of this Section 7.1 may be used to finance other Clinical Trials than the Phase 3 Clinical Trials. 

The Parties agree that Innate’s co-funding commitment for [***] for clarity shall
be mutually agreed by the Parties and approved by the DCC in accordance with Article 4, shall not be [***]. With respect to these mutually agreed and DCC approved externally sponsored or investigator initiated clinical trials, the

  
 2 

 
Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if
publicly disclosed. 
 Parties agree to support these studies using existing uncommitted stocks of monalizumab process B
drug product, to the extent such stocks are available, [***]. 
 Innate shall have the option, upon providing written notice
to MedImmune (“Co-Funding Withdrawal Notice”) on or prior to [***] (“Opt Out Period”), to not participate in the
co-funding. Such right to withdraw shall be exercisable once only in respect of the first Licensed Product. If Innate does not provide a Co-Funding Withdrawal Notice
within the Opt Out Period described above Innate will be obliged to provide co-funding with respect to the applicable Licensed Product as described in this Section 7.1.” 

 

	2.	 Except as expressly set forth herein, all of the terms and conditions of the Agreement remain
unchanged and are in full force and effect. Capitalized terms not otherwise defined in this Second Amendment shall have the meanings respectively ascribed to them in the Agreement. 

 

	3.	 This Amendment, the Agreement, as previously amended, and the Combination License Agreement,
constitute the complete and final and exclusive understanding and agreement of the Parties with respect to the subject matter of the Agreement, and supersede any and all prior or contemporaneous negotiations, correspondence, understanding and
agreements, whether oral or written, between the Parties respecting the subject matter of the Agreement. 

  

	4.	 This Amendment may be executed in counterparts, each of which shall be deemed to be an original, and
all of which taken together shall be deemed to constitute one and the same instrument. The Parties agree that delivery of an executed counterpart of a signature page of this Amendment electronically shall be effective as delivery of a manually
executed counterpart of this Amendment. 

 [Signature page to follow] 

  
 3 

 IN WITNESS WHEREOF, the Parties hereto have caused this Amendment to be duly executed
by their respective authorized representatives as of the Amendment Effective Date set forth above. 
  

					
		  	MEDIMMUNE LIMITED	  	
			
		  	 Signature: s/Adrian Kemp, Director
	  	
			
		  	INNATE PHARMA S.A	  	
			
		  	 Signature: s/Monher Mahoubi, CEO
	  	

 Signature Page to Second Amendment to Co-Development and License
Agreement by and between MedImmune Limited and Innate Pharma S.A.EX-10.2

 Exhibit 10.2 

Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be
competitively harmful if publicly disclosed. 
 CONFIDENTIAL 

DATED OCTOBER 22, 2018 

LICENSE AGREEMENT 

-between- 
 MEDIMMUNE
LIMITED 
 -and- 

INNATE PHARMA S.A. 
  

 
 LICENSE
AGREEMENT 
  
  

 TABLE OF CONTENTS 

 

							
		  		  	 	Page	 
			
	1.	  	DEFINITIONS AND INTERPRETATION	  	 	2	 
			
	2.	  	CLOSING	  	 	18	 
			
	3.	  	TRANSITION OF CERTAIN ACTIVITIES	  	 	18	 
			
	4.	  	LICENCE TERM GRANT OF RIGHTS	  	 	20	 
			
	5.	  	RESTRICTIONS	  	 	24	 
			
	6.	  	DEVELOPMENT PLAN/GOVERNANCE	  	 	24	 
			
	7.	  	ONGOING AND FUTURE CLINICAL TRIALS	  	 	29	 
			
	8.	  	CERTAIN DILIGENCE OBLIGATIONS	  	 	30	 
			
	9.	  	COMMERCIALISATION ACTIVITIES	  	 	31	 
			
	10.	  	PAYMENTS	  	 	32	 
			
	11.	  	RECORDS AND REPORTING	  	 	37	 
			
	12.	  	REGULATORY ACTIVITIES	  	 	38	 
			
	13.	  	INTELLECTUAL PROPERTY	  	 	44	 
			
	14.	  	PRODUCT TRADEMARKS	  	 	49	 
			
	15.	  	CONFIDENTIALITY AND NON-DISCLOSURE	  	 	52	 
			
	16.	  	WARRANTIES	  	 	56	 
			
	17.	  	COMPLIANCE	  	 	60	 
			
	18.	  	INDEMNITY	  	 	62	 
			
	19.	  	LIMITATION OF LIABILITY AND INSURANCE	  	 	65	 
			
	20.	  	TERM AND TERMINATION	  	 	65	 
			
	21.	  	MISCELLANEOUS	  	 	69	 
		
	 SCHEDULE 1 COMMERCIALIZATION PLAN
	  	 	77	 
		
	 SCHEDULE 2 SOTC SERVICES
	  	 	78	 
		
	 SCHEDULE 3 SUPPLY AGREEMENT TERMS
	  	 	79	 
		
	 SCHEDULE 4 LICENSED ANTIBODY
	  	 	80	 
		
	 SCHEDULE 5 EXISTING PRODUCT TRADEMARKS
	  	 	81	 
		
	 SCHEDULE 6 LICENSED MEDI PATENTS
	  	 	82	 
		
	 SCHEDULE 7 AZ CORPORATE MARKS
	  	 	83	 
		
	 SCHEDULE 8 INNATE CORPORATE NAMES
	  	 	84	 
		
	 SCHEDULE 9 INITIAL MEMBERS OF JDC AND JCC
	  	 	85	 
		
	 SCHEDULE 10 DEVELOPMENT PLAN
	  	 	86	 
		
	 SCHEDULE 11 LICENSED MEDI
KNOW-HOW
	  	 	87	 
		
	 SCHEDULE 12 TRADEMARK ASSIGNMENT
	  	 	88	 
		
	 SCHEDULE 16.2 EXISTING RESEARCH AND COLLABORATION AGREEMENTS
	  	 	89	 
		
	 EXHIBIT A AZ PROMOTION PRINCIPLES
	  	 	90	 

  
 -i- 

 LICENSE AGREEMENT 

THIS LICENSE AGREEMENT (the “Agreement”) is made and entered into this 22nd day of October, 2018 (the
“Effective Date”) 
 BETWEEN: 
  

	1.	 MEDIMMUNE LIMITED, a company incorporated in England and Wales with company number 2451177 and with
its registered office at Milstein Building, Granta Park, Cambridge, CB21 6GH, United Kingdom (“MedImmune”); and 

  

	2.	 INNATE PHARMA S.A., a company incorporated in France and with its principal place of business at 117,
Avenue de Luminy – BP 30191 13 009 Marseille, France (“Innate”). 

 MedImmune and Innate are
sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 
 RECITALS: 

WHEREAS, MedImmune is, directly or indirectly, a wholly owned subsidiary of AstraZeneca PLC (AstraZeneca PLC and its
Affiliates being “AstraZeneca”). MedImmune and its Affiliates have experience in the research, development, manufacturing and commercialization of pharmaceutical products worldwide, including treatments for cancer both using small
molecules and large molecules. 
 WHEREAS, Innate is a biopharmaceutical company concentrating its business on
developing treatments for cancer. 
 WHEREAS, MedImmune owns or controls certain Intellectual Property Rights (as
defined herein) with respect to the Licensed Product, so called Lumoxiti® in the US (as further defined herein) in the Territories (as defined herein). 

WHEREAS, MedImmune wishes to grant Innate a license under Intellectual Property Rights owned or Controlled by MedImmune
to Develop, Manufacture, seek registration of and Commercialize the Licensed Product in conditions set forth herein. the Territories, in accordance with the terms and 

WHEREAS, MedImmune has agreed to provide certain transition services to Innate so that the Development, Manufacturing
and regulatory activities to seek registration and Commercialization of the Licensed Product will continue in accordance with MedImmune’s standard practices for a transitional period with the intention that Innate shall have built sufficient
capabilities to take over those activities at the end of the transition period. 

  
 1 

 AGREED TERMS: 
  

	1.	 DEFINITIONS AND INTERPRETATION 

 

	1.1	 Unless otherwise specifically provided in this Agreement, the following terms shall have the following
meanings: 

 “ACCESS 360 Program Logo” means the Trademark and logo set forth on Part 2
of Schedule 7, used in connection with MedImmune and its Affiliates’ patient savings program. 

“Affiliate” means, with respect to a Person, any Person that from time to time directly, or indirectly
through one or more intermediaries, controls, is controlled by or is under common control with such first Person. For purposes of the definition in this clause 1.1 only, “control”, and with correlative meanings, the terms
“controlled by” and “under common control with” mean (a) to possess, directly or indirectly, the power to direct the management or policies of a Person, whether through ownership of voting securities, by
contract relating to voting rights or corporate governance, resolution, regulation or otherwise, or (b) to own, directly or indirectly, more than fifty percent (50%) of the outstanding voting securities or other ownership interest of such
Person. 
 “Agreement” has the meaning set forth in the preamble hereto. 

“Alliance Manager” has the meaning set forth in clause 6.2. 

“Anti-Corruption Laws” means the U.S. Foreign Corrupt Practices Act, as amended, the UK Bribery Act 2010, as
amended, and any other Applicable Laws including applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism. 

“Applicable Law” means applicable laws, rules and regulations, including any rules, regulations, guidelines
or other requirements of the Regulatory Authorities or any Governmental Authority applicable to the Parties or any particular activity under this Agreement, that may be in effect from time to time, including, (i) GCP, (ii) GMP, (iii) GVP,
(iv) the principles that form the basis of the Helsinki Declaration of the World Medical Association, (v) the FFDCA and (vi) the Anti-Corruption Laws, and (vii) Data Protection Law, in each case to the extent they apply to a
Party’s performance of its obligations under this Agreement. 
 “AstraZeneca Corporate Marks” means
the Trademarks and logos identified on Schedule 7 and such names or logos of AstraZeneca as MedImmune may designate in writing to Innate from time to time, including the names “AstraZeneca,” “AZ,” the AstraZeneca
corporate logo, and the ACCESS 360 Program Logo, or any other name or mark including or comprising “AstraZeneca”. 

“AZ’s Global Ethical Interactions Policy” means AstraZeneca’s “Ethical Interactions &
Anti-Bribery/Anti-Corruption Policy”, as available on AstraZeneca’s website from time to 

  
 2. 

 
time at
https://www.astrazeneca.com/sustainability/resources.html#global-policies-and-positions-0
. 
 “AZ Promotion Principles”
means AstraZeneca’s principles for Promotion set forth on
Exhibit A. 

“AZ Site” means, with respect to drug substance for Licensed Product Manufactured or supplied by [***] under
the [***] Supply Agreement, the [***] manufacturing facility at which drug substance is manufactured and, with respect to finished Licensed Product Manufactured or supplied by [***] under the [***] Supply Agreement, the [***] manufacturing facility
located in Italy or, in each case, as otherwise agreed by the Parties. 
 “[***]” means [***]. 

“[***] Supply Agreement” means the biologics Master Supply Agreement relating to (among other products) the
active pharmaceutical ingredient forming part of the Licensed Product entered into between AstraZeneca AB (PUBL) and [***]. 

“BLA” means a Biologics License Application submitted to the FDA under subsection (a) or (k) of
Section 351 of the PHSA or any corresponding application outside the United States, including with respect to the European Union, a Marketing Authorisation Application filed with the EMA pursuant to the centralized approval procedure or with
Swissmedic in Switzerland, or any other applicable Regulatory Authority (if any) in Switzerland or the United Kingdom or a country in Europe with respect to mutual recognition of any other national approval. 

“Block List” means [***] as the same may be modified from time to time by MedImmune or one of its Affiliates
on [***] written notice to Innate or in accordance with such other procedures as may be established by the JCC. 

“[***]” means [***]. 

“[***] Supply Agreement” means the master commercial supply agreement relating to the manufacture of the
finished Licensed Product and entered into between AstraZeneca Pharmaceuticals LP and [***] on [***]. 
 “Breaching
Party” has the meaning set forth in clause 20.2.1. 
 “Business Day” means a day other than a
Saturday or Sunday or a day on which banking institutions in London and Paris are permitted or required to be closed. 

“Calendar Quarter” means each successive period of three (3) calendar months commencing on
January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on December 31, 2018 and the last Calendar Quarter shall end on the last day of the
Term. 
 “Calendar Year” means each successive period of twelve (12) calendar months commencing on
January 1 and ending on December 31, except that the first Calendar Year 

  
 3. 

 
of the Term shall commence on the Effective Date and end on December 31, 2018 and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and
end on the last day of the Term. 
 “Clinical Trial” means a human clinical trial or such other tests and
studies of the Licensed Product in humans to which the applicable regulations on good clinical practice and clinical trials apply. 

“Closing” means the completion of the Transaction in accordance with clause 2. 

“Commercialization” means any and all activities directed to or relating to the preparation for sale of,
offering for sale of or sale of the Licensed Product, including activities related to marketing, Promoting, distributing and importing the Licensed Product for commercial sale and interacting with Regulatory Authorities regarding any of the
foregoing but excluding Manufacturing. When used as a verb, “to Commercialize” and “Commercialising” means to engage in Commercialization and “Commercialized” has a corresponding meaning. 

“Commercialization Budget” means the costs and expenses related to the Commercialization of the Licensed
Product as set out in the Commercialization Plan. 
 “Commercialization Costs” means, [***]: 

 

	 	(a)	 [***]; 

 

	 	(b)	 [***]; 

  

	 	(c)	 [***]; 

  

	 	(d)	 [***]; 

  

	 	(e)	 [***]; 

  

	 	(f)	 [***]; 

  

	 	(g)	 [***]; 

  

	 	(h)	 [***]; and 

 

	 	(i)	 [***]. 

“Commercialization Plan” shall have the meaning set forth in clause 3.6.1. 

“Commercially Reasonable Efforts” means, [***]. 

“Committee” means the Joint Development Committee or the Joint Commercialization Committee, as the context
requires and “Committees” shall mean all of them. 
 “Compliance Audit” has the meaning
set forth in clause 17.2.4 

  
 4. 

 “Concerned Party” has the meaning set forth in clause
21.1.1. 
 “Confidential Information” means any and all Know-How
and Materials, whether oral or in writing or in any other form, disclosed before, on or after the date of this Agreement by one Party to the other Party that is either marked or identified as confidential or proprietary or that is of such a nature
that would be considered by a reasonable person to be confidential or proprietary. The Licensed MedImmune Know-How shall be deemed Innate’s Confidential Information. All other Know-How owned or Controlled by MedImmune or any of its Affiliates shall be deemed MedImmune’s Confidential Information. 

“Control” means, with respect to any item of Information, Regulatory Documentation, material, Patent or other
Intellectual Property Right, possession of the right, whether directly or indirectly and whether by ownership, licence or otherwise (other than by operation of the license and other grants in clause 4.1), to grant a licence, sublicence or other
right (including the right to reference Regulatory Documentation) to or under such Information, Regulatory Documentation, material, Patent or other Intellectual Property Right as provided for herein without violating the terms of any agreement with
any Third Party. 
 “Costs” means both internal and external costs and expenses (including the cost of
allocated FTEs at the applicable FTE Rate quoted by MedImmune). Unless otherwise mutually agreed between the Parties, internal costs incurred by a Party shall be determined by multiplying the applicable FTE Rate quoted by MedImmune by the number of
FTEs utilized to conduct the applicable activities. External costs shall be invoiced [***] for the handling of the third party arrangements. 

“CPP” has the meaning set forth in clause 4.6. 

“CREATE Act” has the meaning set forth in clause 13.5.6. 

“Damages” means any and all direct liabilities, claims, actions, damages, losses, costs or expenses,
including interest, penalties, and reasonable lawyers’ fees and disbursements suffered or incurred by a Party. In calculating Damages, the legal duty to mitigate on the Party suffering the loss shall be taken into account. 

“Data Protection Law” means, all applicable laws, rules and regulations, including any national implementing
legislation relating to privacy and data protection. 
 “Data Subject” means a natural person who is
identified or identifiable natural person. An identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier
or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person. 

“Detail” means that part of an in person,
face-to-face sales call during which a Full Time Sales Representative makes a presentation with respect to the Licensed Product to an Eligible Prescriber, such that the
relevant characteristics of the Licensed Product are 

  
 5. 

 
described by the Full Time Sales Representative in a fair and balanced manner consistent with the requirements of this Agreement and Applicable Law, in a manner that is customary in the
pharmaceutical industry in the United States for the purpose of promoting a prescription pharmaceutical product. When used as a verb, “Detailing” means to perform Details. 

“Development” means all activities related to research, pre-clinical
and other non-clinical testing, test method development and stability testing, toxicology, formulation, clinical studies, statistical analysis and report writing, the preparation and submission of BLAs (and
supplements), regulatory affairs with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required by a Regulatory Authority as a condition or in support of obtaining or maintaining a Regulatory
Approval but not including Manufacture. When used as a verb, “to Develop” and “Developing” means to engage in Development and “Developed” has a corresponding meaning. 

“Development Budget” means the costs and expenses related to the Development of the Licensed Product in the
EU Territory in accordance with the Development Plan. 
 “Development Costs” means, with respect to each
Licensed Product to the extent incurred in accordance with and after the Effective Date of this Agreement and the relevant Development Plan and Development Budget: 
  

	 	(a)	 [***]; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]; 

  

	 	(d)	 [***]; 

  

	 	(e)	 [***]; 

  

	 	(f)	 [***]; and 

 

	 	(g)	 [***]. 

Except to the extent included in subsection (b) above, Development Costs shall not include either Party’s Costs to
the extent they solely relate to activities associated with that Party’s management of its own performance of and compliance with this Agreement. 

“Development Plan” means the Development plan relating to the Licensed Product in the Territories, to be
agreed by the Parties in accordance with clause 6.1.1, and which may be updated or amended from time to time in accordance with clause 6.3.4 

“Disclosing Party” has the meaning set forth in clause 15.1.1. 

“Dispute” has the meaning set forth in clause 21.6.1. 

  
 6. 

 “Dollars” or “$” means United States
Dollars. 
 “Effective Date” has the meaning set forth in the preamble hereto. 

“Eligible Prescriber” means a health care provider that has the authority to prescribe the Licensed Product
under Applicable Law and, with respect to the period prior to the MAH Transfer Date only, (a) is not on the Block List and (b) does not have an Excluded Specialty based on his or her assigned specialty in AstraZeneca’s physician
classification system. 
 “EMA” means the European Medicines Agency and any successor agency thereto. 

“EU MA Transfer Date” means the date on which the EU Marketing Approval is transferred to Innate in
accordance with clause 14.1. 
 “EU Marketing Approval” means an approval of the BLA for the Licensed
Product in one or more countries in the EU Territory by the relevant Regulatory Authority which is necessary for the marketing and sale of the Licensed Product, in the EU Territory, as amended as a consequence of any approved variation to the
Licensed Product in the EU Territory. 
 “EU Regulatory Transition Plan” has the meaning set forth in
clause 12.2.2. 
 “EU Territory” means the United Kingdom, Switzerland and every Member State of the
European Union from time to time (regardless of whether that country ceases to be such a member during the Term). 

“EU Transition Period” means the period commencing on the Effective Date and ending on the EU MA Transfer
Date. 
 “Executives” means, (a) with respect to MedImmune, [***] and (b) with respect to Innate,
[***]. 
 “Existing Product Trademarks” means the Trademarks listed in Schedule 5; together with any
registrations thereof or any pending applications relating thereto. 
 “Existing Product Trials” means the
following Clinical Trials: (i) the pivotal Phase III Clinical trial (NCTO1829711)(also known as the 1053 trial), and (ii) the extended access trial (NCT0350615). 

“Existing Research and Collaboration Agreements” means the agreements set out in
Schedule 16.2. 
 “Exploit” means to make, have made, import, use, sell or offer
for sale, including to research, Develop, Commercialize, register, Manufacture, have Manufactured, hold or keep (whether for disposal or otherwise), have used, export, transport, distribute, Promote, market or have sold or otherwise dispose of.
“Exploitation” means the act of Exploiting a compound, product or process. When used as a verb, “to Exploit” and “Exploiting” means to engage in Exploitation. 

  
 7. 

 “FCA” means the UK Financial Conduct Authority. 

“FDA” means the United States Food and Drug Administration and any successor agency thereto. 

“FFDCA” means the Federal Food, Drug, and Cosmetic Act of the United States, as amended from time to time,
together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto). 

“Field” means all uses, including any therapeutic, prophylactic, diagnostic and palliative uses in humans and
animals. 
 “Field Force” means Innate’s field force involved in the Promotion of the Licensed Product
in the Territories. 
 “First Commercial Sale” means on a country by country basis the first sale of the
Licensed Product for monetary value for use or consumption by the end user following Regulatory Approval permitting such sale in such country. 

“FSMA” means the Financial Services and Markets Act 2000 (as amended). 

“FTE” means the equivalent of one (1) full-time person, or in the case of less than a full-time person,
a full-time equivalent person, of work directly related to the Development or Commercialization of the Licensed Product that is carried out by an appropriately qualified employee or consultant of a Party or its Affiliates, based on [***] or greater
per year. For clarity, any such person who devotes less than [***] shall be treated as an FTE on a pro rata basis based upon the actual number of hours worked divided by [***], all as calculated by MedImmune. 

“FTE Rate” means an annual rate for the time of an FTE of work, [***]. 

“Full Time Sales Representative” means a pharmaceutical sales representative employed by Innate full-time
[***]. 
 “GCP” or “Good Clinical Practices” means, to the extent applicable in the
country where Regulatory Approval is sought, the current standards for good clinical practices relating to clinical trials for pharmaceuticals, as set forth in the United States Code of Federal Regulations or ICH guidelines and applicable
regulations, laws or rules as promulgated thereunder, in each case as amended from time to time, and all other standards of good clinical practice as are required by any Regulatory Authority. 

“GMP” or “Good Manufacturing Practice” means the principle of good manufacturing practice in
respect of medicinal products for human use and investigational medicinal products for human use as required by Applicable Law, including the laws of the European Community and Directive 2003/94/EC as well as any national legislation implementing
the aforesaid Directive and any relevant guidance relating thereto. 

  
 8. 

 “Governmental Authority” means any supranational,
international, federal, state or local court, administrative agency or commission or other governmental authority or instrumentality, domestic or foreign. 

“Government Official” means (a) any Person employed by or acting on behalf of a government, Governmental
Authority, government-controlled agency or entity or public international organisation, (b) any political party, party official or candidate, (c) any Person who holds or performs the duties of an appointment, office or position created by
custom or convention or (d) any Person who holds himself out to be the authorised intermediary of any of the foregoing. 

“GVP” or “Good Pharmacovigilance Practices” means, in addition to the provisions under the
Pharmacovigilance Agreement, all applicable good pharmacovigilance practices promulgated and published by FDA, EMA or any other Regulatory Authorities having jurisdiction over the Development, Manufacture or Commercialization of the Product , as
applicable, pursuant to its regulations, guidelines or otherwise, including as applicable, major pharmacovigilance process and product and/or population specific considerations as defined in (a) European Commission Regulation code relating to
medicinal products for human use, Directives 2010/84/EU and 2012/26/EU respectively, as well as by the Commission Implementing Regulation (EU) No 520/2012 on the Performance of Pharmacovigilance Activities Provided for in Regulation (EC) No 726/2004
and Directive 2001/83/EC, Title IX of the Directive, Article 108a (a) of Directive 2001/83/EC, and principles detailed in the ICH guidelines for pharmacovigilance as well as (b) principles detailed in the United States 21 CFR and Guidance
for Industry Good Pharmacovigilance Practices and Pharmacoepidemiological Assessment. 
 “IFRS” means
generally accepted international accounting principles. 
 “IND” means (a) an investigational new drug
application filed with the FDA for authorisation to commence clinical studies and its equivalent in other countries or regulatory jurisdictions, including a Clinical Trial Application filed with the EMA with respect to the EU Territory or Swissmedic
with respect to Switzerland and (b) all supplements and amendments that may be filed with respect to the foregoing. 

“Indirect Taxes” means value added, sales, consumption, goods and services taxes or other similar taxes
required by Applicable Law including, for the avoidance of doubt, any tax imposed in compliance with the Council Directive of 28 November 2006 on the common system of value added tax (EC Directive 2006/112), to be disclosed as a separate item
on the relevant invoice. 
 “Information” means all technical, scientific and other know-how and information, trade secrets, knowledge, technology, means, methods, processes, practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs,
drawings, assembly procedures, computer programs, apparatuses, specifications, data, results and other material, including: biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical,
pre-clinical, clinical, safety, manufacturing and quality control data and information, including study designs and 

  
 9. 

 
protocols, assays and biological methodology, in each case (whether or not confidential, proprietary, patented or patentable) in written, electronic or any other form now known or hereafter
developed. 
 “Innate” has the meaning set forth in the preamble hereto. 

“Innate Corporate Names” means the Trademarks and logos identified on Schedule 8 and such other
corporate names or logos of Innate as Innate may designate in writing to MedImmune from time to time. 
 “Innate Know-How” means all Know-How Controlled by Innate or any of its Affiliates or its or their Sublicensees that is developed by Innate or any of its Affiliates or its or
their Sublicensees in the course of any Development activities relating to the Licensed Product and shall include all Know-How developed by either Party in accordance with clause 13.1.1. 

“Innate Marketing Materials” has the meaning set forth in clause 9.3. 

“Innate Patents” means all of the Patents Controlled by Innate or any of its Affiliates or its or their
Sublicensees that claim or cover Innate Know-How. 
 “Innate Regulatory
Documentation” means the Regulatory Documentation Controlled by Innate or any of its Affiliates or Sublicensees relating to the Exploitation of the Licensed Product in the Field in the Territories. 

“Intellectual Property Rights” means all Patents, Trademarks, copyrights, design rights, database rights,
domain names, rights in inventions, confidential information, know how, trade names, business names, get-up, logos and trade dress, and all other rights in the nature of intellectual property rights (whether
registered or unregistered) and all applications and rights to apply for the above, anywhere in the world. 
 “IP
Manager” has the meaning set forth in clause 13.4.1. 
 “Joint Development Committee” or
“JDC” has the meaning set forth in clause 6.3.1. 

“Know-How” means any Information which is secret and not in the
public domain, particularly not disclosed in a published Patent, and identified or identifiable in a tangible form. 

“Knowledge” means the good faith actual knowledge of the officers of MedImmune and its Affiliates, within the
remit of their functions within MedImmune, with respect to relevant facts and information after performing a commercially reasonable inquiry with respect to the relevant subject matters. 

“Licensed Antibody” means the anti-CD22 immunotoxin as further described and set forth in Schedule 4
to this Agreement, so called moxetumomab pasudotox-tdfk. 
 “Licensed Livery Period” has the meaning set
forth in clause 14.5.1. 

  
 10. 

 “Licensed MedI
Know-How” means the Know-How Controlled by MedImmune or any of its Affiliates that solely and exclusively relates to the Licensed Antibody and Licensed Product
and (a) is listed in Schedule 11, or (b) has been used by MedImmune or its Affiliates to Develop or Commercialize the Licensed Antibody or Licensed Product in the Field in the Territories prior to or on the Effective Date; or
(c) is developed by MedImmune or any of its Affiliates in connection with the Existing Product Trials, the Existing Research and Collaboration Agreements or any other Development activities relating to the Licensed Antibody or Licensed Product
undertaken by MedImmune or its Affiliates under this Agreement on or after the Effective Date, including Study Results, but in each case ((a), (b) and (c)) excluding any Know-How licensed under the [***]. 

“Licensed MedI Patents” means (a) the Patents owned or Controlled by MedImmune or its Affiliates and
listed in Schedule 6, and (b) the Patents owned or Controlled by MedImmune or its Affiliates in the Territory on or after the Effective Date that solely and exclusively relates to the Licensed Antibody or Licensed Product or otherwise
claims Licensed MedI Know-How, but excluding Patents licensed under the [***]. 

“Licensed [***] Patents” means the Patents listed in the [***], being the Patents licensed by
MedImmune under the [***] and sublicensed to Innate under the [***]. 
 “Licensed Product” means any
product that is comprised of or contains the Licensed Antibody as an active ingredient, whether alone or in combination with other active ingredients and includes the product that has been approved for sale in the United States pursuant to the US
Marketing Approval, so called Lumoxiti® in the US. 
 “Listing Rules” means the Listing Rules of the
FCA made under Part VI of FSMA. 
 “MAH” means, with respect to the Licensed Product in the EU Territory,
the holder of the EU Marketing Approval for the Licensed Product and, with respect to the Licensed Product in the US Territory, the holder of the US Marketing Approval. 

“MAH Related Responsibilities” has the meaning set forth in clause 12.1.2. 

“MAH Transfer Date” has the meaning set forth in clause 12.2.1. 

“Manufacture” means all activities related to the production, manufacture, processing, filling, finishing,
packaging, labelling, shipping and holding of the Licensed Antibody or Licensed Product or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterisation, stability testing, quality assurance and quality control. When used as a verb, “to Manufacture”
and “Manufacturing” means to engage in Manufacture. 
 “Material Agreement” has the
meaning given to it in clause 16.2(e). 
 “Material Anti-Corruption Law Violation” means a violation of an
Anti-Corruption Law relating to the subject matter of this Agreement that would, if it were publicly known, 

  
 11. 

 
be reasonably expected to have a material adverse effect on a Party or on the reputation of a Party because of its relationship with the other Party. 

“Materials” means compounds, compositions of matter, assays, and biological materials useful for the
Exploitation of Licensed Antibodies or Licensed Product. 
 [***] 

“MedI Regulatory Documentation” means the Regulatory Documentation Controlled by MedImmune or any of its
Affiliates relating to the Exploitation of the Licensed Product in the Field in the Territories. 

“MedImmune” has the meaning set forth in the preamble hereto. 

“Member State” means each other country that is currently a member state of the European Union, other than
the United Kingdom and Switzerland. 
 “[***]” means the [***]. 

“[***]” has the meaning set forth in clause [***]. 

“[***]” has the meaning set forth in clause [***]. 

“Net Sales” means, [***]: 
  

	 	(a)	 [***]; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]; 

  

	 	(d)	 [***]; and 

 

	 	(e)	 [***]. 

[***]. 

“New Product Trademarks” means Trademark(s) selected in accordance with clause 14.1.2 together with any
registrations thereof or any pending applications relating thereto in the Territories. 
 “Non-Breaching Party” has the meaning set forth in clause 20.2.1. 
 “Non-Business Days” has the meaning set forth in clause 12.4.6. 
 “Notice
Period” shall have the meaning set forth in clause 20.2.1. 
 “Other AZ IPR” means any Patents or Know-How owned or Controlled by MedImmune or any of its Affiliates which are not Licensed MedI Patents or Licensed MedI Know-How,

  
 12. 

 
but which are necessary to Develop or Commercialize the Licensed Antibody or Licensed Product in the form it is formulated and approved in the US Marketing Approval at the Effective Date in the
Territories as contemplated by this Agreement and (a) has been used by MedImmune or its Affiliates to Develop or Commercialize the Licensed Antibody or Licensed Product in the Field in the Territories prior to or on the Effective Date; or
(b) is developed by MedImmune or any of its Affiliates or its or their respective licensees or sublicensees in connection with the Existing Product Trials or any other Development activities relating to the Licensed Antibody or Licensed Product
undertaken by MedImmune or its Affiliates under this Agreement or undertaken by their respective licensees or sublicensees on or after the Effective Date, but in all cases excluding any Patents and Know-How
licensed under the [***]. 
 “Other Licensees” means Third Parties that may be granted rights under the
Licensed MedI Know-How, Licensed MedI Patents, Innate Know-How and/or Innate Patents outside the Territories. 

“Party” and “Parties” have the meanings set forth in the preamble hereto. 

“Patents” means all patents and patent applications, including, without limitation, any divisional,
continuation, continuation-in-part or registration applications, utility models, design patents, any patent issued with respect to any such patent applications, any
reissue, re-examination, renewal, amendment or extension (including any supplementary protection certificate (SPC) or paediatric extension) of any such patent. 

“Payment” has the meaning set forth in clause 10.9.1. 

“Person” means any individual, sole proprietorship, corporation, partnership, association, joint-stock
company, trust, unincorporated organization, joint venture or other similar entity or organization, including a government or political subdivision, department or agency of a government. 

“Personal Data” means any information relating to a Data Subject. 

“Pharmacovigilance Agreement” has the meaning set forth in clause 12.4.5. 

[***]. 

[***]. 

“PHSA” means the Public Health Service Act as set forth at 42 U.S.C.,Chapter 6A, as may be amended from time
to time, together with any rules, regulations and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto). 

“Product Agreement” means, with respect to the Licensed Product, any agreement entered into by and between
Innate or any of its Affiliates or any of its or their Sublicensees, on the one hand and one (1) or more Third Parties, on the other hand, that is necessary or 

  
 13. 

 
reasonably useful for the Development or Commercialization of the Licensed Product in the Field in the Territories, including (a) clinical trial agreements, (b) contract research
organisation agreements and (c) service agreements. 
 “Processing” means any operation or set of
operations that is performed on Personal Data or on sets of Personal Data, whether or not by automated means, such as collection, recording, organisation, structuring, storage, adaptation or alteration, retrieval, consultation, use, disclosure by
transmission, dissemination or otherwise making available, alignment or combination, restriction, erasure or destruction. 

“Product Copyrights” means all copyrightable subject matter related to the Licensed Product included in the
Product Labelling, the Promotional Materials and any Licensed Product training materials Controlled by MedImmune and provided by MedImmune to Innate in connection with this Agreement. 

“Product Trademarks” means the Existing Product Trademarks and the New Product Trademarks (if any). 

“Product Labelling” means, with respect to the Licensed Product in the Territories, (a) the approved
summary of product characteristics or other full prescribing information for the Licensed Product, including any required patient information, (b) all packaging for the Licensed Product, and (c) all labels and other written, printed or
graphic matter upon a container, wrapper or any package insert utilised with or for the Licensed Product. 

“Product Liability Claim” means a Third Party Claim arising from or occurring as a result of any personal
injury (including death) arising out of or relating to the administration of (a) the Licensed Product, or (b) a procedure provided for or required by a protocol for a Clinical Trial for the Licensed Product to which the trial subject would
not have been exposed but for their participation in the Clinical Trial. 
 “Project Teams” shall have the
meaning set forth in clause 6.3.9(a). 
 “Promotion” means any activities undertaken by a pharmaceutical
company’s field force representatives aimed at encouraging the use of a particular pharmaceutical product, including Detailing. When used as a verb, “to Promote” and “Promoting” means to engage in Promotion.

 “Promotional Materials” means, with respect to the Licensed Product, all written, printed, electronic or
graphic promotional materials, other than Product Labelling. 
 “PTE” shall have the meaning set forth in
clause 13.5.4. 
 “Quality Agreement” means the quality agreement in a form that is customary in the
pharmaceutical industry for the supply of Licensed Product for sale in the Territories entered into between the Parties in accordance with clause 12.4.7. 

“Receiving Party” has the meaning set forth in clause 15.1.1. 

  
 14. 

 “Regulations” means The Transfer of Undertakings
(Protection of Employment) Regulations 2006. 
 “Regulatory Approval” means, with respect to the Licensed
Product and a particular country in either of the Territories, any and all approvals (including approvals of BLAs), licences, registrations or authorisations of any Regulatory Authority necessary to commercially distribute, sell or market the
Licensed Product in the Territories, including, where applicable, (a) pricing or reimbursement approval in such country, (b) pre- and post- approval marketing authorisations (including any
prerequisite Manufacturing approval or authorisation related thereto) and (c) labelling approval. 

“Regulatory Authority” means any applicable supra-national, federal, national, regional, state, provincial or
local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the Exploitation of the Licensed Product, including the FDA in the United States, the
EMA in the European Union, and Swissmedic in Switzerland. 
 “Regulatory Documentation” means: all
(a) applications, registrations, licences, authorisations and approvals (including Regulatory Approvals) necessary for the Development or Commercialization of the Licensed Product in the Field in the Territories; (b) relevant
correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority) relating to the Development or Commercialization of the
Licensed Product in the Field in the Territories and all supporting documents with respect thereto, including any applicable CMC and non-clinical information and all adverse event files, excluding source
documentation associated with individual case safety reports, and complaint files; and (c) clinical and other data contained or relied upon in any of the foregoing. 

“Regulatory Exclusivity” shall mean any exclusive marketing rights or data exclusivity rights conferred by
any applicable Regulatory Authority, other than an issued and unexpired Patent, including any regulatory data protection exclusivity (including, where applicable, pediatric exclusivity or orphan drug exclusivity) or any other exclusivity afforded by
restrictions which restrict the granting by a Regulatory Authority of Regulatory Approval to market a generic product. 

“Relevant Costs” has the meaning set forth in clause 10.4.3. 

“Retained Rights” means the rights of MedImmune, its Affiliates and its and their licensors, (sub)licensees
and contractors to (i) perform its and their obligations under this Agreement and/or, subject to the [***]; (ii) Develop, obtain and maintain Regulatory Approvals for, Manufacture, Commercialize or otherwise Exploit, Licensed Product outside
the Territories; and (iii) Manufacture the Licensed Product for (x) supply to Innate or its Affiliates or licensees for sale in the Territories, or (y) supply to MedImmune or its Affiliates or licensees for sale outside the
Territories; and (iv) with Innate’s prior consent (not to be unreasonably withheld, delayed or conditioned) Develop or otherwise use the Licensed Product in the Territory for sale outside the Territories. 

  
 15. 

 “Regulatory Services” shall have the meaning set forth in
clause 12.5. 
 “Representatives” has the meaning set forth in clause 17.2.2. 

“Service Standard” means, with respect to the provision of any service by MedImmune (including the Regulatory
Services or the performance of any obligation under the Development Plan or the Commercialization Plan), the provision of those services or performance of those obligations (a) with substantially the same degree of skill, quality and care
utilized by MedImmune (or its Affiliates) in performing such activities for itself with respect to the Licensed Antibody or Licensed Product; and (b) in compliance in all material respects with Applicable Laws. 

“SKU” means stock keeping unit. 

“SOTC” means sales order to cash. 

“SOTC Period” has the meaning set forth in clause 3.8. 

“SOTC Services” has the meaning set forth in clause 3.8. 

“Study Results” means any data and information generated as a result of any Clinical Trials performed as part
of the Development Plan. 
 “Sublicensee” means a Person, other than an Affiliate, that is granted a
sublicence by Innate or its Affiliate under the grants in clause 4.1, as provided in clause 4.2. 
 “Supply
Agreement” has the meaning set forth in clause 3.2.1. 
 “Swissmedic” means the Swiss Agency for
Therapeutic Products and any successor agency thereto. 
 “Tax” or “Taxation” means any
form of tax or taxation, levy, duty, charge, social security charge, contribution or withholding of whatever nature (including any related fine, penalty, surcharge or interest) imposed by, or payable to, a Tax Authority. 

“Tax Authority” means any Governmental Authority authorized to levy Tax. 

“Term” has the meaning set forth in clause 20.1. 

“Termination Notice” has the meaning set forth in clause 20.2.1. 

“Territories” means the US Territory and the EU Territory. 

“Third Party” means any Person other than MedImmune, Innate and their respective Affiliates. 

“Third Party Claims” has the meaning set forth in clause 18.1. 

“TM Competitive Infringement” has the meaning set forth in clause 14.3.2. 

  
 16. 

 “Trademark” means any word, name, symbol, colour, shape,
designation or any combination thereof, including any trademark, service mark, trade name, brand name, sub-brand name, trade dress, product configuration, program name, delivery form name, certification mark,
collective mark, logo, tagline, slogan, design or business symbol, that functions as an identifier of source or origin, whether or not registered and all statutory and common law rights therein and all registrations and applications therefor,
together with all goodwill associated with, or symbolised by, any of the foregoing. 
 “Transaction” means
the transactions contemplated by this Agreement. 
 “Transferred Data” means the Personal Data transferred
by MedImmune to Innate pursuant to this Agreement. 
 “Unexpected Transfer Employee” has the meaning set
forth in clause 21.1.1. 
 “US Marketing Approval” means the approval of the BLA for the Licensed Product
in the US Territory by the FDA which was granted on September 13, 2018. 
 “US Territory” means the
United States of America. 
 “US Transfer Date” has the meaning set forth in clause 3.7.1. 

“US Transfer Notice” has the meaning set forth in clause 3.7.1. 

“US Transition Period” means the period commencing on the Effective Date and ending on the US Transfer Date.

  

	1.2	 In this Agreement, except where the context requires otherwise, whenever used the singular includes the
plural, the plural includes the singular, the use of any gender is applicable to all genders and the word “or” has the inclusive meaning represented by the phrase “and/or”. Whenever this Agreement refers to a number of days,
unless otherwise specified, such number refers to calendar days. The headings of this Agreement are for convenience only and do not define, describe, extend or limit the scope or intent of any provision in this Agreement. The term
“including” or “includes” as used in this Agreement means including, without limiting the generality of any description preceding such term. The wording of this Agreement shall be deemed to be the wording mutually chosen by the
Parties and no rule of strict construction shall be applied against any Party. Clause and Schedule headings shall not affect the interpretation of this Agreement. The Schedules form part of this Agreement and shall have effect as if set out in full
in the body of this Agreement. Any reference to this Agreement includes the Schedules. References to clauses and Schedules are to the clauses and Schedules of this Agreement. A reference to a statute or statutory provision is a reference to it as
amended, extended or re-enacted from time to time. A reference to a statute or statutory provision shall include any subordinate legislation made from time to time under that statute or statutory provision.

  
 17. 

	2.	 CLOSING 

Closing shall take place on the Effective Date after the close of the trading day of Euronext Paris. 

 

	3.	 TRANSITION OF CERTAIN ACTIVITIES 

 

	3.1	 Overview. It is the intention of the Parties that, with effect from the Effective Date, Innate shall
immediately become responsible for all Development Costs and all Commercialization Costs relating to the Development and Commercialization of the Licensed Product and Licensed Antibody in the Territories incurred on or after the Effective Date, and
shall be entitled to all revenues (less agreed fees pursuant to this Agreement) generated from Exploitation of the Licensed Product in the Territories. 

  

	3.2	 Supply Agreement 

 

	3.2.1	 As soon as reasonably practicable after the Effective Date, the Parties shall use their respective
reasonable endeavours to agree to a supply agreement to be executed no later than [***] after the Effective Date or such later date as the Parties agree (the “Supply Agreement”). The Parties agree that the terms of the Supply
Agreement shall incorporate the terms set out in Schedule 3, together with such other terms that are customary in the pharmaceutical industry for supply of products similar to the Licensed Product. In negotiating the Supply Agreement, each
Party shall act reasonably and in good faith with a view to reaching agreement as soon as reasonably practicable after the Effective Date. 

  

	3.3	 US Transition Period. During the US Transition Period, the Parties shall collaborate on the
Development and Commercialization of the Licensed Product in the US Territory, in accordance with their respective obligations set forth in the Commercialization Plan. 

 

	3.4	 US Transition Period Committees. During the US Transition Period, the performance of the
Parties’ respective obligations under the Commercialization Plan in the US Territory shall be overseen by the JCC. 

  

	3.5	 EU Transition Period. During the period needed for Innate to take over all responsibilities in Europe
following the transfer of the EU Marketing Approval, MedImmune will provide assistance in accordance with the EU Regulatory Transition Plan. 

  

	3.6	 Commercialization Plan. 

 

	3.6.1	 An initial version of the plan for the Commercialization of the Licensed Product in the US Territory is
attached as Schedule   1 (“Commercialization Plan”), as such Commercialization Plan may be updated from time to time by the JCC. The Parties acknowledge and agree that the initial version of the Commercialization
Plan is consistent with MedImmune and Innate’s obligations under the [***]. 

  
 18. 

	3.6.2	 The Commercialization Plan must include until the end of the US Transition Period: 

 

	 	(a)	 general strategies for Promoting, marketing and distributing the Licensed Product in the US Territory;

  

	 	(b)	 numbers of Full Time Sales Representatives, field based supervisory sales managers and medical/scientific
liaisons (expressed in FTEs) for the Licensed Product; 

  

	 	(c)	 Promotional activities and Detailing plans, including target prescribers and frequency and coverage metrics;

  

	 	(d)	 budgeted expenditure for sales and marketing; 

 

	 	(e)	 summary-level market and sales forecasts for the Licensed Product; 

 

	 	(f)	 a projection of Net Sales for the Licensed Product; 

 

	 	(g)	 SOV (share of voice) objectives; 

 

	 	(h)	 plans regarding distribution; and 

 

	 	(i)	 Innate’s strategy with respect to pricing and reimbursement, managed care and discounts.

  

	3.6.3	 Following the Effective Date, each Party, through its representatives on the Joint Commercialization
Committee, may propose amendments to the Commercialization Plan at any time and the Joint Commercialization Committee shall review the Commercialization Plan at least quarterly for the purpose of considering appropriate amendments with the objective
of optimising the Commercialization of the Licensed Product in the US Territory. Provided they are consistent with the content principles set forth in clause 3.6.2, each Party shall consider all comments made by the other on the Commercialization
Plan and any proposed amendments thereto in good faith. 

  

	3.6.4	 During the US Transition Period, the Joint Commercialization Committee shall review and agree any proposed
amendments to the Commercialization Plan with the objective of optimising the Commercialization of the Licensed Product in the US Territory, and transitioning its Commercialization to Innate, and complying with the provisions of the [***].

  

	3.7	 Commercial Transitional Arrangements. 

 

	3.7.1	 Subject to clause 3.7.2, MedImmune shall be responsible for Commercialization of the Licensed Products in
accordance with the Commercialization Plan until Innate takes full responsibility for such Commercialization. Innate shall serve written notice on MedImmune of the proposed date on which it shall take full responsibility for the Commercialization of
the Licensed Product in the US Territory (the “US Transfer  

  
 19. 

	 	 
Notice”). Unless otherwise agreed by the Parties, such date (the “US Transfer Date”) shall be the earlier of: 

 

	 	(a)	 [***]; and 

  

	 	(b)	 [***]. 

  

	3.7.2	 Innate may not serve the notice contemplated by clause 3.7.1 earlier than [***] and such notice must provide
at least [***] notice of the proposed transfer. However, the Parties agree that Innate may undertake part of Commercialization activities in accordance with the Commercialization Plan starting as of the Effective Date. 

 

	3.7.3	 No later than [***] prior to the US Transfer Date the Parties shall update the Commercialization Plan to
include activities intended to ensure the smooth transfer of all sales and distribution and other Commercialization activities relating to the Licensed Product in the US Territory undertaken by MedImmune or its Affiliates to Innate or its Affiliates
as soon as reasonably practicable after the US Transfer Date or in accordance with clause 3.8, by the end of the SOTC Period. The Commercialization Plan shall include any services to be provided by MedImmune in connection with such transition and,
except to the extent such services are SOTC Services paid for in accordance with clause 3.8, the fee payable (on an FTE basis and at the applicable FTE Rate quoted by MedImmune) by Innate for such activities in accordance with the budget included in
the Commercialization Plan. Innate shall also reimburse MedImmune for any out-of-pocket costs reasonably incurred by MedImmune in performing activities in accordance
with the Commercialization Plan in accordance with the budget included therein. 

  

	3.8	 SOTC Services. Unless otherwise agreed by the Parties, MedImmune shall provide the SOTC services set
out in Schedule 2 (the “SOTC Services”) until such time as (i) [***] and (ii) [***] (the “SOTC Period”), such SOTC Services to be provided on the terms described in Schedule 2. 

 

	4.	 LICENCE TERM GRANT OF RIGHTS 

 

	4.1	 MedImmune Licence. Subject as provided in this clause 4 (including the Retained Rights) and the other
terms and conditions of this Agreement, MedImmune hereby grants, with effect from the Effective Date, to Innate: 

  

	 	(a)	 an exclusive (including with regard to MedImmune and its Affiliates) licence (or sublicence) under the
Licensed MedI Patents and the Licensed MedI Know-How to Develop, obtain and maintain Regulatory Approvals for, Manufacture, Commercialize or otherwise Exploit the Licensed Product and Licensed Antibody in the
Field in the Territories; 

  

	 	(b)	 an exclusive (including with regard to MedImmune and its Affiliates) licence (or sublicence) under the
Licensed MedI Patents and the Licensed MedI Know-How to Develop and Manufacture the Licensed Product and Licensed Antibody in the Field outside the Territories solely (a) for Innate or its Affiliates or
licensees to Develop or Commercialize such Licensed Product and/or such Licensed Antibody 

  
 20. 

	 	 
in the Field in the Territories, and (b) for Innate or its Affiliates or licensees to Manufacture Licensed Product for and supply Licensed Product to MedImmune pursuant to the Supply
Agreement. For the avoidance of doubt, the exclusivity in this grant relates and applies only to Innate’s right to Develop or Commercialize Licensed Product and/or such Licensed Antibody outside the Territory in the Field for the sole purpose
of Development and Commercialization in the Territories and MedImmune and its Affiliates shall retain the right to Develop, Manufacture and Commercialize the Licensed Product and Licensed Antibody outside the Territories for all other purposes in
accordance with the other provisions of this Agreement; 

  

	 	(c)	 a non-exclusive licence (or sublicense) under the Other AZ IPR to
Develop, obtain and maintain Regulatory Approvals for, Manufacture, Commercialize and otherwise Exploit the Licensed Product and Licensed Antibody in the Field in the Territories; and 

 

	 	(d)	 an non-exclusive licence (or sublicence) under the Other AZ IPR to
Develop and Manufacture the Licensed Product and Licensed Antibody in the Field outside the Territories solely (a) for Innate or its Affiliates or licensees to Develop or Commercialize such Licensed Product and/or such Licensed Antibody in the
Field in the Territories, and (b) for Innate or its Affiliates or licensees to Manufacture Licensed Product for and supply Licensed Product to MedImmune pursuant to the Supply Agreement. 

 

	 	(e)	 a non-exclusive,
non-transferrable, non-sublicensible royalty free paid-up licence to use the AstraZeneca Corporate Marks and Product Copyrights
on Product Labelling and Innate’s Promotional Materials, including the Innate Marketing Materials solely to the extent necessary for Innate to Commercialize the Licensed Product in the Territories, subject to and in accordance with the terms of
this Agreement. 

 Subject to (i) Applicable Law, and (ii) MedImmune being compensated for any
Costs incurred in connection therewith, and to the extent practicable, Innate, its Affiliates and its Sublicensee shall be afforded access to MedImmune’s Access 360 Program, and/or other related patient savings programs (i.e., AZ&Me)
in the US in connection with Innate’s Exploitation of the Licensed Product in the US Territory. 
  

	4.2	 Sublicences and Subcontracting. 

 

	4.2.1	 Subject as provided in this clause 4.2, Innate may grant sublicences under the licences granted in clause
4.1: 

  

	 	(a)	 to its Affiliates; 

 

	 	(b)	 with respect to US activities, while MedImmune holds the US Marketing Approval, to any Third Party, subject
to MedImmune’s prior written consent (such consent not to be unreasonably withheld or delayed); 

  
 21. 

	 	(c)	 without consent provided it is with respect to US activities, after such time as MedImmune (or any of its
Affiliates) ceases to hold the US Marketing Approval; 

  

	 	(d)	 without consent to any person in connection with the development, reproduction and use of Innate’s
Promotional Materials for the sole purpose of Commercializing the Licensed Product in the US Territory in accordance with this Agreement; 

  

	 	(e)	 once Innate hold the EU Marketing Approval, with respect to European activities, to any person without
consent. 

 For clarity, until such time when Innate holds the US Marketing Approval or the EU Marketing
Approval (as applicable), any sublicence to an Affiliate with respect to the US activities or the EU activities (as applicable) shall automatically terminate on such Person ceasing to be an Affiliate of Innate. 

 

	4.2.2	 Any sublicences granted under clause 4.2.1 (whether to an Affiliate or a Third Party) shall be consistent
with, and expressly made subject to, the terms and conditions of this Agreement. Innate shall cause each Sublicensee to comply with the applicable terms and conditions of this Agreement, as if such Sublicensee were a Party to this Agreement.

  

	4.2.3	 Subject to clauses 4.2.4, Innate may subcontract with an Affiliate or a Third Party to perform any or all of
its obligations hereunder without MedImmune’s consent. 

  

	4.2.4	 The appointment of a Sublicensee or other subcontractor shall not relieve Innate of its obligation hereunder
or any liability and Innate shall be and remain fully responsible and liable for the acts and omissions of its Sublicensees and subcontractors. 

  

	4.2.5	 The agreement pursuant to which Innate grants rights to any Sublicensee or engages any subcontractor must be
consistent in all material respects with this Agreement and without limitation must (a) contain terms obligating such Sublicensee or subcontractor to comply with the confidentiality, intellectual property and all other relevant provisions of
this Agreement and (b) contain terms obligating such Sublicensee or subcontractor to permit MedImmune rights of inspection, access and audit substantially similar to those provided to MedImmune by this Agreement, while MedImmune holds the US
Marketing Approval and in the period prior to the grant of EU Marketing Approval. Innate shall ensure that each Sublicensee and subcontractor accepts and complies with all applicable terms and conditions of this Agreement (including any obligations
applicable to Affiliates). Innate hereby waives any requirement that MedImmune exhausts any right, power or remedy, or proceed against any Sublicensee or subcontractor for any obligation or performance under this Agreement prior to proceeding
directly against Innate. 

  

	4.3	 Retained Rights of MedImmune. Notwithstanding anything to the contrary in this Agreement and without
limitation of any rights granted or reserved to MedImmune pursuant to any other term or condition of this Agreement, MedImmune hereby expressly retains, on behalf of itself and its Affiliates (and on behalf of its licensors, (sub)licensees and
contractors) all right, title and interest in and to the Licensed MedI Patents, the Licensed MedI Know-How and the Product Trademarks for purposes of performing or exercising the Retained Rights, provided
that, except with respect to the performance by 

  
 22. 

	 	 
MedImmune of its obligations under this Agreement or [***], the performance or exercise of the Retained Rights does not conflict with the exclusivity of any exclusive licence granted to Innate
under clause 4.1 or under the [***]. [***]. 

  

	4.4	 No Other Rights Granted by MedImmune. Except as expressly provided herein and without limiting the
foregoing, MedImmune grants no other right or licence, including any rights or licences to the Licensed MedI Patents, the Licensed MedI Know-How, Other AZ IPR, the Product Trademarks, the AstraZeneca Corporate
Marks or any other Patent or Intellectual Property Rights not otherwise expressly granted herein. 

  

	4.5	 Grants to MedImmune. 

 

	4.5.1	 Innate hereby grants to MedImmune a perpetual and irrevocable,
non-exclusive, royalty-free licence under the Innate Patents, the Innate Know-How and the Innate Regulatory Documentation, to perform its obligations under this
Agreement and the [***] or to perform or exercise the Retained Rights. 

  

	4.5.2	 MedImmune may grant sublicences under the licence granted in clause 4.5.1 to its Affiliates and Other
Licensees but shall otherwise not have any rights to grant sublicences under that licence without Innate’s prior written consent (such consent not to be unreasonably withheld, delayed or conditioned). For clarity, any sublicence to an Affiliate
shall automatically terminate on such Person ceasing to be an Affiliate of MedImmune. MedImmune shall remain fully responsible and liable for the acts and omissions of its sublicensees. 

 

	4.6	 Rights of Reference. If MedImmune transfers the EU Marketing Approval or US Marketing Approval to
Innate, subject to MedImmune’s securing similar right of reference for Innate, its Affiliates and Sublicensees to the Regulatory Documentation of MedImmune, its Affiliates and its Other Licensees, Innate shall and does hereby grant to MedImmune
and its Affiliates a licence and right of reference, with the right to grant sublicences and further rights of reference through multiple tiers, under such marketing approvals and any other Innate Regulatory Documentation as necessary for purposes
of exercising the Retained Rights. Innate shall not grant any such licence or right of reference to any Third Party for Commercialization of the Licensed Product outside of the Territories. Innate shall, at MedImmune’s reasonable request and
cost, obtain any certificates of pharmaceutical products for the Licensed Product (“CPP”) and provide any appropriate authorisations to the applicable Regulatory Authority to permit MedImmune (or its Affiliates and designees) such
rights of reference. Innate shall not withdraw, or permit to be withdrawn, the US Marketing Approval or the EU Marketing Approval, any CPP or any other Innate Regulatory Documentation without providing at least [***] prior written notice to
MedImmune, and on request shall transfer any such marketing approval or other Innate Regulatory Documentation to MedImmune. Innate shall give Medimmune at least [***] prior written notice of any planned variations or other amendments to the US
Marketing Approval or the EU Marketing Approval or such other Innate Regulatory Documentation that would require a new CPP to be issued. 

  
 23. 

	4.7	 No Other Rights Granted by Innate. Except as expressly provided herein, Innate grants no other right
or licence, including any rights or licences to the Innate Patents, the Innate Know-How, the Innate Regulatory Documentation or any other Patent or Intellectual Property Rights not otherwise expressly granted
herein. 

  

	4.8	 Know-How Transfer. During the [***] period following
MedImmune’s receipt of notification that Innate is ready to receive Licensed MedI Know-How MedImmune shall provide Innate with electronic (or tangible embodiments, if electronic is not available) of the
Licensed MedI Know-How. MedImmune shall be responsible for the cost of providing one (1) set of copies (electronic, where they exist) only. MedImmune shall use Commercially Reasonable Efforts to provide
Innate with all reasonable assistance required in order to transfer the Licensed MedI Know-How to Innate hereunder. 

  

	5.	 RESTRICTIONS 

 

	5.1	 Territorial Restrictions. 

 

	5.1.1	 Innate acknowledges that MedImmune has reserved to itself and its Affiliates the right to distribute,
market, Promote, offer for sale or sell the Licensed Product outside the Territories. To the extent permitted by Applicable Law, Innate shall not, and shall not permit any of its Affiliates, distributors or Sublicensees to, distribute, market,
Promote, offer for sale or sell the Licensed Product actively or passively to any Person outside the Territories. 

  

	5.1.2	 Having granted the licences hereunder giving Innate and its Affiliates the exclusive right to distribute,
market, Promote, offer for sale or sell the Licensed Product inside the Territories, to the extent permitted by Applicable Law, save to the extent required for MedImmune to perform its obligations under this Agreement MedImmune, shall not, and shall
not permit any of its Affiliates, distributors or Sublicensees, , to, distribute, market, Promote, offer for sale or sell the Licensed Product actively or passively to any Person in the Territories. 

 

	5.1.3	 Neither Party shall [***]. 

 

	6.	 DEVELOPMENT PLAN/GOVERNANCE 

 

	6.1.1	 An initial version of the plan for the continued Development of the Licensed Antibody and Licensed Product
in the EU Territory and the related budget is attached as Schedule 10 (the “Development Plan”), as such Development Plan may be updated from time to time by the JDC. The Parties acknowledge and agree that the initial version
of the Development Plan is consistent with MedImmune Innate’s obligations under the [***]. 

  

	6.2	 Alliance Managers. 

With effect from the Effective Date, each Party shall appoint a person (an “Alliance Manager”) who shall
manage and facilitate communications between the Parties under this Agreement and who shall work together to resolve quickly any issues between the Parties that may arise in connection with this Agreement. Each Party may replace its

  
 24. 

 
Alliance Manager at any time by notice in writing to the other Party. In particular the Alliance Managers shall: 
  

	 	(a)	 attend meetings of the Committees as non-voting participants;

  

	 	(b)	 assist the chairperson of each Committee with respect to notifying the applicable members of such Committee
of meetings and providing agendas and related information to such members; 

  

	 	(c)	 assist the chairperson of each Committee to circulate for review, and obtain approval of, the minutes of
each meeting of such Committee; 

  

	 	(d)	 facilitate the delivery of reports relating to Development and Commercialization activities; and

  

	 	(e)	 otherwise coordinate the Parties’ activities under this Agreement, any transitional services agreement,
any supply agreement and [***]. 

  

	6.3	 Committees. 

 

	6.3.1	 Joint Development Committee. 

 

	 	(a)	 Innate and MedImmune shall establish a joint development collaboration committee in accordance with this
clause 6.3.1 (the “JDC”). The JDC shall remain in effect as from the Effective Date until the EU Marketing Approval is obtained and transferred to Innate (or until such time as the JDC determines that there is no reasonable prospect
of the EU Marketing Approval being obtained). If the JDC is disbanded pursuant to the preceding sentence and the Parties thereafter decide to commence or re-commence any Development activities, the JDC shall
be re-established and remain in effect until for the duration of performance of such Development activities. 

  

	 	(b)	 The JDC shall serve as a forum for discussing and sharing Information and materials; discussing strategy
regarding the Development of the Licensed Product in the Territories and, in particular, the strategies and actions required to obtain the EU Marketing Approval, and discussing the allocation of Development activities to be conducted by Innate and
MedImmune respectively. 

  

	6.3.2	 Each Party shall appoint [***] as its voting members of the JDC. Each Party’s representatives on the
JDC as of the Effective Date are set forth in Schedule 9. The JDC shall be chaired by a representative of Innate. The chairperson shall be responsible for calling meetings, setting the agenda, circulating the agenda at least [***] to each
meeting and distributing minutes of the meetings within [***] following such meetings (provided that the chairperson may elect to delegate the performance of its responsibilities to other members of the JDC from time to time), but will not otherwise
have any greater power or authority than any other member of the JDC. The chairperson shall coordinate with each Party to schedule each JDC meeting in good time in advance of such meeting. Each Party shall disclose to the chairperson any proposed
agenda items, along with appropriate 

  
 25. 

	 	 
information and materials as early as reasonably practicable in advance of such meeting, but no less than [***]. The chairperson shall not unreasonably reject any proposed call for a JDC meeting
or proposed agenda items made by either Party. At least one (1) member of the JDC selected by Innate and one (1) member of the JDC selected by MedImmune shall have substantial experience in pharmaceutical product research and development,
and all of the members of the JDC shall have such expertise as appropriate to the activities of the JDC. Each Party may replace its members of the JDC upon written notice to the other Party, provided that any such substitute member shall have
substantially the equivalent functional expertise, experience and seniority as the member that such person replaces provided that the Parties shall use Commercially Reasonable Efforts to keep replacements to a minimum. From time to time, the JDC may
invite non-voting personnel of either Party to participate in discussions of the JDC. An alternate voting member designated by a Party may serve temporarily in the absence of a permanent voting member
appointed by such Party, and either Party may also designate one or more non-voting consultants to such Party who are under written obligations of confidentiality to such Party as JDC observers who may attend
the JDC meetings in an observational or advisory capacity only. 

  

	6.3.3	 The JDC shall hold meetings at such times and places as shall be determined by a majority of the entire
membership of the committee, but in no event shall such meetings be held less frequently than once every [***]. Meetings of the JDC will alternate between the offices of the Parties, unless otherwise agreed upon by the members of the JDC, or may be
held via internet, telephonically or by videoconference; provided that at least [***] shall be held in person. Meetings of the JDC will be effective only if at least [***] of each Party are in attendance or participating in the meeting. Each Party
will be responsible for the expenses incurred in connection with its employees, consultants and its members of the JDC attending or otherwise participating in JDC meetings. 

 

	6.3.4	 Either Party may convene at any time a meeting of the JDC to discuss and, if agreed, approve any increase in
the amount of Costs likely to be incurred in connection with Development activities that exceed the corresponding budgeted amount for those activities. If the JDC shall not be able to reach a decision on any additional Costs and Budgets, then
neither Party shall be liable under this Agreement to the other for any failure to achieve or delay in achieving any obligation the satisfaction of which is contingent upon the incurrence of such additional Costs. 

 

	6.3.5	 The JDC’s responsibilities will include, among others, (i) reviewing and approving the Development
Plan, Development Budget, Regulatory Documentation and EU Regulatory Transition Plan, and any amendments thereto, (ii) reviewing and approving protocols for any new Clinical Trials and any amendments or modifications to such protocols or
studies, (iii) performing quarterly reviews of the progress of Development and considering any proposed additional studies, (iv) facilitating the exchange of information and materials, (v) reviewing and advising on a proposal by
either Party to stop an Existing Product Trial or any new Clinical Trial of the Licensed Product, (vi) reviewing and commenting on allocation of responsibility for Development activities between the Parties, (vii) discussing each
Party’s progress under the Development Plan, including reviewing progress toward timelines and budget, Study Results and the status of achieving Regulatory Approval; (viii) providing strategic direction and consultation with respect to
Development of Licensed 

  
 26. 

	 	 
Products (including regulatory strategy); (ix) coordinating communication between the Parties; (x) resolving disputes between the Parties relating to the Development Plan or relating to any
pharmacovilance maters that cannot be resolved at the respective functional teams of the Parties, and (xi) performing such other functions as designated to the JDC under this Agreement or mutually agreed between the Parties. For clarity, any
and all decisions taken by JDC through the responsibilities defined in this section 6.3.5 shall be consistent with the provisions of the Development Plan, the Budget, the Costs and the Supply Agreement (including the supply forecasts for the
Licensed Products). Notwithstanding anything to the contrary set forth in this Agreement, the JDC will have no authority to (a) amend, modify or waive compliance with this Agreement or otherwise impose any obligation on the Parties in deviation
from this Agreement, or (b) resolve any dispute concerning the validity, compliance with, or breach of, this Agreement. 

  

	6.3.6	 The JDC shall make decisions on all matters within the scope of` its authority only by unanimous consent,
with the MedImmune voting members cumulatively having one (1) vote and the Innate voting members cumulatively having one (1) vote, irrespective of the number of members actually in attendance at a meeting. In the event that unanimity
cannot be reached by the JDC on a matter before it for decision within [***] after the matter was first considered by it then the matter may be referred by either Party to the Executives, who shall meet (in person, via internet, telephonically or by
videoconference) and attempt to resolve the matter within [***] of such referral. In the event that the Executives are unable to reach consensus within such [***] period, subject to clause 6.3.6 Innate shall have the final decision making authority
[***]. 

  

	6.3.7	 Prior to and during such time as MedImmune is MAH of the US Marketing Approval or EU Marketing Approval, as
the case may be, [***]. Upon and after such time as Innate is MAH of the US Marketing Approval or EU Marketing Approval, as the case may be, [***]. 

  

	6.3.8	 Joint Commercialization Committee. 

 

	 	(a)	 Formation and Purpose. Promptly following the Effective Date, the Parties shall form a joint
commercialisation committee (the “Joint Commercialization Committee” or “JCC”) to oversee and coordinate the Parties activities with respect to, and optimise the Commercialization of the Licensed Product in the US
Territory during the US Transition Period. The initial members of the JCC (and their functional responsibilities) are set forth on Schedule 9. The JCC shall be chaired by a representative of MedImmune. The chairperson shall be responsible for
calling meetings, setting the agenda, circulating the agenda at least [***] prior to each meeting and distributing minutes of the meetings within [***] following such meetings (provided that the chairperson may elect to delegate the performance of
its responsibilities to other members of the JCC from time to time), but will not otherwise have any greater power or authority than any other member of the JCC. The chairperson shall coordinate with each Party to schedule each JCC meeting in good
time in advance of such meeting. Each Party shall disclose to the chairperson any proposed agenda items, along with appropriate information and materials as early as reasonably practicable in advance of such meeting, but no less than [***]. The
chairperson shall not unreasonably reject any proposed call for a JCC meeting 

  
 27. 

	 	 
or proposed agenda items made by either Party. At least one (1) member of the JCC selected by Innate and one (1) member of the JCC selected by MedImmune shall have substantial
experience in commercialization of pharmaceutical products in the US Territory, and all of the members of the JCC shall have such expertise as appropriate to the activities of the JCC. Each Party may replace its members of the JCC upon written
notice to the other Party, provided that any such substitute member shall have substantially the equivalent functional expertise, experience and seniority as the member that such person replaces provided that the Parties shall use Commercially
Reasonable Efforts to keep replacements to a minimum. From time to time, the JCC may invite non-voting personnel of either Party to participate in discussions of the JCC. An alternate voting member designated
by a Party may serve temporarily in the absence of a permanent voting member appointed by such Party, and either Party may also designate one or more non-voting consultants to such Party who are under written
obligations of confidentiality to such Party as JCC observers who may attend the JCC meetings in an observational or advisory capacity only. 

  

	 	(b)	 Meetings. The JCC shall hold meetings at such times and places as shall be determined by a majority
of the entire membership of the committee, but in no event shall such meetings be held less frequently than once every [***]. Meetings of the JCC will alternate between the offices of the Parties, unless otherwise agreed upon by the members of the
JCC, or may be held via internet, telephonically or by videoconference; provided that at least [***] shall be held in person. Meetings of the JCC will be effective only if at least two JCC members of each Party are in attendance or participating in
the meeting. Each Party will be responsible for the expenses incurred in connection with its employees, consultants and its members of the JCC attending or otherwise participating in JCC meetings. 

 

	 	(c)	 Either Party may convene at any time a meeting of the JCC to discuss and, if agreed, approve any increase in
the amount of Costs likely to be incurred in connection with Commercialization activities that exceed the corresponding budgeted amount for those activities. If the JCC shall not be able to reach a decision on any additional Costs and Budgets, then
neither Party shall be liable under this Agreement to the other for any failure to achieve or delay in achieving any obligation the satisfaction of which is contingent upon the incurrence of such additional Costs. 

 

	 	(d)	 Specific Responsibilities of the JCC. In support of its responsibility for overseeing, coordinating
and optimising the Commercialization of the Licensed Product in the US Territory during the US Transition Period, the JCC shall: 

  

	 	(i)	 review and approve the Commercialization Plan and anticipated Commercialization Costs;

  

	 	(ii)	 facilitate the flow of information with respect to Commercialization activities being conducted for the
Licensed Product in the US Territory during the US Transition Period; 

  
 28. 

	 	(iii)	 discuss pricing, reimbursement and discount strategy for the Licensed Product in the US Territory;

  

	 	(iv)	 discuss and seek to finalise the draft commercial transition plan in accordance with clause 3.7 and the
provisions of the Development Plan, and oversee the implementation of the commercial transition plan; 

  

	 	(v)	 discuss demand planning and supply forecast (subject to the provisions of the [***] Supply Agreement and
[***] Supply Agreement). 

  

	 	(e)	 Decision Making. The JCC shall make decisions on all matters within the scope of its authority only
by unanimous consent, with the MedImmune voting members cumulatively having one (1) vote and the Innate voting members cumulatively having one (1) vote, irrespective of the number of members actually in attendance at a meeting. In the
event that unanimity cannot be reached by the JCC on a matter before it for decision, having considered the matter in good faith with a view to mutually beneficial resolution, within fifteen (15) days after the matter was first considered by it
then the matter may be referred by either Party to the Executives, who shall meet (in person, via internet, telephonically or by videoconference) and attempt to resolve the matter within fifteen (15) days of such referral. In the event that the
Executives are unable to reach consensus within such fifteen (15) day period, Innate shall have the final decision making authority [***]. 

  

	 	(f)	 Disbandment. The JCC shall cease to exist from the end of the US Transition Period and thereafter
responsibility for the oversight of Commercialization of the Licensed Product in the US Territory shall pass to Innate (or as otherwise agreed in the commercial transition plan). If the Parties elect to form a Committee for the oversight of
Commercialization activities in the EU Territory, then the JCC shall be reconstituted with such roles and responsibilities as the Parties may agree. 

  

	6.3.9	 Joint Working Groups. 

 

	 	(a)	 The Parties will either directly or through the JDC or JCC establish one or more operational teams, which
may be formal or informal, including with respect to transition, supply chain, pharmacovigilance, regulatory and other matters. Such teams shall be made up of an adequate number of persons from each Party with the necessary skills to coordinate and
execute the day-to-day activities required for the implementation of the decisions from each Committee (the “Project Teams”). 

 

	 	(b)	 The Project Teams shall periodically, or at the request of the Committees, submit to the applicable
Committees progress reports in relation to its activities under the Development and Commercialization Plans. 

  

	7.	 ONGOING AND FUTURE CLINICAL TRIALS 

 

	7.1	 Existing Product Trials. Following the Effective Date, MedImmune shall continue, unless otherwise
indicated by the Commercialization Plan or Development Plan or directed by the JDC or JCC, to conduct any Existing Product Trial that commenced prior to the 

  
 29. 

	 	 
Effective Date and shall be responsible for the activities associated therewith. Innate shall be responsible for, and shall reimburse MedImmune for, any and all Costs incurred by MedImmune or its
Affiliates in connection with any Existing Product Trial (including those related to pharmacovigilance) from the Effective Date in accordance with the Commercialization Plan or the Development Plan. MedImmune shall notify Innate as soon as
reasonably practicable of any material developments or results in respect of any Existing Clinical Trial, including providing Innate with an electronic copy of such results, which shall be deemed to be Licensed MedI
Know-How. 

  

	7.2	 Existing Research and Collaboration Agreements. Prior to the Effective Date, MedImmune has entered
into the Existing Research and Collaboration Agreements. Following the Effective Date, the JDC or JCC (as relevant) shall monitor MedImmune’s performance under such Existing Research and Collaboration Agreements, which shall be at Innate’s
cost and expense. MedImmune shall notify Innate as soon as reasonably practicable of any material developments or results in respect of any Existing Research and Collaboration Agreements as well as the completion of the collaboration and/or the
termination of any such Existing Research and Collaboration Agreement. MedImmune shall provide Innate with a copy of such results in the format received, which shall be deemed to be Licensed MedI Know-How.

  

	7.3	 Additional Trials. Without limiting Innate’s responsibility for all Development Costs, Innate
shall be responsible for all Costs associated with any new Clinical Trials relating to the Licensed Antibody or Licensed Product in the Territories and, subject to MedImmune agreeing to provide support to Innate in connection with such new Clinical
Trial, which agreement shall not be unreasonably withheld or delayed if such Clinical Trials are required to obtain Regulatory Approval, shall reimburse MedImmune for all such Costs incurred by it and its Affiliates in connection with any such new
Clinical Trial, provided that the protocols and supervising of such Clinical Trials have been agreed by the JDC. MedImmune shall notify Innate as soon as reasonably practicable of any request from any Regulatory Authority for any new Clinical Trial
for the Licensed Antibody or Licensed Product in the Territories and any material developments or results in respect of such trial. MedImmune shall not be under any obligation to undertake or fund any additional Clinical Trials of the Licensed
Antibody or Licensed Product in the Territories. For the avoidance of doubt, Innate shall be responsible for all Costs associated with any life cycle management related to the Licensed Product in the Territories. 

 

	8.	 CERTAIN DILIGENCE OBLIGATIONS 

 

	8.1	 Development Diligence: Pre-Transfer of Marketing Approvals.

  

	 	(a)	 From the Effective Date until the MAH Transfer Date, MedImmune shall use its Commercially Reasonable Efforts
to comply with its obligations under the Commercialization Plan. For the duration of the Development Plan, MedImmune shall use its Commercially Reasonable Efforts to comply with its obligations under the Development Plan. 

  
 30. 

	 	(b)	 From such time as Innate commences its first activities under the Commercialization Plan until the MAH
Transfer Date for the US Marketing Approval, Innate shall, at MedImmune’s reasonable request, use Commercially Reasonable Efforts to support MedImmune to maintain the US Marketing Approval in the Field in the US Territory.

  

	 	(c)	 During the period that MedImmune is providing the Regulatory Services, it shall provide (or procure the
provision of) such services in accordance with the Service Standard. 

  

	 	(d)	 From the Effective Date until the MAH Transfer Date for the EU Marketing Approval (provided the EU Marketing
Approval is granted), Innate shall, at MedImmune’s reasonable request, use Commercially Reasonable Efforts to support MedImmune to obtain and, following grant of the EU Marketing Approval, maintain, the EU Marketing Approval in the Field in the
EU Territory. 

  

	9.	 COMMERCIALISATION ACTIVITIES 

 

	9.1	 Responsibility for Commercialization. 

 

	9.1.1	 Following the end of the US Transition Period (with respect to the US Territory), Innate shall:

  

	 	(a)	 be responsible for Commercialization of the Licensed Product in the Field in the US Territory at its cost
and expense; 

  

	 	(b)	 subject to Applicable Law, invoice and book sales, establish all terms of sale (including pricing and
discounts) and warehouse and distribute the Licensed Product in the Field in the Territories and perform or cause to be performed all related services; and 

  

	 	(c)	 subject to clause 12.4, handle all returns, recalls or withdrawals, order processing, invoicing, collection,
distribution and inventory management with respect to the Licensed Product in the Territories. 

  

	9.1.2	 From the Effective Date, Innate shall be responsible for the Commercialization of the Licensed Product in
the EU Territory (subject to the EU Marketing Approval being granted and transferred from MedImmune to Innate). 

  

	9.2	 Markings. Subject to any local regulatory requirements, Innate shall be identified on the Licensed
Product Labelling. All changes to the Licensed Product Labelling required to so identify Innate shall be at Innate’s cost. The timing of any such changes shall be agreed by the Parties following discussions by the JCC, taking into account
existing inventory of Licensed Product and Manufacturing and regulatory requirements. 

  

	9.3	 Promotional Materials. Following the Effective Date and as part of the Commercialization Plan,
MedImmune shall provide to Innate MedImmune Promotional Materials so that Innate can develop its own Promotional Materials (including web and 

  
 31. 

	 	 
social media content) for the Licensed Product (collectively, the “Innate Marketing Materials”). The Innate Marketing Materials shall be consistent with the Product Labelling in
all material respects. Innate shall provide copies of the Innate Marketing Materials to the JCC for review promptly following their creation by Innate or a material amendment, and prior to their use. Innate shall be responsible for creating any
necessary local variants of the Innate Marketing Materials for use in each country in the Territories and shall ensure that such marketing materials are consistent with the Innate Marketing Materials provided to the JCC for review. Innate shall use
Promotional Materials that are consistent with the Innate Marketing Materials provided to the JCC for review (and only such marketing materials, together with Product Labelling) in Commercializing the Licensed Product in the Territories. While
MedImmune is the MAH, (a) all Innate Marketing Materials for the Licensed Product in the US must be approved by MedImmune in writing prior to its use (such approval not to be unreasonably withheld, delayed or conditioned) and (b) after any
such approval the approved Innate Marketing Materials shall, at MedImmune’s reasonable request, be subject to re-approval by MedImmune (such re-approval not to be
unreasonably withheld, delayed or conditioned). 

  

	9.4	 Promotion of Products. Until such time as MedImmune (or any of its Affiliates) ceases to be the MAH
in the US with respect to Innate and during the SOTC Period with respect to MedImmune, each Party shall train the Field Force and ensure that all Promotional activities relating to the Licensed Product are undertaken in accordance with standards
equivalent to, or higher than, the AZ Promotion Principles. 

  

	10.	 PAYMENTS 

  

	10.1	 Upfront Amount. In partial consideration of the rights granted by MedImmune to Innate under this
Agreement, Innate shall pay to MedImmune a non-refundable one-time upfront payment of fifty million Dollars ($50,000,000) (“Upfront Amount”) on the
later of the Effective Date and January 31, 2019, by way of electronic transfer to the account set forth in clause 10.8. 

  

	10.2	 Milestone Payments. In partial consideration of the rights granted by MedImmune to Innate hereunder,
Innate shall pay MedImmune the following milestone payments within [***] after the first achievement of each of the following milestone events, which payments shall be a one-time payment, non-refundable, non-creditable and fully earned upon achievement of the relevant milestone event: 

 

							
		 	  

Milestone Event
  
	  	  

Milestone Payment ($)
  
	  	

  

							
		 	  

The date on which gross sales of Licensed Product during the 2019 Calendar Year in the US Territory equals or exceeds
[***].
  
	  	  

10,000,000
	  	

  
 32. 

							
		 	  

Date on which MedImmune files for the BLA (or its European equivalent) with the EMA (or files for the BLA (or its
European equivalent) in [***].
  
	  	  

15,000,000
	  	

  

	10.3	 Determination that milestones have occurred. Either Party shall notify the other promptly of the
achievement of each of the events identified as a milestone in clause 10.2. 

  

	10.4	 Other Payments 

 

	10.4.1	 The Development Plan includes that Development Budget (which includes the budget for the Regulatory
Services), and the Commercialization Plan includes, a budget for the Supply Expenses, as such budgets may be updated from time to time by mutual agreement, and may be supplemented by budgets for other services that are not included in the SOTC
Services (together the “Budgets”). 

  

	10.4.2	 The Costs incurred by MedImmune and its Affiliates pursuant to any Budgets and pursuing the
Commercialization Plan and Development Plan, shall be reimbursed by Innate on a quarterly basis in arrears, upon receipt from MedImmune of an invoice including reasonable supporting evidence of the Costs, provided that such Costs have not already
been compensated under this Agreement. Any Costs incurred by MedImmune and its Affiliates in excess of [***] of the amount budgeted for the applicable Calendar Quarter in any given Budget (the “Excess Costs”) shall be reimbursable
by Innate only if (i) such Excess Costs were incurred as a result of circumstances outside MedImmune’s control or otherwise by the occurrence of a force majeure event, (ii) the incurrence of such Excess Costs was approved by the JDC
or JCC, or (iii) such Excess Costs were not incurred as a result of MedImmune’s failure to perform the corresponding obligations in the Development Plan or Commercialization Plan (as the case may be) in accordance with the Services
Standard. 

  

	10.4.3	 [***]. 

  

	10.5	 [***]. Innate shall make the payments set forth in, and contemplated by, the [***]. Other than those
payments, no other payments shall be due by Innate in respect of the [***]. 

  

	10.6	 [***]. Innate shall make the payments set forth in, and contemplated by, the [***]. Other than those
payments, no other payments shall be due by Innate in respect of the [***]. 

  

	10.7	 No other payments. The payments referred to in this clause 10, clause 3.8 and Schedule 2 and
clause 3.2 and Schedule 3 are Innate’s sole payment obligations to MedImmune, its Affiliates and their respective licensors or contractors in respect of the grant of licenses described in clause 4 and the Development and
Commercialization obligations undertaken by MedImmune under this Agreement. 

  

	10.8	 Mode of Payment; Offsets. All payments to MedImmune under this Agreement shall be made by deposit of
Dollars in the requisite amount to the UK bank account notified in 

  
 33. 

	 	 
advance by MedImmune to Innate, or such other account as MedImmune may from time to time designate by notice to Innate. Neither Party shall have the right to offset, set off or deduct any amounts
from or against other amounts due hereunder. For the purpose of calculating any sums due under, or otherwise reimbursable pursuant to, this Agreement (including the calculation of Net Sales expressed in currencies other than Dollars), the Parties
shall convert any amount expressed in a foreign currency into Dollar equivalents using its, its Affiliate’s or Sublicensee’s, as applicable, standard conversion methodology consistent with GAAP. 

 

	10.9	 Taxes. 

  

	10.9.1	 General. The Upfront Amount, milestone payments and other payments payable by Innate to MedImmune
pursuant to this Agreement (each, a “Payment”) shall be paid without any deduction or withholding for or on account of any Tax, except for any such deduction or withholding required by Applicable Law. The Parties acknowledge and
agree that in accordance with Applicable laws as of the Effective Date, no withholding Tax should apply. Except as provided in this clause 10.9.1, MedImmune shall be solely responsible for paying any and all taxes (other than withholding taxes
required by Applicable Law to be deducted from Payments and remitted by Innate) levied on account of, or measured in whole or in part by reference to, any Payments it receives. Innate shall deduct or withhold from the Payments any taxes that it is
required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if MedImmune is entitled under any applicable Tax treaty to a reduction of rate of, or the elimination of, applicable withholding Tax, it may deliver to Innate or the
appropriate Governmental Authority (with the assistance of Innate to the extent that this is reasonably required and is requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve Innate of its
obligation to withhold such Tax and Innate shall apply the reduced rate of withholding or dispense with withholding, as the case may be; provided that Innate has received evidence that MedImmune has duly delivered all applicable forms (and
that, if applicable, all governmental authorisations that are required to be received by the appropriate Party have been so received) at least [***] prior to the time that the Payments are due. If, in accordance with the foregoing, Innate withholds
any amount, it shall pay to MedImmune the balance when due, make timely payment to the proper taxing authority of the withheld amount and send to MedImmune proof of such payment within [***] following such payment. If Innate shall have transferred
(whether by way of legal or equitable assignment, declaration of trust, novation or otherwise) the benefit in whole or in part of this Agreement or shall, after the Effective Date, have changed its Tax residence or the permanent establishment to
which the rights under this Agreement are allocated and, a payment under this Agreement is subject to a requirement to withhold for or on account of Tax where the payment would not have been subject to such withholding requirement in the absence of
such transfer, change of Tax residence or permanent establishment, then Innate or its assignee (as the case may be) shall be obliged to pay to MedImmune such sum as will, after such deduction or withholding has been made, leave MedImmune with the
same amount as it would have been entitled to receive in the absence of any such requirement to make a deduction or withholding; provided that, upon Innate’s or its assignee’s reasonable request, if MedImmune is entitled under any
applicable Tax treaty to a reduction of rate of, or the elimination of, any applicable withholding Tax, it shall deliver to Innate or its assignee or 

  
 34. 

	 	 
the appropriate Governmental Authority (with the assistance of Innate or its assignee to the extent that this is reasonably required) the prescribed forms necessary to reduce the applicable rate
of withholding or to relieve Innate of its obligation to withhold such Tax. 

  

	10.9.2	 Indirect Tax. Notwithstanding anything contained in clause 10.9.1, this clause 10.9.2 shall apply
with respect to Indirect Tax. All amounts expressed to be payable under this Agreement (including the Upfront Amount) by any Party to this Agreement which (in whole or in part) constitute the consideration for any supply for Indirect Tax purposes
are deemed to be exclusive of any Indirect Tax which is chargeable on that supply, and accordingly, if any Indirect Tax is or becomes chargeable on any supply made by any Party to this Agreement (the “Supplier”) and the Supplier or
an Affiliate of the Supplier is required to account to the relevant Tax Authority for the Indirect Tax, the Party receiving such chargeable supply (the “Recipient”) shall pay to the Supplier (in addition to and at the same time as
paying any other consideration for such supply, or [***] after the receipt by the Recipient of an appropriate invoice in respect of such Indirect Tax) an amount equal to the amount of the Indirect Tax (and such Supplier must promptly provide an
appropriate invoice in respect of such Indirect Tax to the Recipient to the extent that such an invoice has not already been provided). 

  

	10.9.3	 Tax Warranties. In this clause 10.9.3: 

 

	 	(a)	 references to “committing tax evasion” shall include: 

 

	 	(i)	 fraudulently or dishonestly failing to pay any amount of tax to the relevant Tax Authority within any
applicable time limit for the payment of such tax without incurring interest and/or penalties; and 

  

	 	(ii)	 fraudulently or dishonestly claiming any relief, allowance, credit, deduction, exemption or set off in
respect of any tax (or relevant to the computation of any income, profits or gains for the purposes of any tax), or any right to or actual repayment of or saving of tax; and 

	 	

	 	(iii)	 “tax” or “taxation” means: 

 

	 	(1)	 taxes on gross or net income, profits and gains, and 

 

	 	(2)	 all other taxes, levies, duties, imposts, charges and withholdings of any nature, including any excise,
property, wealth, capital, value added, sales, use, occupation, transfer, franchise and payroll taxes and any national insurance or social security contributions, together with all penalties, charges, fees and interest relating to any of the
foregoing or to any late or incorrect return in respect of any of them. 

  

	 	(b)	 Each Party represents, warrants and undertakes that 

 

	 	(i)	 neither it nor its Affiliates shall commit tax evasion; 

  
 35. 

	 	(ii)	 neither it nor its Affiliates shall undertake any activities which would facilitate or otherwise result in
another person committing tax evasion; and 

  

	 	(iii)	 it and its Affiliates shall maintain reasonable procedures designed to prevent any employees, agents or
other persons who perform services for them or on their behalf from undertaking any activities which would facilitate or otherwise result in another person committing tax evasion. 

 

	 	(c)	 Each Party shall promptly report any apparent breach of clause 10.9.3(b) to the other Party.

  

	 	(d)	 Each Party shall: 

 

	 	(i)	 answer, in reasonable detail, any written or oral inquiry from the other Party related to Innate’s
compliance with clause 10.9.3(b), 10.9.3(c) and 10.9.3(d); 

	 	

	 	(ii)	 facilitate the interview of staff employed by Innate (or any agent of Innate) at any reasonable time
specified by the other arty related to compliance with this clause 10.9.3; and 

	 	

	 	(iii)	 co-operate with the other Party and/or any regulator or Governmental
Authority in relation to any investigation relating to the matters referred to in this clause. 

 Breach
of this clause 10.9.3 shall be deemed a material breach under clause 20.2.1, and for that purpose a breach of clause 10.9.3(b) or 10.9.3(c) shall be regarded as incapable of remedy. 

 

	10.9.4	 Unless otherwise expressly provided, all payments due by one party to another under the Agreement shall be
made against invoices. 

  

	10.10	 Interest on Late Payments. If either Party fails to pay any amount payable under this Agreement by
the due date for payment then, without prejudice to any other rights or remedies that the other Party may have, interest shall accrue thereon (before and after any judgment) at an annual rate [***], as adjusted from time to time and published by
[***], such interest to run from the date on which payment of such sum became due until payment thereof in full together with such interest. Notwithstanding the previous sentence, the payable interest rate shall never be less than [***].

  

	10.11	 The consideration paid by Innate under this Agreement shall be allocated to the Licensed MedI Patents, the
Licensed MedI Know-How, the Product Trademarks and other commitments made by MedI under this Agreement. No portion of the consideration shall be allocated to the [***]. 

  
 36. 

	11.	 RECORDS AND REPORTING 

 

	11.1	 Development Records. MedImmune, with respect to its Development activities in the EU Territory (and,
if applicable, the US Territory) relating to the Licensed Product (including any Existing Product Trial), and Innate to the extent that Innate is engaged in any Development of the Licensed Product, shall, and shall cause its Affiliates to, maintain,
in good scientific manner, complete and accurate books and records pertaining to such Development activities. Such books and records shall (a) be appropriate for Patent and regulatory purposes, (b) be in compliance with Applicable Law,
(c) properly reflect all work done and results achieved in the performance of its Development activities hereunder, (d) record only such activities and not include or be commingled with records of activities outside the scope of this
Agreement and (e) be retained by MedImmune or Innate (as applicable) for at least [***] after the expiration or termination of this Agreement in its entirety or for such longer period as may be required by Applicable Law. 

 

	11.2	 Development Reports. During the period when the JDC operates between the Parties as contemplated by
this Agreement, within [***] following the end of each Calendar Quarter during which a Party is conducting Development activities with respect to the Licensed Product in the EU Territory, such Party shall provide the JDC with a report summarising
its activities to Develop the Licensed Product in the Territories, such report to include a summary of the work completed, a summary of the work in progress, and, if applicable, a summary of a current schedule of planned activities in the Calendar
Quarter following the reporting period. Such report shall contain sufficient detail to enable the JDC to assess each Party’s compliance with its obligations set forth in clause 8.1. 

 

	11.3	 Financial Records. Each Party shall and shall cause its Affiliates (and if applicable, Innate’s
Sublicensees) to, keep complete and accurate financial books and records pertaining to the Commercialization of the Licensed Product hereunder, including books and records of Development Costs, Commercialization Costs, other fees pursuant to this
Agreement and Net Sales of Licensed Product, in sufficient detail to calculate and verify all amounts payable hereunder. Such records shall be in compliance with Applicable Law. Each Party shall and shall cause its Affiliates and (if applicable,
Innate’s Sublicensees) to, retain such books and records until the later of (a) [***] after the end of the period to which such books and records pertain and (b) the expiration of the applicable Tax statute of limitations (or any
extensions thereof) or for such longer period as may be required by Applicable Law. 

  

	11.4	 Commercialization Reports. Within [***] following the end of each Calendar Quarter during which
MedImmune is providing SOTC Services, MedImmune will provide Innate with a report summarising MedImmune’s activities to Commercialize the Licensed Product in the US Territory pursuant to the SOTC Services, such report to include a summary of
the work completed, a summary of the work in progress, and, if applicable, a summary of a current schedule of planned activities in the Calendar Quarter following the reporting period. Such report shall not be required to be any more detailed or
comprehensive than any similar report MedImmune would use for internal reporting purposes. If during the 2019 Calendar Year Innate carries out any Commercialization activities with respect to the US Territory, then it shall, within [***] following
the end of each Calendar Quarter during 

  
 37. 

	 	 
which Innate is conducting those activities, provide MedImmune with a report summarising Innate’s activities to Commercialize the Licensed Product in the US Territory, such report to include
a summary of the work completed, a summary of the work in progress, and, if applicable, a summary of a current schedule of planned activities in the Calendar Quarter following the reporting period. Each such report shall contain sufficient detail to
enable the other Party to assess the reporting Party’s compliance with its obligations under the Commercial Plan and commercial transition plan, as applicable, including: (a) field force size and allocation; (b) the number and
position of Details in the applicable period; (c) the nature of Promotional activities and Licensed Product sampling activities; (d) market and sales promotional programs; and (e) the conduct of advertising, public relations and other
promotional programs, including professional symposia and speaker and peer-to-peer activity programs used in the Commercialization of the Licensed Product.

  

	11.5	 Audit. In respect of any Calendar Year in which SOTC Services are being provided, at the request of
either Party, the other Party shall and shall cause its Affiliates to, permit such Party or an independent auditor designated by such Party and reasonably acceptable to the other Party, not more than once in respect of each such Calendar Year and at
reasonable times and upon reasonable notice, to audit the books and records maintained pursuant to this clause 11 to ensure the accuracy of all reports and payments made hereunder. Except as provided below, the cost of this audit shall be borne by
the auditing Party, unless the audit reveals, with respect to the period covered by the audit, a variance of more than [***] from the reported financial amounts for such period, in which case the audited Party shall bear the cost of the audit.
Unless disputed pursuant to clause 11.6, if such audit concludes that (a) additional amounts were owed by the audited Party, then the audited Party shall pay the additional amounts, with interest from the date originally due or (b) excess
payments were made by the auditing Party, the audited Party shall reimburse such excess payments, in either case ((a) or (b)), within [***] after the date on which such audit is completed by the auditing Party. 

 

	11.6	 Audit Dispute. In the event of a dispute arising out of or in connection with any audit under clause
11.5, the Parties agree to submit the dispute, in the first instance, to administered expert proceedings in accordance with the Rules for the Administration of Expert Proceedings of the International Chamber of Commerce. After the International
Centre for ADR’s notification of the termination of the administered expert proceedings, the dispute, if it has not been resolved, shall be resolved in accordance with the dispute resolution mechanism set out in clause 21.6.

  

	12.	 REGULATORY ACTIVITIES 

 

	12.1	 Regulatory Approvals. 

 

	12.1.1	 During: 

  

	 	(a)	 the US Transition Period, MedImmune or its Affiliate shall remain the MAH for the Licensed Product in the US
Territory and use Commercially Reasonable Efforts to maintain the US Marketing Approval (provided that nothing in this clause 

  
 38. 

	 	 
12.1.1(a) shall impose any obligation on MedImmune with respect to the costs of new Clinical Trials for the Licensed Product in the US); and 

 

	 	(b)	 the EU Transition Period, MedImmune shall in accordance with the Development Plan continue to prepare and,
once prepared, submit the BLA to the EMA and Swissmedic to obtain the EU Marketing Approval and in connection with this shall have the right (following consultation with Innate through the JDC) to conduct communications with the EMA and Swissmedic
in the EU Territory in its name, 

 provided that, MedImmune shall have no obligation to carry out any Development
activities with respect to the Licensed Product unless set forth in the Development Plan. 
  

	12.1.2	 Until the MAH Transfer Date in the US Territory or the EU Territory, as the case may be, the Parties
acknowledge that MedImmune (or an Affiliate of MedImmune) holds (or will hold) the US Marketing Approval and the EU Marketing Approval (as applicable) and has certain rights and obligations under Applicable Law as a holder of such approvals and is
required to undertake or have undertaken certain activities in connection with such approvals (the “MAH Related Responsibilities”). During such time that MedImmune is the holder of the US Marketing Approval and/or the EU Marketing
Approval, subject to the terms of this Agreement, Innate shall cooperate fully with MedImmune in the discharge of the MAH Related Responsibilities and shall use Commercially Reasonable Efforts to perform its Development and Commercialization
activities with respect to the Licensed Product under the US Marketing Approval or EU Marketing Approval, as applicable, and otherwise act under and in accordance with such approvals and the AZ Promotion Principles. During the Term, if necessary to
permit Innate or its nominee to lawfully perform all or some of the MAH Related Responsibilities on behalf of MedImmune, or its Affiliate as contemplated by this Agreement, MedImmune or its Affiliate, as holder, shall provide Innate or its nominee
with a power of attorney or delegation of authority. 

  

	12.2	 Transfers of Regulatory Approvals. 

 

	12.2.1	 Subject to Applicable Law, MedImmune shall transfer the (i) US Marketing Approval to Innate on the US
Transfer Date, and (ii) EU Marketing Approval (if obtained) to Innate in accordance with the EU Regulatory Transition Plan, (either date being a “MAH Transfer Date”). 

 

	12.2.2	 Innate and MedImmune shall ensure that the Commercialization Transition Plan contains provisions relating to
the transfer of the US Marketing Approval and shall prepare and agree, acting through the JDC, a regulatory transition plan for the transfer of the EU Marketing Approval (once approved and agreed, the “EU Regulatory Transition
Plan”). The EU Regulatory Transition Plan shall include any services to be provided by MedImmune in connection with such transition and the fee payable (on an FTE basis and at the applicable FTE Rate quoted by MedImmune) by Innate for such
activities. 

  

	12.2.3	 Following an MAH Transfer Date, Innate shall be the MAH for the US Marketing Approval or the EU Marketing
Approval and shall assume all regulatory responsibilities 

  
 39. 

	 	 
with respect to the Licensed Product in the US Territory or EU Territory, as the case may be. 

  

	12.2.4	 On or prior to the Effective Date and on an on-going basis
thereafter promptly upon the creation or receipt of, or update to MedI Regulatory Documentation, MedImmune shall provide Innate with an electronic copy of the MedI Regulatory Documentation relating to the Licensed Product in the US Territory or EU
Territory, as applicable, through an electronic repository in a form agreed between the Parties. The MedI Regulatory Documentation shall not include any source documents associated with individual case safety reports and MedImmune shall not be
required to transfer any such documents or reports. For the avoidance of doubt, MedI Regulatory Documentation constitutes Licensed MedI Know How and shall remain as such notwithstanding the transfer of the US Marketing Approval or EU Marketing
Approval to Innate. Accordingly, such Information may only be used or disclosed by Innate or its Affiliates or Sublicensees in accordance with the terms and conditions of this Agreement. 

 

	12.3	 Communications and Filings with Regulatory Authorities. 

 

	12.3.1	 With respect to the Licensed Product, the MAH shall be responsible for all communications with the
Regulatory Authorities in the US Territory and EU Territory (as applicable) with respect to the Licensed Product. 

  

	12.3.2	 While MedImmune is the MAH with respect to the Licensed Product, it shall wherever practicable provide
Innate with reasonable advance notice of all meetings, conferences, discussions or other communications (whether face-to-face or teleconference and including any meeting
of experts convened by a Regulatory Authority concerning any topic relevant to the Licensed Product) with a Regulatory Authority concerning any matter relating to the Licensed Product in the Territories within [***] after the earliest of the
occurrence, notice or scheduling of such meeting (or as quickly as feasibly possible if the meeting is scheduled with less than a [***] prior notice), including copies of all related documents and other relevant information relating to such
meetings, conferences, discussions or other communications. Innate shall have the right to have reasonable representation present at and to participate in such meetings, conferences, discussions and other communications. 

 

	12.3.3	 While MedImmune is the MAH in either of the Territories, it shall promptly provide Innate with the following
, or if not practicable to provide, written summaries of the following: 

  

	 	(a)	 copies of all regulatory correspondence to or from the Regulatory Authorities relating to the Licensed
Product in the US Territory or EU Territory (as applicable); 

  

	 	(b)	 advance copies of material submissions and filings (e.g., INDs, BLAs, major supplements or amendments to the
foregoing, material labelling supplements, Regulatory Authority meeting requests and core data sheets) to the Regulatory Authorities and a reasonable opportunity to comment in advance on such submissions (which comments MedImmune shall consider in
good faith and shall be incorporated therein to the extent reasonable); 

  
 40. 

	 	(c)	 notices of any revocations of Regulatory Approvals with respect to the Licensed Product and any Licensed
Product recalls or withdrawals in the Territories; 

  

	 	(d)	 reasonable responses to inquiries by Innate regarding the Regulatory Approval and Commercialization
processes for the Licensed Product in the Territories, including reasonable access to MedImmune’s personnel in connection with such inquiries; 

  

	 	(e)	 copies of all other documents and correspondence pertaining to the Licensed Product in the Territories after
they have been submitted to, or received from, the Regulatory Authorities in the Territories; and 

  

	 	(f)	 if and to the extent not provided in accordance with the Pharmacovigilance Agreement, any other material
safety information in relation to the Licensed Product outside the Territories to the extent that such information might reasonably be expected to be relevant to the Development or Commercialization of the Licensed Product in the Territories by
Innate. 

  

	12.3.4	 MedImmune shall, where practicable and feasible, take into account Innate’s comments provided as part
of the discussions at the JCC and JDC (where applicable) with respect to any filing with, response to, or interactions with the Regulatory Authorities relating to the Licensed Product in the US Territory or EU Territory in each case in accordance
with the Commercialization Plan and Development Plan. 

  

	12.4	 Recalls, Suspensions or Withdrawals. 

 

	12.4.1	 Notification. Each Party shall notify the other Party promptly (but in no event later than [***])
following its determination that any event, incident or circumstance has occurred that may result in the need for a recall, market suspension or market withdrawal of the Licensed Product (whether in the Territories or outside the Territories) and
shall include in such notice the reasoning behind such determination and any supporting facts. 

  

	12.4.2	 Conduct. As between the Parties, the MAH shall have final decision making authority with respect to
Product recalls in the Territories and shall have the right to make the final determination whether to voluntarily implement any such recall, market suspension or market withdrawal in the Field in the Territories, including any retraction of
Promotional Materials; provided that prior to any implementation of such a recall, market suspension or market withdrawal, including any retraction of Promotional Materials, the MAH shall consult with the other Party and shall consider the
other Party’s comments in good faith. If a recall, market suspension or market withdrawal, including any retraction of Promotional Materials, is mandated by a Regulatory Authority in the Territories, as between the Parties, the MAH shall
initiate such a recall, market suspension or market withdrawal in compliance with Applicable Law. For all recalls, market suspensions or market withdrawals undertaken pursuant to this clause 12.4.2, as between the Parties, the MAH shall be solely
responsible for the execution thereof. 

  

	12.4.3	 Costs of Recalls, Suspensions or Withdrawals. 

  
 41. 

 During the Term, subject to clause 18, Innate shall be responsible for all
costs of any recall, market suspension or market withdrawal of the Licensed Product, except in the event and to the extent that such recall, market suspension or market withdrawal resulted from MedImmune’s or its Affiliate’s breach of its
obligations under this Agreement or the [***] or MedImmune’s negligence, in which case, MedImmune shall bear the expense of such recall, market suspension or market withdrawal. 

 

	12.4.4	 Pharmacovigilance 

 

	 	(a)	 During the period during which pharmacovigilence responsibilities are transferring from MedImmune to Innate
with respect to the Licensed Product in the Territories (the “Pharmacovigilance Transfer Period”) and subject to what may be otherwise agreed by the Parties in the transition services agreement: 

 

	 	(i)	 MedImmune shall hold and maintain the Global Safety Database for the Licensed Product and have
responsibility for maintenance of reference safety information for both Development and Commercialization use; 

  

	 	(ii)	 MedImmune shall prepare periodic/aggregate safety reports, manage signal detection/surveillance, global
(English language) literature, and other such global safety activities as are required; 

  

	 	(iii)	 MedImmune shall be responsible for consumer facing safety and pharmacovigilance activities including adverse
event collection, following up and processing, as well as medical inquiries/information, local language literature and other such local activities in the Territories as are required. 

 

	 	(iv)	 the applicable MAH will be responsible for all pharmacovigilance related submissions to Regulatory
Authorities 

 During the Pharmacovigilence Transfer Period, the Parties will work together in good faith
to transfer responsibility for pharmacovigilance in the Territories from AZ/MedI to Innate as soon as practical but not later than the earlier of 1) [***] or 2) [***]. 
  

	 	(b)	 Following the transfer of pharmacovigilance activities in accordance with clause 12.4.4 (a):

  

	 	(i)	 Innate shall hold and maintain the Global Safety Database for the Licensed Product and have responsibility
for the maintenance of reference safety information for both Developmentand Commercialization use. 

  

	 	(ii)	 Innate shall prepare periodic/aggregate safety reports, manage signal detection/surveillance, global
(English language) literature, and other such global safety activities. 

  

	 	(iii)	 Innate shall be responsible for consumer facing safety and pharmacovigilance activities including adverse
event collection and 

  
 42. 

 
following up, Medical inquiries/information, local language literature and other such Local activities in the Territories as are required. 

 

	 	(iv)	 Innate will be responsible for all pharmacovigilance related submissions to Regulatory Authorities in any
countries where the applicable Regulatory Approval has been transferred to Innate. 

  

	 	(c)	 Prior to the date (if any) on which the BLA is submitted to the EMA, MedImmune and Innate will appoint
pharmacovigilance transition teams to discuss any pharmacovigilance activities to be included in the EU Regulatory Transition Plan. 

  

	12.4.5	 Pharmacovigilance Agreement. The Parties shall enter into a separate pharmacovigilance or safety data
exchange agreement in a form that is customary in the pharmaceutical industry (“Pharmacovigilance Agreement”) reasonably in advance of Innate taking full responsibility for any Commercialization or Development activity with respect
to the Licensed Product, outlining their respective responsibilities with respect to the exchange of safety information and the performance of pharmacovigilance activities for the Licensed Product in accordance with clause 12.4.4.

  

	12.4.6	 Pending execution of such Pharmacovigilance Agreement, and unless otherwise agreed: 

 

	 	(a)	 Innate shall notify MedImmune of any adverse events or special situations (including but not limited to
reports of exposure during pregnancy or breastfeeding; overdose, abuse and misuse; off-label use, mediation errors; lack of therapeutic effect, occupational exposure, unexpected therapeutic or clinical benefit
and infectious agents) associated with the Licensed Product in the Territories within [***] after the first receipt of such information (such notice to be provided to [***]); provided that (i) if a case is received during a period of [***]
(“non-Business Days”), Innate will forward details of the case on the next Business Day and (ii) the Parties shall put in place procedures to ensure that Innate will forward any report of
an adverse event received during a period of [***] in accordance with 12.4.6 in order to ensure the safety of patients; 

  

	 	(b)	 at MedImmune’s request, Innate shall cooperate with MedImmune and provide such assistance as MedImmune
may reasonably require to enable it to investigate and follow-up any reports of adverse events or other safety-relevant information associated with the Licensed Product; and 

 

	 	(c)	 the Parties shall put in place procedure(s) to perform reconciliation as MedImmune, as MAH, deems reasonably
necessary. 

  

	12.4.7	 Quality Agreement. The Parties shall enter into the Quality Agreement as soon as reasonably
practicable after, and in any event no later than [***] after, the Effective Date, outlining their respective quality related responsibilities with respect to the Licensed Product. 

 

	12.4.8	 Standard Response Letters. During the period commencing on the Effective Date and ending on the EU MA
Transfer Date (or the date, if any, on which the Parties determine 

  
 43. 

	 	 
that they shall not obtain a BLA with respect to the EU Territory), MedImmune shall be responsible for developing and updating the template for standard response letters for use in connection
with the Licensed Product and shall provide a copy of such template letters to Innate. Innate shall use such template letters in preparing standard response letters for use in the Territories; provided that the MAH shall be responsible for preparing
any country-specific standard response letters for use in the Territories. Innate shall not include any information in any standard response letter that is not included in a then-current MedImmune template letter without MedImmune’s prior
written consent, such consent not to be unreasonably withheld, conditioned or delayed. 

  

	12.5	 Compensation for Regulatory Support and Services. 

In consideration of the performance of regulatory services being provided by MedImmune to Innate in accordance with this
clause 12 (and other provisions of this Agreement) (the “Regulatory Services”), Innate shall pay to MedImmune in accordance with clause 10.8 for the provision of those Regulatory Services. 

 

	13.	 INTELLECTUAL PROPERTY 

 

	13.1	 Ownership of Technology. 

 

	13.1.1	 As between the Parties, Innate shall own and retain all right, title and interest in and to any and all
Information and inventions that are conceived, discovered, developed or otherwise made by or on behalf of either Party or its Affiliates under or in connection with this Agreement, whether or not patented or patentable and any and all Patents and
other Intellectual Property Rights with respect thereto. 

  

	13.1.2	 The determination of whether Information and inventions are conceived, discovered, developed or otherwise
made by a Party for the purpose of allocating proprietary rights (including Patent, copyright or other Intellectual Property Rights) therein, shall, for purposes of this Agreement, be made in accordance with Applicable Law in the United States
irrespective of where or when such conception, discovery, development or making occurs. Each Party shall, and does hereby, assign, and shall cause its Affiliates to so assign, to the other Party, without additional compensation, such right, title
and interest in and to any Information and inventions as well as any Intellectual Property Rights with respect thereto, as is necessary to fully effect, as applicable, the allocation of ownership provided for in clause 13.1.1. 

 

	13.1.3	 Each Party shall cause all Persons who perform any activities for or on its behalf under this Agreement or
who conceive, discover, develop or otherwise make any Information or inventions by or on behalf of it or its Affiliates or, in the case of Innate, its Sublicensees, under or in connection with this Agreement to be under an obligation to assign (or,
if the Party is unable to cause such Person to agree to such assignment obligation despite such Party using reasonable efforts to negotiate such assignment obligation, then to grant an exclusive licence under) their rights in any Information and
inventions resulting therefrom to such Party, except where Applicable Law requires otherwise and except in the case of governmental, not-for-profit and public
institutions that have standard policies against such 

  
 44. 

	 	 
an assignment (in which case, a suitable licence or right to obtain such a licence, shall be obtained). 

 

	13.2	 [***]. Innate acknowledges that [***] all rights, title and interest in the Intellectual Property Rights
licensed to [***]. Except as expressly granted in the [***], Innate shall not acquire any right, title or interest whatsoever in or to any such Intellectual Property Rights. 

 

	13.3	 Third Party Agreements. The Parties acknowledges that the rights, obligations and procedures set out
in this clause 13 are subject to the terms and conditions of the [***] as they apply to the maintenance, prosecution, defence and infringement of the Intellectual Property Rights licensed thereunder and to the extent that there is an inconsistency
between the provisions of this clause 13 and the [***] with respect to such matters, the terms of the [***] shall prevail. 

  

	13.4	 Co-ordination. 

 

	13.4.1	 Promptly following the Effective Date, each Party shall appoint one (1) patent attorney from within its
organisation (each an “IP Manager”) to act as its main point of contact between the Parties for all Patent and Trademark matters addressed under this Agreement and, in particular, the remaining provisions of this clause 13.4. The IP
Managers shall establish and oversee mutually agreeable procedures for (a) liaising with regard to Patent and Trademark prosecution, enforcement and defence activities under this Agreement and the [***]] and (b) coordinating communications
with respect to such matters. 

  

	13.4.2	 If MedImmune receives documents relating to [***] prosecution, maintenance or defence of the Intellectual
Property Rights licensed thereunder to MedImmune or otherwise has rights to make decisions or influence [***] decisions with respect to the Intellectual Property Rights licensed thereunder, MedImmune’s IP Manager shall provide Innate with
copies of the relevant documents or notices received from [***] in so far as they relate to the Licensed Product or Licensed Antibody in the Territories and MedImmune shall consider in good faith any comments from Innate with respect thereto. To the
extent MedImmune takes over responsibility for patent prosecution under the [***], all such prosecution with respect to the [***] (the “[***]”) shall be coordinated by the IP Managers in accordance with clause 13.4.1.

  

	13.5	 Prosecution and Maintenance of Patent Rights. 

 

	13.5.1	 Innate shall be primarily responsible for and shall use Commercially Reasonable Efforts to control the
preparation, filing, prosecution (including conducting or handling any interferences, oppositions, action for declaratory judgment, nullity actions, reissue proceedings, reexaminations and challenges to title) and maintenance of the Licensed MedI
Patents, and [***] subject to [***] to the extent MedImmune has the corresponding responsibility under the [***]; provided that Innate shall provide MedImmune with advance copies of, and a reasonable opportunity to comment upon, proposed patent
filings, related prosecution strategies and proposed correspondence with patent officials or other Third Parties relating to any [***] subject to [***], and will consider comments received

  
 45. 

	 	 
from MedImmune with respect to such proposed filings, strategies and correspondence in good faith. 

  

	13.5.2	 Innate shall further be responsible for all Costs incurred or invoiced by either Party and its Affiliates as
of the Effective Date and thereafter associated with the Licensed MedI Patents. 

  

	13.5.3	 If Innate decides not to file, prosecute or maintain a Licensed MedI Patent or [***], it shall give
MedImmune reasonable notice to that effect sufficiently in advance of any deadline for any filing with respect to such Licensed MedI Patent or such [***], as applicable, in which case any and all rights under this Agreement with respect to such
Licensed MedI Patent and such [***] shall cease with respect to Innate. After receiving such notice, MedImmune may elect by written notice to Innate within [***] after receiving such notice from Innate to file, prosecute and maintain the relevant
Licensed MedI Patent or [***], at its sole cost and expense. If MedImmune does so elect, Innate shall cooperate with MedImmune as necessary to enable MedImmune to perform such acts as may be reasonably necessary for MedImmune to file, prosecute or
maintain such Licensed MedI Patent or [***], including the execution and filing of appropriate instruments and to facilitate the transition of such patent activities to MedImmune. 

 

	13.5.4	 Innate shall be responsible for and shall control, in consultation with MedImmune, the selection of the
appropriate Licensed MedI Patents as listed in the patent information section of the BLA for the Licensed Product for filing to obtain a Patent Term Extension (“PTE”) pursuant to all Applicable Laws, including supplementary
protection certificates and any other extensions that are now or become available in the future wherever applicable to Licensed MedI Patents and [***] that are applicable to the Licensed Product in the Territory. The IP Managers shall discuss
Innate’s proposed strategy for patent term extensions and patent listings and Innate shall consider MedImmune’s comments with respect to such strategy in good faith, but without derogating from Innate’s right to be ultimately
responsible for and to control such strategy. MedImmune shall provide prompt and reasonable assistance, if requested by Innate and at Innate’s cost and expense, to obtain such extensions or listings. Notwithstanding the foregoing, MedImmune
shall continue to be responsible for and shall control the filing of the PTE application in the United States that are in process as at the Effective Date. 

  

	13.5.5	 Promptly after the Effective Date, and following Innate’s written request, MedImmune shall
(a) provide to Innate all information, including a correct and complete list of all Patents covering the Licensed Product or otherwise necessary to enable Innate to make filings with Regulatory Authorities with respect to the Licensed MedI
Patents and [***] including as required or allowed in connection with (i) in the United States, the FDA’s Purple Book and (ii) outside the United States, under the national implementations of Section 10.1(a)(iii) of Directive
2001/EC/83 or other international equivalents, and (b) cooperate with Innate at Innate’s reasonable request and cost and expense in connection therewith, including meeting submission deadlines, in each case, to the extent required or
permitted by Applicable Laws. Promptly after the Effective Date and not less than [***] prior to any subsequent deadline with respect to the foregoing, the Parties shall discuss and identify those Patents claiming or covering the Licensed Product
and the process of review of such Patents for submission to the applicable Regulatory Authorities. Innate shall have 

  
 46. 

	 	 
the right, at its sole discretion, to submit or de-list any Licensed Medi Patent or [***] with respect to any Regulatory Authority with prior notice to
MedImmune. 

  

	13.5.6	 Notwithstanding anything to the contrary in this clause 13, neither Party shall have the right to make an
election under the Cooperative Research and Technology Enhancement Act of 2004, 35 U.S.C. 103(c)(2)-(c)(3) (the “CREATE Act”) when exercising its rights under this clause 13.5.6 without the prior written consent of the other Party.
With respect to any such permitted election, the Parties shall use reasonable efforts to cooperate and coordinate their activities with respect to any submissions, filings or other activities in support thereof. The Parties acknowledge and agree
that this Agreement is a “joint research agreement” as defined in the CREATE Act. 

  

	13.6	 Defence of Third Party Claims/Oppositions. 

 

	13.6.1	 Except as otherwise provided in clause 19, neither Party makes any warranty with respect to the validity,
perfection, or dominance of any Patent (including the Licensed MedI Patents or [***]) or proprietary right or with respect to the absence of rights in Third Party Patents which may be infringed by the Development, Manufacture or Exploitation of any
Licensed Antibody or Licensed Product. If a Third Party asserts a Patent or other right owned by it is infringed by the Development, Manufacture or Exploitation of any Licensed Antibody or Licensed Product, or either Party discovers such a Patent or
right, the Party first obtaining knowledge of such a claim or potential claim shall immediately provide the other Party written notice and the related facts in reasonable detail. In the event the Parties cannot agree on the defense of any such
claim, such defense shall be controlled by Innate; provided that MedImmune shall have the right to participate and to be represented in any such action by counsel of its selection at its sole discretion. Innate shall also have the right to control
settlement of such claim and shall be solely responsible for paying any settlement amounts. Innate shall not settle any such claim, suit, or proceeding prior to discussing the settlement with MedImmune to the extent such proceedings may impact
MedImmune’s Retained Rights. Subject to the foregoing, Innate shall consider comments received from MedImmune with respect to such settlement arrangements in good faith. If Innate chooses to settle such claim, suit or proceedings on the basis
that it takes a license from the Third Party, then Innate shall be solely responsible for all such costs associated with such license. Innate shall, as between the Parties be solely responsible for any award of damages and costs awarded against it
or MedImmune in any such proceedings. 

  

	13.6.2	 Either Party may commence an opposition, action for declaratory judgment, nullity action, interference, re-examination, or other attack upon the validity, title, or enforceability of any Patents Controlled by a Third Party that cover the Development, Manufacture or Exploitation of any Licensed Antibody or Licensed
Product and are not Licensed MedI Patents or [***], at its own expense, but shall notify the other before commencing such action to enable the Parties to cooperate, with such cooperation not to be unreasonably withheld or delayed.

  
 47. 

	13.7	 Infringement by Third Parties 

 

	13.7.1	 The Party first having knowledge that any Licensed MedI Patent has been infringed or misappropriated by a
Third Party in any country shall promptly notify the other in writing. 

  

	13.7.2	 Innate shall have the first right, but not the obligation, to institute, prosecute, and control any action
or proceeding or negotiation of any settlements with respect to any infringement of Licensed MedI Patents (with the other Party having the right to participate in such action or negotiations at its expense and be represented if it so desires).
Innate shall not have the right to make any admission in connection with any infringement litigation or settle any infringement in a manner that has or would reasonably be expected to have a material adverse effect on MedImmune Retained Rights or
involves any admission by, MedImmune, or which would involve any cost or expense to MedImmune or any of its Affiliates without the express written consent of MedImmune (which consent shall not be unreasonably withheld, conditioned or delayed). If
necessary, MedImmune agrees in any such action to be joined as a claimant and to give Innate reasonable assistance and any needed authority to control, file, and to prosecute such action, at Innate’s expense. If Innate elects not to institute
and prosecute such action or proceeding or to conduct such negotiation, Innate will discuss with MedImmune the reasons for this decision and MedImmune may, to the extent required to ensure compliance with [***], step in Innate’s rights for
purposes of this clause 13.7.2, with the consent of Innate not to be unreasonably withheld. 

  

	13.7.3	 Any damages or monetary awards relating to the Licensed MedI Patents shall be applied as follows:
(a) to reimburse any and all out-of-pocket costs incurred by Innate in bringing suit; (b) to reimburse any and all out-of-pocket costs incurred by MedImmune in relation to the suit; and (c) any remaining damages shall be [***]. 

 

	13.7.4	 Where Innate activities under this Agreement result in the necessity of any licences to Third Party’s
Patents, and MedImmune had no Knowledge (without performing a commercially reasonable inquiry with respect to the relevant subject matters) of the need for such licenses prior to the Effective Date, Innate shall be solely responsible for obtaining
such Third Party licence(s) at its own expense and cost. 

  

	13.7.5	 MedImmune shall not grant its Other Licensees rights in breach of the exclusive licenses granted to Innate
hereunder, and shall not grant such licenses unless each such Other Licensee agrees to contractual obligations reciprocal to those obligations of Innate whereby data and information of Innate are able to be shared and used for the benefit of such
Other Licensee on substantially similar terms. 

  

	13.8	 Other AZ IPR 

Unless otherwise agreed by the parties, MedImmune shall have the sole right and responsibility, but not the obligation, with
regard to the maintenance, prosecution, defence and infringement of any Intellectual Property Rights, or any other matters, in connection with the Other AZ IPR. 

  
 48. 

	14.	 PRODUCT TRADEMARKS 

 

	14.1	 Ownership of Corporate Names and Product Trademarks; New Product Trademarks 

 

	14.1.1	 Ownership. As between the Parties except as otherwise expressly provided, (a) MedImmune (or one
of its Affiliates) shall remain the sole and exclusive owner of the AstraZeneca Corporate Names, and (b) Innate shall remain the sole and exclusive owner of the Innate Corporate Names. Subject to the license referred to in clause 14.1.2 being
agreed and entered into, in consideration for MedImmune’s right hereunder, MedImmune shall, or shall procure that one of its Affiliates shall, assign, on the terms of the assignment attached at Schedule 12, the Product Trademarks to
Innate within an agreed time after the Effective Date. 

  

	14.1.2	 In consideration of MedImmune’s agreement to assign, and to cause its Affiliate to assign, to Innate
all of MedImmune’s or its Affiliate’s ownership rights in and to the Product Trademarks, Innate shall grant to MedImmune an exclusive (including with regard to Innate and its Affiliates), irrevocable, perpetual, royalty-free, fully paid-up, fully transferable, with the right to grant sublicenses through multiple tiers, license to use the Product Trademarks, including any New Product Marks, to Manufacture or have Manufactured the Licensed
Product and other products anywhere in the world and to Commercialize and otherwise Exploit the Licensed Product (and other products) outside the Territories, pursuant to a separate trademark license agreement to be negotiated between the Parties in
good faith and to be executed no later than [***] after the Effective Date. 

  

	14.1.3	 New Product Trademarks. Innate shall have the right, but not the obligation, at its sole cost and
expense, to select Trademarks, other than the Existing Product Trademarks, for use in the Commercialization of the Licensed Product in the Territories subject to the following conditions: 

 

	 	(a)	 Innate shall, at its sole cost and expense, be responsible for all activities relating to the selection and
use of such Trademark in connection with the Licensed Product in the Territories including any searches and obtaining all required approvals from Regulatory Authorities for such use; and 

 

	 	(b)	 as long as MedImmune is the MAH, any New Product Trademark must be approved for use with the Licensed
Product in the Territories by MedImmune, such approval not to be unreasonably withheld, conditioned or delayed. 

  

	14.2	 Prosecution of Product Trademarks. 

 

	14.2.1	 Unless otherwise agreed by the Parties, Innate shall be responsible for and shall use Commercially
Reasonable Efforts to register, prosecute and maintain any registration or application for the Product Trademarks in the Territories, and such other Trademark rights in the Product Trademarks as MedImmune may require outside the Territories,
providing Innate with a list of countries in which Innate needs to secure/maintain such Trademark rights for the possible use by AZ, in a manner that is consistent with its practices for registration, prosecution and maintenance of product
trademarks for its other products, 

  
 49. 

	 	 
using counsel of its own choice. Innate shall (i) provide MedImmune each quarter, a detailed, written report identifying the current status of all Trademark applications and registrations
for the Product Trademarks by country; (ii) notify MedImmune of, and make its Commercially Reasonable Efforts to consult with MedImmune, with respect to, any substantive issue and/or any opposition or cancellation proceeding that may be raised
or asserted against any Trademark application or registration for the Product Trademarks prior to taking any action in response thereto; (iii), from time to time, upon MedImmune’s request, provide MedImmune with copies of any registration
certificates, renewal applications and certificates, registration applications, pleadings, and/or other documentation or information as MedImmune may request relating to any Trademark application or registration for the Product Trademarks; and
(iv) use its Commercially Reasonable Efforts to consult with MedImmune prior to taking any action to (A) abandon or withdraw any Trademark application for a Product Trademark or (B) permit any Trademark registration a Product
Trademark to lapse, to expire or to be cancelled. 

  

	14.2.2	 Subject to clause 14.2.1, if Innate decides to abandon a registration or application for a Product
Trademark, Innate shall so notify MedImmune promptly in writing at least [***] prior to any deadlines by which an action must be taken to establish or preserve all rights under such Product Trademark in the Territories (or outside the Territories
for any registration or application for a Product Trademark outside the Territories) and MedImmune may on notice to Innate assume control over, and at MedImmune’s election ownership of, such application and registration and the further
prosecution (including application), administration, maintenance and defence of such Product Trademark at its sole cost and expense, and Innate shall execute such assignments, powers of attorney or other instruments and shall take such other actions
as MedImmune may reasonably request to transfer ownership of such Product Trademark registration or application to MedImmune and/or to give MedImmune control over such Product Mark registration or application so as to allow MedImmune to pursue or
resume such Trademark registration, maintenance or renewal efforts. 

  

	14.3	 Infringement of the Product Trademarks. 

 

	14.3.1	 Each Party shall provide to the other Party prompt written notice of any actual or threatened infringement
of the Product Trademarks in the Field and of any actual or threatened claim that the use of a Product Trademark violates the rights of any Third Party, in each case, of which such Party becomes aware, and the IP Managers shall promptly discuss such
notice and the potential enforcement strategies available. 

  

	14.3.2	 As between the Parties, Innate shall have the first right to defend against any claim by any Third Party
that the use of any of the Product Marks by Innate (or by AZ outside of the Territories) infringes, dilutes, misappropriates or otherwise violates such Third Party Trademark or constitutes unfair trade practices or another like offense (each, a
“TM Infringement Claim”) or take such action as Innate deems necessary against a Third Party based on any alleged, threatened or actual infringement, dilution, misappropriation or other violation of or unfair trade practices or any
other like offence relating to, the Product Trademarks by a Third Party in connection with the Exploitation of the Licensed Product 

  
 50. 

	 	 
(a “TM Competitive Infringement”) at its sole cost and expense and using counsel of its own choice. 

 

	14.3.3	 If Innate decides to defend against a TM Infringement Claim in accordance with clause 14.3.2 or to commence
proceedings in relation to a TM Competitive Infringement in accordance with clause 14.3.2, in the case of a TM Infringement Claim with respect to the Commercialization of the Licensed Product outside the Territories or, in the case of a TM
Competitive Infringement, and the Licensed Product is Commercialized under the Product Trademark outside of the Territories, then MedImmune shall have the right to join any such defence or infringement action, and participate with its own counsel,
at its sole cost and expense; provided that Innate shall retain control of the defence or prosecution of such claim, suit or proceeding, including the response to any defence or defence of any counterclaim raised in connection therewith; provided
that MedImmune shall have right to be consulted regarding any settlement thereof and Innate shall not be able to enter into any settlement that may undermine MedImmune’s rights and interest in the Product Trademarks outside the Territories. If
Innate decides not to commence proceedings in relation to a TM Competitive Infringement in accordance with clause 14.4.2 or to control the defence of a TM Infringement Claim in accordance with clause 14.4.2, MedImmune shall have the right to assume
such defence or take such action as it deems necessary against the relevant Third Party at its sole cost and expense and using counsel of its own choice and shall be entitled to retain any damages to other amounts collected in connection therewith.

  

	14.4	 Oversight of Product Trademarks. 

 

	14.4.1	 Innate shall comply with all Trademark marking requirements as MedImmune may specify or as may be required
by Applicable Law and with all such Trademark usage guidelines as MedImmune may furnish to Innate from time to time in all jurisdictions in the Territories concerning AstraZeneca Corporate Marks. 

 

	14.4.2	 Neither Party shall at any time use the other Party’s Corporate Name, or any variation thereof, or
other word, name, letter or combination substantially similar thereto, or any other Trademark of the other Party or any of its Affiliates, except in accordance with written instructions received from the other Party, as required by Applicable Law or
as expressly provided under this Agreement. 

  

	14.4.3	 Without limiting this clause 14.4, neither Party shall, and shall not permit its Affiliates or its or their
licensees to, (a) use in their respective businesses, any Trademark that is confusingly similar to, misleading or deceptive with respect to or that dilutes any (or any part) of the other Party’s corporate marks (including AstraZeneca
Corporate Marks), (b) knowingly do any act that endangers, destroys or similarly affects, in any material respect, the value of the goodwill pertaining to the other Party’s corporate marks (including AstraZeneca Corporate Marks) or
(c) attack, dispute or contest the validity of or ownership of the other Party’s corporate marks (including AstraZeneca Corporate Marks) anywhere in the Territories or any registration applications or any registrations issued or issuing
with respect thereto. Each Party agrees and shall cause its Affiliates and licensees, to conform (i) to AstraZeneca’s standards for the protection of the other Party’s corporate marks

  
 51. 

	 	 
(including AstraZeneca Corporate Marks) and (ii) to maintain the quality standards of the other Party and its Affiliates with respect to the goods sold and services provided in connection
with the such other Party’s corporate marks. 

  

	14.4.4	 As between the Parties, MedImmune and its Affiliates shall retain all right, title and interest in and to
the AstraZeneca Corporate Marks. 

  

	14.5	 Changes to Livery and Labelling 

 

	14.5.1	 Concurrently with the transfer of the US Marketing Approval or the EU Marketing Approval (as the case may
be) to Innate or promptly thereafter, Innate shall file any necessary variations to such transferred approval to replace the MedImmune livery on Product Labelling of the Licensed Product with the livery of Innate; provided that Innate shall continue
to use AstraZeneca Corporate Marks as required pursuant to clause 14.5. Notwithstanding the foregoing, and subject in all respects to compliance with all Applicable Law, and the terms of, and any restrictions imposed under, all applicable Regulatory
Approvals, Innate may in each jurisdiction in the Territories, following the transfer of the relevant approval for such jurisdiction to Innate, sell any Licensed Product purchased from MedImmune in AstraZeneca’s livery for the lesser of (i)
[***] after the US Transfer Date for the US Marketing Approval or EU Transfer Date (or any longer period as may be reasonably agreed between the Parties), as the case may be] and (ii) [***] (such period being the “Licensed Livery
Period”). 

  

	15.	 CONFIDENTIALITY AND NON-DISCLOSURE 

 

	15.1	 Confidentiality Obligations. 

 

	15.1.1	 At all times during the Term and for a period of ten (10) years following termination or expiration
thereof, each Party (the “Receiving Party”) shall (i) keep confidential and not disclose to any Third Party, other than its and its Affiliates’ officers, directors, other employees, contractors and advisors on a need to
know basis, any Confidential Information provided to it by the other Party (the “Disclosing Party”) and (ii) not publish or otherwise use, directly or indirectly, for any purpose, such Confidential Information, except to the
extent permitted by the terms of this Agreement or to the extent such use is necessary for the fulfilment of the Receiving Party’s obligations under this Agreement. The Receiving Party shall cause all of its and its Affiliates’ officers,
directors, other employees, contractors and advisors to whom the Receiving Party has disclosed Confidential Information to comply with confidentiality and non-use obligations at least as restrictive as those
set out in this Agreement and shall be liable to the Disclosing Party for any breach thereof by such Affiliates, officers, directors, other employees, contractors and advisors. 

 

	15.1.2	 The obligations of confidentiality and non-use herein shall not
extend to any Confidential Information that, in the case of clause 15.1.1, (a) is or comes into the public domain without breach of this Agreement, (b) is received by a Party from a Third Party (other than an Affiliate of Disclosing Party)
without any obligation of confidentiality and without breach of this Agreement, or (c) the Receiving Party can prove was already in its possession without any limitation on use or disclosure prior to the Effective Date. 

  
 52. 

	15.1.3	 Nothing in this clause 15 shall prevent either Party from using and disclosing Confidential Information to
the extent reasonably required for the Receiving Party’s performance of its obligations and exercise of its rights granted to it under this Agreement or other agreement between the Parties. In particular either Party shall be entitled to use
and disclose Confidential Information of the other relating to the Licensed Product for Patent filing and prosecution purposes, for the purposes of making BLAs and for the purposes of appointing Third Parties to Manufacture the Licensed Product.

  

	15.1.4	 In addition each Party shall be entitled to disclose the terms of this Agreement on a confidential basis to
actual or potential investors or in connection with any permitted assignment under this Agreement or in connection with any proposed grant of a sub-license by Innate or MedImmune as permitted by this
Agreement, provided that in each case the Receiving Party shall cause any and all parties to whom such disclosure is made to comply with confidentiality and non-use obligations at least as restrictive as those
set out in this Agreement and shall be liable to the Disclosing Party for any breach thereof by such parties. 

  

	15.1.5	 This Agreement shall not restrict the Receiving Party from complying with a lawfully issued governmental
order or legal requirement or requirement under applicable stock exchange rules to produce or disclose Confidential Information; provided, however, that, in the event of governmental orders, the Receiving Party shall promptly notify the Disclosing
Party to enable the Disclosing Party to oppose the order or obtain a protective order and the Receiving Party shall cooperate fully with the Disclosing Party in any such proceeding. If the Receiving Party is legally required or required under
applicable stock exchange rules to disclose Confidential Information, the Receiving Party and the Disclosing Party will endeavour to agree to a mutually satisfactory means to disclose such information. Nothing contained herein shall prohibit either
of the Parties from immediately disclosing results of any Clinical Trial to the extent necessary to prevent or mitigate a serious health hazard; provided, however, that the Party intending to make such disclosure shall notify the other Party prior
to and immediately after such disclosure and, to the extent it is reasonably practicable to do so, the nature and content of such disclosure shall be agreed between the Parties. 

 

	15.1.6	 The Parties acknowledge that each of them shall use Commercially Reasonable Efforts to monitor scientific
publications to prevent any adverse effect from premature publication relating to the Licensed Antibodies or Licensed Products. If a Party wishes to make a publication or communication with respect to any results arising out of any Clinical Trials
initiated prior to the Effective Date or, with respect to MedImmune or any of its Affiliates, with respect to any Clinical Trials conducted outside the Territories, it shall provide a draft to the other Party, which will have [***] to provide
comments. The Party proposing to make a publication or communication shall, in good faith, consider the comments made by the other Party and shall defer the publication or communication for a period of time not exceeding [***] if a Patent may be
filed using the Information or Know How covered in the proposed publication or communication. Notwithstanding the foregoing, neither Party will publish or present any Confidential Information of the other Party without such other Party’s prior
written consent, such consent not to be unreasonably withheld, delayed or conditioned. Notwithstanding anything contained herein to the contrary, each Party shall be permitted to make whatever public disclosure is required by Applicable Law in

  
 53. 

	 	 
connection with any Clinical Trial using or involving the Licensed Antibody, including Clinical Trials transparency laws governing disclosure of results, protocols, and other items.

  

	15.1.7	 As between the Parties, Innate shall have the sole right to make scientific publications with respect to
Clinical Trials initiated after the date on which MedImmune ceases to hold any Regulatory Approvals in the Territories. 

  

	15.2	 Use of Name. 

Neither Party shall use the name, insignia, symbol, trademark, trade name or logotype of the other Party or its Affiliates in
relation to this transaction or otherwise in any public announcement, press release, or other public document without the prior written consent of such other Party, which consent shall not be unreasonably withheld, delayed or conditioned, except for
those disclosures for which consent has previously been obtained; provided, however, that either Party may use the name of the other Party in any document required to be filed with any Government Authority, including the FDA and the Securities and
Exchange Commission or otherwise as may be required by Applicable Laws, provided that such disclosure shall be governed by this clause 15. Further, the restrictions imposed on each Party under this clause 15.2 are not intended, and shall not be
construed, to prohibit a Party from identifying the other Party in its internal business communications, provided that any Confidential Information in such communications remains subject to this clause 15. Moreover, and notwithstanding the
foregoing, MedImmune and its Affiliates and Innate and its Affiliates and Sublicensees shall have the right to use the name of MedImmune and its Affiliates to the extent necessary or useful in connection with the Exploitation of the Licensed Product
or perform the activities as contemplated by this Agreement in their negotiations and work with subcontracting and sublicensing transactions in connection therewith provided that any Confidential Information in such communications remains subject to
this clause 15. 
  

	15.3	 Public Announcements. 

 

	15.3.1	 Neither Party shall issue any other public announcement, press release or other public disclosure regarding
this Agreement or its subject matter without the other Party’s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned, except for any such disclosure that is, in the opinion of the disclosing Party’s
counsel, required by Applicable Law, the Listing Rules or any other rules of a stock exchange (including Paris Euronext) on which the securities of the disclosing Party are listed (or to which an application for listing has been submitted). Without
limiting the foregoing, Innate shall be entitled to communicate with respect to the status of the Licensed Product and any activities under this Agreement, including any registration, launch, or commercialization of the Licensed Product, as long as
such communication does not include any MedImmune Confidential Information. 

  

	15.3.2	 In the event a Party is, in the opinion of its counsel, required by Applicable Law, the Listing Rules or any
other rules of a stock exchange (including Paris Euronext) on which its securities are listed (or to which an application for listing has been submitted) to make such 

  
 54. 

	 	 
a public disclosure, such Party shall submit the proposed disclosure in writing to the other Party as far in advance as reasonably practicable (having regard to the requirements of the Applicable
Law, the Listing Rules or other stock exchange rules, as applicable) so as to provide a reasonable opportunity to comment thereon. Neither Party shall be required to seek the permission of the other Party to repeat any information regarding the
terms of this Agreement or any amendment hereto that has already been publicly disclosed by such Party or by the other Party, in accordance with this clause 15.3; provided that such information remains accurate as of such time and provided
the frequency and form of such disclosure are reasonable. 

  

	15.4	 Return of Confidential Information. Upon the expiration or termination of this Agreement for any
reason, either Party may request in writing and the non-requesting Party shall either, with respect to Confidential Information to which such non-requesting Party does
not retain rights under the surviving provisions of this Agreement, at the requesting Party’s election, (a) promptly destroy all copies of such Confidential Information in the possession or control of the
non-requesting Party and confirm such destruction in writing to the requesting Party or (b) promptly deliver to the requesting Party, at the non-requesting
Party’s sole cost and expense, all copies of such Confidential Information in the possession or control of the non-requesting Party. Notwithstanding the foregoing, the
non-requesting Party shall be permitted to retain such Confidential Information (i) to the extent necessary or useful for purposes of performing any continuing obligations or exercising any ongoing rights
hereunder and, in any event, a single copy of such Confidential Information for archival purposes and (ii) any computer records or files containing such Confidential Information that have been created solely by such non-requesting Party’s automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such
non-requesting Party’s standard archiving and back-up procedures, but not for any other uses or purposes. All Confidential Information shall continue to be subject
to the terms of this Agreement for the period set forth in clause 15.1. 

  

	15.5	 Privileged Communications. 

 

	15.5.1	 In furtherance of this Agreement, it is expected that the Parties may, from time to time, disclose to one
another privileged communications with counsel, including opinions, memoranda, letters and other written, electronic and verbal communications. Such disclosures are made with the understanding that they shall remain confidential in accordance with
this clause 15, that they will not be deemed to waive any applicable attorney-client or attorney work product or other privilege and that they are made in connection with the shared community of legal interests existing between MedImmune and Innate,
including the community of legal interests in avoiding infringement of any valid, enforceable patents of Third Parties and maintaining the validity of the Licensed MedI Patents and Innate Patents. 

 

	15.5.2	 In the event of any litigation (or potential litigation) with a Third Party related to this Agreement or the
subject matter hereof, the Parties shall, upon either Party’s request, enter into a reasonable and customary joint defence agreement. In any event, each Party shall consult in a timely manner with the other Party before engaging in any conduct
(e.g., 

  
 55. 

	 	 
producing information or documents) in connection with litigation or other proceedings that could conceivably implicate privileges maintained by the other Party. 

 

	15.5.3	 Notwithstanding anything contained in this clause 15.5, nothing in this Agreement shall prejudice a
Party’s ability to take discovery of the other Party in disputes between them relating to the Agreement and no information otherwise admissible or discoverable by a Party shall become inadmissible or immune from discovery solely by this clause
15.5. 

  

	16.	 WARRANTIES 

 

	16.1	 Mutual Warranties. MedImmune and Innate each warrants to the other, as of the Effective Date, and
covenants that: 

  

	 	(a)	 it is a corporation duly organised, validly existing and in good standing under the laws of the jurisdiction
of its organization and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform this Agreement; 

  

	 	(b)	 its execution of this Agreement has been duly authorised by all necessary corporate action and does not
violate: (i) such Party’s charter documents, bylaws or other organisational documents; (ii) in any material respect, any agreement, instrument or contractual obligation to which such Party is bound; (iii) any requirement of any
Applicable Law; or (iv) any order, writ, judgment, injunction, decree, determination or award of any court or Governmental Authority presently in effect applicable to such Party; 

 

	 	(c)	 its performance and exercise in accordance with this Agreement of the obligations and transactions
contemplated hereby do not violate in any material respect, any agreement, instrument or contractual obligation to which such Party is bound; 

  

	 	(d)	 this Agreement is a legal, valid and binding obligation of such Party enforceable against it in accordance
with its terms and conditions, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general
principles of equity (whether enforceability is considered a proceeding at law or equity); 

  

	 	(e)	 it is not under any obligation, contractual or otherwise, to any Person that conflicts with or is
inconsistent in any material respect with the terms of this Agreement or that would impede the diligent and complete fulfilment of its obligations hereunder; and 

 

	 	(f)	 neither it nor any of its Affiliates has been debarred or is subject to debarment and neither it nor any of
its Affiliates will use in any capacity, in connection with the services or activities to be performed under this Agreement, any Person who has been debarred pursuant to Section 306 of the FFDCA or who is the subject of a conviction described
in such section. It agrees to inform the other Party in writing promptly if it or any such Person who is performing services hereunder is debarred or is the subject of a conviction described in Section 306 or if any action, suit, claim,

  
 56. 

	 	 
investigation or legal or administrative proceeding is pending or, to the best of its or its Affiliates’ Knowledge, is threatened, relating to the debarment or conviction of it or any such
Person performing services or activities hereunder. 

  

	16.2	 Additional Warranties of MedImmune. MedImmune further warrants to Innate, as of the Effective Date:

  

	 	(a)	 it has the right to grant the licences and sublicences specified herein on the terms as specified herein;

  

	 	(b)	 Development of the Licensed Antibody and the Licensed Product and
pre-commercialization Manufacturing and Commercialization activities with respect to the Licensed Product have been conducted by MedImmune in accordance with Applicable Laws and Regulatory Approvals in all
material respects; 

  

	 	(c)	 it has no Knowledge of any safety or efficacy issues with the Licensed Antibody or the Licensed Product
which have not been disclosed to the applicable Regulatory Authority with regard to its labelled indication which would materially adversely affect: (i) the maintenance of the US Marketing Approval, (ii) the application for and grant of
the EU Marketing Approval, or (iii) the Exploitation of the Licensed Products in the Territories; 

  

	 	(d)	 to its Knowledge, it has complied in all material respects with pharmacovigilance requirements in accordance
with Applicable Laws; 

  

	 	(e)	 the [***] Supply Agreement, the [***] Supply Agreement and [***] Agreement are the only material agreements
relating to the Licensed Product in force on the Effective Date and entered into by MedImmune or one of its Affiliates and necessary to Develop, Manufacture and Commercialize the Licensed Product entered into by MedImmune or its Affiliates (the
“Material Agreements”); 

  

	 	(f)	 true and updated copies of the Material Agreements, subject to redaction of terms deemed by MedImmune
commercially sensitive or confidential, have been provided by MedImmune to Innate; 

  

	 	(g)	 the Material Agreements are in force and the [***] Supply Agreement and [***] Supply Agreement have been
performed substantially in accordance with their respective terms; 

  

	 	(h)	 MedImmune has performed its payment and diligence related obligations contained in the [***] Agreement;

  

	 	(i)	 to its Knowledge, MedImmune has received no notice of breach or termination of any Material Agreement, nor
has it acted, or failed to act in any way that would reasonably be expected to lead to termination of the [***] Supply Agreement and [***] Supply Agreement; 

  
 57. 

	 	(j)	 MedImmune has diligently prepared the Development Plan, Commercialization Plan and related Budgets in good
faith, based on reasonable assumptions and assessments; 

  

	 	(k)	 MedImmune has no Other Licensees (excluding [***] and [***]); 

 

	 	(l)	 the studies under the Existing Research and Collaboration Agreements listed on Schedule 16.2 Part 1 (Non-Clinical) are not conducted in humans. all Intellectual Property Rights relating to the Licensed Product arising therefrom will according to the terms thereof either belong to MedImmune or MedImmune has an
option to acquire a license to such Intellectual Property Rights; 

  

	 	(m)	 MedImmune has not received any written claim or demand alleging that the Development and Commercialization
of the Licensed Product as contemplated by this Agreement infringe any Intellectual Property Rights owned by any Third Party; 

  

	 	(n)	 to MedImmune’s Knowledge, there is no claim for revocation, opposition or rectification of any Licensed
MedI Patent; 

  

	 	(o)	 to MedImmune’s Knowledge, no Person is infringing or threatening to infringe the Licensed MedI Patent
in the Territories; 

  

	 	(p)	 the Licensed MedI Patents, Licensed MedI Know-How and Other AZ IPR
are all of the Patents and Know-How owned or Controlled by MedImmune and its Affiliates that are necessary and have been used by MedImmune for the Development and Commercialization of the Licensed Product in
the Territories as of the Effective Date; 

  

	 	(q)	 MedImmune or one of its Affiliates is the owner of the specific registered Product Trademarks identified in
Schedule 7 hereto; 

  

	 	(r)	 to MedImmune’s Knowledge, none of MedImmune’s current officers, directors or employees that have
been involved in the Development of the Licensed Product has been debarred; 

  

	 	(s)	 neither MedImmune nor to MedImmune’s Knowledge, any of MedImmune’s officers, directors, employees,
agents, representatives, consultants or subcontractors hired in connection with the subject matter of this Agreement, has made, solicited or received anything of value that would or has put it in violation of the Anti-Corruption Laws during the
three (3) years preceding the Effective Date; and 

  

	 	(t)	 MedImmune is resident in the United Kingdom for Tax purposes. 

 

	16.3	 Limitation of Liability. In respect of the warranties set forth in clauses 16.2(a) to 16.2(r):

  

	 	(a)	 MedImmune shall not be liable in respect of any Warranty Claim, unless [***]. 

  
 58. 

	 	(b)	 The aggregate liability of MedImmune in respect of all Warranty Claims shall not exceed [***].

  

	 	(c)	 MedImmune shall not be liable for any Warranty Claim unless and until it has received from Innate written
notice containing reasonable details of the relevant Warranty Claim including the amount of the Warranty Claim on or before the date that falls [***] after the Effective Date. 

 

	 	(d)	 Innate shall not be entitled to make a Warranty Claim to the extent it [***]. 

 

	 	(e)	 Innate shall not be entitled to make a Warranty Claim to the extent that it [***]. 

 

	16.4	 Additional Warranties of Innate. Innate further warrants to MedImmune, as of the Effective Date,
that: 

  

	 	(a)	 neither Innate nor to Innate’s Knowledge, any of the Innate Representatives has made, solicited or
received anything of value that would or has put it in violation of the Anti-Corruption Laws during the [***] preceding the Effective Date; and 

  

	 	(b)	 Innate is resident in France for Tax purposes. 

 

	16.5	 DISCLAIMER OF WARRANTIES. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH HEREIN, NEITHER PARTY MAKES ANY
REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL OR EXPRESS OR IMPLIED, INCLUDING ANY
WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

  

	16.6	 ADDITIONAL WAIVER. SUBJECT TO CLAUSE 16.2, INNATE AGREES THAT THE LICENSED MEDI PATENTS AND THE
PRODUCT TRADEMARKS ARE LICENSED “AS IS,” “WITH ALL FAULTS,” AND “WITH ALL DEFECTS,” AND INNATE EXPRESSLY WAIVES ALL RIGHTS TO MAKE ANY CLAIM WHATSOEVER AGAINST MEDIMMUNE FOR BREACH OF PROMISE, GUARANTEE OR WARRANTY OF
ANY KIND RELATING TO THE LICENSED MEDI PATENTS OR THE PRODUCT TRADEMARKS. 

  

	16.7	 MedImmune Covenants 

 

	16.7.1	 Other Licensees. The agreements entered with Other Licensees shall not materially adversely affect
Innate’s rights under this Agreement. 

  

	16.7.2	 [***] Supply Agreement MedImmune, in so far as it relates to the Licensed Product, shall not agree to
amend the [***] Supply Agreement, in such a manner that would reasonably be expected to materially adversely affect its ability to supply the License Product to Innate. 

  
 59. 

	 	 
Furthermore, MedImmune shall use its Commercially Reasonable Efforts to comply with the provisions of the [***] Supply Agreement relating to the Licensed Product and to avoid taking steps (or
omitting to take steps) that are reasonably likely to give rise to a termination of the [***] Supply Agreement insofar as it relates to the Licensed Product. MedImmune shall not terminate the [***] Supply Agreement as it relates to the Licensed
Produce without Innate’s agreement prior to the end of any period during which MedImmune is supplying bulk drug substance for the Licensed Product to Innate. 

 

	16.7.3	 Material Agreements. MedImmune shall not enter into any Material Agreement without Innate’s
prior consent and review of the applicable terms and conditions. 

  

	17.	 COMPLIANCE 

 

	17.1	 Statements and Compliance with Applicable Law. Each Party shall and shall cause its respective
Affiliates to, comply with all Applicable Law with respect to the Development and Commercialization of the Licensed Product and shall avoid and shall cause its Affiliates and its and their employees, representatives, agents, and distributors to
avoid, taking or failing to take, any actions or to give information that MedImmune knows or reasonably should know would jeopardise the goodwill or reputation of Innate or the Licensed Product or any Trademark associated therewith, or would impact
the performance of the Agreement. Until such time as MedImmune and any of its Affiliates ceases to be involved in the Manufacture of the Licensed Product, Innate shall and shall cause its Affiliates to, comply with all Applicable Law with respect to
the Development and Commercialization of the Licensed Product and shall avoid and shall cause its Affiliates and its and their Sublicensees, employees, representatives, agents, and distributors to avoid, taking or failing to take, any actions or to
give information that Innate knows or reasonably should know would jeopardise the goodwill or reputation of MedImmune or the Licensed Product or any Trademark associated therewith or would impact the performance of the Agreement.

  

	17.2	 Anti-Bribery and Anti-Corruption Compliance. 

 

	17.2.1	 Each Party agrees, on behalf of itself, its officers, directors and employees and on behalf of its
Affiliates, agents, representatives, consultants and subcontractors hired in connection with the subject matter of this Agreement (together with Innate, the “Representatives”) that for the performance of its obligations hereunder:

  

	 	(a)	 the Representatives shall not directly or indirectly pay, offer or promise to pay or authorise the payment
of any money or give, offer or promise to give or authorise the giving of anything else of value, to: (i) any Government Official in order to influence official action; (ii) any Person (whether or not a Government Official) (x) to
influence such Person to act in breach of a duty of good faith, impartiality or trust (“acting improperly”), (y) to reward such Person for acting improperly or (z) where such Person would be acting improperly by receiving the money or
other thing of value; (iii) any Person (whether or not a Government Official) while knowing or having reason to know that all or any portion of the money or other thing of value will be paid, offered, promised or given to or will otherwise
benefit, a Government 

  
 60. 

	 	 
Official in order to influence official action for or against either Party in connection with the matters that are the subject of this Agreement; or (iv) any Person (whether or not a
Government Official) to reward that Person for acting improperly or to induce that Person to act improperly; and 

  

	 	(b)	 the Representatives shall not, directly or indirectly, solicit, receive or agree to accept any payment of
money or anything else of value in violation of the Anti-Corruption Laws. 

  

	17.2.2	 Each Party shall and shall cause the Representatives to comply with (a) such Anti-Corruption Laws as
are relevant to it or the Territories; (b) its own internal policies relating to anti-corruption; and (c) in connection with activities under this Agreement, AZ’s Global Ethical Interactions Policy. If MedImmune makes any material
change to AZ’s Global Ethical Interactions Policy, it shall notify Innate of such change in writing. 

  

	17.2.3	 Each Party, on behalf of itself and the other Representatives shall promptly inform the other Party upon
receiving a formal notification that it or any of its Representatives is the target of a formal investigation by a Governmental Authority for a Material Anti-Corruption Law Violation. 

 

	17.2.4	 For the purpose of auditing and monitoring the performance of its compliance with this clause 17.2, each
Party (the “Auditing Party”) will, subject to the terms of this clause 17.2.4 and not more than once in each Calendar Year, permit any independent auditors appointed by the other Party (the “Audited Party”) for such
purpose and any Governmental Authority to have access to any premises of the Audited Party or other Representatives used in connection with this Agreement (such access to be at reasonable times and on reasonable notice), together with a right to
access personnel and records that relate to this Agreement (“Compliance Audit”). 

  

	 	(a)	 To the extent that any Compliance Audit requires access and review of any commercially or strategically
sensitive information or agreements, such independent auditor shall only report back such information as is directly relevant to informing on compliance with the particular provisions of this Agreement or the agreement being audited.

  

	 	(b)	 the Audited Party shall, and shall cause the Innate Representatives to, provide all cooperation and
assistance during normal working hours as reasonably requested by its independent auditor for the purposes of a Compliance Audit. The Auditing Party shall cause any substantially consistent such auditor to enter into a confidentiality agreement with
the applicable requirements of clause 15, and to cause the minimum amount of disruption to the business of the Audited Party and its Representatives and to comply with relevant building and security regulations. 

 

	 	(c)	 The Parties shall bear their own costs of a Compliance Audit or rendering assistance under this clause
17.2.4. 

  

	17.2.5	 If either Party becomes aware that the Other Party (or its Representative) has or may have committed a
Material Anti-Corruption Law Violation, such Party shall have the right, in 

  
 61. 

	 	 
addition to any other rights or remedies under this Agreement or to which it may be entitled in law or equity, to terminate this Agreement immediately and in its entirety upon written notice to
the other Party if the breaching Party does not cure such Material Anti-Corruption Law Violation within [***] of learning of such Material Anti-Corruption Law Violation. To cure such Material Anti-Corruption Law Violation, the breaching Party must
take such steps, additional measures, representations, warranties, undertakings and other provisions, in each case, as the other Party believes in good faith are reasonably necessary in order to avoid a subsequent violation or continuing violation
of the Anti-Corruption Laws. 

  

	17.2.6	 Any termination of this Agreement pursuant to clause 17.2.5 shall be treated as a termination for breach and
the consequences of termination set forth in clause 20.3 shall apply. 

  

	17.2.7	 Either Party may disclose the terms of this Agreement or any action taken under this clause 17.2 to prevent
a potential violation or continuing violation of applicable Anti-Corruption Laws, including the identity of the other Party or its Representative and the payment terms, to any Governmental Authority if such Party determines, upon advice of counsel,
that such disclosure is necessary. 

  

	17.3	 DATA PROTECTION; PRIVACY 

 

	17.3.1	 MedImmune and Innate agree that, for the purposes of Data Protection Law, each of MedImmune and Innate are
independent data controllers. 

  

	17.3.2	 If Data Protection Law requires that any notice be sent to any Data Subject or otherwise in connection with
the transfer of Personal Data under or pursuant to this Agreement, the relevant Party shall be responsible for preparing and providing such notice at its sole cost and expense; provided, that that Party shall provide a copy of any such proposed
notice to the other Party sufficiently in advance of any deadline in respect of such notice so as to allow for a reasonable opportunity for the other Party to review and approve the content of such notice, such approval not to be unreasonably
withheld or delayed. 

  

	17.3.3	 Each Party shall provide the other with such assistance as may be reasonably requested to ensure that each
Party complies with their obligations under applicable law, including Data Protection Law. For clarity, such assistance may include cooperating in response to requests from data subjects or supervisory authorities, or the provision of information
relating to Transferred Data, including providing copies of any relevant fair processing notices or consent forms provided to Data Subjects 

  

	17.3.4	 No Transferred Data shall be transferred outside the European Economic Area unless such transfer is to a
country that the European Commission has decided from time to time ensures an adequate level of protection in accordance with Data Protection Law. 

  

	18.	 INDEMNITY 

 

	18.1	 Indemnification of MedImmune. Subject to clause 19, Innate hereby agrees to indemnify, defend, and
hold harmless MedImmune, its Affiliates, and each of its and their respective employees, officers, directors and agents from and against any and all Damages incurred 

  
 62. 

	 	 
by them resulting from or arising out of or in connection with any suits, claims, actions or demands made or brought by a Third Party (collectively, “Third Party Claims”) against
MedImmune, its Affiliates or their respective employees, officers, directors or agents, that result from or arise out of (i) the Development, Manufacture, use, handling, storage, Commercialization, or other disposition of Licensed Products by
(or on behalf of, including where MedImmune or an Affiliate is providing SOTC Services) Innate or its Affiliates, agents, Distributors, Sublicensees or other sublicensees in the Territories (including with respect to the Product Liability Claim), in
each case on or after the Effective Date, (ii) any material breach by Innate of its obligations hereunder, (iii) MedImmune’s performance of the Regulatory Services in accordance with this Agreement and the Development Plan, or
otherwise in accordance with any instruction or direction given by Innate or any of its Affiliates, except to the extent such Damages arise due to MedImmune’s refusal to follow relevant instruction or direction given in accordance with
Applicable Law by Innate or any of its Affiliates, or (iv) Innate’s negligence or wilful misconduct, except in any case, to the extent such Damages are Damages for which MedImmune has an obligation to indemnify Innate, its Affiliates or
their respective employees, officers, directors or agents pursuant to clause 18.2, as to which Damages each Party shall indemnify the other to the extent of their respective liability for such Damages. Notwithstanding this clause 18.1, Innate shall
not indemnify MedImmune for Damages arising as a consequence of a breach by Innate of the [***] relating to its failure to manufacture Licensed Products in accordance with the requirements of [***] or corresponding provisions of the [***].

  

	18.2	 Indemnification of Innate. 

Subject to clause 19, MedImmune hereby agrees to indemnify, defend and hold harmless Innate, its Affiliates, and each of its
and their respective employees, officers, directors and agents from an against any and all Damages incurred by them resulting from or arising out of or in connection with any Third Party Claims (including Product Liability Claims) against Innate,
its Affiliates or their respective employees, officers, directors or agents, and also any other Damages with respect to (d) and (e) below, in each case that result from or arise out of: 

 

	 	(a)	 the Manufacture, Development, Exploitation, use, handling, storage, sale or other disposition of Licensed
Product by MedImmune or its Affiliates, agents, distributors or sublicensees in each case prior to the Effective Date; 

  

	 	(b)	 the Manufacture, Development, Commercialization, Exploitation, use, handling, storage, sale or other
disposition of Licensed Product by MedImmune or its Affiliates, agents, distributors or sublicensees outside of the Territories; 

  

	 	(c)	 any material breach by MedImmune of its obligations hereunder; 

 

	 	(d)	 any [***]; 

  

	 	(e)	 any [***]; 

  

	 	(f)	 the conduct by MedImmune or its Affiliates of any Existing Clinical Trials; 

  
 63. 

	 	(g)	 the conduct by MedImmune or its Affiliates of any activities under any Existing Research and Collaboration
Agreements; and 

  

	 	(h)	 MedImmune’s negligence or wilful misconduct; except in any case, to the extent such Damages are Damages
for which Innate has an obligation to indemnify MedImmune, its Affiliates or their respective employees, officers, directors or agents pursuant to clause 18.1, as to which Damages each Party shall indemnify the other to the extent of their
respective liability for such Damages. 

  

	18.3	 Mechanism. 

 

	18.3.1	 In the event that a Party (the “Indemnified Party”) is seeking indemnification under clause
18.1 or 18.2, it shall notify the other Party (the “Indemnifying Party”) in writing of the relevant Third Party Claim and the relevant Damage for which indemnification is sought as soon as reasonably practicable after becoming aware
of such claim. Such notices shall contain a description of the Third Party Claim and the nature and amount of the Damage (to the extent known). The Indemnified Party shall furnish promptly to the Indemnifying Party copies of all papers and official
documents received in respect of such Third Party Claim or Damage. For the avoidance of doubt, all indemnification claims in respect of a Party, its Affiliates, and each of its and their respective employees, officers, directors and agents shall be
made solely by such Party to this Agreement. To the extent that the Indemnifying Party irrevocably commits to indemnify any Indemnified Party in respect of the Third Party Claim, the Indemnified Party shall permit the Indemnifying Party to assume
direction and control of the defense of the relevant Third Party Claim (including without limitation the right to settle the claim solely for monetary consideration), and shall cooperate as requested (at the expense of the Indemnifying Party) in the
defense of the claim. 

  

	18.3.2	 Notwithstanding clause 18.3.1, the failure to give timely notice to the Indemnifying Party shall not release
the Indemnifying Party from liability to the Indemnified Party to the extent the Indemnifying Party is not prejudiced thereby and, for the avoidance of doubt, the Indemnifying Party shall not be liable to the extent any Damage is caused by any delay
by the Indemnified Party in providing such notice. Notwithstanding the provisions of clause 18.3.1 requiring the Indemnified Party to tender to the Indemnifying Party the exclusive ability to defend such claim, if the Indemnifying Party does not
satisfy the condition set forth in clause 18.3.1 to, or declines to or fails to timely assume control of the relevant Third Party Claim, the Indemnified Party shall be entitled to assume such control, conduct the defense of, and settle such claim,
all at the sole costs and expense of the Indemnifying Party; provided, however, that neither Party shall settle or dispose of any such claim in any manner that would adversely affect the rights or interests or admit fault, of the other Party without
the prior written consent of such other Party, which shall not be unreasonably withheld, delayed or conditioned. Each Party, at the other Party’s expense and reasonable request, shall cooperate with such other Party and its counsel in the
course of the defense or settlement of any such claim, such cooperation to include without limitation using reasonable efforts to provide or make available documents, information, and witnesses. 

  
 64. 

	19.	 LIMITATION OF LIABILITY AND INSURANCE 

 

	19.1	 Special, Indirect and Other Losses. EXCEPT IN CIRCUMSTANCES OF NEGLIGENCE OR INTENTIONAL MISCONDUCT
BY A PARTY OR ITS AFFILIATES, OR WITH RESPECT TO THIRD PARTY CLAIMS UNDER CLAUSES 18.1 AND 18.2, IN NO EVENT SHALL EITHER PARTY OR ITS RESPECTIVE AFFILIATES AND SUBLICENSEES BE LIABLE FOR SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL, OR CONSEQUENTIAL
DAMAGES, OR FOR LOSS OF PROFITS (WHETHER DIRECT OR OTHERWISE), IN EACH CASE WHETHER IN CONTRACT, WARRANTY, TORT, STRICT LIABILITY, OR OTHERWISE. NOTWITHSTANDING THE FOREGOING, THE EXCLUSION IN THIS CLAUSE 19.1 SHALL NOT APPLY TO CLAIMS UNDER CLAUSES
18.2(d) AND 18.2(e) WITH RESPECT TO LOSS OF PROFITS. 

  

	19.2	 Insurance. 

Each Party shall have and maintain such type and amounts of liability insurance covering the Manufacture, supply, use and sale
of the Licensed Product as is normal and customary in the pharmaceutical industry generally for Persons similarly situated, but in any event no less than is adequate to cover a Party’s exposure given its obligations under this Agreement, and
shall upon request provide the other Party with a copy of its certificate of insurance in that regard, along with any amendments and revisions thereto. It is expressly acknowledged and agreed that, with respect to MedImmune, reasonably sufficient
and appropriate self-insurance shall satisfy MedImmune’s obligations under this clause. 
  

	19.3	 Nothing in this Agreement excludes or limits either Party’s liability for fraud, or for death or
personal injury caused by its negligence or that of its employees or agents. 

  

	19.4	 MedImmune and its Affiliates’ maximum aggregate liability to Innate with respect to any claim under the
indemnity in clause 18.2(d) or 18.2(e), when taken together with any liability to Innate with respect to any Warranty Claims, shall not exceed [***]. 

  

	20.	 TERM AND TERMINATION 

 

	20.1	 Term and Expiration. This Agreement shall commence on the Effective Date and, unless earlier
terminated in accordance herewith, shall continue in force and effect in any given country of the Territories until the latest of: (a) the expiry of the last Patent within the Licensed MedI Patents in such country, (b) any Regulatory
Exclusivity in such country, and (c) the fifteenth anniversary of the First Commercial Sale of Licensed Product in such country (the “Term”). Following the expiration of the Term for the Licensed Product in a country, the
grants in clause 4.1 shall become or remain non-exclusive (as applicable), perpetual, irrevocable, fully paid and royalty-free for the Licensed Product in that country. 

 

	20.2	 Termination of Agreement. 

 

	20.2.1	 Material Breach. In the event that either Party (the “Breaching Party”) shall be in
material breach in the performance of any of its obligations under this Agreement, in addition to any other right and remedy the other Party (the “Non-Breaching Party”) may

  
 65. 

	 	 
have (including in the case of MedImmune its rights to terminate this Agreement in accordance with clause 20.2.2), the Non-Breaching Party may terminate
this Agreement by providing [***] (the “Notice Period”) prior written notice (the “Termination Notice”) to the Breaching Party and specifying the breach and its claim of right to terminate; provided that the
termination shall not become effective at the end of the Notice Period if (a) the Breaching Party cures the breach specified in the Termination Notice during the Notice Period or (b) provided that such breach does not relate to non-payment, if such breach cannot be cured within the [***] cure period, this Agreement shall not terminate pursuant to this clause 20.2.1 if the Breaching Party has made diligent efforts to cure such breach within
such period and this Agreement shall remain in effect for such period after the Notice Period as may be reasonable in the circumstances as long as the Breaching Party continues to use diligent efforts to cure the breach with a reasonable expectation
that cure will be effected as promptly as practicable thereafter and in any event within [***] after expiration of the Notice Period. If the existence or cure of a material breach is disputed, except with respect to a material breach involving any
of the AstraZeneca Corporate Mark or Innate Corporate Mark, this Agreement cannot be terminated until the existence and absence of cure of a material breach have been determined pursuant to Section 21.6.2 and then if such material breach is not
cured within [***] following the arbitration award. 

  

	20.2.2	 Termination by MedImmune. 

 

	 	(a)	 Patent Challenge. In the event that Innate or any of its Affiliates or Sublicensees institutes,
prosecutes or otherwise participates in (or in any way aids any Third Party in instituting, prosecuting or participating in), at law or in equity or before any administrative or regulatory body, including the U.S. Patent and Trademark Office or its
foreign counterparts, any claim, demand, action or cause of action for declaratory relief, damages or any other remedy or for an enjoinment, injunction or any other equitable remedy, including any interference,
re-examination, opposition or any similar proceeding, alleging that any claim in a Licensed MedI Patent is invalid, unenforceable or otherwise not patentable or would not be infringed by Innate’s
activities absent the rights and licences granted hereunder, MedImmune shall have the right to immediately terminate this Agreement, including the rights of any Sublicensees, upon written notice to Innate. 

 

	 	(b)	 Abandonment. In the event that Innate ceases to perform all Commercialization activities with respect
to the Licensed Product in the US Territory or the EU Territory for a consecutive period of [***], and Innate does not recommence Commercialization activities within [***] of receiving from MedImmune a notice specifying that Innate must recommence
Commercialisation, MedImmune shall be entitled to immediately terminate this Agreement with respect to whichever of the Territories such activities have ceased, including the rights of any Sublicensees, upon written notice to Innate.

  

	20.2.3	 Termination for Convenience. 

 

	 	(a)	 Subject to compliance with clause 20.2.3(b), Innate may terminate this Agreement at any time upon [***]
prior written notice to MedImmune. 

  
 66. 

	 	(b)	 Together with the notice of termination sent in accordance with clause 20.2.3(a), Innate shall send
MedImmune its proposed approach to ensuring an orderly and efficient transition of the Licensed Product business back to MedImmune, which may include a draft transition services agreement. The Parties shall use their respective Commercially
Reasonable Efforts to negotiate in good faith and agree to a transition plan and/or transition agreement, including how any existing stock of Licensed Product held by Innate, will be sold by Innate (including under any sales order to cash
arrangement agreed with MedImmune) during the transitional period. Notwithstanding clause 20.2.3(a), no termination shall take effect until the transition plan and/or transition services agreement has been agreed in writing by the Parties.

  

	20.2.4	 Termination for Insolvency. In the event that either Party: 

 

	 	(a)	 files for protection under bankruptcy or insolvency laws; 

 

	 	(b)	 makes an assignment for the benefit of creditors; 

 

	 	(c)	 has a moratorium agreed or declared in respect of, or affecting all or a material part of its indebtedness;

  

	 	(d)	 appoints or suffers appointment of a receiver or trustee over substantially all of its property that is not
discharged within [***] after such filing; 

  

	 	(e)	 proposes a written agreement of composition or extension of its debts; 

 

	 	(f)	 proposes or is a party to any dissolution or liquidation; 

 

	 	(g)	 files a petition under any bankruptcy or insolvency act or has any such petition filed against it that is
not discharged within [***] of the filing thereof; 

  

	 	(h)	 admits in writing its inability generally to meet its obligations as they fall due in the general course; or

  

	 	(i)	 suffers anything analogous to or having a substantially similar effect to any of the events specified in
clauses 20.2.4(a) to 20.2.4(h), 

 then the other Party may terminate this Agreement in its entirety
effective immediately upon written notice to such Party. 
  

	20.3	 Consequences of Termination of this Agreement. In the event of a termination (but not expiry) of this
Agreement by Innate or by MedImmune pursuant to clause 20.2: 

  

	 	(a)	 all rights and licences granted to Innate by MedImmune hereunder and the [***] shall immediately terminate
and all sublicenses granted by Innate with respect thereto shall automatically terminate; 

  
 67. 

	 	(b)	 to the extent that the US Marketing Approval or the EU Marketing Approval have been transferred to Innate,
Innate shall transfer such marketing approvals and any other Regulatory Approvals relating to the Licensed Product in the Territories back to MedImmune or its nominee; 

 

	 	(c)	 Innate shall and hereby does, and shall cause its Affiliates and its and their Sublicensees to, effective as
of termination, assign to MedImmune or its nominee all of its right, title and interest in and to all Innate Regulatory Documentation, the Product Trademarks and any New Product Trademarks (together with any domain names and social media identifiers
that incorporate any of the Product Trademarks or any New Product Trademarks) and any and all copyrights and any and all promotional, marketing or other materials used in connection with the Licensed Product; 

 

	 	(d)	 other than in cases of termination under clause 20.2.3(a), where clause 20.2.3(b) shall prevail, Innate
shall, at MedImmune’s option, either sell any existing stock of Licensed Product held by Innate in the market under a sales order to cash arrangement, or shall transfer such stock to MedImmune [***], on such reasonable terms as the parties will
negotiate in good faith; 

  

	 	(e)	 unless otherwise requested by MedImmune, Innate shall and hereby does, and shall cause its Affiliates and
its and their Sublicensees to, effective as of termination, assign to MedImmune or its nominee all of its right, title and interest in and to any and all Trademarks that Innate has used in connection with the Licensed Product (together with any
domain names and social media identifiers that incorporate any such Trademarks) (excluding any Innate Corporate Names); 

  

	 	(f)	 Innate shall and hereby does, and shall cause its Affiliates and its and their Sublicensees to, effective as
of termination, grant MedImmune a worldwide, exclusive, royalty-free licence and right of reference, with the right to grant multiple tiers of sublicenses and further rights of reference, in and to the Innate Patents, and the Innate Know-How, and Innate’s rights in and to any jointly conceived information to Exploit any Licensed Product and/or exercise the Retained Rights; 

 

	 	(g)	 at MedImmune’s written request, Innate shall, and cause its Affiliates and its and their Sublicensees
to, assign to MedImmune all Product Agreements relating to the Licensed Product, unless, with respect to any Product Agreement, the Product Agreement expressly prohibits such assignment, in which case Innate (or such Affiliate or Sublicensee, as
applicable) shall cooperate with MedImmune in all reasonable respects to secure the consent of the applicable Third Party to such assignment or the Product Agreement relates to the Licensed Product and another product and if any such consent cannot
be obtained with respect to the Product Agreement or the Product Agreement is not exclusive to the Product, Innate shall, and cause its Affiliates and its and their Sublicensees to, obtain for MedImmune substantially all of the practical benefit and
burden under the Product Agreement, including by (i) entering into appropriate and reasonable alternative arrangements 

  
 68. 

	 	 
on terms agreeable to MedImmune and (ii) subject to the consent and control of MedImmune, enforcing, at MedImmune’s cost and expense and for the account of MedImmune, any and all rights
of Innate (or such Affiliate or Sublicensee, as applicable) against the other party thereto arising out of the breach or cancellation thereof by such other party or otherwise; 

provided that if Innate terminates this Agreement pursuant to clause 20.2.1, MedImmune shall reimburse Innate for all costs
reasonably incurred by Innate in complying with its obligations under this clause 20.3 and provided further that if the termination is with respect to one of the Territories only, the obligations above shall apply only with respect to the US
Territory or EU Territory where the activities have ceased (as applicable); 
  

	20.4	 Remedies. Except as otherwise expressly provided herein, termination of this Agreement in accordance
with the provisions hereof shall not limit remedies that may otherwise be available in law or equity. 

  

	20.5	 Accrued Rights; Surviving Obligations. Termination or expiration of this Agreement for any reason
shall be without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from obligations that are expressly indicated to survive the
termination or expiration of this Agreement. Without limiting the foregoing, the following provisions of this Agreement shall survive the termination or expiration of this Agreement for any reason: (a) [***]; (b) [***]; and (c) any other
provisions which are expressed to survive termination or expiry or which are required to give effect to such termination or expiry. 

  

	21.	 MISCELLANEOUS 

 

	21.1	 Employees who Transfer under the Regulations. 

 

	21.1.1	 Innate and MedImmune do not intend that as a consequence of the transaction effected hereunder (including
any transfer of rights or assets that may occur upon a termination of this Agreement) any employees of Innate or any of its Affiliates (“Employees”) shall transfer to MedImmune or to Innate (or their Affiliates or successors) under
this Agreement or by operation of law. If, under the Regulations, the contract of employment of any person is found or alleged to have effect after the Effective Date as if originally made with MedImmune or Innate or their Affiliates or successors)
(the “Concerned Party”), as a consequence of the transaction effected hereunder and to the extent permitted by Applicable Laws (an “Unexpected Transfer Employee”): 

 

	 	(a)	 The Concerned Party will, upon becoming aware of any Unexpected Transfer Employee, notify the other Party
immediately or as soon as is reasonably practicable in writing; 

  

	 	(b)	 The other Party agrees that in consultation with the Concerned Party, it will within [***] of being so
requested by the Concerned Party (as long as the request is made no later than [***] after notification under clause 21.1.1(a)), make (or procure there is made) to that Unexpected Transfer Employee an offer in writing to employ him under a new
contract of employment to take effect upon the termination referred to 

  
 69. 

	 	 
below on the same terms and conditions as that person’s contract of employment immediately before the Effective Date, or on terms and conditions which, when taken as a whole, do not
materially differ from the terms and conditions of employment of that person immediately before the Effective Date (save as to the identity of the employer and any terms relating to an occupational pension scheme). The Concerned Party shall give the
other Party all reasonable co-operation and assistance to procure that the Unexpected Transfer Employee accepts the offer of employment; 

 

	 	(c)	 upon the expiry of [***] following the offer in clause 21.1.1(b) being made (or on the expiry of [***] from
the Concerned Party’s request under clause 21.1.1(b) if the offer is not made as requested), the Concerned Party may terminate the employment of the Unexpected Transfer Employee provided that: 

 

	 	(i)	 it does so in accordance with all legal requirements and any procedure that may be given to it by the other
Party; and 

  

	 	(ii)	 it takes all other steps to mitigate any payments or entitlements due to the Unexpected Transfer Employee
and any potential liability of the other Party under the indemnity at clause 21.1.1(d). 

  

	 	(d)	 Provided that the termination is effected within [***] of the notification under clause 21.1.1(a), the other
Party shall indemnify the Concerned Party for any employment liabilities in relation to: 

  

	 	(i)	 the employment of the Unexpected Transfer Employee after the Effective Date until any such termination (save
to the extent that the Concerned Party has acted unlawfully in respect thereof); and 

  

	 	(ii)	 the termination of employment of the Unexpected Transfer Employee. 

 

	21.1.2	 MedImmune and Innate shall give each other any assistance that either may reasonably require to comply with
the Regulations in relation to the Unexpected Transferring Employees and in contesting any claim by any Employee at or before the Effective Date resulting from or in connection with this Agreement. 

 

	21.2	 Force Majeure. In this Agreement, “Force Majeure” means an event which is beyond a non-performing Party’s reasonable control, including an act of God, strike, lock-out or other industrial/labour disputes (whether involving the workforce of the Party so
prevented or of any other Person), war, riot, civil commotion, terrorist act, epidemic, quarantine, fire, flood, storm, earthquake or natural disaster. A Party that is prevented or delayed in its performance under this Agreement by an event of Force
Majeure (a “Force Majeure Party”) shall, as soon as reasonably practical but no later than [***] after the occurrence of a Force Majeure event, give notice in writing to the other Party specifying the nature and extent of the event
of Force Majeure, its anticipated duration and any action being taken to avoid or minimize its effect. Subject to providing such notice and to this clause 21.2, the Force Majeure Party shall not be liable for delay in performance or for non-performance of its obligations under this Agreement, in whole or in part, except as 

  
 70. 

	 	 
otherwise provided in this Agreement, where non-performance or delay in performance has resulted from an event of Force Majeure. The suspension of
performance allowed hereunder shall be of no greater scope and no longer duration than is reasonably required and the Force Majeure Party shall exert all reasonable efforts to avoid or remedy such Force Majeure. 

 

	21.3	 Export Control. This Agreement is made subject to any restrictions concerning the export of products
or technical information from the United States or other countries that may be imposed on the Parties from any technical information acquired from time to time. Neither Party shall export, directly or indirectly, the other Party under this Agreement
or any products using such technical information to a location or in a manner that at the time of export requires an export licence or other governmental approval, without first obtaining such export licence or other governmental approval.

  

	21.4	 Assignment. 

 

	21.4.1	 Unless otherwise expressly provided herein, neither Party may assign any of its rights or obligations under
this Agreement in any country in whole or in part without the prior written consent of the other Party, except that each Party shall have the right, without such consent, (i) to perform any of its obligations and exercise any of its rights
under this Agreement through, and to assign all of its rights and obligations under this Agreement to, any of its Affiliates; and (ii) on written notice to the other Party, to assign all of its rights and obligations under this Agreement to a non-Affiliate successor in interest, whether by merger, consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar transaction, to all or substantially all of the business relating
to the Licensed Product. In the event that a Party performs its obligations or exercises its rights under this Agreement through an Affiliate or assigns its rights and obligations to an Affiliate as permitted under this clause 21.4.1, doing so shall
not relieve the relevant Party of its responsibilities for the performance of its obligations under this Agreement, and the relevant Party shall remain responsible for the performance by its Affiliates and shall cause its Affiliates to comply with
the provisions of this Agreement in connection with such performance). 

  

	21.4.2	 This Agreement shall survive any succession of interest permitted pursuant to clause 21.4.1, whether by
merger, consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar transaction, provided, that, in the event of such merger, consolidation, reorganization, acquisition, stock purchase, asset purchase or other similar
transaction, no Intellectual Property Rights of the acquiring corporation and its Affiliates (other than a Party and its Affiliates prior to such acquisition) shall be included in the technology licensed hereunder, unless such Intellectual Property
Rights arise as a result of the performance of this Agreement by such corporation after such transaction becomes effective. 

  

	21.4.3	 Any attempted assignment or delegation in violation of this clause 21.4 shall be void and of no effect.

  
 71. 

	21.5	 Severability. If any provision of this Agreement is held to be invalid, illegal or unenforceable, in
any respect, then such provision will be given no effect by the Parties and shall not form part of this Agreement. To the fullest extent permitted by Applicable Law and if the rights and obligations of a Party will not be materially and adversely
affected all other provisions of this Agreement shall remain in full force and effect and the Parties will use all reasonable efforts to negotiate a provision in replacement of the provision held invalid, illegal or unenforceable that is consistent
with Applicable Law and achieves, as nearly as possible, the original intention of the Parties. To the fullest extent permitted by Applicable Law, the Parties waive any provision of law that would render any provision in this Agreement invalid,
illegal or unenforceable in any respect. 

  

	21.6	 Dispute Resolution. 

 

	21.6.1	 Escalation to Executives. In the event of any dispute between the Parties arising out of or in
connection with this Agreement, including any question regarding its existence, validity or termination (“Dispute”), either Party may, by written notice to the other, have such Dispute referred to the Executives for attempted
resolution by good faith negotiations within [***] after such notice is received. 

  

	21.6.2	 Arbitration. In the event the Parties are unable to resolve a Dispute in accordance with clause
21.6.1 any dispute arising out of or in connection with this Agreement, shall be referred to and finally resolved by arbitration under the Arbitration Rules of the International Chamber of Commerce (ICC), which Rules are deemed to be incorporated by
reference into this clause. One or more arbitrators shall be appointed in accordance with the said Rules. The seat, or legal place, of arbitration shall be London. The language to be used in the arbitral proceedings shall be English.

  

	21.6.3	 Pendency of Arbitration. During the period of time that any arbitration proceeding described in
clause 21.6.2 is pending under this Agreement, the Parties shall continue to comply with all those terms and provisions of this Agreement that are not the subject of, and the performance of which are not otherwise implicated by, such pending
arbitration proceeding. 

  

	21.6.4	 Interim and Conservatory Measures. Nothing contained in this Agreement shall preclude any Party from
seeking interim or other equitable or provisional relief from a court of competent jurisdiction to preserve the status quo or prevent irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing arbitration
proceeding. 

  

	21.6.5	 Patent Disputes. Notwithstanding anything to the contrary, any and all issues regarding the scope,
inventorship, construction, validity, or enforceability of Patents shall be determined in a court of competent jurisdiction under the local patent laws of the jurisdictions having issued the Patents in question. 

 

	21.6.6	 Confidentiality. The Parties agree that any arbitration conducted pursuant to this clause 21.6 shall
be kept confidential and that the existence of the proceeding and any element of it (including any pleadings or briefs submitted by the Parties, any testimony or oral 

  
 72. 

	 	 
submissions, and any orders or awards) shall not be disclosed beyond the arbitrators, the Parties, and their respective counsel, accountants, auditors, insurers and reinsurers, or any other
Person necessary to the conduct of the arbitration. These confidentiality obligations shall not apply if: (a) disclosure is required by Applicable Law, or in judicial or administrative proceedings; or (b) disclosure is necessary to enforce
rights arising out of an arbitral award or order. 

  

	21.7	 Governing Law. The interpretation and construction of this Agreement (including non-contractual disputes) shall be governed by the laws of England and Wales excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to
the substantive law of another jurisdiction. 

  

	21.8	 Notices. Any notice, request, or other communication permitted or required under this Agreement shall
be in writing, shall refer specifically to this Agreement, and shall be deemed given only if hand delivered, sent by an internationally recognised overnight delivery service, costs prepaid, or sent by email (providing such email is read receipted
and such notice is also despatched by an internationally recognised overnight delivery service, costs prepaid, on same day) to the Party to whom notice is to be given at the following address (or at such other address such Party may have provided to
the other Party in accordance with this clause 21.8. 

  

	21.8.1	 Notice Requirements. 

 

	21.8.2	 Address for Notice. 

 

	 	(a)	 If to Innate, to: 

Innate Pharma S.A. 

17, Avenue de Luminy - BP 30191 

13276 Marseille Cedex 09 FRANCE 

Attention: [***] 

Email: [***] 

and with a copy (which shall not constitute effective notice) to: 

[***] 

Email: [***] 

Attention: [***]] 

Such notice, shall be deemed to have been given as of the date delivered by hand, or on the second business day (at the place
of delivery) after deposit with an internationally recognised overnight delivery service, whichever is the earlier. 
  

	 	(b)	 If to MedImmune, to: 

  
 73. 

 MedImmune LLC 

One MedImmune Way 

Gaithersburg 

MD 20878 

USA 

[***] 

with a copy (which shall not constitute effective notice) to: 

[***] 

and with a copy (which shall not constitute effective notice) to: 

[***] 

Such notice, shall be deemed to have been given as of the date delivered by hand, or on the second business day (at the place
of delivery) after deposit with an internationally recognised overnight delivery service, whichever is the earlier. 
  

	21.9	 Entire Agreement; Amendments 

 

	21.9.1	 This Agreement and any document referred to in it constitutes the entire agreement between the Parties with
respect to its subject matter hereof and thereof. This Agreement supersedes all prior arrangements, undertakings, understandings and agreements, whether written or oral, with respect to its subject matter. Each Party confirms that in entering into
this Agreement it is not relying on any statements, representations, warranties, or covenants made by a Party or its representative prior to entering into this Agreement, except as specifically set out in the Agreement. Each Party waives all rights
and remedies which, but for this clause 21.9, might otherwise be available to it in respect of any such representation, warranty, collateral contract or other assurance. 

 

	21.9.2	 Any amendment or modification of this Agreement must be in writing and signed by authorised representatives
of both Parties. 

  

	21.9.3	 This clause 21.9 shall not exclude or limit liability for fraud or fraudulent misrepresentation.

  

	21.9.4	 In the event of any inconsistencies between this Agreement and any Schedules or other attachments hereto,
the terms of this Agreement shall control. 

  

	21.10	 English Language. The language of this Agreement is English and all documents, notices, waivers and
all other written communications or otherwise between the Parties in connection with this Agreement shall be in English. If this Agreement is translated into any other language, the English language text shall prevail. 

 

	21.11	 Waiver and Non-Exclusion of Remedies. A Party’s failure
to enforce, at any time or for any period of time, any provision of this Agreement, or to exercise any right or remedy shall not constitute a waiver of that provision, right or remedy or prevent such Party from

  
 74. 

	 	 
enforcing any or all provisions of this Agreement and exercising any rights or remedies. To be effective any waiver must be in writing. 

 

	21.12	 No Benefit to Third Parties. Except for any rights and immunities granted in this Agreement to any
Affiliates, the Contracts (Rights of Third Parties) Act 1999 shall not apply to this Agreement. Any Person who is not a party to this Agreement (including any employee, officer, agent, representative or subcontractor of either Party) shall not have
the right (whether under the Contracts (Rights of Third Parties) Act 1999 or otherwise) to enforce any provision of this Agreement which expressly or by implication confers a benefit on that Person without the express prior agreement in writing of
the Parties, which agreement must refer to this clause 21.12. 

  

	21.13	 Further Assurance. Each Party shall perform all further acts and things and execute and deliver such
further documents as may be necessary or as the other Party may reasonably require to implement or give effect to this Agreement. 

  

	21.14	 Relationship of the Parties. It is expressly agreed that the relationship between Innate and
MedImmune shall not constitute a partnership, joint venture, or agency. Neither Innate nor MedImmune shall have the authority to make any statements, representations, or commitments of any kind, or to take any action, which shall be binding on the
other Party, without the prior consent of such other Party to do so. 

  

	21.15	 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which
shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by PDF format via email or other electronically transmitted signatures and such signatures shall be deemed to bind
each Party hereto as if they were original signatures. 

 SIGNATURE PAGE FOLLOWS. 

  
 75. 

 THIS AGREEMENT IS EXECUTED by the authorised representatives of the Parties as of the date first
written above. 
  

			
	MEDIMMUNE LIMITED	  	INNATE PHARMA S.A.
		
	By: /s/ Jane Osbourn	  	By: /s/ Mondher Mahjoubi
		
	Name: Jane Osbourn	  	Name: Mondher Mahjoubi
		
	Title: VP R&D	  	Title: CEO

 Signature page to the License Agreement 

 SCHEDULE 1 

COMMERCIALIZATION PLAN 

[***] 

 SCHEDULE 2 

SOTC SERVICES 
 [***] 

[Signature page to the License Agreement] 

 SCHEDULE 3 

SUPPLY AGREEMENT TERMS 

[***] 

 SCHEDULE 4 

LICENSED ANTIBODY 

[***] 

 SCHEDULE 5 

EXISTING PRODUCT TRADEMARKS 

[***] 

 SCHEDULE 6 

LICENSED MEDI PATENTS 

[***] 

 SCHEDULE 7 

AZ CORPORATE MARKS 

[***] 

 SCHEDULE 8 

INNATE CORPORATE NAMES 

[***] 

 SCHEDULE 9 

INITIAL MEMBERS OF JDC AND JCC 

[***] 

 SCHEDULE 10 

DEVELOPMENT PLAN 
  

[***] 

 SCHEDULE 11 

LICENSED MEDI KNOW-HOW 

[***] 

 SCHEDULE 12 

TRADEMARK ASSIGNMENT 

[***] 

 SCHEDULE 16.2 

EXISTING RESEARCH AND COLLABORATION AGREEMENTS 

[***] 

 EXHIBIT A 

AZ PROMOTION PRINCIPLES 

[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]